1510 |
Książka
AHFS Formulary service 2000 Bethesda - 3546 p |
|
2000 |
3291 |
Czasopismo
Acta Pol Pharm 2012 ; 69, 1: 95-105. |
Physical and chemical properties and stability of sodium cefazolin in buffered eye drops determined with HPLC method.
Kodym A, Bilski P, Domanska A, Lukasz Helminiak, Jablonska M, Jachymska A. |
2012 |
795 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2338-2339. |
21-day compatibility of hydromorphone hydrochloride and promethazine hydrochloride in a cassette.
Henderson F. |
1996 |
3316 |
Czasopismo
Chem Pharm Bull 2012 ; 60, 1: 86-93. |
A 5% Glucose Infusion Fluid Provokes Significant Precipitation of Phenytoin Sodium Injection via Interruption of the Cosolvent Effect of Propylene Glycol.
Onuki Y, Ikegami-Kawai M, Ishitsuka K, Hayashi Y, Takayama K. |
2012 |
3958 |
Czasopismo
J Infect Dis 1988 ; 157, 3: 600-601. |
A Dilute Solution of Vancomycin and Heparin Retains Antibacterial and Anticoagulant Activities .
Henrickson K.J; . Powell K.R; . Schwartz C.L. |
1988 |
2242 |
Czasopismo
Int J Pharm 1998 ; 167, 1-2: 223-228. |
A note on the solution chemistry of carboplatin in aqueous solutions.
Lederer M, Leipzig-Pagani E. |
1998 |
1232 |
Czasopismo
Br J Pharm Pract 1987 ; 9: 223-226, 236. |
A physical compatibility study of furosemide & flucloxacillin injections.
Beatson C, Taylor A. |
1987 |
3847 |
Czasopismo
J Pain Palliat Care Pharm 2016 ; 29, 4: 370-373. |
A Pilot Chemical and Physical Stability Study of Extemporaneously Compounded Levetiracetam Intravenous Solution.
Raphael C.D, Zhao F, Hughes S.E, Juba K.M. |
2016 |
401 |
Czasopismo
Aust J Hosp Pharm 1991 ; 21: 115-118. |
A preliminary study of the stability of midazolam in polypropylene syringes.
Peterson GM, Khoo BHC, Galloway JG, Paterson J. |
1991 |
2203 |
Czasopismo
J Oncol Pharm Practice 2007 ; 13: 119-126. |
A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'.
Kaestner S, Sewell G. |
2007 |
2560 |
Czasopismo
Aust J Hosp Pharm 1994 ; 24: 312-316. |
A short-term stability study of an oral solution of dexamethasone.
Accordino A, Chambers R, Thomson B. |
1994 |
3279 |
Czasopismo
J Clin Pharm Ther 2012 ; 37, 1: 71-73. |
A stability indicating assay for a combination of morphine sulphate with levomepromazine hydrochloride used in palliative care.
Al-Tannak N.F, Cable C.G, McArthur D.A, Watson D.G |
2012 |
3817 |
Plakat
Gerpac Congress, Giens, France 2015 |
A stability study of 25 mg/mL phenylephrine hydrochloride and 5 mg/mL tropicamide eye drops.
Stordeur F, Chanat C, Brandely M.L, Chast F. |
2015 |
3685 |
Czasopismo
EJHP 2017 ; 24:4 : 235-241 |
A stability study of amphotericin B, colistin and tobramycin in a hydrophilic suspension commonly used for selective decontamination of the digestive tract by HPLC and in vitro potency measurements.
Pfeifer C, Noll S, Gerecke H, Fassauer G, Jira T, Remane Y , Vogel J, Frontini R, Reinhardt R. |
2017 |
3438 |
Czasopismo
J Pharm Biomed Anal 2013 ; 83 : 164-170. |
A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids.
Respaud R, Quenum L, Plichon C, Tournamille J.F, Gyan E, Antier D, Viaud-Massuard M.C. |
2013 |
554 |
Czasopismo
J Parenter Sci Technol 1991 ; 45: 212-217. |
A study of the interaction of selected drugs and plastic syringes.
Speaker TJ, Turco SJ, Nardone DA, Miripol JE. |
1991 |
525 |
Czasopismo
Int J Pharm 1990 ; 65: 49-56. |
A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters.
De Vroe C, De Muynck C, Remon JP, Samsom M. |
1990 |
2894 |
Czasopismo
J Dermatolog Treat 2004 ; 15: 295-302. |
A topical azythromycin preparation for the treatment of acne vulgaris and rosacea.
McHugh RC, Sangha ND, Mc Carty MA et al. |
2004 |
4045 |
Czasopismo
J Pharm Biomed Anal 2016 ;124:365-373 |
A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor.
Sestak V, Roh J, Klepalova L, Kovarikova P. |
2016 |
1332 |
Czasopismo
J Clin Hosp Pharm 1981 ; 6: 209-211. |
Absorption of isosorbide dinitrate by PVC infusion bags and administration sets.
Lee MG, Fenton-May V. |
1981 |
3595 |
Laboratorium
Hospira 2009 |
Aciclovir - Summary of Product Characteristics
|
2009 |
3933 |
Laboratorium
Teva Laboratoire 2015 |
Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit
|
2015 |
576 |
Czasopismo
Drug Intell Clin Pharm 1980 ; 14: 353-357. |
Activity of antibiotic admixtures subjected to different freeze-thaw treatments.
Holmes CJ, Ausman RK, Walter CW, Kundsin RB. |
1980 |
1624 |
Czasopismo
Am J Health-Syst Pharm 2000 ; 57: 760-762. |
Activity of dalteparin sodium in polypropylene syringes.
Louie S, Chin A, Gill MA. |
2000 |
811 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1296-1298. |
Activity of enoxaparin sodium in tuberculin syringes for 10 days.
Charland SL, Davis DD, Tillman DJ. |
1998 |
466 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2172-2175. |
Activity of octreotide acetate in a total nutrient admixture.
Ritchie DJ, Holstad SG, Westrich TJ, Hirsch JD, O'Dorisio TM. |
1991 |
375 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1511-1514. |
Activity of urokinase diluted in 0.9% sodium chloride injection or 5% dextrose injection and stored in glass or plastic syringes.
Patel JP, Tran LT, Sinai WJ, Carr LJ. |
1991 |
156 |
Czasopismo
Anticancer Drugs 1995 ; 6: 163-164. |
Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.
Barberi-Hayob M, Merlin JL, Vigneron M, Conroy T. |
1995 |
4567 |
Czasopismo
Pharmaceutics 2021 ;13, 458. |
Addition of Regular Insulin to Ternary Parenteral Nutrition: A Stability Study.
Henry H, Lannoy D, Maboudou P, Seguy D, Dine T, Pigny P, Odou P. |
2021 |
64 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1672. |
Additional data on visual compatibility of foscarnet sodium with morphine sulfate.
DiStefano JE, Outman WR. |
1992 |
1242 |
Czasopismo
Pharm Weekbl [Sci] 1988 ; 10: 213-216. |
Adsorption of human and porcin insulins to intravenous administration sets.
Tol A, Quik RFP, Thyssen JHH. |
1988 |
2119 |
Czasopismo
Eur J Anaesthesiol 2003 ; 20: 124-126. |
Adsorption of sufentanil to epidural filters and catheters.
Westphal M, Hohage H, Buerckle H, Van Aken H, Ermert T, Brodner G. |
2003 |
167 |
Czasopismo
Int J Pharm 1994 ; 103: 87-92. |
Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters.
Francomb MM, Ford JL, Lee MG. |
1994 |
3508 |
Laboratorium
Sanofi Aventis Group 2013 |
Aflibercept (Zaltrap®) - Summary of Product characteristics
|
2013 |
3635 |
Laboratorium
Novartis Pharmaceuticals UK Ltd 2015 |
Aldesleukine (Proleukin®) - Summary of Product Characteristics
|
2015 |
3417 |
Plakat
ADKA Congress, Dresden, Germany 2013 |
Aliquotierte Levosimendanlösungen - stabil ?
Trittler R, Hecklinger J. |
2013 |
3616 |
Laboratorium
Boehringer Ingelheim 2012 |
Altéplase (Actilyse®) - Résumé des caractéristiques du produit
|
2012 |
4471 |
Laboratorium
Kyowa Kirin Pharma 2019 |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
|
2019 |
3598 |
Laboratorium
Clinigen Healthcare Ltd 2016 |
Amifostine (Ethyol®) - Résumé des caractéristiques du produit
|
2016 |
3549 |
Laboratorium
B Braun 2012 |
Amikacine B Braun - Résumé des caractéristiques du produit.
|
2012 |
3524 |
Laboratorium
Sanofi 2013 |
Amiodarone hydrochloride (Cordarone®) - Summary of Product Characteristics.
|
2013 |
3527 |
Laboratorium
Glaxo Smith Kline 2018 |
Amoxicillin (Amoxil®) – Summary of Product Characteristics
|
2018 |
3545 |
Laboratorium
Mylan SAS 2009 |
Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
|
2009 |
265 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1463-1464. |
Amphotericin B does not mix with fat emulsion.
Trissel LA. |
1995 |
1498 |
Czasopismo
Ann Pharmacotherapy 1996 ; 30: 409-412. |
Amphotericin B formulated in a lipid emulsion.
Cleary JD. |
1996 |
2043 |
Czasopismo
Antimicrob Agents Chemother 1998 ; 42: 762-766. |
Amphotericin B in lipid emulsion : stability, compatibility, and in vitro antifungal activity.
Walker S, Tailor SAA, Lee M, Louie L, Louie M, Simor AE. |
1998 |
793 |
Czasopismo
J Antimicrob Chemother 1996 ; 37: 1165-1169. |
Amphotericin B intralipid formulation: stability and particule size.
Ranch?re JY, Latour JF, Fuhrmann C, Lagallarde C, Loreuil F. |
1996 |
984 |
Czasopismo
Ann Pharmacotherapy 1996 ; 30: 298. |
Amphotericin B is incompatible with lipid emulsions.
Ericsson O, Hallmen AC, Wikstrom I. |
1996 |
3398 |
Laboratorium
Gilead Science (France) 2013 |
Amphotéricine B (Ambisome®) - Résumé des caractéristiques du produit
|
2013 |
3591 |
Laboratorium
Bristol Myers Squibb 2011 |
Amphotericine B (Fungizone®) - Résumé des caractéristiques du produit
|
2011 |
1758 |
Czasopismo
Can J Hosp Pharm 1999 ; 52: 90. |
Ampicillin and ciprofloxacin incompatibility.
Lewis GM, Donelly RF. |
1999 |
1392 |
Czasopismo
Can J Hosp Pharm 1999 ; 52: 90. |
Ampicillin and ciprofloxacin incompatibility.
Lewis GM, Donnelly RF. |
1999 |
3528 |
Laboratorium
Essential generics 2012 |
Ampicillin sodium – Summary of Product Characteristics
|
2012 |
3576 |
Laboratorium
Prostrakan 2012 |
Amsacrine (Amsalyo®) - Résumé des caractéristiques du produit
|
2012 |
805 |
Czasopismo
Hosp Pharm 1997 ; 32: 1013-1020. |
An automated process for determining the physical compatibility of drugs.
Oskroba DM, Leissing NC, Trissel LA. |
1997 |
3760 |
Czasopismo
J Oncol Pharm Practice 1996 ; 2: 107-112. |
An evaluation of the stability of granulocyte colony stimulating factor on the short-term storage and delivery from an elastomeric infusion system.
Tivnann H, Gaines-Gas R, Thorpe R et al. |
1996 |
4681 |
Czasopismo
Hosp Pharm 2022 ; 57, 1: 69-75. |
An Exploratory Study of a New Vancomycin Eye Drops Formulation for Extemporaneous Compounding.
Chen P, Mar Z, Giannetti A, Hughes S, Gilbert J, Zhao F. |
2022 |
124 |
Czasopismo
Int Pharm J 1993 ; 7: 14-19. |
An in vitro interaction between promethazine hydrochloride and chloroquine phosphate.
Abubakar AA, Mustapha A, Wambebe OC. |
1993 |
3725 |
Czasopismo
Dysphagia 2014 |
An investigation into the stability and sterility of citric acid solutions used for cough reflex testing.
Falconer J.R, Wu Z, Lau H, Sue J, Wang L, Pottinger S, Lee E, Alazawi N, Kalllesen M, Gargiulo D.A, Swift S, Svirskis D. |
2014 |
3190 |
Czasopismo
Advance in Haematology 2009 Article ID 704928, 5 page |
An NMR Study of the Bortezomib Degradation under Clinical Use Conditions.
Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC, Pagliuca R, Mazzarelli V, Ottiero M, Scalfaro M, |
2009 |
4736 |
Czasopismo
J Pharm Biomed Anal 2023 |
An Ultra-High-Performance Chromatography method to study the long term stability of gemcitabine in dose banding conditions.
Closset M, Colsoul ML, Goderniaux N, Bihin B, Jamart J, Onorati S, Soumoy L, Hecq JD, Odou P, Galanti L. |
2023 |
1895 |
Czasopismo
J Pharm Biomed Anal 2004 ; 35: 57-64. |
Analysis by liquid chromatography and infrared spectrometry of di(2-ethylhexyl)phtalate released by multilayer infusion tubing.
Bourdeaux D, Sautou-Miranda V, Bagel-Boithias S, Boyer A, Chopineau J. |
2004 |
1917 |
Czasopismo
J Pharm Biomed Anal 1997 ; 15: 537- 543. |
Analysis of gentamicin sulfate and a study of its degradation in dextrose solution.
Graham AE, Speicher E, Williamson B. |
1997 |
2148 |
Czasopismo
Anal Biochem 2002 ; 309: 117-126. |
Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.
Lanvers C, Pinheiro JPV, Hempel G, Wuerthwein G, Boos J. |
2002 |
3567 |
Laboratorium
Pfizer 2020 |
Anidulafungin (Ecalta®) - Summary of Product Characteristics.
|
2020 |
3006 |
Czasopismo
J Am Acad Dermatol 1987 ; 16: 984-988. |
Anthralin stability in various vehicles.
Green PG, Kennedy CT, Forbes DR. |
1987 |
1230 |
Czasopismo
Br J Pharm Pract 1986 ; 8: 218-220. |
Anti-emetic / diamorphine mixture compatibility in infusion pumps.
Regnard C, Pashley S, Westrope F. |
1986 |
1893 |
Czasopismo
Ann Pharmacotherapy 2004 ; 38: 569-573. |
Anti-Xa stability of diluted enoxaparin for use in pediatrics.
Dager WE, Gosselin RC, King JF, Christensen CL, Owings JT, Larkin EC. |
2004 |
4445 |
Czasopismo
Chemotherapy 1979 ; 25: 336-345. |
Antibiotic compatibility and stability in a parenteral nutrition solution.
Reed M.D, Perry E.B, Fennell S.J, Brissie E.O, Ball W.D. |
1979 |
1386 |
Czasopismo
Pharm J 1983 ; 231- 233. |
Antibiotic interactions.
Gove L. |
1983 |
3952 |
Czasopismo
Hemodial Int 2010 ; 14, 3 : 322-326. |
Antibiotic lock: In vitro stability of gentamicin and sodium citrate stored in dialysis catheters at 37°C.
Battistella M,. Vercaigne L.M, Cote D,. Lok C.E. |
2010 |
3951 |
Czasopismo
Hemodial Int 2009 ; 13, 3: 322-328. |
Antibiotic lock: In vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37°C
Battistella M, Walker S, law S, Lok C. |
2009 |
1103 |
Czasopismo
J Pediatr 1988 ; 112: 813-817. |
Antibiotic stability in a pediatric parenteral alimentation solution.
Fox AS, Boyer KM, Sweeney HM. |
1988 |
4776 |
Czasopismo
Pharmaceutics 2023 ; 15: 2143. |
Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures.
Tomczak S, Chmielewski, M, Szkudlarek J, Jeliinska A. |
2023 |
2268 |
Czasopismo
Ann Pharmacotherapy 2008 ; 42, 4: 511-515. |
AntiXa stability of diluted dalteparin for pediatric use.
Goldenberg NA, Jacobson L, Hthaway H, Tripputi M, Primeaux J, Child J. |
2008 |
3615 |
Laboratorium
Archimeded Pharma 2012 |
Apomorphine (Apomorphine Archimedes®) - Résumé des caractéristiques du produit
|
2012 |
3227 |
Czasopismo
Braz J Pharm Sci 2014 ; 50, 3 : 521-527. |
Application of capillary electrophoresis to the simultaneous determination and stability study of four extensively used penicillin derivatives
Simon B, Hancu G, Gy?resi A. |
2014 |
4579 |
Czasopismo
Processes 2021 , 9, 453. |
Application of the HPLC Method in Parenteral Nutrition
Assessment: Stability Studies of Ondansetron
Tomczak S, Radwan V, Jelinska A, Stawny M. |
2021 |
3295 |
Laboratorium
LFB Biom?dicaments 2018 |
Argatroban - Résumé Caractéristiques du Produit
|
2018 |
2277 |
Laboratorium
GlaxoSmithKline 2008 |
Argatroban - Summary of Product Characteristics
|
2008 |
4726 |
Laboratorium
Mylan 2023 |
Arsenic trioxide Mylan - Résumé des caractéristiques du produit
|
2023 |
3445 |
Czasopismo
Krankenhauspharmazie 2013 ; 34, 8: 410-411. |
Aseptische Herstellung applikationsfertiger Adrenalin-Dauerinjektionen 20 µg/ml.
Heeb R.M, Thiesen J, Krämer I. |
2013 |
1160 |
Czasopismo
Int J Pharm 1986 ; 32: 123-131. |
Aspects of the degradation kinetics of doxorubicin in aqueous solution.
Beijnen JH, van der Houwen OAGJ, Underberg WJM. |
1986 |
4292 |
Czasopismo
Drugs R D 2019 19: 127–140. |
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
Vimpolsek M, Gottar-Guillier M, Rossy E. |
2019 |
4676 |
Plakat
EAHP Congress Vienna 2022 |
Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days.
Borišek R, Šmid I. |
2022 |
4645 |
Czasopismo
JAC Antimicrob Resist 2021 |
Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy.
Jamieson C, Drummond F, Hill T, Ozolina L, Gilchrist M, Seaton R.A, Santillo M, Wilkinson A-S, Allwood M.C. |
2021 |
2139 |
Czasopismo
EJHP Science 2006 ; 12,5: 96-99. |
Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities.
Serrurier C, Chenot ED, Vigneron J, May I, Demor? B. |
2006 |
2815 |
Czasopismo
EJHP 2009 ; 15, 4: 30-32. |
Assessment of stability in extemporaneously prepared venlafaxine solutions.
Kervale JG, Castagnet S, Chiadmi F, Schlatter J, Benabadji Z, Cisternino S, Fontan JE. |
2009 |
4434 |
Czasopismo
Clin Ther 2019 ; 41, 10: 2162-2170. |
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. |
2019 |
4512 |
Czasopismo
EJHP 2020 2020;0:1-5. |
Assessment of the stability of citrate- buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements
Jamieson C,Ozolina L,Seaton RA, Gilchrist M, Hills T, Drummond F, Wilkinson AS. |
2020 |
4218 |
Czasopismo
EJHP 2020 ; 27, 2: 90-94. |
Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INfusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements.
Allwood M.C,Stonkute D, Wallace A, Wilkinson A-S, Hills T, Jamieson C, |
2020 |
1873 |
Czasopismo
Clin Ther 2003 ; 25: 1219-1224. |
Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days/ In vitro study.
Laposata M, Johnson SM. |
2003 |
1608 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 397-400. |
Assessment of the stability of teicoplanin in intravenous infusions.
Galanti LM, Hecq JD, Jeuniau P, Vanbeck D, Jamart J. |
2001 |
4532 |
Laboratorium
Roche Products Limited 2021 |
Atezolizumab (Tecentriq®) - Summary of Product Characteristics
|
2021 |
3629 |
Laboratorium
Actavis UK 2014 |
Atracurium (Atracurium solution for injection/infusion®) - Summary of Product Characteristics
|
2014 |
3676 |
Laboratorium
Hospira 2014 |
Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit
|
2014 |
711 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 492-496. |
Avaibility of diazepam from plastic containers.
Cloyd JC, Vezeau C, Miller KW. |
1980 |
177 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2213-2216. |
Avaibility of lorazepam after simulated administration from glass and polyvinyl chloride containers.
Mancano MA, Boullata JI, Gelone SP, Zitterman RE, Borenstein MR. |
1995 |
1102 |
Czasopismo
Eur J Clin Pharmacol 1981 ; 19: 181-185. |
Availability of isosorbide dinitrate, diazepam and chlormethiazole, from i.v. delivery systems.
Cossum PA, Roberts MS. |
1981 |
4467 |
Laboratorium
Roche Products Limited 2020 |
Avastin - Summary of Product Characteristics
|
2020 |
4474 |
Laboratorium
Merck 2023 |
Avelumab (Bavencio®) - Summary of Product Characteristics
|
2023 |
3236 |
Laboratorium
Celgene 2011 |
Azacitidine (Vidaza®) - Résumé des caractéristiques du produit
|
2011 |
3547 |
Laboratorium
Sanofi-Aventis France 2011 |
Aztréonam (Azactam®) - Résumé des caractéristiques du produit
|
2011 |
94 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1970. |
Aztreonam-vancomycin incompatibility.
Chandler SW, Folstad J, Trissel LA. |
1990 |
3683 |
Laboratorium
Aguettant 2014 |
Baclofen - Résumé des caractéristiques du produit
|
2014 |
2729 |
Czasopismo
J Pharm Clin 1995 ; 14, 2: 106-111. |
Bains de bouche antifongiques: études de stabilité.
Vincent I, Schmit B, Houze S, benhaiem N, Jacques L, Taburet AM. |
1995 |
3261 |
Laboratorium
Bristol Myers Squibb 2011 |
Belatacept (Nulojix®) – Résumé des caractéristiques du produit
|
2011 |
3936 |
Laboratorium
GlaxoSmithKline Laboratoire 2016 |
Bélimumab (Benlysta®) – Résumé des caractéristiques du produits
|
2016 |
3721 |
Laboratorium
Spectrum Pharmaceuticals 2014 |
Belinostat (Beleodaq®) - Summary of Product Characteristics
|
2014 |
3158 |
Laboratorium
Astellas Pharma GmbH 2014 |
Bendamustine (Levact®) - Summary of Product Characteristics
|
2014 |
2288 |
Laboratorium
Cephalon 2008 |
Bendamustine hydrochloride (Treanda®) – Summary of Product Characteristics
|
2008 |
3585 |
Laboratorium
Genus Pharmaceuticals 2008 |
Benzylpenicillin sodium - Summary of Product Characteristics
|
2008 |
4582 |
Czasopismo
J Pharm Technol 2021 |
Beyond-Use Dates Assignment for Pharmaceutical Preparations: Example of Low-Dose Amiodarone Capsules.
Brun D, Curti C, Lamy E, Jean C, Bertault-Përez P, Broggi J, Tintori G, Vanelle P. |
2021 |
3978 |
Czasopismo
Am J Health-Syst Pharm 2017 ; 74,9: 202-210 |
Beyond-use dating of lidocaine alone and in two “magic mouthwash” preparations.
Kirk L.M, Brown S.D, Luu Y, Ogle A, Huffman J, O. Lewis P.O. |
2017 |
1269 |
Czasopismo
J Clin Pharm Ther 1988 ; 13: 335-340. |
Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units.
DeMuynck C, De Vroe C, Remon JP, Colardyn F. |
1988 |
857 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 1323-1328. |
Binding of selected drugs to a “treated” inline filter.
Kanke M, Eubanks JL, DeLuca PP. |
1983 |
3696 |
Czasopismo
Braz J Pharm Sci 2012 ; 48, 4: 691-698. |
Biological and physicochemical stability of ceftazidime and aminophylline on glucose parenteral solution.
Santos C.A.D, Oliveira-Nascimento L, Knirsch M.C, Stephano M.A, Pessoa J?nior A, Penna T.C.V. |
2012 |
3539 |
Laboratorium
The Medecines Company 2013 |
Bivalirudin (Angiox®) - Summary of Product Characteristics.
|
2013 |
4154 |
Laboratorium
Accord Health Care 2018 |
Bleomycin sulfate- Summary of Product Characteristics
|
2018 |
3646 |
Laboratorium
Sanofi Aventis France 2013 |
Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit
|
2013 |
3774 |
Laboratorium
Amgen 2016 |
Blinatumomab - (Blincyto®) - Summary of Product Characteristics
|
2016 |
1911 |
Laboratorium
Janssen-Cilag Ltd 2016 |
Bortezomib (Velcade®) - Summary of Product Characteristics
|
2016 |
3537 |
Czasopismo
Krankenhauspharmazie 2013 ; 34,11: 500-505. |
Bortezomib zur subkutanen Applikation.
Lipp HP, Gfrörer W, Riedmüller S. |
2013 |
3495 |
Laboratorium
Takeda 2013 |
Brentuximab (Adcetris®) - Summary of Product Characteristics
|
2013 |
705 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 183-187. |
Bretylium tosylate admixture compatibility. II : Dopamine, lidocaine, procainamide, and nitroglycerin.
Lee YC, Malick W, Amann AH, Baaske DM, Shah JJ, Wagenknecht DM, Carter JE. |
1981 |
743 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 803-808. |
Bretylium tosylate intravenous admixture compatibility. I: Stability in common large-volume parenteral solutions.
Lee YC, Baaske DM, Amann AH, Carter JE, Mooers MA, Wagenknecht DM, Lai CM. |
1980 |
2878 |
Czasopismo
Can J Hosp Pharm 2009 ; 62, 5: 375-380. |
Buffered Lidocaine Hydrochloride Solution With and Without Epinephrine: Stability in Polypropylene Syringes.
Pascuet E, Donnelly RF, Garceau D, Vaillancourt R. |
2009 |
3653 |
Laboratorium
Laboratoire Léo 2013 |
Bumétanide (Burinex®) - Résumé des caractéristiques du produit
|
2013 |
3684 |
Laboratorium
Laboratoire Léo 2012 |
Bumétanide (Burinex®) - Résumé des caractéristiques du produit
|
2012 |
181 |
Czasopismo
Med Sci Monit 2015 ; 21:1138-1145. |
Butorphanol and Ketamine Combined in Infusion Solutions for Patient-Controlled Analgesia Administration: A Long-Term Stability Study.
Fuchao Chen, Hui Xiong, Jinguo Yang, Baoxia Fang, Jun Zhu, Benhong Zhou. |
2015 |
3237 |
Laboratorium
Sanofi Aventis France 2011 |
Cabazitaxel (Jevtana®) - Résumé des caractéristiques du produit.
|
2011 |
3644 |
Laboratorium
Hameln Pharmaceuticals 2010 |
Calcium gluconate® - Summary of Product Characteristics
|
2010 |
4689 |
Czasopismo
Braz J Pharm Sci 2022 ;58: e19175 |
Captopril oral solution for pediatric use: formulation, stability study and palatability assessment in vivo.
Dysarz L.P, Tavares M, Viçosa A.L, Ribeiro M.F, Teixeira R.G.S, Elias S.C, Márcio R. M. |
2022 |
4345 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2019 |
Carbidopa Capsules for Insulinoma Diagnostic: Compounding and Stability Study.
Curti C, Mathias F, Savelli M, Garrigue P, Lamy E, Guillet B, Vanelle P. |
2019 |
2253 |
Czasopismo
J Synchrotron Rad 2001 ; 8: 716-718. |
Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS.
Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S. |
2001 |
2254 |
Czasopismo
New J Chem 2000 ; 24: 1003-1008. |
Carboplatin decomposition in aqueous solution with chloride ions monitored by X-ray absorption spectroscopy.
Curis E, Provost K, Nicolis I, Bouvet D, B?nazeth S, Crauste-Manciet S, Brion F, Brossard D. |
2000 |
3348 |
Laboratorium
Amgen 2016 |
Carfilzomib (Kyprolis®) - Résumé des caractéristiques du produit
|
2016 |
3314 |
Laboratorium
Bristol Myers Squibb 2011 |
Carmustine (Bicnu®) – Résumé des caractéristiques du produits
|
2011 |
3167 |
Czasopismo
Farm Hosp 2010 ;34:293-7. |
Carvedilol stability in paediatric oral liquid formulations.
Buontempo F, Bernabeu E, Glisoni RJ, Quiroga E, Bregni C, Chiappetta DA. |
2010 |
4067 |
Czasopismo
Pharmazie 2017 ;72:197-199 |
Caspofungin infusion solutions (50 mg/mL): chemical stability and antifungal activity against Candida spp.
Pinder N, Pelzl L.H; Walther G, Backhaus J, Kurzai O, Hoppe-Ticky T. |
2017 |
1519 |
Laboratorium
Merck Sharp Dohme 2015 |
Caspofungine (Cancidas®) - Summary of Product Characteristics
|
2015 |
2343 |
Laboratorium
Fresenius Biotech 2009 |
Catumaxomab (Removab®)
|
2009 |
3546 |
Laboratorium
Panpharma SA 2007 |
Cefamandole Flavelab - Résumé des caractéristiques du produit
|
2007 |
1479 |
Czasopismo
Krankenhauspharmazie 1995 ; 1: 9-12. |
Cefamandolnafat und metronidazol. Chemische stabilität in einer mischung zur intravenösen infusion.
Digel S. |
1995 |
3548 |
Laboratorium
Bristol Myers Squibb 2007 |
Cefepime (Maxipime®) - Summary of Product caracteristics.
|
2007 |
2093 |
Laboratorium
Shionogi B.V. 2020 |
Cefiderocol (Fetcroja®)- Summary of Product Characteristics
|
2020 |
3544 |
Laboratorium
Pfizer 2006 |
Cefoperazone (Cefobid®) - Summary of Product Characteristics
|
2006 |
1206 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 564. |
Cefoperazone-aminoglycoside incompatibility.
Frear RS. |
1983 |
3677 |
Laboratorium
Sanofi Aventis France 2008 |
Cefpirome (Cefrom®) - Résumé des caractéristiques du produit
|
2008 |
2902 |
Laboratorium
Forrest Pharmaceuticals 2015 |
Ceftazidime - avibactam (Avycaz®) - Summary of Product Characteristics
|
2015 |
3883 |
Laboratorium
Arrow 2016 |
Ceftazidime - Résumé des caractéristiques du produit
|
2016 |
273 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1302-1305. |
Ceftazidime degradation rates for predicting stability in a portable infusion-pump reservoir.
Van Doorne V, Bernaards J, DeJonge P. |
1996 |
697 |
Czasopismo
Can J Hosp Pharm 1988 ; 41: 65-71. |
Ceftazidime stability in normal saline and dextrose in water.
Walker SE, Dratnitsaris G. |
1988 |
3543 |
Laboratorium
Wockhardt 2013 |
Ceftazidime – Summary of Product Characteristics
|
2013 |
4650 |
Laboratorium
Advanz Pharma 2021 |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
|
2021 |
3803 |
Laboratorium
Laboratoires Merck Sharp & Dohme Chibret 2020 |
Ceftolozane / tazobactam (Zerbaxa®) - Summary of Product Characteristics
|
2020 |
3828 |
Plakat
ASHP Midyear 2015 |
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
Thabit A.K, Hamada Y, Nicolau D.P. |
2015 |
3523 |
Laboratorium
Roche 2018 |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
|
2018 |
2302 |
Laboratorium
Lettre AFFSAPS 30 November 2008 2008 ; 61, 5: 356-357. |
Ceftriaxone et incompatibilités physico-chimiques, particulièrement avec les solutions contenant des sels de calcium.
|
2008 |
3687 |
Laboratorium
Stravencon 2013 |
Cefuroxime sodium - Summary of Product Characteristics
|
2013 |
275 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1461-1462. |
Cephalosporin-pentamidine isethionate incompatibilities.
Lewis JD, El-Gendy A. |
1996 |
674 |
Czasopismo
Can J Hosp Pharm 1992 ; 45: 237-242. |
Cephalotin stability in normal saline, five percent dextrose in water, and Dianeal* solutions.
Walker SE, Paton TW, Oreopoulos DG. |
1992 |
2220 |
Laboratorium
Merck Serono 2015 |
Cétuximab (Erbitux®) - Dossier scientifique
|
2015 |
2389 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 69-74. |
Characterization of an extemporaneous liquid formulation of lisinopril
Thompson KC, Zhao Z, Mazakas JM, Beasley CA, Reed RA, Moser CL. |
2003 |
410 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1500-1506. |
Characterization of cisplatin degradation as affected by pH and light.
Zieske PA, Koberda M, Hines JL, Knight CC, Sriram R, Raghavan NV, Rabinow BE. |
1991 |
2723 |
Czasopismo
J Ped Hematol Oncol 2004 ; 26: 179-184. |
Chemical and functional analysis of hydroxyurea oral solutions.
Heeney MM, Whorton MR, Howard TA. |
2004 |
3898 |
Czasopismo
EJHP 2016 ;23:288-293 |
Chemical and microbiological stability studies of an aqueous solution of pravastatin sodium salt for drug therapy of the dysphagic patients
Bonacucina G, Logrippo S, Cespi M, Ganzetti R, Casettari L, Sestili M, Perinelli D.R, Ricciutelli M, Marziali A, Polidori C, Pa |
2016 |
3622 |
Czasopismo
Int J Pharm Compound 2014 ; 18, 2 : 152-158. |
Chemical and Physical Compatibility of an Intravenous Solution of Epinephrine with Calcium Chloride.
Weeks Phillip A, Teng Yang, Wu Lei, Sun Mary, Yang Zhen, Chow Diana S-L. |
2014 |
2803 |
Czasopismo
Respiratory Care 2008 ; 683, 12: 1716-1722. |
Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium or acetylcysteine sodium.
Bonasia PJ, McVicar WK, Williams B, Ong S. |
2008 |
2201 |
Czasopismo
EJHP Science 2007 ; 13, 3: 55-59. |
Chemical and physical stability of dexrazoxane, diluted with Ringer's lactate solution, in polyvinyl and polyethylene containers.
Kaiser J.D, Vigneron J, Zenier H, May I, Demor? B. |
2007 |
2188 |
Czasopismo
EJHP Science 2007 ; 13, 2: 40-47 |
Chemical and physical stability of diluted busulfan infusion solutions.
Karstens A, Krämer I. |
2007 |
482 |
Czasopismo
J Parenter Sci Technol 1991 ; 45: 108-112. |
Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.
Beijnen JH, Beijnen-Bandhoe U, Dubbelman AC, Van Gijn R, Underberg WJM. |
1991 |
436 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2635-2637. |
Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4°C for 35 days.
Mitrano FP, Outman WR, Baptista RJ, Palombo JD. |
1991 |
903 |
Czasopismo
J Parenter Sci Technol 1993 ; 47: 35-39. |
Chemical compatibility of cefmetazole sodium with ranitidine hydrochloride during simulated Y-site administration.
Inagaki K, Gill MA, Okamoto MP, Takagi J. |
1993 |
4428 |
Czasopismo
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132. |
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. |
2004 |
380 |
Czasopismo
Crit Care Med 1995 ; 23: 1061-1066. |
Chemical compatibility of inotropic and vasoactive agents delivered via a multiple line infusion system.
Grillo JA, Gonzalez ER, Ramaiya A, Karnes HT, Wells B. |
1995 |
1730 |
Czasopismo
Act Pharm Nord 1991 ; 3: 251. |
Chemical compatibility of mitoxantrone and etoposide (VP-16).
Björkman S, Roth B. |
1991 |
1461 |
Czasopismo
J Pharm Pharmacol 1994 ; 46: 951-955. |
Chemical incompatibility between procainamide hydrochloride and glucose following intravenous admixture.
Sianipar A, Parkin JE, Sunderland VB. |
1994 |
585 |
Czasopismo
J Clin Pharm Ther 1988 ; 13: 199-205. |
Chemical stabilities of cefaperazone sodium and ceftazidime in 5% dextrose and 0.9% sodium chloride injections.
Das Gupta V, Bethea C, Dela Torre M. |
1988 |
961 |
Czasopismo
J Clin Pharm Ther 1990 ; 15: 187-196. |
Chemical stabilities of cefuroxime sodium and metronidazole in an admixture for intravenous infusion.
Barnes AR. |
1990 |
693 |
Czasopismo
J Clin Pharm Ther 1988 ; 13: 329-334. |
Chemical stabilities of famotidine and ranitidine hydrochloride in intravenous admixtures.
Das Gupta V, Parasrampuria J, Bethea C. |
1988 |
631 |
Czasopismo
J Parenter Sci Technol 1985 ; 39: 145-148. |
Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion.
Das Gupta V, Stewart KR. |
1985 |
2986 |
Czasopismo
J Clin Pharm Ther 1988 ; 13: 165-169. |
Chemical stabilities of isoetharine hydrochloride, metaproterenol sulphate and terbutaline sulphate after mixing with normal saline for respiratory therapy.
Gupta VD, Parasrampurian J, Gardner SN. |
1988 |
1331 |
Czasopismo
J Clin Hosp Pharm 1986 ; 11 : 449-452. |
Chemical stabilities of lignocaine hydrochloride and phenylephrine hydrochloride in aqueous solution.
Das Gupta V, Steward KR. |
1986 |
657 |
Czasopismo
J Clin Pharm Ther 1996 ; 21: 173-175. |
Chemical stability and adsorption of atracurium besylate injections in disposable plastic syringes.
Pramar YV, Loucas VA, Word D. |
1996 |
667 |
Czasopismo
J Clin Pharm Ther 1994 ; 19: 195-198. |
Chemical stability and adsorption of succinylcholine chloride injections in disposable plastic syringes.
Pramar YV, Moniz D, Hobbs D. |
1994 |
2173 |
Czasopismo
EJHP Science 2006 ; 12, 6: 135-139. |
Chemical stability and microbiological potency of intravenous vancomycin hydrochloride syringes for use in the neonatal intensive care.
Grioffiths W, Favet J, Ing H, Sadeghipour F, Bonnabry P. |
2006 |
1813 |
Czasopismo
Int J Pharm Compound 2003 ; 7, 4: 310-312. |
Chemical stability of cefuroxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Gupta VD. |
2003 |
2875 |
Czasopismo
Can J Hosp Pharm 2004 ; 57, 5: 283.287. |
Chemical Stability of 4-Aminopyridine Capsules.
Donnelly RF. |
2004 |
2319 |
Czasopismo
EJHP Science 2009 ; 15, 1: 11-14. |
Chemical stability of a solution of bupivacaine hydrochloride 0.125% and sufentanil citrate 0.5 µg/ml for filling syringes using a repeater pump.
Janssen K, Wisselo R, Geerlings C, Schouten J.P. |
2009 |
2586 |
Czasopismo
Br Assoc Dermatol 1998 ; 139 (suppl 52): 8-1. |
Chemical stability of adepalene and tretinoin when combined with benzoyl peroxyde in presence and in absence of visible light and ultraviolet radiation.
Martin B, Meunier C, Montels D. |
1998 |
2252 |
Czasopismo
Neuromodulation 2007 ; 10, 1: 1-5. |
Chemical stability of admixture combining ziconotide and bupivacaine during simulated intrathecal administration.
Shields D, Montenegro R, Aclan J. |
2007 |
2249 |
Czasopismo
Neuromodulation 2007 ; 10, 1: 12-17. |
Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration.
Shields D, Montenegro R, Aclan J. |
2007 |
2280 |
Czasopismo
Int J Pharm Compound 2008 ; 12, 5: 463-466. |
Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration.
Shields DE, Aclan J, Szatkowski A. |
2008 |
2251 |
Czasopismo
Neuromodulation 2005 ; 8, 4: 257-263. |
Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration.
Shields D, Montenegro R, Ragusa M. |
2005 |
2298 |
Czasopismo
Int J Pharm Compound 2008 ; 12, 6: 553-557. |
Chemical stability of admixtures containing ziconotide 25 mcg/ml and morphine sulfate 10 mg/ml or 20 mg/ml during simulated intrathecal administration.
Shields D.E, Aclan J, Szatkowski A. |
2008 |
647 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 347-348. |
Chemical stability of amiodarone hydrochloride in intravenous fluids.
Pramar YV. |
1997 |
2877 |
Czasopismo
Int J Pharm Compound 2009 ; 13, 5: 445-446. |
Chemical Stability of Amitriptyline Hydrochloride in Oral Liquid Dosage Forms.
Das Gupta V. |
2009 |
2737 |
Czasopismo
J Pharm Pharmacol 1996 ; 48, 1: 22-26. |
Chemical stability of artesunate injection and proposal for its administration by intravenous infusion.
Batty KT, Ilett KF, Timothy Davis ME. |
1996 |
3534 |
Czasopismo
Am J Health-Syst Pharm 2013 ; 70:2137-2142 |
Chemical stability of azacitidine suspensions for injection after cold-chain reconstitution of powder and storage
Legeron R, Xuereb F, Djabarouti S, Saux M.C, Breilh D. |
2013 |
3418 |
Czasopismo
Int J Pharm Bio Sci 2013 ; 3, 1: 449-458. |
Chemical stability of bortezomib solutions in original manufacturer vial at room temperature and in syringe at 4°C.
Berruezo garcia J, Espinosa Bosch M, Sanchez Rojas F, Bosch Ojeda C |
2013 |
3349 |
Czasopismo
Int J Pharm Bio Sci 2012 ; 2, 3: 344-350. |
Chemical stability of bortezomib solutions in original manufacturer vials.
Bosch-Ojeda C, Sanchez-Rojas M.F, Espinosa-Bosch M. |
2012 |
3180 |
Czasopismo
Int J Pharm Compound 2011 ; 15, 1: 78-80. |
Chemical stability of brompheniramine maleate in an oral liquid dosage form.
Gupta VD, Gupta VS. |
2011 |
3086 |
Czasopismo
Anaesthesia 2000 ; 55, 9: 853-858. |
Chemical stability of bupivacaine, lidocaine and epinephrine in pH-adjusted solutions.
Robinson, J, Fernando, R, Sun Wai, W.Y., Reynolds, F. |
2000 |
1814 |
Czasopismo
Int J Pharm Compound 2003 ; 7, 2: 152-154. |
Chemical stability of cefazolin sodium after reconstituting in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Gupta VD. |
2003 |
4244 |
Plakat
2019 |
Chemical Stability of Cloxacillin in Sterile Water for Injection (SWFI) Stored in Polypropylene (PP) Syringes (50 and 100 mg/mL) and Glass Vials (250 mg/mL) at 4°C and 25°C.
Perks W, Marchensano R, Law S, Iazetta J, Walker SE. |
2019 |
1229 |
Czasopismo
Br J Pharm Pract 1990 ; 12: 53-54, 60. |
Chemical stability of cytarabine and vinblastine injections.
Weir PJ, Ireland DS. |
1990 |
1372 |
Czasopismo
Int J Pharm Compound 2007 ; 11, 1: 79-81. |
Chemical Stability of Desonide in Ear Drops.
Gupta,VD. |
2007 |
1701 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 395-397. |
Chemical stability of dexamethasone sodium phosphate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes.
Gupta VD. |
2002 |
1806 |
Czasopismo
Can J Hosp Pharm 2002 ; 55, 5: 307-312. |
Chemical stability of dimenhydrinate in minibags and polypropylene syringes.
Donnely RF. |
2002 |
1277 |
Czasopismo
Can J Hosp Pharm 1999 ; 52: 150-155. |
Chemical stability of diphenhydramine hydrochloride in minibags and polypropylene syringes.
Donnelly RF. |
1999 |
4778 |
Czasopismo
Int J Pharm Compound 2023 ; 27, 4: 347-351. |
Chemical stability of epinephrine 10 µg/mL doluted in 0.9% sodium chloride and stored in polypropylene syringes at 4°C and 25°C.
Hook R, Neault A, Scharer D, Law S, Walker S.E, Ma N.H, Riss V. |
2023 |
4393 |
Plakat
Sunnybrook Health Sciences Centre 2020 |
Chemical Stability of Epinephrine Diluted in 0.9% Sodium Chloride and Stored in Polypropylene (PP) Syringes at 4°C and 25°C.
Hook R, Riss V, Neault A, Ma N, Law S, Walker S.E. |
2020 |
2886 |
Czasopismo
Int J Pharm Compound 2009 ; 13, 3: 250-253. |
Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A methods of compounding.
Garg S, Svirskis D, Al-Kabba M, Farhan S, Komeshi M, Lee J, Liu Q, Naidoo S. |
2009 |
4418 |
Czasopismo
J Pediatr Pharmacol Ther 2004 ; 9, 4: 254-258. |
Chemical Stability of Extemporaneously Prepared Lorazepam Suspension at Two Temperatures.
Ellaria Lee W-M, Lugo R.A, Rusho W.J, MacKay M, Sweeley J. |
2004 |
2031 |
Czasopismo
Int J Pharm Compound 2005 ; 9: 482-483. |
Chemical stability of fentanyl in polypropylene syringes and polyvinylchloride bags.
Donnelly RF. |
2005 |
1680 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 468-470. |
Chemical stability of furosemide in minibags and polypropylene syringes.
Donnelly RF. |
2002 |
2367 |
Czasopismo
Int J Pharm Compound 2005 ; 9, 5: 399-401. |
Chemical stability of hydralazine hydrochloride after reconstitution in 0.9% sodium chloride injection or 5% dextrose injection for infusion.
Gupta V.D. |
2005 |
2835 |
Czasopismo
Int J Pharm Compound 2007 ; 11, 3: 259-261. |
Chemical Stability of Hydrocortisone in an Oral Liquid Dosage Form without Suspending Agents
Das Gupta V. |
2007 |
2659 |
Czasopismo
Int J Pharm Compound 2010 ; 14, 2: 160-164. |
Chemical stability of hydromorphone hydrochloride in patient-controlled analgesia injector.
Khondkar D, Chopra P, McArter JP, Rosen JA, Li SK. |
2010 |
2837 |
Czasopismo
Int J Pharm Compound 2005 ; 9, 2: 165-166. |
Chemical Stability of Isoniazid in an Oral Liquid Dosage Form
Das Gupta V, Sood A. |
2005 |
1750 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 463-465. |
Chemical stability of meperidine hydrochloride in polypropylene syringes.
Donelly RF, Bushfield TL. |
1998 |
2843 |
Czasopismo
Int J Pharm Compound 2004 ; 8, 6: 489-491. |
Chemical Stability of Methadone Concentrate and Powder Diluted in Orange-Flavored Drink
Donnelly R. |
2004 |
1627 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 148-150. |
Chemical stability of methylprednisolone sodium succinate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes.
Das Gupta V. |
2001 |
1957 |
Czasopismo
Int J Pharm Compound 2005 ; 9, 1: 72-74. |
Chemical stability of metoclopramide hydrochloride injection diluted with 0.9% sodium chloride injection in polypropylene syringes at room temperature.
Gupta VD. |
2005 |
2376 |
Czasopismo
J Sep Sci 2007 ; 30, 12: 1233-1238. |
Chemical stability of midazolam injection by high performance liquid chromatography.
de Diego M, Godoy G, Mennikent S. |
2007 |
3998 |
Czasopismo
Int J Pharm Compound 2017 ; 21:4 :347-351 |
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia.
Robert J, Sorrieul J, Rossignol E, Beaussart H, Kieffer H, Folliard C, Dupoiron D, Devys C. |
2017 |
154 |
Czasopismo
Pharm Res 1990 ; 7: 452-460. |
Chemical stability of pentostatin (NSC-218321), a cytotoxic and immunosuppressant agent.
Al-Razzak LA, Benedetti AE, Waugh WN, Stella VJ. |
1990 |
3278 |
Czasopismo
Int J Pharm Compound 2012 ; 16, 1: 80-81. |
Chemical Stability of Pentoxifylline in a Topical Cream.
Gupta Vishnu D |
2012 |
2849 |
Czasopismo
Int J Pharm Compound 2005 ; 9, 6: 484-486. |
Chemical Stability of Perphenazine in Oral Liquid Dosage Forms
Das Gupta V. |
2005 |
1631 |
Czasopismo
Int J Pharm Compound 2008 ; 12, 4: 372-374. |
Chemical stability of perphenazine in two commercially available vehicles for oral liquid dosage forms
Gupta VD. |
2008 |
1891 |
Czasopismo
Int J Pharm Compound 2004 ; 8, 2: 153-155. |
Chemical stability of phenylephrine hydrochloride after reconstitution in 0.9% sodium chloride injection for infusion.
Gupta VD. |
2004 |
2876 |
Czasopismo
Int J Pharm Compound 2009 ; 13, 5: 438-439. |
Chemical Stability of Scopolamine Hydrobromide Nasal Solution.
Das Gupta V. |
2009 |
684 |
Czasopismo
Ann Pharmacotherapy 1990 ; 24: 1056-1058. |
Chemical stability of suramin in commonly used infusion fluids.
Beijnen JH, Van Gijn R, Horenblas S, Underberg WJM. |
1990 |
3835 |
Czasopismo
Current Ther Res 2015 ; 77: 99-104. |
Chemical Stability of Telavancin in Elastomeric Pumps.
Sand P, Aladeen T, Kirkegaard P, LaChance D, Slover C. |
2015 |
1933 |
Czasopismo
Int J Pharm Compound 2004 ; 8, 5: 404-406. |
Chemical stability of terbutaline sulfate injection after diluting with 0.9% sodium chloride injection when stored at room temperature in polyvinyl chloride bags.
Gupta VD. |
2004 |
1827 |
Czasopismo
J Parenter Sci Technol 1990 ; 44: 332-335. |
Chemical stability of the antitumor mitomycin C in solutions for intravesical instillation.
Beijnen JH, Van Gijn R, Underberg WJM. |
1990 |
381 |
Czasopismo
J Parenter Sci Technol 1993 ; 47: 166-171. |
Chemical stability of the cardioprotective agent ICRF-187 in infusion fluids.
Beijnen JH, Van Gijn R. |
1993 |
527 |
Czasopismo
J Clin Pharm Ther 1987 ; 12: 339-342. |
Chemical stability of thiopental sodium injection in disposable plastic syringes.
Das Gupta V, Neal Gardner S, Jolowsky CM, Newcomer DR, Stewart KR. |
1987 |
172 |
Czasopismo
J Parenter Sci Technol 1992 ; 46: 111-116. |
Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids.
Beijnen JH, van Gijn R, Challa EE, Kaijser GP, Underberg WJM. |
1992 |
2248 |
Czasopismo
Neuromodulation 2007 ; 10, 1: 6-11. |
Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration.
Shields D, Montenegro R. |
2007 |
4412 |
Czasopismo
J Pediatr Pharmacol Ther 2014 ;19,1:25–29. |
Chiral Stability of an Extemporaneously Prepared Clopidogrel Bisulfate Oral Suspension.
Tynes C.R, Livingston B, Patel H, Arnold J.J. |
2014 |
3326 |
Czasopismo
J Pharm Pract and Res 2012 ; 42, 2: 106-110. |
Chiral stability study of oral liquid clopidrogel formulations for infants.
Mihaila B, Ellis D, Rozek T, Milne R. |
2012 |
3507 |
Laboratorium
AbbVie 2013 |
Chirocaine - Summary of Product Characteristics
|
2013 |
2199 |
Laboratorium
Mundipharma 2007 |
Chlorhydrate d'oxycodone (Oxynorm®)– Résumé des caractéristiques du produits
|
2007 |
3596 |
Laboratorium
Sanofi 2014 |
Chlorpromazine (Largactil®) - Summary of Product Characteristics
|
2014 |
3520 |
Laboratorium
Sanofi 2011 |
Cidomycin - Summary of product Chracteristics.
|
2011 |
3592 |
Laboratorium
Sandoz 2008 |
Cimetidine - Résumé des caractéristiques du produit
|
2008 |
1201 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 1919-1922. |
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.
Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. |
1981 |
1203 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 1173-1174. |
Cimetidine hydrochloride compatibility with preoperative medications.
Yuhas EM, Lofton FT, Baldinus JG, Mayron D. |
1981 |
747 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 390-392. |
Cimetidine hydrochloride compatibility. I: Chemical aspects and room temperature stability in intravenous infusion fluids.
Rosenberg HA, Dougherty JT, Mayron D, Baldinus JG. |
1980 |
268 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1850-1851. |
Ciprofloxacin and sodium phosphate not compatible during actual Y-site injection.
Benjamin BE. |
1996 |
1393 |
Czasopismo
Pharm J 1987 ; 238: 290. |
Ciprofloxacin lactate infusion.
Lyall D, Blythe J. |
1987 |
3529 |
Laboratorium
Hospira 2013 |
Ciprofloxacin – Summary of Product Characteristics
|
2013 |
1500 |
Czasopismo
Ann Pharmacotherapy 1996 ; 30: 87. |
Ciprofloxacin-ampicillin sulbactam incompatibility.
Melonakos TK. |
1996 |
3601 |
Laboratorium
Actavis 2012 |
Cisatracurium Actavis - Résumé des Caractéristiques du Produit
|
2012 |
4769 |
Czasopismo
Pharmaceutics 2023 ;15,1404 |
Cisatracurium Besylate 10 mg/mL Solution Compounded in a Hospital Pharmacy to Prevent Drug Shortages : A Stability Study Involving Four Degradation Products.
Roche M, Danel C, Simon N, Kouach M, Bouchfaa M, Berneron C, Odou P, Lannoy D. |
2023 |
3578 |
Laboratorium
Accord Healthcare 2011 |
Cisplatin - Summary of Product Characteristics
|
2011 |
4084 |
Laboratorium
Accord Health Care 2017 |
Cisplatine - Résumé des caractéristiques du produits
|
2017 |
3579 |
Laboratorium
Janssen Cilag 2005 |
Cladribine Janssen Cilag - Résumé des caractéristiques du produit
|
2005 |
3526 |
Laboratorium
Pharmacia 2010 |
Clindamycin (Dalacin®) - Summary of Product Characteristics
|
2010 |
2238 |
Laboratorium
Baxter 2018 |
Clinomel - Résumé des caractéristiques du produit
|
2018 |
2272 |
Laboratorium
Genzyme 2006 |
Clofarabine (Evoltra®) – Résumé des caractéristiques du produits
|
2006 |
4515 |
Czasopismo
Pharmaceutics 2020 |
Co-Administration of Drugs and Parenteral Nutrition: In Vitro Compatibility Studies of Loop Diuretics for Safer Clinical Practice.
Tomczak S, Stawny M, Jelinska A. |
2020 |
4178 |
Czasopismo
EJHP 2017 ; 25, e2 |
Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration.
Post T.E, Kamerling I, van Rossen R, Burggraaf J, Stevens J, Dijkmans A, Heijerman H, Touw D, van Velzen A, Wilms E. |
2017 |
1974 |
Czasopismo
J Pain Symptom Manage 1996 ; 12, 3: 168-171. |
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
Chandler SW, Trissel LA, Weinstein SM |
1996 |
1978 |
Czasopismo
Clin Ther 1992 ; 14, 2: 192-195. |
Comparative sorption of clomipramine, viloxazine and maprotiline hydrochlorides in polyvinylchloride bags and glass vials.
Airaudo C, Bianchi C, Verdier M, Gayte-Sorbier A. |
1992 |
4317 |
Czasopismo
J Pharm Technol 2019 ;35,3:105-109 |
Comparative Stability of Oral Vitamin K Liquids Stored in Refrigerated Amber Plastic Syringes.
Lawson S, Lewis P, Peacock G, Brown S. |
2019 |
4140 |
Czasopismo
Int J Pharm Compound 2018 ;22,4:340-344 |
Comparative Stability of Vitamin K1 Oral Liquids Prepared in Sterile Water for Injection and Stored in Amber Glass Bottles and Amber Plastic Syringes.
Huffman J, Brown S, Lewis P, Lawson S, Ogle A, Peacock G. |
2018 |
2042 |
Czasopismo
Antimicrob Agents Chemother 2002 ; 46: 2327-2332. |
Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).
Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM. |
2002 |
4279 |
Czasopismo
Bio Drugs 2019 ; 33: 193–205. |
Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J, Sanchez-Martin R, Pérez-Robles R, Salmeron-Garcia A, Casares S, Cabeza J, Cuadros-Rodriguez L, Navas N. |
2019 |
1651 |
Czasopismo
J Clin Pharm Ther 2002 ; 27: 205-209. |
Comparison of ceftazidime degradation in glass bottles and plastic bags under various conditions.
Ars?ne M, Favetta P, Favier B, Bureau J. |
2002 |
1246 |
Czasopismo
Pharm Weekbl [Sci] 1990 ; 12: 188-189. |
Comparison of clonazepam sorption to polyvinyl chloride-coated and polyethylene-coated tubings.
Hooymans PM, Janknegt R, Lohman JJHM. |
1990 |
4642 |
Plakat
SEFH Congress (Virtual) October 2021 2021 |
Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia.
Larossa garcia M, Jimenez-Lozano I, Boix-Montanés A, Mallandrich Miret M, Clemente Bautista M, cabanas Poy M.J., Gorgas Torner |
2021 |
3464 |
Czasopismo
Enferm Clin 2011 21:25-29. |
Compatibilidad física de la amiodarona en perfusión continua
Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. |
2011 |
3466 |
Czasopismo
Enferm Intensiva 2011 ;22:78-82. |
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos
B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. |
2011 |
3212 |
Czasopismo
Enferm Intensiva 2011 ;22:78-82. |
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos.
Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. |
2011 |
3134 |
Czasopismo
Enferm Intensiva 2010 ; 21: 96-103. |
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.
Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. |
2010 |
3465 |
Czasopismo
Enferm Intensiva 2010 ;21:96-103. |
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.
E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. |
2010 |
4332 |
Plakat
JFSPH 2019 2019 |
Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI).
Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI) |
2019 |
2109 |
Czasopismo
Pharmactuel 2006 ; 39: 71-75. |
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pelletier E, Forest JM, Hildgen P. |
2006 |
3766 |
Czasopismo
Pharmactuel 2014 ; 47, 3 : 161-165. |
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Forrest J.M, Hildgen P. |
2014 |
3964 |
Czasopismo
Pharmactuel 2017 ; 50,1 : 27-33. |
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. |
2017 |
3176 |
Plakat
16èmes JFSPH, Sion, 18-19 novembre 2010 |
Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté.
Humbert Delaloye V, Berger M, Voirol P, Pannatier A. |
2010 |
2879 |
Plakat
GSASA Congress - Lucerne - Switzerland 2008 |
Compatibilité entre amiodarone, catecholamines et/ou nitroprussiate de sodium, administré en continu par voie veineuse aux soins intensifs adultes.
Imesch G., Humbert-Delaloye V., Berger M., Pannatier A. |
2008 |
1909 |
Czasopismo
J Pharm Clin 2000 ; 19: 248-251. |
Compatibilité et stabilité du mélange bupivacaïne-sufentanil en poche.
Farhang-Asnefi S, Barre J, Callaert S, Boutros A, Causse R, Thebault A. |
2000 |
3767 |
Czasopismo
Pharmactuel 2014 ; 47, 3 : 167-172. |
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Legris M.E, Lavoie A, Forrest J.M, Hildgen P. |
2014 |
3824 |
Czasopismo
Pharmactuel 2023 2023;56,3:91-98 |
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Boudi S, Roy H, Forest JM, Leclair G. |
2023 |
4742 |
Czasopismo
Pharmactuel 2022 ; 55, 4: 247-255. |
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Macoviciuc M, Nguyen C, Forest J-M, Leclair G. |
2022 |
3823 |
Czasopismo
Pharmactuel 2015 ; 48, 3 : 146-152. |
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. |
2015 |
4389 |
Czasopismo
Pharmactuel 2019 ;52,4:206-213 |
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. |
2019 |
3985 |
Plakat
Hopipharm Congress 2017 - Nancy 2017 |
Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro.
Manai M., Soussi M.A., Lazreg O., Drira C., Ben Tekaya S. et Razgallah Khrouf M. |
2017 |
3216 |
Czasopismo
Pharmactuel 2011 ; 44, 1 : 14-18 |
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. |
2011 |
4354 |
Plakat
GERPAC Congress 2019 2019 |
Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables.
Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. |
2019 |
4654 |
Plakat
Communication personnelle 2021 |
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. |
2021 |
3177 |
Plakat
16èmes JFSPH, Sion, 18-19 novembre 2010 2010 |
Compatibilités physico-chimique entre catécholamines, amiodarone, et/ou nitroprussiate de sodium intraveineux.
Humbert-Delaloye V, Berger M, Pannatier A. |
2010 |
36 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. |
1995 |
311 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 167-169. |
Compatibility and activity of enoxaparin sodium in 0.9% sodium chloride injection for 48 hours.
Newborn AL, Kessler JM, Joyner KA. |
1996 |
3498 |
Czasopismo
Ann Pharmacotherapy 2008 ; 42, 10: 1416-1424. |
Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions.
Akapo S, Gupta J, martinez E, Mccrea C, Ye L, Roach M |
2008 |
2787 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62, 8: 828-833. |
Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium.
Lee TY, Chen CM, Lee CN, Chaing YC. |
2005 |
310 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 510-514. |
Compatibility and pH variability of four injectable phenytoin sodium products.
Markowsky SJ, Kohls PR, Ehresman D, Leppik I. |
1991 |
1932 |
Czasopismo
Int J Pharm Compound 2004 ; 8,5: 398-403. |
Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate.
Trissel LA, Zhang Y. |
2004 |
284 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2560-2564. |
Compatibility and stability of aztreonam and vancomycin hydrochloride.
Trissel LA, Xu QA, Martinez JF. |
1995 |
3159 |
Czasopismo
Acta Anaesthesiol Taiwan 2010 ; 48, 3 : 117-121. |
Compatibility and stability of binary mixtures of ketorolac tromethamine and tramadol hydrochloride injection concentrate and diluted infusion solution.
Lin, T.-F., Lin, F.-S., Chou, W.-H., Yeh, Y.-C., Lin, C.-P., Fan, S.-Z., Sun, W.-Z. |
2010 |
695 |
Czasopismo
Drug Intell Clin Pharm 1988 ; 22: 873-875. |
Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions.
Zbrozek AS, Marble DA, Bosso JA. |
1988 |
3125 |
Czasopismo
Int J Pharm Compound 2010 ; 14, 4: 346-349. |
Compatibility and Stability of Cefotaxine, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin.
Baker D S, Waldrop Bruce, Arnold John. |
2010 |
1943 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 1924-1927. |
Compatibility and stability of ceftazidime sodium and tenoxicam in 5% dextrose injection.
Wang DP, Chiou AHJ, Lee DKT. |
2004 |
639 |
Czasopismo
Drug Intell Clin Pharm 1987 ; 21: 806-810. |
Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes.
Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ. |
1987 |
566 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 91-94. |
Compatibility and stability of clindamycin phosphate with intravenous fluids.
Porter WR, Johnson CA, Cohon MS, Gillespie W. |
1983 |
2022 |
Czasopismo
J Pain Symptom Manage 2005 ; 30: 80-86. |
Compatibility and stability of dexamethasone sodium phosphate and ketamine hydrochloride subcutaneous infusions in polypropylene syringes.
Watson DG, Lin M, Morton A, Cable CG, McArthur DA. |
2005 |
4431 |
Czasopismo
Medicine 2018 ; 97:50(e13698) |
Compatibility and stability of dezocine and tropisetron in 0.9% sodium chloride injection for patient-controlled analgesia administration.
Chen P, Chen F, Zhou B-H. |
2018 |
731 |
Czasopismo
Am J Hosp Pharm 1978 ; 35: 669-672. |
Compatibility and stability of diazepam injection following dilution with intravenous fluids.
Morris ME. |
1978 |
1058 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 1690-1691. |
Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.
Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. |
1983 |
1405 |
Czasopismo
J Clin Pharm Ther 1998 ; 23: 67-72. |
Compatibility and stability of fentanyl admixtures in polypropylene syringes.
Peterson GM, Miller KA, Galloway JG, Dunne PF. |
1998 |
2205 |
Czasopismo
Arzneimittel Forschung 2006 ; 56, 10: 714-720. |
Compatibility and stability of furosemide and dexamethasone combined in infusion solutions.
Negro S, Rendon AL, Azuara ML, S?nchez Y, Fern?ndez-Carballido A, Barcia E. |
2006 |
29 |
Czasopismo
J Pharm Sci 1995 ; 84: 267-268. |
Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions.
Pinguet F, Rouanet P, Martel P, Fabbro M, Salabert D, Astre C. |
1995 |
9 |
Czasopismo
Can J Hosp Pharm 1992 ; 45: 187-192. |
Compatibility and stability of hyaluronidase and hydromorphone.
Walker SE, Lau DWC. |
1992 |
1194 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 1007-1009. |
Compatibility and stability of labetolol hydrochloride in commonly used intravenous solutions.
Yuen PHC, Taddei CR, Wyka BE, Chaudry IA. |
1983 |
1658 |
Czasopismo
J Am Pharm Assoc 2000 ; 40: 520-524. |
Compatibility and stability of linezolid injection admixed with aztreonam or piperacillin sodium.
Zhang Y, Xu QA, Trissel LA, Willimas KY. |
2000 |
1659 |
Czasopismo
J Am Pharm Assoc 2000 ; 40: 509-514. |
Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics.
Xu QA, Trissel LA, Williams KY. |
2000 |
1668 |
Czasopismo
Ann Pharmacotherapy 2000 ; 34: 996-1001. |
Compatibility and stability of linezolid injection admixed with three quinolone antibiotics.
Zhang Y, Xu QA, Trissel LA, Williams KY. |
2000 |
2353 |
Czasopismo
Int J Pharm Compound 2000 ; 4, 6: 476-479. |
Compatibility and stability of linezolid injection admixted with gentamicin sulfate and tobramycin sulfate.
Xu Q.A, Trissel L.A, Zhang Y, Williams K.Y. |
2000 |
4034 |
Czasopismo
Afr J Pharm Pharmacol 2012 ;27,6:2055-2060 |
Compatibility and stability of lornoxicam with morphine, tramadol or fentanyl in infusion solutions.
Chen F-C, Fang B-X, Li P, Zheng F, Shi X-Y. |
2012 |
1866 |
Czasopismo
Int J Pharm 1998 ; 174: 157-177. |
Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone.
Vermeire A, Remon JP. |
1998 |
3434 |
Czasopismo
Can J Hosp Pharm 2013 ; 66, 3 : 167-170. |
Compatibility and Stability of Morphine Sulphate and Naloxone Hydrochloride in 0.9% Sodium Chloride for Injection.
Kistner C, Ensom M.H.H, Decarie D, Lauder G, Carr R.R. |
2013 |
4310 |
Czasopismo
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16. |
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. |
2017 |
6 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2138-2142. |
Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C.
Trissel LA, Xu QA, Martinez JF, Fox JL. |
1994 |
25 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 1410-1414. |
Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions.
McGuire TR, Narducci WA, Fox JL. |
1993 |
872 |
Czasopismo
Ann Pharmacotherapy 1997 ; 31: 1465-1470. |
Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions.
Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F. |
1997 |
1286 |
Czasopismo
Ann Pharmacotherapy 1998 ; 32: 1013-1016. |
Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion solutions.
Trissel LA, Xu QA, Gilbert DL. |
1998 |
2312 |
Czasopismo
Int J Pharm Compound 2009 ; 13, 1: 78-80. |
Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration.
Trissel L.A, Trusley C, Kupiec T.C, Ben M. |
2009 |
2227 |
Czasopismo
Int J Pharm Compound 2008 ; 12, 2: 156-160. |
Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration.
Trusley C, Ben M, Kupiec TC, Trissel LA. |
2008 |
2228 |
Czasopismo
Int J Pharm Compound 2008 ; 12,2: 170-173. |
Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration.
Kupiec T, Ben M, Trusley C, Trissel LA. |
2008 |
2281 |
Czasopismo
Int J Pharm Compound 2008 ; 12, 5: 460-462. |
Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration.
Ben M, Kupiec T, Trusley C, Trisel LA. |
2008 |
3075 |
Czasopismo
EJHP Science 2009 ; 15, 4: 78-82. |
Compatibility and stability of parenteral analgesic admixtures for multimodal analgesia
Balayssac D, Badaroux L, Rodier C, Sautou-Miranda V, Bazin JE, Chopineau J. |
2009 |
3366 |
Czasopismo
J Pharm Sci 2012 ; DOI 10.1002 / jps.23403 |
Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration.
Kwong Glover Z.W, Gennaro L, Yadav S, Demeule B, Wong P.Y, Sreedhara A. |
2012 |
925 |
Czasopismo
Can J Hosp Pharm 1998 ; 51: 55-57. |
Compatibility and stability of propafenone hydrochloride with five critical-care medications.
Dupuis LL, Trope A, Giesbrecht E, Wong B. |
1998 |
934 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 318-321. |
Compatibility and stability of ranitidine hydrochloride with six cephalosporins during simulated Y-site administration.
Inagaki K, Kambara M, Mizuno M, Okuda J, Gill MA, Nishida M. |
1998 |
3927 |
Czasopismo
Int J Pharm Compound 2017 ; 21, 1 : 66-75. |
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate.
Wu G,Yeung S,Chen F. |
2017 |
3928 |
Czasopismo
Int J Pharm Compound 2017 ; 21, 1: 76-82. |
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride.
Wu G, Yeung S, Chen F. |
2017 |
3327 |
Czasopismo
Am J Health-Syst Pharm 2012 ; 69:1405-1409 |
Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions.
LaPlante K.L, Woodmansee S, Mermel L.A. |
2012 |
4693 |
Czasopismo
Drug Design Dev Ther 2022 ;16:1433-1440. |
Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection.
Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L. |
2022 |
3132 |
Czasopismo
J Palliat Med 2010 ; 13, 3: 273-277. |
Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine.
Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. |
2010 |
2211 |
Czasopismo
J Clin Pharm Ther 2007 ; 32: 441-444. |
Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients.
Negro S, Salama A, S?nchez Y, AzuaraM.L, Barcia B. |
2007 |
1671 |
Czasopismo
Int J Pharm 1996 ; 139: 243-247. |
Compatibility and stability of vancomycin hydrochloride with PVC infusion material in various conditions using stability-indicating high-performance liquid chromatographic assay.
Khalfi F, Dine T, Gressier B, Luyckx M, Brunet C, Ballester L, Goudaliez F, Cazin M, Cazin JC. |
1996 |
4061 |
Czasopismo
Int J Pharm Compound 2018 ; 22,1 :86-94 |
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous granisetron hydrochloride.
Wu George, Powers Dan, Yeung S, Chen F, Neelon K. |
2018 |
4062 |
Czasopismo
Int J Pharm Compound 2018 ;22,1:76-85 |
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection.
Wu George, Powers Dan, Yeung S, Chen F, Neelon K. |
2018 |
1033 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 985-989. |
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection.
Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK. |
1999 |
1606 |
Czasopismo
Am J Health-Syst Pharm 2001 ; 58: 594-598. |
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection.
Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK. |
2001 |
1325 |
Czasopismo
JPEN 1982 ; 6: 163-165. |
Compatibility of 5-fluorouracil and total nutrition solutions.
Hardin TC, Clibon U, Page CP, Cruz AB. |
1982 |
4435 |
Czasopismo
Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27. |
Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection.
Hanifah S, Nugroho B.H, Chabib L. |
2020 |
307 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Trissel LA, Martinez JF. |
1994 |
3 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Trissel LA, Martinez JF. |
1995 |
390 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1482-1485. |
Compatibility of aminophylline and methylprednisolone sodium succinate intravenous admixtures.
Johnson CE, Cohen IA, Craft DA, Lizer MH. |
1986 |
364 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 97-100. |
Compatibility of aminophylline and verapamil in intravenous admixtures.
Johnson CE, Lloyd CW, Mesaros JL, Rubley GJ. |
1989 |
1259 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 900-901. |
Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5% dextrose injection.
Jhunjhunwala VP, Bhalla HL. |
1981 |
1172 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 377-378. |
Compatibility of amphotericin B with certain large-volume parenterals.
Jurgens RW, DeLuca PP, Papadimitriou D. |
1981 |
2900 |
Czasopismo
EJHP 2009 ; 15, 5: 32-38. |
Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration.
Hines S, Pleasance S. |
2009 |
2125 |
Czasopismo
Hospital Pharmacist 2003 ; 10: 354-361. |
Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration.
Gardiner PR. |
2003 |
1982 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 834-837. |
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Trissel LA, Ogundele AB. |
2005 |
1055 |
Czasopismo
Can J Hosp Pharm 1983 ; 36: 43-52. |
Compatibility of antibiotics and other drugs in total parenteral nutrition solutions.
Faragos S. |
1983 |
431 |
Czasopismo
Am J Hosp Pharm 1975 ; 33: 1010-1013. |
Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures.
McRae MP, King JC. |
1975 |
3019 |
Czasopismo
Curr Med Res Opin 2007 ; 23: 2477-2483. |
Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs.
Bonasia P, Cook C, Cheng Y et al. |
2007 |
3764 |
Czasopismo
Am J Health-Syst Pharm 2014 2014; 71: 1831-1832. |
Compatibility of argatroban injection with select antiarrhythmic drugs
Jakimczuk P.J, Churchwell M.D, Howard M.S, Mauro V.F, Alexander K.S, Boddu S.H.S. |
2014 |
2004 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 1381-1384. |
Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
Patel K, Hursting MJ. |
2005 |
1963 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 2415-2418. |
Compatibility of argatroban with selected cardiovascular agents.
Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. |
2004 |
1260 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 871-875. |
Compatibility of azathioprime sodium with intravenous fluids.
Johnson CA, Porter WA. |
1981 |
4456 |
Czasopismo
Scientific reports 2020 10:1788 |
Compatibility of aztreonam in four commercial peritoneal dialysis fluids.
Tobudic S, Prager I, Kussmann M, Obermüller M, Ursli M, Zeitlinger M, Wiesholzer M, Burgmann H, Poeppl W, Reznicek G. |
2020 |
99 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Trissel LA, Martinez JF. |
1995 |
4177 |
Czasopismo
Int J Pharm Compound 2018 ;22,6:516-526 |
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide,
Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. |
2018 |
2774 |
Czasopismo
Ann Pharmacotherapy 2004 ; 38: 967-972. |
Compatibility of Budesonide Inhalation Suspension with Four Nebulizing Solutions.
McKenzie J.E, Mario Cruz-Rivera M. |
2004 |
529 |
Czasopismo
Pharm Weekbl [Sci] 1991 ; 13: 254-256. |
Compatibility of bupivacaine and iohexol in two mixtures for paediatric regional anaesthesia.
Van Asten P, Glerum JH, Spaanderman ER, Van Niekerk J, Van Dijk A. |
1991 |
220 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 61-64. |
Compatibility of bupivacaine hydrochloride and morphine sulfate.
Johnson CE, Christen C, Perez MM, Ma M. |
1997 |
221 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2149. |
Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate.
Neels JT. |
1992 |
3378 |
Czasopismo
Am J Health-Syst Pharm 2013 ; 70:515-519. |
Compatibility of butorphanol and droperidol in 0.9% sodium chloride injection
Chen F-C, Fang B-X, Li P, Yang J-G, Zhou B-H. |
2013 |
3805 |
Czasopismo
Am J Health-Syst Pharm 2015 ; 72:1374-1378. |
Compatibility of butorphanol with granisetron in 0.9% sodium chloride injection packaged in glass bottles or polyolefin bags.
Chen F.C, Xiong H, Liu H.M, Fang B.X, Li P. |
2015 |
3910 |
Czasopismo
EJHP 2016 ; 23: 352-358. |
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.
Polonini H.C, Silva S .L, de Almeida T.R, Brand?o M.A, Ferreira A.O. |
2016 |
4732 |
Czasopismo
Am J Health-Syst Pharm 2023 80, 3;164–170 |
Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration.
Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E. |
2023 |
2247 |
Czasopismo
Int J Pharm Compound 2008 ; 12, 3: 276-278. |
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Chan P, Heatherly K, Kupiec T.C, Trissel L.A. |
2008 |
3542 |
Czasopismo
Am J Health-Syst Pharm 2015 ; 72:390-395 |
Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion
Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E. |
2015 |
93 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2185-2188. |
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Hutchings SR, Rusho WJ, Tyler LS. |
1996 |
79 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 111-113. |
Compatibility of cefoperazone sodium and cimetidine hydrochloride in 5% dextrose injection.
Lee DKT, Wang DP, Lee A. |
1991 |
87 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 108-110. |
Compatibility of cefoperazone sodium and furosemide in 5% dextrose injection.
Lee DKT, Lee A, Wang DP. |
1991 |
1670 |
Czasopismo
Pharmazie 1998 ; 53: 112-116. |
Compatibility of cefpirome and cephalotin with PVC bags during simulated infusion and storage.
Khalfi F, Dine T, Gressier B, Luyckx M, Brunet C, Ballester L, Goudaliez F, Kablan J, Cazin M, Cazin JC. |
1998 |
3249 |
Czasopismo
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. |
2011 |
900 |
Czasopismo
Ann Pharmacotherapy 1992 ; 26: 1221-1226. |
Compatibility of ceftazidime and aminophylline admixtures for different methods of intravenous infusion.
Pleasants RA, Vaughan LM, Williams DM, Fox JL. |
1992 |
3984 |
Czasopismo
Hosp Pharm 2017 ,52;3 : 221-228 |
Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.
Meyer K, Santarossa M, Danziger L.H, Wenzler E. |
2017 |
2269 |
Czasopismo
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. |
2008 |
3846 |
Czasopismo
Pharmazie 2016 71: 185?191. |
Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions.
Polonini HC, Silva SL, Cunha CN, Brand?o MAF, Ferreira AO. |
2016 |
434 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2166-2171. |
Compatibility of ciprofloxacin injection with selected drugs and solutions.
Goodwin SD, Nix DE, Heyd A, Wilton JH. |
1991 |
14 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1193-1195. |
Compatibility of ciprofloxacin lactate with sodium bicarbonate during simulated Y-site administration.
Gilbert DL, Trissel LA, Martinez JF. |
1997 |
4460 |
Czasopismo
Scientific reports 2019 9:6512 |
Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions.
Kussmann M, Ferth A, Obermüller M, Pichler P, Zeitlinger M, Wiesholzer , Burgmann H, Poeppl W, Reznicek G. |
2019 |
299 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Trissel LA, Martinez JF, Gilbert DL. |
1997 |
413 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1373-1377. |
Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection.
Stewart CF, Fleming RA. |
1990 |
565 |
Czasopismo
Drug Intell Clin Pharm 1986 ; 20: 960-963. |
Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions.
Marble DA, Bosso JA, Townsend RJ. |
1986 |
644 |
Czasopismo
Drug Intell Clin Pharm 1988 ; 22: 54-57. |
Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles.
Marble DA, Bosso JA, Townsend RJ. |
1988 |
421 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 839-843. |
Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures.
Foley PT, Bosso JA, Bair JN, Townsend RJ. |
1985 |
3012 |
Czasopismo
Hosp Pharm 2015 ; 50, 3: 214-220. |
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Sullivan T, Forrest J.M, Leclair G. |
2015 |
549 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 121-122. |
Compatibility of common respiratory therapy drug combinations.
Owsley HD, Rusho WJ. |
1997 |
132 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 181-184. |
Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
Najari Z, Rusho WJ. |
1997 |
3715 |
Czasopismo
Am J Health-Syst Pharm 2014 ; 71:1534-1535 |
Compatibility of conivaptan injection with select cardiovascular medications.
Mauro V.F, Howard M.S, Boddu S.H.S, Churchwell M.D. |
2014 |
227 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2292. |
Compatibility of cyclizine lactate and haloperidol lactate.
Fawcett JP, Woods DJ, Munasiri B, Becket G. |
1994 |
3981 |
Czasopismo
EJHP 2017 ;24:162?166 |
Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study
He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. |
2017 |
389 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2161-2166. |
Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride.
Walker SE, DeAngelis C, Iazzetta J, Eppel JG. |
1991 |
712 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 496-500. |
Compatibility of diazepam with intravenous fluid containers and administration sets.
Parker WA, MacCara ME. |
1980 |
2087 |
Czasopismo
Pharmactuel 2004 ; 37: 17-20. |
Compatibility of dimenhydrinate injectable by Y administration.
Ferreira E, Forest JM, Hildgen P. |
2004 |
250 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 566-569. |
Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials.
Mazzo DJ, Nguyen-Huu JJ, Pagniez S, Denis P. |
1997 |
1754 |
Czasopismo
Int J Pharm Compound 1999 ; 3: 241-244. |
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Trissel LA, Gilbert DL, Wolkin AC. |
1999 |
2262 |
Czasopismo
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. |
2008 |
251 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Trissel LA, Gilbert DL, Martinez JF. |
1997 |
1897 |
Czasopismo
EJHP 2001 ; 7, 3: 108-115. |
Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage.
Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. |
2001 |
789 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 604-606. |
Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system.
Garner SS, Wiest DB. |
1990 |
963 |
Czasopismo
J Clin Pharm Ther 1990 ; 15: 371-376. |
Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside.
Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. |
1990 |
3708 |
Plakat
ECOP 2 Krakow 2014 |
Compatibility of epirubicin-loaded DC Beads with different contrast media.
Sarakbi I, Thiesen J, Krämer I. |
2014 |
3918 |
Czasopismo
J Oncol Pharm Practice 2016 ; 22: 749-756. |
Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media.
Sarakbi I, Krämer I. |
2016 |
8 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 368-371. |
Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration.
Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER. |
1988 |
4598 |
Czasopismo
Int J Pharm Compound 2021 ;78,4:336-349 |
Compatibility of Estradiol, Estriol; Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base.
Polonini H, Dijkers E, Ferreira A, Zander C, Taylor S. |
2021 |
319 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 997-999. |
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Hadzija BW, Lubarsky DA. |
1995 |
1410 |
Czasopismo
J Am Pharm Assoc 1999 ; 39: 141-145. |
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
Trissel LA, Martinez JF, Simmons M. |
1999 |
1722 |
Czasopismo
EJHP 2002 ; 2: 33-40. |
Compatibility of etoposide solution with polyvinyl chloride and low density polyethylene containers and its stability in different storage conditions.
Gras C, Sautou-Miranda V, Bagel-Boithias S, Brigas F, Chopineau J. |
2002 |
1803 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. |
2003 |
1993 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 1190-1192. |
Compatibility of fentanyl citrate, ketamine hydrochloride, and droperidol in 0.9% sodium chloride injection stored in polyvinyl chloride bags.
Lee DKT, Wang DP, Harsono R, Wong CY. |
2005 |
104 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 185-189. |
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Hall PD, Yui D, Lyons S, Bosso JA. |
1997 |
244 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Trissel LA, Martinez JF. |
1994 |
4458 |
Czasopismo
Eur J Clin Microbiol Infec Dis 2017 36:2237–2242. |
Compatibility of fosfomycin with different commercial peritoneal dialysis solutions.
Kussmann M, Baumann A, Hauer S, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Poeppl W, Reznicek G. |
2017 |
367 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 116-119. |
Compatibility of furosemide with aminoglycoside admixtures.
Thompson DF, Allen LV, Desai SR, Rao PS. |
1985 |
1423 |
Czasopismo
J Am Pharm Assoc 1999 ; 39: 514-518. |
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
Trissel LA, Martinez JF, Gilbert DL. |
1999 |
4534 |
Czasopismo
Int J Pharm Compound 2021 ;25,5:422-426 |
Compatibility of Gestrinone, Nimesulide, and Piroxican in Pentravan for Transdermal and Transmucosal Application.
Polonini H, De Oliveira Ferreira A, Dijkers. |
2021 |
49 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 208. |
Compatibility of granisetron hydrochloride with selected alkaline drugs.
Trissel LA, Martinez JF. |
1995 |
182 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Trissel LA, Gilbert DL, Martinez JF. |
1997 |
1676 |
Czasopismo
Int J Pharm 1997 ; 154: 95-102. |
Compatibility of granisetron towards glass and plastics and its stability under various storage conditions.
Hourcade F, Sautou-Miranda V, Normand B, Laugier M, Picq F, Chopineau J. |
1997 |
982 |
Czasopismo
Ann Pharmacotherapy 1995 ; 29: 1168. |
Compatibility of haloperidol and diphenhydramine in a hypodermic syringes.
Ukhun IA. |
1995 |
1970 |
Czasopismo
Support Care Cancer 2003 ; 11, 2: 107-113. |
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. |
2003 |
617 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 843-844. |
Compatibility of haloperidol lactate and heparin sodium.
Solomon DA, Nasinnyk KK. |
1982 |
229 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2962-2963. |
Compatibility of haloperidol lactate with benztropine mesylate.
Jackson CW, Cunningham K. |
1994 |
341 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 1352-1355. |
Compatibility of heparin sodium and morphine sulfate.
Baker DE, Yost GS, Craig VL, Campbell RK. |
1985 |
767 |
Czasopismo
Ann Pharmacotherapy 1997 ; 31: 789-790. |
Compatibility of hydromorphone and prochlorperazine, and irritation due to subcutaneous prochlorperazine infusion.
Trinkle R. |
1997 |
216 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2963. |
Compatibility of hydromorphone hydrochloride with haloperidol lactate and ketorolac tromethamine.
Huang E, Anderson RP. |
1994 |
4558 |
Czasopismo
Milit Med 2016 ; 181, 10:1305. |
Compatibility of Hydroxyethyl Starch and Tranexamic Acid for Battlefield Co-Administration.
Studer, N.M, Yassin, A.H, Keen, D.E. |
2016 |
1910 |
Laboratorium
Baxter 2002 |
Compatibility of imiglucerase (personal communication)
|
2002 |
21 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 2803-2809. |
Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions.
Bigley FP, Forsyth RJ, Henley MW. |
1986 |
2090 |
Czasopismo
Pharmactuel 2004 ; 37: 193-196. |
Compatibility of injectable pantoprazole in Y-site administration.
Pere H, Chasse V, Forest JM, Hildgen P. |
2004 |
4521 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2020 |
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. |
2020 |
2164 |
Czasopismo
Perit Dial Int 2006 ; 26, 4: 498-502. |
Compatibility of insulin over 24 hours in standard and bicarbonate-based peritoneal dialysis solutions contained in bags made of different materials.
Voges M, Divinop-Filho JC, Faict D, Somers F, Vermeulen P. |
2006 |
4398 |
Czasopismo
J Pharm Pract and Res 2020 |
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
Smith E. K., Shergold J.A., McWhinney B.C. |
2020 |
4440 |
Czasopismo
Ann Nutr Metab 2018 ; 73: 227-233. |
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.
Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. |
2018 |
3459 |
Czasopismo
Cancer Chemother Pharmacol 2013 ; 72: 509-513. |
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Sun S, Schaller J, Placek J, Duersch B. |
2013 |
4464 |
Czasopismo
PlosOne 2018 13(1): e0190577. |
Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion.
Garcia J, Garg A, Song Y, Fotios A, Andersen C, Garg S. |
2018 |
3948 |
Czasopismo
JPEN 2012 ;30. 416?424. |
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . |
2012 |
312 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 570-571. |
Compatibility of iron dextran with neonatal parenteral nutrient solutions.
Mayhew SL, Quick MW. |
1997 |
313 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2233-2235. |
Compatibility of iron dextran with total nutrient admixtures.
Tu YH, Knox NL, Biringer JM, Eichman ML, Schweinsberg PD, Howard JR. |
1992 |
3829 |
Plakat
ASHP Midyear 2015 |
Compatibility of isavunazonium sulfate during simulated Y-site administration.
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. |
2015 |
1864 |
Czasopismo
Pain 1998 ; 75: 389-390. |
Compatibility of ketamine and morphin injections.
Lau MH, Hackman C, Morgan DJ. |
1998 |
1934 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 1438-1445. |
Compatibility of ketamine hydrochloride and fentanyl citrate in polypropylene syringes.
Ambados F, Brealey J. |
2004 |
321 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 205. |
Compatibility of ketamine hydrochloride and meperidine hydrochloride.
Ambados F. |
1997 |
469 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1097-1100. |
Compatibility of ketorolac tromethamine injection with common infusion fluids and administration sets.
Floy BJ, Royko CJ, Fleitman JS. |
1990 |
4603 |
Czasopismo
Hosp Pharm 2021 ; 56, 4: 228-234. |
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. |
2021 |
1072 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 1458-1459. |
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. |
1999 |
4176 |
Czasopismo
Am J Health-Syst Pharm 2018 ;75:1467-1477 |
Compatibility of linezolid with commercial peritoneal dialysis solutions
Poeppl W, Rainer-Harbach E, Kussmann M, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Reznicek G. |
2018 |
2466 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 1750-1753. |
Compatibility of lithium citrate syrup with 10 neuroleptic solutions
Theesen KA, Wilson JE, Newton DW, Ueda CT. |
1981 |
218 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2311. |
Compatibility of magnesium sulfate and morphine sulfate in 0.9% sodium chloride injection.
Vogt C, Ruggaber S. |
1993 |
1047 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 323-324. |
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.
Souney PF, Colucci RD, Mariani G, Campbell D. |
1984 |
298 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 320-321. |
Compatibility of mannitol and sodium bicarbonate in injectable fluids.
Matuschka PR, Smith WR, Vissing RS. |
1995 |
1415 |
Czasopismo
JPEN 1999 ; 23: 67-74. |
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. |
1999 |
4507 |
Czasopismo
Am J Health-Syst Pharm 2020 ;77,23:1980-1985 |
Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing.
Ross E, Salinas A, Petty K, Her C, Carpenter J. |
2020 |
4376 |
Czasopismo
Int J Pharm Compound 2020 ;24,1:83-85 |
Compatibility of Melphalan in Iodinated Contrast Media.
Shi Z, Abruzzo T, Wanasathop A, Li S K. |
2020 |
266 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
Compatibility of meropenem with commonly used injectable drugs.
Patel PR. |
1996 |
3922 |
Czasopismo
Perit Dial Int 2016 doi:10.3747/pdi.2016.0001 |
Compatibility of meropenem with different commercial dialysis solutions.
Wiesholzer, Winter A, Kussmann M, Zeitlinger M, Pichler P, Burgmann H, Reznicek G,Poepp l W. |
2016 |
2108 |
Czasopismo
Int J Pharm Compound 2006 ; 10: 230-232. |
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Trusley C, Kupiec TC, Trissel LA. |
2006 |
186 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2020-2022. |
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.
Swart EL, Mooren RAG, Van Loenen AC. |
1995 |
1842 |
Czasopismo
Arzneimittel Forschung 1995 ; 45: 93-98. |
Compatibility of morphin, baclofen, floxuridine and fluorouracil in an implantable infusion pump.
Sadjack A, Wintersteiger R. |
1995 |
980 |
Czasopismo
Aust J Hosp Pharm 1995 ; 25: 352. |
Compatibility of morphine and ketamine for subcutaneous infusion.
Ambados F. |
1995 |
1492 |
Czasopismo
Can J Hosp Pharm 1995 ; 48: 155-160. |
Compatibility of morphine and midazolam or haloperidol in parenteral admixtures.
LeBelle MJ, Savard C, Gagnon A. |
1995 |
1020 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 67. |
Compatibility of morphine sulfate injection and prochlorperazine injection.
Zuber DEL. |
1987 |
519 |
Czasopismo
Aust J Hosp Pharm 1991 ; 21: 316. |
Compatibility of morphine tartrate admixtures in polypropylene syringes.
Poggi GL. |
1991 |
616 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 841-843. |
Compatibility of nalbuphine hydrochloride with other preoperative medications.
Jump WG, Plaza VM, Poremba A. |
1982 |
405 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 1108-1109. |
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Nieves-Cordero AL, Luciw HM, Souney PF. |
1985 |
2550 |
Czasopismo
Aust J Hosp Pharm 1993 ; 23: 35-37. |
Compatibility of nebulizer solutions
Roberts GW, Rossi S.O.P. |
1993 |
316 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2611-2613. |
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Veltri M, Lee CKK. |
1996 |
1200 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 1737-1742. |
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. |
1981 |
1960 |
Czasopismo
J Pharm Biomed Anal 2005 ; 37: 259-264. |
Compatibility of nitroglycerin, diazepam and chlorpromazine with a new multilayer material for infusion containers.
Kambia NK, Dine T, Dupin-Spriet T, Gressier B, Luycks M, Goudaliez F, Brunet C. |
2005 |
3865 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 3 : 236-238. |
Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration.
Vicky M, Samit S, Jaymin P, Michael C T. |
2016 |
2012 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 2001-2005. |
Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers.
Bougouin C, Thelcide C, Crespin-Maillard F, Maillard C, Kinowski JM, Favier M. |
2005 |
16 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1554-1556. |
Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration.
Chung KC, Moon YSK, Chin A, Ulrich WU, Gill MA. |
1995 |
332 |
Czasopismo
Ann Pharmacotherapy 1995 ; 29: 1106-1109. |
Compatibility of ondansetron hydrochloride with meperidine hydrochloride for combined administration.
Xu QA, Trissel LA, Fox JL. |
1995 |
1725 |
Czasopismo
Can J Hosp Pharm 2001 ; 54: 112-113. |
Compatibility of oxytocin, zidovudine, and penicillin G.
Oliver C, Law S. |
2001 |
1865 |
Czasopismo
Int J Pharm 1999 ; 178: 77-82. |
Compatibility of paclitaxel in 5% glucose solution with ECOFLAC® low-density polyethylene containers - Stability under different storage conditions.
Sautou-Miranda V, Brigas F, Vanheerswinghels S, Chopineau J. |
1999 |
158 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2804-2810. |
Compatibility of paclitaxel injection vehicle with intravenous administration and extension sets.
Trissel LA, Xu QA, Kwan J, Martinez JF. |
1994 |
2016 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 1998-2000. |
Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration.
Xu QA, Trissel LA. |
2005 |
3210 |
Czasopismo
Int J Pharm Compound 2011 ; 15, 3: 259-261. |
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.
Jasti Bhaskara R, Saraf Poonam. |
2011 |
301 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. |
1997 |
4538 |
Czasopismo
Archives of Disease in Childhood 2020 ; 105: 395-397. |
Compatibility of pentoxifylline and parenteral medications.
Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. |
2020 |
81 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 672-678. |
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Trissel LA, Martinez JF. |
1994 |
1501 |
Czasopismo
Int J Pharm 1999 ; 185: 113-121. |
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. |
1999 |
391 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 1620-1624. |
Compatibility of premixed theophylline and methylprednisolone sodium succinate intravenous admixtures.
Johnson CE, Cohen IA, Michelini TJ, McMahon RE. |
1987 |
372 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 609-612. |
Compatibility of premixed theophylline and verapamil intravenous admixtures.
Johnson CE, Lloyd CW, Aviles AI, Rybarz KL. |
1988 |
1860 |
Czasopismo
Int J Pharm 1996 ; 130: 251-255. |
Compatibility of propofol diluted in 5% glucose with glass and plastics (polypropylene, molyvinylchloride) containers.
Sautou-Miranda V, Levadoux E, Groueix MT, Chopineau J. |
1996 |
300 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Trissel LA, Gilbert DL, Martinez JF. |
1997 |
1863 |
Czasopismo
Journal of clinical anesthesia 1996 ; 8: 329-336. |
Compatibility of propofol, fentanyl,and vecuronium mixtures designed for potential use in anesthesia and patient transport.
Isert PR, Lee D, Naidoo D, Carasso ML, Kennedy RA. |
1996 |
1198 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 1685-1687. |
Compatibility of propranolol hydrochloride injection with intravenous infusion fluids in plastic containers.
Cummings DS, Park MK, Howard B. |
1982 |
3913 |
Czasopismo
EJHP 2018 ;25,3:150-156. |
Compatibility of proton pump inhibitors in a preservative-free suspending vehicle.
Polonini H.C, Silva S.L, Loures S, Almy R, Balland A, Brandao M.A.F, Ferreira A.O. |
2018 |
59 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Trissel LA, Gilbert DL, Martinez JF, Kim MC. |
1997 |
1665 |
Czasopismo
J Clin Pharm Ther 2002 ; 21: 39-45. |
Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine.
Öster Svedberg K, McKenzie J, Larrivee-Elkins C. |
2002 |
295 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1048-1051. |
Compatibility of selected critical care drugs during Y-site administration.
Yamashita SK, Walker SE, Choudhury T, Iazzetta J. |
1996 |
1035 |
Czasopismo
J Parenter Sci Technol 1983 ; 37: 129-132. |
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.
Bisaillon S, Sarrazin R. |
1983 |
207 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2024-2025. |
Compatibility of tacrolimus injection with cimetidine hydrochloride injection in 0.9% sodium chloride injection.
Ku YM, Min DI, Kumar V, Noormohamed SE. |
1995 |
3827 |
Plakat
ASHP Midyear 2015 |
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
Ghazi I.M, Hamada Y, Nicolau D.P. |
2015 |
1165 |
Czasopismo
Int J Pharm 1980 ; 4: 263-265. |
Compatibility of the cephalosporin, cefamandole nafate with injections.
Bowtle WJ, Heasman MJ, Prince AP, Easthope DA. |
1980 |
249 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Trissel LA, Martinez JF. |
1996 |
1420 |
Czasopismo
J Clin Pharm Ther 1999 ; 24: 125-132. |
Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. |
1999 |
1338 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 777-778. |
Compatibility of total nutrient admixtures and secondary cardiovascular medications.
Baptista RJ, Dumas GJ, Bistrian BR, Condella F, Blackburn GL. |
1985 |
2002 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 1299-1302. |
Compatibility of tramadol hydrochloride injection with selected drugs and solutions.
Abanmy NO, Zaghloul IY, Radwan MA. |
2005 |
4407 |
Czasopismo
Am J Health-Syst Pharm 2020 ;77,8:649–657. |
Compatibility of treprostinil sodium and dopamine hydrochloride during simulated Y-site administration.
Bustin A, Ramsey Z, Hanna B, Kaushal G. |
2020 |
924 |
Czasopismo
J Pharm Pharmacol 1998 ; 50: 407-411. |
Compatibility of tropisetron with glass and plastics. Stability under different storage conditions.
Brigas F, Sautou-Miranda V, Normand B, Geneve S, Chopineau J. |
1998 |
3813 |
Czasopismo
Hosp Pharm 2015 ; 50, 8: 710-713. |
Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery.
Teibel H.M, Knoderer C.A, Nichols K.R. |
2015 |
1748 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 354-355. |
Compatibility of vancomycin hydrochloride and famotidine in 5% dextrose injection.
Wang DP, Wang MT, Wong CY, Lee DKT. |
1997 |
1228 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 380-381. |
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Allen LV, Stiles ML. |
1981 |
730 |
Czasopismo
Am J Hosp Pharm 1977 ; 34: 939-943. |
Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.
Allen LV, Saul Levinson R, Phisutsinthop D. |
1977 |
1067 |
Czasopismo
EJHP 1999 ; 5: 106-110. |
Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers.
Zeidler C, Dettmering D, Schrammel W, Spieteller M. |
1999 |
1057 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
Compatibility of verapamil hydrochloride injection with commonly used additives.
Cutie MR. |
1983 |
706 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 231. |
Compatibility of verapamil hydrochloride with other additives.
Cutie MR. |
1981 |
371 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 142-145. |
Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection.
Thompson DF, Stiles ML, Allen LV, Tu YH. |
1988 |
552 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 356-358. |
Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions.
Martinez JF, Trissel LA, Gilbert DL. |
1997 |
4319 |
Czasopismo
Hosp Pharm 2020 ; 55, 5: 332-337. |
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. |
2020 |
54 |
Czasopismo
J Pharm Clin 1995 ; 14: 26-30. |
Compatibility PVC-psychotropic drugs during an infusion.
Bureau A, Lahet JJ, D?Athis P, Vailleau JL, Cosmidis V, Martin L. |
1995 |
1713 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 311-315. |
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Trissel LA, Saenz CA. |
2002 |
1721 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 69-72. |
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Trissel LA, Williams KY, Baker MB. |
2001 |
1925 |
Czasopismo
J Am Pharm Assoc 2000 ; 40: 515-519. |
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
Trissel LA , Williams KY, Gilbert DL. |
2000 |
1662 |
Czasopismo
J Oncol Pharm Practice 2002 ; 8: 33-37. |
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
Trissel LA, Saenz CA, Ingram DS, Ogundele AB. |
2002 |
1712 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 230-233. |
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Trissel LA, Saenz CA. |
2002 |
4404 |
Plakat
JFSPH 2019 2019 |
Compatibility studies of seven commonly used drugs for parenteral administration in palliative care.
Müller U, Haller F, Wiedemeier P, Steuer C. |
2019 |
162 |
Czasopismo
Int J Pharm 1994 ; 105: 83-87. |
Compatibility study of methotrexate with PVC bags after repackaging into two types of infusion admixtures.
Benaji B, Dine T, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Gressier B, Cazin M, Cazin JC. |
1994 |
1888 |
Czasopismo
Ziekenhuisfarmacie 1986 ; 2: 45-48. |
Compatibility study of midazolam.
Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. |
1986 |
1468 |
Czasopismo
Int J Pharm 1994 ; 107: 111-119. |
Compatibility with medical plastics and stability of continuously and simultaneously infused isosorbide dinitrate and heparin.
Sautou V, Chopineau J, Gremeau I, Chevrier R, Bruneaux F. |
1994 |
4027 |
Czasopismo
Hosp Pharm 2017 ;52,10:685-690 |
Compatibility, Stability, and Efficacy of Vancomycin Combined With Gentamicin or Ethanol in Sodium Citrate as a Catheter Lock Solution.
Wei Y, WonJoon Yang J, Boddu S, Jung R, Churchwell M. |
2017 |
4023 |
Czasopismo
Hosp Pharm 2017 ; 52,7 : 478-482. |
Compounded Apixaban Suspensions for Enteral Feeding Tubes.
Carabello M, Donmez S, Nathan K, Zhao F. |
2017 |
3983 |
Czasopismo
EJHP 2016 ; 24: 157-161. |
Compounding and stability evaluation of atorvastatin extemporaneous oral suspension using tablets or pure powder.
Zaid A.N, Assali M, Zalmout S, Basheer A. |
2016 |
2988 |
Czasopismo
J Clin Pharm Ther 2007 ; 32: 489-496. |
Compounding of vitamin A, D3, E, and K3 supplements for cystic fibrosis patients: formulation and stability study.
Huyghebaert N, de Beer J, Vervaet C et al. |
2007 |
1278 |
Czasopismo
Can J Hosp Pharm 1998 ; 51: 13-19. |
Concentration and solution dependent stability of cloxacillin intravenous solutions.
Walker SE, Dufour A, Iazetta J. |
1998 |
1674 |
Czasopismo
Hosp Pharm 1998 ; 33: 1515-1522. |
Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration.
Trissel LA, Gilbert DL, Martinez JF. |
1998 |
2490 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 304-307. |
Concentration uniformity of extemporaneously prepared ranitidine suspension
Karnes HT, Harris SR, Garnett WR, March C. |
1989 |
1637 |
Czasopismo
Can J Hosp Pharm 2000 ; 53: 24-31. |
Concentration-dependant compatibility and stability of dexamethasone and midazolam.
Wong AH, Law S, Walker SE, Bowles SK. |
2000 |
1070 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 1891. |
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium.
Balthasar JP. |
1999 |
269 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 84-85. |
Concentration-dependent precipitation of sodium bicarbonate with ciprofloxacin lactate.
Trissel LA. |
1996 |
3262 |
Czasopismo
J Oncol Pharm Practice 2011 ; 17, 4: 395-399. |
Conditions causing gemcitabine crystallization.
Manners S, Galettis P, de Souza P. |
2011 |
3718 |
Laboratorium
Bayer Healthcare Corporation 2012 |
Conivaptan (Vaprisol®) - Summary of Product Characteristics
|
2012 |
2446 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1299-1301. |
Content uniformity and stability of nifedipine in extemporaneously compounded oral powders
Helin MM, Kontra KM, Naaranlahti TJ, Wallenius KJ. |
1998 |
4470 |
Czasopismo
Critical care 2005 ; 9(Suppl 1) P37 |
Continuous versus intermittent infusion of temocillin in intensive care unit patient.
Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. |
2005 |
2231 |
Czasopismo
J Antimicrob Chemother 2008 ; 61, 2: 382-388. |
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. |
2008 |
501 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 129-130. |
Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection.
Senholzi CS, Kerns MP. |
1985 |
1371 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 2436. |
Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection.
Bornstein M, Templeton RJ. |
1985 |
1302 |
Czasopismo
Drug Intell Clin Pharm 1988 ; 22: 173-174. |
Cyclosporine binding to components in medication administration sets.
Parr MD, Barton SD, Haver VM, Porter WH. |
1988 |
3580 |
Laboratorium
Accord Healthcare France 2016 |
Cytarabine Accord - Résumé des caractéristiques du produit
|
2016 |
850 |
Czasopismo
Drug Intell Clin Pharm 1982 ; 16: 765-767. |
Cytosine arabinose stability in intravenous admixtures with sodium bicarbonate and in plastic syringes.
Munson J, Kubiak EJ, Cohon MS. |
1982 |
3605 |
Laboratorium
Lipomed 2010 |
Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit
|
2010 |
3267 |
Laboratorium
Lipomed 2011 |
Dacarbazine Lipomed - Summary of Product Characteristics
Lipomed Laboratories |
2011 |
3266 |
Laboratorium
Lipomed 2011 |
Dacarbazine solutions: In Use stability of dacarbazine lipomed®
Lipomed Laboratories |
2011 |
4153 |
Laboratorium
Orphan Europe (UF) Limited 2014 |
Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics
|
2014 |
3752 |
Laboratorium
Durata Therapeutics Holding 2014 |
Dalbavancin (Dalvance®) - Summary of Product Characteristics
|
2014 |
1509 |
Laboratorium
Norgine 2014 |
Dantrolene sodium (Dantrium®) - Summary of Product Characteristics
|
2014 |
3218 |
Czasopismo
Perit Dial Int 2011 ; 31: 492?495. |
Daptomycin Compatibility in Peritoneal Dialysis Solutions
Peyro Saint Paul L, Albessard F, Gaillard C, Debruyn D, Ryckelynck J Ph, Antoine Coquerel, Lobbedez T |
2011 |
2271 |
Laboratorium
Novartis 2006 |
Daptomycine (Cubicin®) Résumé des caractéristiques du produits
|
2006 |
4190 |
Laboratorium
Janssen 2018 |
Daratumumab (Darzalex®) - Summary of Product Characteristics.
|
2018 |
4785 |
Laboratorium
Janssen-Cilag International NV 2023 |
Darzalex 1800 mg solution for injection - Summary of Product characteristics.
|
2023 |
3604 |
Laboratorium
Sanofi Aventis France 2012 |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
|
2012 |
3577 |
Laboratorium
Galen Limited |
Daunorubicine (Daunoxome®) - Résumé des caractéristiques du produit
|
|
4355 |
Laboratorium
Jazz Pharmaceuticals UK 2019 |
Daunorubicine/cytarabine liposomale (Vyxeos®) - Summary of Product Characteristics
|
2019 |
2217 |
Czasopismo
Ziekenhuisfarmacie 1997 ; 13, 1: 21-23. |
De stabiliteit van clonazepaminjectievloeistof.
Guchelaar H.J, Hartog M.E. |
1997 |
2240 |
Laboratorium
Janssen Pharmaceuticals 2019 |
Décitabine (Dacogen®) - Summary of Product caracteristics
|
2019 |
1882 |
Czasopismo
Ziekenhuisfarmacie 1993 ; 9: 97-101. |
Decrease of sufentanil citrate concentration during formulation and application of an epidural infusion solution.
Bosch EH, Van Doorne H, Brouwers JRBJ, Marskamp A, Meevis RF. |
1993 |
3671 |
Laboratorium
Teva UK Ltd 2016 |
Deferoxamine - Résumé des caractéristiques du produit
|
2016 |
3701 |
Laboratorium
Gentium SPa 2014 |
Defibrotide (Defitelio®) - Summary of Product Characteristics
|
2014 |
2291 |
Czasopismo
Drug Dev Ind Pharm 2000 ; 26, 11: 1221-1226. |
Degradation kinetics of neostigmine in solution.
Yeh MK. |
2000 |
3390 |
Czasopismo
Int J Pharm 1993 ; 99: 73-78. |
Degradation kinetics of the antitumor drug nimustin (ACNU) in aqueous solution.
Van der Houwen, O.AG.J, Beijnen J.H, Bult A, Bekers O, Goossen R.M.J, Underberg W.J.M. |
1993 |
1157 |
Czasopismo
Int J Pharm 1988 ; 43: 131-138. |
Degradation kinetics of vinblastine sulphate in aqueous solutions.
Vendrig DEMM, Smeets BPGM, Beijnen JH, van der Houwen OAGJ, Holthuis JJM. |
1988 |
2570 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 1205-1207. |
Degradation of captopril in solutions compounded from tablets and standard powder.
Chan DS, Sato AK, Claybaugh JR. |
1994 |
3093 |
Czasopismo
J Pharm Sci 2010 ; 99, 3 : 1288-1298. |
Degradation of paclitaxel and related compounds in aqueous solutions III: Degradation under acidic pH conditions and overall kinetics
Tian J, Stella VJ. |
2010 |
2243 |
Czasopismo
Int J Pharm 1997 ; 146: 263-269. |
Degradation pathway of carboplatin in aqueous solution.
Pujol M, Girona V, Prat J, Munoz M, De Bolos J. |
1997 |
4636 |
Czasopismo
J Oncol Pharm Practice 2022 ; |
Design and stability of pediatric oral formulation of imatinib
Hinterlang M, Gendron A, Fleury F, Rieutord A, Vrana A , Schlatter J, Annereau M. |
2022 |
2884 |
Czasopismo
Int J Pharm 2015 ; 487 : 270-273. |
Design and stability study of a paediatric oral solution of methotrexate 2 mg/ml
Vrignaud S, Briot T, Launay A, Kempf M, Lagarce F. |
2015 |
3886 |
Czasopismo
Eur J Pharm Sci 2016 ; 92 : 220-223. |
Design and stability study of an oral solution of amlodipine besylate for pediatric patients.
van der Vossen A.C, van der Velde I, Smeets O.S.N.M,. Postma D.J, Vermes A,. Koch B.C.P, Vulto A.G,.Hanff L.M. |
2016 |
3361 |
Czasopismo
Int J Pharm 2012 ; 423: 360-364. |
Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide.
Santovena A, Hernandez-Paiz Z, Farina J.B. |
2012 |
2717 |
Czasopismo
J Liquid Chrom 1995 ; 18: 3117-3128. |
Determination of ceftazidime and pyridine by HPLC: application to a viscous eye drop formulation.
Barnes AR. |
1995 |
1757 |
Czasopismo
J Clin Pharm Ther 1998 ; 23: 311-314. |
Determination of compatibility and stability of drugs used in palliative care.
Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P. |
1998 |
835 |
Czasopismo
Int J Pharm 1979 ; 4: 21-26. |
Determination of the stability of mitomycin C by high performance liquid chromatography.
Edwards D, Selkirk AB, Taylor RB. |
1979 |
2239 |
Czasopismo
Chinese J New Drugs 2005 ; 14, 2: 189-191. |
Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry.
Wang C, Zhang X, Liu HY. |
2005 |
3296 |
Czasopismo
J Chromatographic Sci 2009 ; 47: 1-7. |
Determination of Tramadol, Metamizole, Ropivacaine, and Bupivacaine in Analgesic Mixture Samples by HPLC with DAD Detection.
Salmeron-Garcia A, Navas N, Martin A, Roman E, Cabeza J, Capitan-Vallvey L.F |
2009 |
3971 |
Czasopismo
Int J Pharm Compound 2017 ; 21, 2 : 164-170. |
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs.
Gorman G, Sokom S, Coward L, Arnold J J. |
2017 |
4750 |
Czasopismo
Pharmaceutics 2023 ,15, 755. |
Development and Stability of a New Formulation of Pentobarbital Suppositories for Paediatric Procedural Sedation.
Lebrat M, Bouattour Y, Gaudet C, Yessaad M, Jouannet M, Wasiak M, Dhifallah I, Beyssac E, Garrait G, Chennell P, Sautou V. |
2023 |
3875 |
Czasopismo
EJHP 2016 ; 23: 4: 213-218. |
Development and stability study of glibenclamide oral liquid paediatric formulations for the treatment of permanent neonatal diabetes mellitus.
Estevez P, Boscolo O, Quiroga E, Penuto R.F, Buontempo F, Tripodi V, Lucangioli S. |
2016 |
2317 |
Czasopismo
EJHP Science 2009 ; 15, 1: 3-5. |
Development and stability testing of a concentrated injectable clonidine solution for intrathecal analgesia.
Hollenwaeger M, Borquin Challandes I, Fallab L.C, Schaad N, Zelger G. |
2009 |
4498 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2020 |
Development and validation of a new HPLC method for the analysis of a novel oral suspension formulation of 50 mg/mL ursodesoxycholic acid for newborns.
Hausherr A, Roessle C, Pinet E, Vasseur V, Abarou T, Benakouche S, Bourdon O, Storme T. |
2020 |
4628 |
Czasopismo
Pharmaceuticals 2021 ; 14, 943. |
Development and Validation of a New Storage Procedure to Extend the In-Use Stability of Azacitidine in Pharmaceutical Formulations.
Iudicello A, Genovese F, Strusi V, Dominici M, Ruozi B. |
2021 |
3319 |
Czasopismo
Int J Pharm 2012 ; 433, 1-2 : 119-120. |
Development and validation of a paediatric oral formulation of clonidine hydrochloride
de Goede A.L, Boedhram R.R, Eckhardt M, Hanff L.M, Koch B.C.P, Vermaat C.H, Vermes A. |
2012 |
2165 |
Czasopismo
J Liquid Chrom Rel Technol 2006 ; 29, 16: 2353-2365. |
Development and validation of an HPLC method for oxytocin in Ringer’s lactate and its application in stability analysis.
Kumar V, Madabushi R, Derendorf H, Boothby LA, Breland BD, Hatton RC, Doering PL. |
2006 |
3399 |
Plakat
EAHP Congress Paris 2013 |
Development of a hydrochlorothiazide 0.5 mg/mL oral solution for children.
Li Y.Y, Postma D.J, Wagenaar H.W.G. |
2013 |
4653 |
Czasopismo
EJHP 2021 ; 28: 331-335. |
Development of a sterile morphine hydrogel for the local treatment of painful skin ulcers.
Jansen MMPM, van Waas VPH, Verzijl JM, Burger D. |
2021 |
3297 |
Czasopismo
Chromatographia 2008 ; 68, 9-10: 767-772. |
Development of an LC–DAD Method for Analysis of Dexketoprofen, Tramadol, and Haloperidol. Study of the Stability of Mixtures Used for Patient-Controlled Analgesia.
Salmeron-Garcia A, Lopez-Lopez E, Roma E, Cabeza J, Navas N, Capitan-Vallvey L.F. |
2008 |
2904 |
Czasopismo
Ann Pharm Fr 2005 ; 63: 162-166. |
Development of an oxybutynin chloride solution: from formulation to quality control.
Fratta A, Bordenave J, Boissinot C, Le Grand J, Esquirol C, Radideau E, Benoit G. |
2005 |
650 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 274-277. |
Development of clonidine hydrochloride injections for epidural and intrathecal administration.
Trissel LA, Hassenbusch SJ. |
1997 |
3285 |
Czasopismo
Yakugaku Zasshi 2009 129, 6: 767-771. |
Development of New Mixing Method of Busulfex® Injecton for the Purpose of Improvement of Medical Safety Method; The Prefilled Syringe Method.
Senoo M, Tajika K, Shimizu H, Hamada M, Dobashi Y, Dan K, Katayama S. |
2009 |
3569 |
Czasopismo
EJHP 2014 ;21:34-38 |
Development of ready-to-use cefuroxime syringes for use in ophthalmology.
Fleury-Souverain S, Sadeghipour F, Bonnabry P. |
2014 |
2287 |
Czasopismo
EJHP Science 2008 ; 14, 1: 14-18. |
Development of ready-to-use ketamine hydrochloride syringes for safe use in post-operative pain.
Stucki MC, Leury-Souverain S, Sautter AM, Sadeghipour F, Bonnabry P. |
2008 |
4229 |
Czasopismo
Int J Pharm Compound 2017 ;24,6:519-527 |
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure.
Ma N, Perks W, Law S, John I, Walker S. |
2017 |
2759 |
Czasopismo
Pediatr Neurol 1999 ; 20: 195-197. |
Development of two stable oral suspensions of gabapentin.
Nahata MC. |
1999 |
2721 |
Czasopismo
J Pad Ophtalmol Strabismus 2000 ; 37, 6: 333-337. |
Development of Two Stable Oral Suspensions of Levodopa-Carbidopa for Children With Amblyopia
Nahata MC, Morosco RS, Leguire LE. |
2000 |
2949 |
Czasopismo
Pharmazie 2007 ; 62: 519-521. |
Development validation and stability study of pediatric atenolol syrup.
Foppa T, Murakami FS, Silva MAS. |
2007 |
3700 |
Czasopismo
Braz J Pharm Sci 2010 ; 46, 1 : 109-114. |
Development, stability and in vitro permeation studies of gels containing mometasone furoate for the treatment of dermatitis of the scalp.
Salgado A.C.G.B; Silva A.M.N.N; Machado M.C.J.C; Duarte MA.S.C; Ribeiro, Helena M.O.M. |
2010 |
4712 |
Plakat
GERPAC Congrès - octobre 2022 2022 |
Développement de formulations buvables de vinorelbine à usage pédiatrique.
Macqueron L, Régnier L, Robinet P, Leroy AM, Lester MA, Boivin PN, Le Corre P. |
2022 |
3668 |
Laboratorium
Hospira 2015 |
Dexamethasone - Summary of Product Characteristics
|
2015 |
3851 |
Czasopismo
Can J Hosp Pharm 2016 ; 69, 1: 49-51. |
Dexamethasone 1 mg/mL Suspension Prepared from Crushed Tablets: Stability in Glass and Plastic Bottles and Plastic Syringes.
Ensom M.H.H, D?carie D. |
2016 |
28 |
Czasopismo
PDA J Pharm Sci Technol 1996 ; 50: 261-267. |
Dexamethasone phosphate stability and contamination of solutions stored in syringes.
Lau DWC, Law S, Walker SE, Iazzetta J. |
1996 |
3581 |
Laboratorium
Clinigen Healthcare 2013 |
Dexrazoxane (Cardioxane®) - Résumé des caractéristiques du produit
|
2013 |
2224 |
Czasopismo
Bolletino SIFO 2007 ; 53: 178-180. |
Dexrazoxane: Stabilià in soluzione.
Romanazzi C, Sferra S, Campi A, Rabino B, Barbieri M, Castellani S, Sabbatini L, Scanavacca P. |
2007 |
1388 |
Czasopismo
Pharm J 1982 ; 228: 238-239. |
Diamorphine hydrochloride compatibility with saline.
Page J, Hudson S. |
1982 |
1385 |
Czasopismo
Pharm J 1985 ; 235: 171. |
Diamorphine injection BP incompatibility.
Kirk B, Hain WR. |
1985 |
506 |
Czasopismo
J Pharm Pharmacol 1989 ; 41: 275-277. |
Diamorphine stability in aqueous solution for subcutaneous infusion.
Omar OA, Hoskin PJ, Johnston A, Hanks W, Turner P. |
1989 |
3885 |
Czasopismo
Int J Pharm 2016 ; 506 : 414-419. |
Diazepam sorption to PVC- and non-PVC-based tubes in administration sets with quantitative determination using a high-performance liquid chromatographic method.
Su-Eon Jin, Siwon You, Seungho Jeon, Sung-Joo Hwang. |
2016 |
3613 |
Laboratorium
Primius Lab 2013 |
Dihydralazine (Nepressol®) - Résumé des caractéristiques du produit
|
2013 |
1809 |
Czasopismo
EJHP 2003 ; 3: 34-42. |
Diluted solution of sodium ioxitalamate in paediatrics: A stability and cost effectiveness study.
Arrault XL, Rieutord A, Hassan M, Brion F. |
2003 |
2292 |
Czasopismo
EJHP 2016 ;23:22-27 |
Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability
Philipp E, Braitsch M, Bichsel T, Mühlebach S. |
2016 |
2074 |
Czasopismo
Ann Intern Med 1998 ; 128: 1049. |
Dissolving phenytoin precipitate in central venous access device.
Tse T, Abdullah R. |
1998 |
4487 |
Czasopismo
Pharmaceutics 2020 ; 12, 786. |
Do Ophthalmic Solutions of Amphotericin B Solubilised in 2-Hydroxypropyl- -Cyclodextrins Possess an Extended Physicochemical Stability?
Chennell P, Yessaad M, Abd El Kader F, Jouannet M, Wasiak M, Bouattour Y, Sautou V. |
2020 |
3606 |
Laboratorium
Wokhardt 2013 |
Dobutamine - Summary of Product Characteristics
|
2013 |
1352 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 2588-2589. |
Dobutamine-heparin mixture inadvisable.
Hasegawa GR, Eder JF. |
1984 |
3130 |
Laboratorium
Sanofi Avantis France 2009 |
Docétaxel (Taxotere®) – Résumé des caractéristiques du produits
|
2009 |
3911 |
Czasopismo
EJHP 2017 ; 24: 230-234. |
Does an interaction exist between ketamine hydrochloride and Becton Dickinson syringes?
Closset M, Hecq J D, Gonzalez E, Bihin B, Jamart J, L Galanti L. |
2017 |
3638 |
Laboratorium
Hospira 2010 |
Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics
|
2010 |
1397 |
Czasopismo
Pharm J 1990 ; 244: 218. |
Dopamine dilutions.
Garner ST, Murdoch JM. |
1990 |
2332 |
Laboratorium
Janssen-Cilag 2009 |
Doripenem (Doribax®) - Laboratoire informations
|
2009 |
3612 |
Laboratorium
Amdipharm Mercury Company 2012 |
Doxapram (Dopram) - Summary of Product Characteristics
|
2012 |
3645 |
Laboratorium
Accord Healthcare 2014 |
Doxorubicin - Summary of Product Characteristics
|
2014 |
3142 |
Laboratorium
SP Europe 2010 |
Doxorubicin hydrochloride liposome (Caelyx®) - Summary of Product Characteristics
|
2010 |
3143 |
Laboratorium
Teva Laboratoire 2015 |
Doxorubicin hydrochloride liposome (Myocet®) - Summary of Product Characteristics
|
2015 |
3144 |
Laboratorium
Ortho Biotech 2010 |
Doxorubicin liposome (Doxil®) - Product Information
|
2010 |
681 |
Czasopismo
Can J Hosp Pharm 1991 ; 44: 71-78. |
Doxorubicin stability in syringes and glass vials and evaluation of chemical contamination.
Walker S, Lau D, DeAngelis C, Iazetta J, Coons C. |
1991 |
3402 |
Czasopismo
J Oncol Pharm Practice 2013 ; 19, 1: 65-74. |
Doxorubicin-loaded drug-eluting beads (DC Bead®) for use in transarterial chemoembolization: A stability assessment.
Hecq, J.-D., Lewis, A.L., Vanbeckbergen, D., Athanosopoulos, A., Galanti, L., Jamart, J., Czuczman, P., Chung, T. |
2013 |
4009 |
Laboratorium
Panpharma 2017 |
Droperidol - Résumé des Caractéristiques du Produit
|
2017 |
1187 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 94-97. |
Droperidol stability in intravenous admixtures.
Ray JB, Newton DW, Nye MT, Leet WA. |
1983 |
2146 |
Czasopismo
Am J Health-Syst Pharm 2006 ; 63: 2379-2382. |
Drug compatibility with new polyolefin infusion solution containers.
Trissel LA, Xu QA, Baker M. |
2006 |
763 |
Czasopismo
Cancer Treat Rep 1985 ; 69: 1325-1326. |
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. |
1985 |
817 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 683-685. |
Drug stability and pyridine generation in ceftazidime injection stored in an elastomeric infusion device.
Stendal TL, Klem W, Tonnesen HH, Kjonniksen I. |
1998 |
1928 |
Czasopismo
J Pain Symptom Manage 2004 ; 28, 3: 268-272. |
Drug stability testing to support clinical feasibility investigations for intrathecal baclofen-clonidine admixture.
Alvarez JC, De Mazancourt Ph, Chartier-Kastler E, Denys P. |
2004 |
1088 |
Czasopismo
JAMA 1984 ; 252: 2392. |
Drug trapping in intravenous infusion side arms.
Johnston A, McKenzie MA, Krasnow SH, Hood MA, Cohen MH. |
1984 |
4608 |
Laboratorium
Astra Zeneca 2021 |
Durvalumab (Imfinzi - Summery of Product Characteristics, updated August 2021)
|
2021 |
2348 |
Laboratorium
Alexion Europe SAS 2007 |
Eculizumab (Soliris®) – Summary of Product Characteristics
|
2007 |
348 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 335-339. |
Effect of a polyethylene-lined administration set on the avaibility of diazepam injection.
Hancock BG, Black CD. |
1985 |
170 |
Czasopismo
Am J Hosp Pharm 1975 ; 62: 44-45. |
Effect of briefly heating cyclophosphamide solutions.
Brooke D, Scott JA, Bequette RJ. |
1975 |
2396 |
Czasopismo
Am J Health-Syst Pharm 2008 ; 65: 441-447. |
Effect of buffer and antioxidant on stability of a mercaptopurine suspension
Aliabadi HM, Romanick M, Desai S, Lavasanifar A. |
2008 |
351 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 2795-2799. |
Effect of flow rate and type of IV container on adsorption of diazepam to IV administration systems.
Yliruusi JK, Uotila JA, Kristoffersson ER. |
1986 |
2361 |
Czasopismo
J Clin Pharm Ther 2009 ; 34, 4 : 423-428. |
Effect of freeze-thawing on the long-term stability of calcium levofolinate in 5% dextrose stored on polyolefin infusion bags.
Lebitasy M, Hecq J.D, Athanassopoulos A, Vanbeckbergen D, Jamart J, Galanti L. |
2009 |
575 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 104-108. |
Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags.
Holmes CJ, Ausman RK, Kundsin RB, Walter CW. |
1982 |
2020 |
Czasopismo
Can J Hosp Pharm 2005 ; 58: 65-70. |
Effect of freezing on stability of a fortified 5 mg/ml ticarcillin ophtalmic solution.
Blondeel S, Pelloquin A, Pointereau-Bellanger A, Thuillier A, Fernandez C. |
2005 |
2110 |
Czasopismo
EJHP Science 2006 ; 12, 3: 52-56. |
Effect of freezing, long term storage and microwave thawing on the stability of ceftriaxone sodium in 5% dextrose infusion polyolefin bags at 2-8°C.
Hecq JD, Evrard JM, Vanbeckbergen DF, Jamart J, Galanti LM. |
2006 |
2015 |
Czasopismo
Ann Pharmacotherapy 2005 39: 1654-1658. |
Effect of freezing, long term storage, and microwave thawing on the stability of ketorolac tromathamine.
Hecq JD, Boitquin LP, Vanbeckbergen DF, Jamart J, Galanti LM. |
2005 |
3076 |
Czasopismo
Ann Pharm Fr 2009 ; 67: 427-432. |
Effect of freezing, long-term storage and microwave thawing on the stability of a mixture of diclofenac and sodium bicarbonate in glucose 5% polyolefin bags.
François JH, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. |
2009 |
1958 |
Czasopismo
EJHP Science 2005 ; 11: 23-25. |
Effect of freezing, long-term storage and microwave thawing on the stability of cefuroxime sodium in 5% dextrose infusion polyvinyl chloride bags.
Hecq JD, Schlesser V, Vanbeckbergen D, Jamart J, Galanti L. |
2005 |
2320 |
Czasopismo
EJHP Science 2009 ; 15, 1: 15-19. |
Effect of freezing, long-term storage and microwave thawing on the stability of sodium folinate.
Cadrobbi J, Hecq J.D, Vanbeckbergen D, Jamart J, Galanti L. |
2009 |
1892 |
Czasopismo
Int J Pharm Compound 2004 ; 8, 2: 156-159. |
Effect of freezing, long-term storage and microwave thawing on the stability of tramadol in 5% dextrose infusion in polyvinyl chloride bags.
Lebrun J, Hecq JD, Vanbeckbergen D, Jalart J, Galanti LM. |
2004 |
2034 |
Czasopismo
EJHP Science 2005 ; 11, 5: 111-113. |
Effect of freezing, long-term storage and microwave thawing on the stability of vancomycin hydrochloride in 5% dextrose infusions.
Rodenbach MP, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. |
2005 |
1648 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 391-394. |
Effect of freezing, long-term storage, and microwave thawing on the stability of cefepime in 5% dextrose infusion polyvinyl chloride bags.
Schlesser V, Hecq J-D, Vanbeckbergen D, Jamart J, Galanti LM. |
2002 |
1258 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 537-540. |
Effect of gentamicin on heparin activity.
Tyler LS, Rehder TL, Davis RB. |
1981 |
510 |
Czasopismo
Pharm World Sci 1993 ; 15: 269-275. |
Effect of glucose 5% solution and bupivacaine hydrochloride on absorption of sufentanil citrate in a portable pump reservoir during storage and simulated infusion by an epidural catheter.
Roos PJ, Glerum JH, Schroeders MJH. |
1993 |
3439 |
Czasopismo
Perit Dial Int 2013 ; 33:458-461 |
Effect of Glucose Concentration on the Stability of Daptomycin in Peritoneal Solutions.
Parra M.A, Campanero M.A, S?daba B, Irigoyen A, Garc?a-L?pez L,Fernandez-Reyes M.J, Ramon Azanza J. |
2013 |
729 |
Czasopismo
Am J Hosp Pharm 1977 ; 34: 1071-1074. |
Effect of inline filtration on the potency of drugs administered intravenously.
Rusmin S, Welton S, DeLuca P, DeLuca PP. |
1977 |
703 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 935-941. |
Effect of inline filtration on the potency of low-dose drugs.
Butler LD, Munson JM, DeLuca PP. |
1980 |
4439 |
Czasopismo
Nutrients 2019 ; 11: 559. |
Effect of Lipid Emulsion on Stability of Ampicillin in Total Parenteral Nutrition.
Stawny M, Gostynska A, Dettlaff K, Jelinska A, Główka E, Ogrodowczyk M. |
2019 |
509 |
Czasopismo
Pharm World Sci 1993 ; 15: 139-144. |
Effect of pH absorption of sufentanil citrate in a portable pump reservoir during storage and administration under simulated epidural conditions.
Roos PJ, Glerum JH, Meilink JW, Zwang L. |
1993 |
464 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 2209-2213. |
Effect of pretreatment with 0.9% sodium chloride or insulin solutions on the delivery of insuline from an infusion system.
Furberg H, Kruse Jensen A, Salbu B. |
1986 |
160 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2701-2704. |
Effect of sodium chloride concentration and temperature on melphalan stability during storage and use.
Pinguet F, Martel P, Rouanet P, Fabbro M, Astre C. |
1994 |
2953 |
Czasopismo
J Pharm Sci 1982 ; 71: 585-587. |
Effect of some formulation adjuncts o the stability of benzoyl peroxide.
Gupta VD. |
1982 |
587 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 1024-1025. |
Effect of storage temperature and time stability of cefmenoxime, ceftriaxone, and cefotetan in 5% dextrose injection.
Smith BR. |
1983 |
347 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2627-2630. |
Effect of syringe filter and IV administration set on delivery of propofol emulsion.
Bailey LC, Tang KT, Rogozinski BA. |
1991 |
3284 |
Czasopismo
Yakugaku Zasshi 2008 ; 128, 8: 1221-1226. |
Effect of the Admixture of Tetracycline and Nadifloxacin Ointments on Their Stability and Their Antibacterial Activity.
Kawamoto T, Tayama Y, Sawa A, monde T, Sashima S, Yoshioka M, Miyake K, Morita S, Kihira K. |
2008 |
2008 |
Czasopismo
Ann Pharmacotherapy 2005 ; 39: 1244-1248. |
Effect of the freezing conditions and microwave thawing power on the stability of cefuroxime in dextrose 5% infusion polyolefin bags at 4°C.
Hecq JD, Boitquin LP, Vanbeckbergen DF, Jamart J, Galanti LM. |
2005 |
352 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 2789-2794. |
Effect of tubing length on adsorption of diazepam to polyvinyl chloride administration sets.
Yliruusi JK, Uotilo JA, Kristoffersson ER. |
1986 |
2115 |
Czasopismo
J Pain Symptom Manage 2006 ; 31, 6: 563-567. |
Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion.
Schneider JJ, Good Ph, Ravenscroft PJ,. |
2006 |
194 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1559-1562. |
Effect of vehicle ionic strength on sorption of nitroglycerin to a polyvinyl chloride administration set.
Loucas SP, Maager P, Mehl B, Loucas ER. |
1990 |
1349 |
Czasopismo
Aust J Hosp Pharm 1987 ; 17: 31-34. |
Effects of freezing, long term storage and microwave thawing on the stability of three antibiotics reconstituted in minibags.
Sanburg AL, LyndonRC, Sunderland B. |
1987 |
1946 |
Czasopismo
Can J Hosp Pharm 2004 ; 57, 5: 276-282. |
Effects of freezing, long-term storage, and microwave thawing on the stability of piperacillin plus tazobactam in 5% dextrose for infusion.
Hecq JD, Berlage V, Vanbeckbergen D, Jamart J, Galanti L. |
2004 |
2432 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 2483-2487. |
Effects of ingredients on stability of captopril in extemporaneously prepared oral liquids
Lye MY, Yow KL, Lim LY, Chan SY, Chan E, Ho PC. |
1997 |
1353 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 1835-1837. |
Effects of presaturation on nitroglycerin delivery by polyvinyl chloride infusion sets.
Nix DE, Tharpe WN, Francisco GE. |
1984 |
592 |
Czasopismo
J Pharm Clin 1989 ; 8: 101-106. |
Effects of storage temperature and pH on the stability of cefotaxime in PVC bags.
Barthes D, Fauconneau B, Martin JP, Courtois P. |
1989 |
1736 |
Czasopismo
J Clin Pharm Ther 1999 ; 24: 145-150. |
Effects of sucrose, citric buffer and glucose oxidase on the stability of captopril in liquid formulations.
Liu J, Chan Y, Ho PC. |
1999 |
146 |
Czasopismo
Clin Ther 1992 ; 14: 821-824. |
Effects of temperature, solution composition, and type of container on the stability and absorption of carmustine.
Hadji-Minaglou-Gonzalvez MF, Gayte-Sorbier A, Airauto CB, Verdier M. |
1992 |
4314 |
Czasopismo
J Am Pharm Assoc 2017 ; 56, 4: 457-461. |
Effects of Time and Storage Conditions on the Chemical and Microbiologic Stability of Diluted Buprenorphine for Injection.
DenHerder J.M, Reed R.L, Sargent J.L, Bobe G, Stevens J.F, Helen E Diggs H.E. |
2017 |
4331 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2019 |
Emulsion Stability of Different Intravenous Propofol Formulations in Simulated Co-Administration with Remifentanil Hydrochloride.
Nilsson N, Nezvalova-Henriksen K, Tho I. |
2019 |
4717 |
Laboratorium
2022 Daiichi Sankyo Europe Gmb |
Enhertu®- Résumé des caractéristiques du produit
|
2022 |
3862 |
Czasopismo
Hosp Pharm 2016 ; 51, 3: 246-251. |
Enzymatic Stability of Alteplase Solution for Injection: Effect of Various Methods of Thawing Frozen Solutions.
Cutshall B.T, Gorman G.S, Freeman M.K ,. Kyle J.A. |
2016 |
2307 |
Czasopismo
Palliative Med 1995 ; 9, 4: 315-318. |
Epidural diamorphine and bupivacaine stability study.
Kreeger L, Cowin P, Noble-Gresty J, Naysmith A. |
1995 |
3642 |
Laboratorium
International Medication System (UK) 2013 |
Epinephrine - Résumé des Caractéristiques du Produit
|
2013 |
659 |
Czasopismo
Can J Hosp Pharm 1996 ; 49: 62-65. |
Epinephrine stability in plastic syringes and glass vials.
Donnely RF, Yen M. |
1996 |
683 |
Czasopismo
Can J Hosp Pharm 1990 ; 43: 265-272. |
Epirubicin stability in syringes and glass vials and evaluation of chemical contamination.
Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C. |
1990 |
3632 |
Laboratorium
Hospira 2017 |
Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics
|
2017 |
798 |
Czasopismo
Ann Pharmacotherapy 1996 ; 30: 1501-1502. |
Epoetin alfa loss with NaCl 0.9% dilution.
Widness JA, Schmidt R. |
1996 |
3934 |
Laboratorium
GlaxoSmithKline Laboratoire 2016 |
Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
|
2016 |
3250 |
Laboratorium
Eisai Ltd 2011 |
Eribulin (Halaven®) - Summary of Product Characteristics.
|
2011 |
1912 |
Laboratorium
Merck Sharp Dohme 2016 |
Ertapenem (Invanz®) - Summary of Product Characteristics
|
2016 |
4480 |
Laboratorium
Jazz Pharmaceuticals UK. 2020 |
Erwinase, Lyophilisate for solution for injection.
|
2020 |
3674 |
Laboratorium
PanPharma 2016 |
Erythromycin lactobionate - Summary of Product Characteristics
|
2016 |
4700 |
Laboratorium
AS Kalceks 2022 |
Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics
|
2022 |
3607 |
Laboratorium
AOP Orphan Pharmaceuticals AG 2013 |
Esmolol hydrochloride for injection - Summary of Product Characteristics
|
2013 |
2284 |
Laboratorium
Astra Zenaca 2007 |
Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics
|
2007 |
4612 |
Czasopismo
OFIL 2014 24;2:86-90 |
Estabilidad de la solución de gentamicina y heparina para sellado de catéter.
Villaba-Moreno AM, Gil-Navarro MV, Cotrina-Luque J, Pérez-Moreno MA, Chamorro-de Vega E. |
2014 |
3489 |
Czasopismo
Farm Hosp 1998 ; 22, 5: 249-251. |
Estabilidad de las soluciones orales de clohidrato de metadona al 0,1% y 0,5% en suero fisiologico.
Soy D, Roca M, Deulofeu R, Montes E, Codina C, Ribas J. |
1998 |
2202 |
Czasopismo
Investig Clin Farm 2005 ; 2, 4: 195-203. |
Estabilidad de parecoxib en dilucion con ostros farmacos y administrado en perfusion continua IV para el control del dolor postoperatorio.
Acin Lazaro MP, bono Arino C, martinez Bazan R, manzanares Marin I, Faci Bouthelier A, Velamazan Blocona MJ, Facorro Gaspar E, |
2005 |
2105 |
Czasopismo
Farm Hosp 1999 ; 23: 357-360. |
Estabilidad de una mezcla de etomidato y pentotal para administracion intravenosa en bolo.
Valverde molina F, Hernandez Hernandez G, Munoz Castillo M, Novales Duran J, Gallego Fernandez C. |
1999 |
3198 |
Czasopismo
Farm Hosp 2008 ; 32, 6 : 344-348. |
Estabilidad en suero fisiológico del busulfán intravenoso en un envase de poliolefinas.
Nebot Martinez J, Alos Alminana M, Diez Sales O. |
2008 |
2100 |
Czasopismo
Farm Hosp 1995 ; 19: 38-40. |
Estabilidad fisica y quimica del sulfato magnesico combinado con heparina sodica en solucion salina al 0,9 por 100.
Gervas S, Gosalbez F. |
1995 |
2103 |
Czasopismo
Farm Hosp 1999 ; 23: 103-108. |
Estabilidad y compatibilidad del metamizol en jeringa y en mezclas intravenosas.
Noguera Rodriguez A, Sancho Chust V, Medina Hernandez C, Medina Hernandez MJ, Jimenez Torrez NV. |
1999 |
2841 |
Czasopismo
Atencion Pharmaceutica 2009 ; 11, 3: 161-166. |
Estudio de estabilidad de la mezcla ondansetron-dexametasona en cloruro sodico 0,9%.
Gonzalves Navaro M, Carril Aviles M, Borras Almenar C, Romero Crespo I, Jimenez Torres NV. |
2009 |
3706 |
Czasopismo
Farm Hosp 2014 ;38, 3:154-161 |
Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia.
Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B. |
2014 |
3384 |
Czasopismo
Farm Hosp 2013 ;37,1:10-14 |
Estudio de estabilidad de tiaprida en disolución para administración en perfusión intravenosa continua.
Otero F.M |
2013 |
2104 |
Czasopismo
Farm Hosp 2000 ; 24: 145-150 |
Estudio de la estabilidad de mezclas ciclofosfamida/mesna e ifosfamida/mesna en soluciones intravenosas de gran volumen.
Iriarte Izura MA, Gozalo garcia MJ, Marcotegui Ros F, Nagore Indurain C, Urdaniz Baztan AO. |
2000 |
3655 |
Laboratorium
Bristol Myers Squibb 2016 |
Etoposide phosphate (Etopophos®) - Résumé des caractéristiques du produit
|
2016 |
2181 |
Czasopismo
Bull Cancer 1995 ; 82: 189-195. |
Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique.
Milano G, Renée N. |
1995 |
3791 |
Plakat
Apifh Congress, Paris November 2014 2014 |
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. |
2014 |
3240 |
Plakat
Congrès SFPO 2011 |
Etude de la stabilité d'une solution de bortézomib à 1 mg/mL conditionnée en seringue de polypropylène.
Perissutti M, Vigneron J, Zenier H, May I, Demoré B. |
2011 |
504 |
Czasopismo
Sci Tech Pharm 1987 ; 3: 33-40. |
Etude de la stabilité dans des solutions diluées destinées à la perfusion de deux antimitotiques dérivés de la podophyllotoxine : l’étoposide (VP 16), le téniposide (VM 26).
Hamon M, Plas-Remoissenet D, Kubab-Alajati S. |
1987 |
1455 |
Czasopismo
J Pharm Clin 1995 ; 14: 178-179. |
Etude de la stabilité de deux benzamides antiémétiques en poches PVC de chlorure de sodium 0.9% et de glucose 5% sur une période de 5 mois.
Demoré B, Raffy F, Commun N, Vigneron J, Hoffman MA, Hoffman M. |
1995 |
4007 |
Plakat
Hopipharm Congress 2017-Nancy 2017 |
Etude de la stabilité de la vancomycine à 40 mg/ml au cours d'une perfusion de 24 heures.
Masse M, Genay S, Carta N, Delannoy-Rousseli?re C, Moreau F, Barthelemy C, Faure K, Decaudin B, Odou P. |
2017 |
3761 |
Książka
Master en pharmacie - University of Geneva 2014 |
Etude de la stabilité de solutions de prostaglandine E1 à 48 et 72 heures en vue d'une administration parentérale en continu à des patients de néonatalogie.
Chavan E. |
2014 |
3447 |
Plakat
SFPO Congress, Mandelieu, France 2013 |
Etude de la stabilité d’une solution de bortézomib à 2,5 mg/mL par chromatographie liquide à haute performance couplée à un détecteur à barrettes de diodes et à un détecteur évaporatif à diffusion de lumière.
Giovanelli M, Vigneron J, May I, Nicolas A. |
2013 |
4714 |
Plakat
GERPAC Congrès - octobre 2022 2022 |
Etude de stabilité d'un biosimilaire du Bevacizumab dans les flacons et après dilution dans du NaCl 0.9% en poche de polyoléfine.
Vieillard V, Paul M |
2022 |
3848 |
Praca dyplomowa
Thèse de doctorat en pharmacie 2014 |
Etude de stabilité d'un collyre à l'amphotéricine B 0,5%.
Dermu Marine. |
2014 |
4041 |
Plakat
SNPHPU Congress 12th 2017 |
Etude de stabilité d'un collyre de ceftazidime à 50mg/ml conditionné en flacon de polyéthylène basse densité.
Jobard M, Brandely-Piat M-L, El Deeb G, Labat L, Cros C, Chast F, Batista R. |
2017 |
4424 |
Plakat
11ème Recontres Convergences Santé Hôpital 2016 |
Etude de stabilité d'une suspension buvable de cloxacilline à usage pédiatrique.
Barbazan C, Le Daré, Lester M-A, Boivin P-N. |
2016 |
4578 |
Praca dyplomowa
2011 |
Etude de stabilité de médicaments anticancéreux injectables : apports analytiques et pharmaceutiques
Respaud R. |
2011 |
4786 |
Plakat
SFPO Congress 2023 |
Etude de stabilité de solutions de pembrolizumab à 1 et 4 mg/mL à 5 et 25°C dans des poches de NaCl 0,9% en polyoléfine .
Avrillon K, Le Guyader G, Doillet H, Jaskowiec C, Paul M, Poullain S. |
2023 |
3120 |
Plakat
Congrès HOPIPHARM 2010 |
Etude de stabilité de solutions intravitréennes de vancomycine à 10 mg/ml.
Maillot-Pyszczek V, Bourdeaux D, Sautou V, Chopineau J. |
2010 |
1520 |
Laboratorium
B Braun 2001 |
Etude de stabilité des médicaments en Ecoflac®
|
2001 |
2760 |
Czasopismo
Pharm Hosp et Clin 2007 ; 42, 171 : 171-176. |
Etude de stabilité d’un collyre à ,6 mg/ml de ticarciline.
Galvez O,Mullot JU, Mullot H, Simon L, Grippi R, Payen C, Bonneau D, Huart B, Gentes P. |
2007 |
4066 |
Plakat
APHIF 2017 - Congress 2017 2017 |
Etude de stabilité physico-chimique et microbiologique des collyres de ciclosporine à 0.5 ; 5 et 20 mg/mL conditionnés en flacons de polyéthylène basse densité.
Mordohay A, Chanat C, Bezia C, Fresneau J, Jobard M, Brandely-Piat M.L, Batista R. |
2017 |
1289 |
Czasopismo
Pharmakon 1998 ; 116: 145-148. |
Etude de stabilité visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosémide et de l’héparine sodique en perfusion continue.
Hecq JD, Evrard JM, Gillet P, Grosdent N. |
1998 |
3383 |
Czasopismo
Farm Hosp 2013 ;37,1:4-9 |
Evaluación de la estabilidad de un jarabe de hidrato de cloral al 7% en envases mono y multidosis bajo condiciones ambiente y de refrigeración.
Bustos-Fierro C, Olivera M. E, Manzo P.G, Jimenez-Kairuz A.K. |
2013 |
4643 |
Czasopismo
EJHP 2021 |
Evaluation of 30-day stability of morphine hydrochloride and clonidine at high and low concentrations in polypropylene syringes.
Catry E, Colsoul M-L, Closset M, Nyssen C, Hubert J, Soumoy L, Bihin B, Jamart J, Hecq J-D, Galanti L. |
2021 |
1645 |
Czasopismo
EJHP 2010 ; 16: 42-47. |
Evaluation of a diltiazem hydrochloride gel for the treatment of anal fissure.
Pinto JF, Salgado AC, Alves ML, Alves S, Neves C, Falcao F. |
2010 |
2991 |
Czasopismo
Drug Dev Ind Pharm 1997 ; 23: 285-291. |
Evaluation of oil/water-type cyclosporine gel ointment with commercially available oral solution.
Tamura T, Takayama K, Satoh H et al. |
1997 |
4627 |
Czasopismo
Adv Ther 2019 36:442–450 |
Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D, Yun J, Hwang S-J, Park SJ. |
2019 |
4637 |
Czasopismo
Braz J Pharm Sci 2021 ;57: e18896. |
Evaluation of physicochemical and microbiological stability of liquid preparation from tizanidine hydrochloride tablets - a Hospital concern.
Gobetti C, da Silva Bitencourt, A, Vinícius Ayres M, Peixoto de Freitas A.L, Loureiro Mendez A.S, Garcia C.V. |
2021 |
739 |
Czasopismo
Am J Hosp Pharm 1978 ; 35: 402-406. |
Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate.
Cradock JC, Kleinmann LM, Rahman A. |
1978 |
3861 |
Czasopismo
J Pharm Pract and Res 2016 ; 46: 28-33. |
Evaluation of stability of melatonin in extemporaneously compounded oral suspensions.
Friciu M , Savji T , Zaraa S, Leclair G. |
2016 |
4525 |
Czasopismo
Adv Ther 2020 ; 37: 4308–4324. |
Evaluation of the Physico-Chemical and Biological
Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D, Kim J, Yun J, Park S.J. |
2020 |
4003 |
Czasopismo
EJHP 2017 ; 25, 3: 157-164. |
Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab).
Kim J, Chung J, Park S, Jung S, Kang D. |
2017 |
3825 |
Czasopismo
J Pharm Pract and Res 2015 ; 496: 421-431. |
Evaluation of the physicochemical and functional stability of diluted REMSIMA(R) upon extended storage—A study compliant with NHS (UK) guidance.
Young B.L, Ali Khan M, Chapman T.J, Parry R,. Connolly M.A, Watts A.G. |
2015 |
2730 |
Czasopismo
J Pharm Pract and Res 2015 ; 45: 152-158. |
Evaluation of the physicochemical compatibility of cyclosporin infusion and parenteral nutrition when intravenously administered via the same central line lumen.
Coutsouvelis J, Yao-Da Dong, Witney K, Li W, Corallo C. |
2015 |
4252 |
Czasopismo
Int J Pharm Compound 2019 ;23,2:163-166 |
Evaluation of the Physicochemical Stability of Amiodarone Hydrochloride in Syringes for the Intensive Care Unit.
Lardinois B, Dimitriou A, Delcave C, Jamart J, Bihin B, Soumoy L, Hecq JD, Galanti LM. |
2019 |
4157 |
Czasopismo
Pediatric Anesthesia 2018 |
Evaluation of the stability and stratification of propofol and ketamine mixtures for pediatric anesthesia.
Izgi M, Basara B, Muderrisoglu A, Yilbas A.A, Uluer M.S, Celebioglu B. |
2018 |
3345 |
Czasopismo
Int J Pharm Compound 2012 ; 16, 5: 428-430. |
Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date.
Peacock G.F, Sauvageot J. |
2012 |
3667 |
Czasopismo
Int J Pharm Compound 2014 ; 18, 3: 253-255. |
Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F,Sauvageot Jurgita |
2014 |
4117 |
Czasopismo
Drug Design Dev Ther 2017 ;11:2087-2097 |
Evaluation of the stability of linezolid in aqueous solution and commonly used intravnous fluids.
Taylor R, Sunderland B, Luna G, Czarniak P. |
2017 |
3843 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 1: 81-85 |
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date.
Peacock G.F, Sauvageot J, Hill A, Killian A. |
2016 |
2828 |
Czasopismo
J Clin Pharm Ther 2008 ; 33, 3: 263-271. |
Evaluation of the stability of morphine sulphate in combination with Instillagel®.
Abdelmageed R, Labyad N, Watson DG, Pournamdari M, Cable CG, Stanley E. |
2008 |
4373 |
Czasopismo
EJHP 2020 ; 27(e1):e87-e92. |
Evaluation of the stability of vancomycin solutions at concentrations used in clinical services.
Masse M, Genay S, Martin Mena A, Carta N, Lannoy D, Barthélémy C, Décaudin B, Odou P. |
2020 |
4426 |
Czasopismo
Medicine 2019 98:21(e15747) |
Evaluation of Y-site compatibility of home total parenteral nutrition and intravenous loop diuretics.
Watrobska-Swietlikowska D, Pietka M, Stanislaw Klek S. |
2019 |
3408 |
Czasopismo
Pharmactuel 2013 ; 46, 1 : 16-21. |
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Tollec S, Touzin K, Pelletier E, Forest J.M. |
2013 |
829 |
Czasopismo
Int J Pharm 1988 ; 42: 41-46. |
Examination of sorption and photodegradation of amsacrine during storage in intravenous burette administration sets.
Cartwright-Shamoon JM, McElnay JC, D'Arcy PF. |
1988 |
3759 |
Czasopismo
Yakugaku Zasshi 2014 ; 134, 2: 293-298. |
Examination of the cause of changing solution color by mixing aminophylline and dopamine, the compatibility of which was indicated by the supplier.
Igarashi K, Kawahara M. |
2014 |
3169 |
Czasopismo
Pain Clinic 1999 ; 11: 213-216. |
Experimentation about precipitation of pharmacological association: morphine and ketorolac.
Raffaeli W, Pari G, Visani L et al. |
1999 |
2932 |
Czasopismo
J Pharm Pract and Res 2005 ; 35: 181-182. |
Extemporaneous isoniazid mixture: stability implications.
Haywood A, Mangan M, Grant G et al. |
2005 |
4729 |
Czasopismo
Pharmaceutics 2023 ; 15, 208. |
Extemporaneous Preparation of 20 mg/mL Ganciclovir in Artificial Tears in Comparison with SterileWater for Ophthalmic Administration: Formulation and Stability Study.
Leanpolchareanchai J, Tangteerakoon P, Supapsophon P, Sukavatcharin S, Simaroj P, Suksiriworapong J. |
2023 |
2926 |
Czasopismo
Am J Health-Syst Pharm 2006 ; 63: 254-257. |
Extemporaneous sildefanil citrate oral suspensions for the treatment of pulmonary hypertension in children.
Nahata MC, Morosco RS, Brady MT. |
2006 |
3682 |
Czasopismo
EJHP 2016 ;23:33-37 |
Extemporaneous sotalol hydrochloride oral solutions for use in paediatric cardiology: formulation and stability study.
Klovrzova S, Zahalka L, Kriz T, Zahalkova O, Matysova L, Sklubalova Z, Horak P. |
2016 |
4780 |
Czasopismo
Int J Pharm Compound 2023 ;27,3:256-262 |
Extemporaneous Topical Minoxidil Solutions for the treatment of Alopecia : Stability Studies and Incorporation Tests of Active Ingredients in ALOPLUS FAST Base.
Spennacchio A, Lopedota AA, Dibenedetto MT, La Forgia FM, Fontana S, Franco M, Denora N. |
2023 |
4436 |
Czasopismo
Anaesthesiol Intensive Ther 2018 ; 50, 3: 221-225. |
Extended compatibility of fentanyl and ketamine in dextrose 5%.
Hanifah S, Kennedy R.A; Ball P.A. |
2018 |
4755 |
Czasopismo
J Oncol Pharm Practice 2023 |
Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4°C and 25°C.
Vieillard V, Le Guyader G, Jallades A, Astier A. |
2023 |
110 |
Czasopismo
Int J Pharm 1989 ; 54: 181-189. |
Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers.
Vincke BJ, Verstraeten AE, El Eini DID, Mc Carthy TM. |
1989 |
4191 |
Czasopismo
GaBI Journal 2018 |
Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at varioustemperatures.
Vieillard V, Astier A, Paul M. |
2018 |
1995 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 1073-1074. |
Extended stability of ascorbic acid in 5% dextrose injection and 0.9% sodium chloride injection.
Chin A, Liu S, Ting-Chan J, Gill MA. |
2005 |
4026 |
Czasopismo
Hosp Pharm 2017 ; 52, 8 : 570-573 |
Extended Stability of Epinephrine Hydrochloride Injection in Polyvinyl Chloride Bags Stored in Amber Ultraviolet Light-Blocking Bags.
Van Matre E.T, Ho K.C., Lyda C, Fullmer B.A, Oldlan A.R, Kiser T.H. |
2017 |
88 |
Czasopismo
J Acquired Immune Defic Syndr 1992 ; 5: 354-358. |
Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis.
Mole L, Oliva C, O?Hanley P. |
1992 |
3350 |
Czasopismo
Am J Health-Syst Pharm 2012 ; 69:1999-2001 |
Extended stability of intravenous acetaminophen in syringes and opened vials.
Kwiatkowski J.L, Johnson C.E, Wagner D.S. |
2012 |
4737 |
Czasopismo
Hosp Pharm 2023 ; 58, 2/ 183-187. |
Extended Stability of Isoproterenol Hydrochloride Injection in Polyvinyl Chloride Bags Stored in Amber Ultraviolet Light Blocking Bags.
Van Matre E.T, Rice P.J, Wempe M.F, Lyda C, Kiser T.H. |
2023 |
3301 |
Czasopismo
Hosp Pharm 2012 ; 47, 4: 289-292. |
Extended Stability of Magnesium Sulfate Infusions Prepared in Polyolefin Bags.
Sayre B.E, Prettyman T, Kaushal G. |
2012 |
3866 |
Czasopismo
Int J Pharm Compound 2016 ; 30, 3 : 247-249. |
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children.
Nahata M C. |
2016 |
2097 |
Czasopismo
Int J Pharm Compound 2006 ; 10: 156-158. |
Extended stability of oxytocin in common infusion solutions.
Trissel LA, Zhang Y, Douglass K, Kastango E. |
2006 |
2337 |
Czasopismo
Can J Hosp Pharm 2009 ; 62, 2: 135-141. |
Extended Stability of Pantoprazole for Injection in 0.9% Sodium Chloride or 5% Dextrose at 4°C and 23°C
Walker S.E, Iazzetta J, Law S. |
2009 |
4271 |
Czasopismo
Adv Ther 2019 |
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Yun J, Kim J, Chung J, Hwang S-J, Park S-J. |
2019 |
3329 |
Czasopismo
Hosp Pharm 2012 ; 47, 7: 538-543. |
Extended Stability of Sodium Bicarbonate Infusions Prepared in Polyolefin Bags.
Sayre B.E, Prettyman T, Kaushal G. |
2012 |
3945 |
Czasopismo
Can J Hosp Pharm 2017 ; 70,1 : 7-12. |
Extended Stability of Sodium Phosphate Solutions in Polyvinyl Chloride Bags.
Perks W, Iazzetta J, Chan P.C, Brouzas A, Law S,Walker S.E. |
2017 |
4016 |
Czasopismo
Ann Pharm Fr 2017 ; 75, 6: 420-435. |
Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bag.
Vieillard V, Paul M, Ibrahim T, Astier A. |
2017 |
4649 |
Czasopismo
GaBI Journal 2021 ; 10, 4 |
Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices.
Davies L, Milligan K, Corris M, Clarke I, Dwyer P, Lee S-E, Teraoka J, Crouse-Zeineddini J, Hippenmeyer J. |
2021 |
2642 |
Czasopismo
Int J Pharm 1982 ; 11, 4: 329-336. |
Factors affecting captopril stability in aqueous solution
Timmins P, Jackson IM, Yu-chang John Wang. |
1982 |
1182 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 1449-1454. |
Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate.
Mason NA, Cline S, Hyneck ML, Berardi RR, Ho NFH, Flynn GL. |
1981 |
122 |
Czasopismo
Int J Pharm Pract 1993 ; 2: 39-43. |
Factors affecting the physical and chemical stability of morphine sulphate solutions stored in syringes.
Grassby PF, Hutchings L. |
1993 |
522 |
Czasopismo
Can J Hosp Pharm 1989 ; 42: 97-103. |
Famotidine stability in total parenteral nutrient solutions.
Walker SE, Iazetta J, Lau DWC, Madorin PL. |
1989 |
3463 |
Czasopismo
Nursing 2011 ; 29 :62-6 |
Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad.
Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R. |
2011 |
3758 |
Czasopismo
J Pharm Pract and Res 2014 ; 44, 89?94 |
Feasibility and stability of metaraminol in pre-filled syringes.
To T.P, Ching M.S, Booth J.C, Zeglinski P, McGrath A, Elli A.G,Garrett K. |
2014 |
3819 |
Czasopismo
J Pharm Biomed Anal 2015 ; 118: 105-112. |
Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions.
Ferreiraa A.O, Poloninia H.C, Silva S.L, Patricio F.B, Brand?oa M.A.F, Raposoa N.R.B. |
2015 |
3503 |
Laboratorium
Hameln Pharmaceuticals 2012 |
Fentanyl - Summary of product Characteristics
|
2012 |
3618 |
Laboratorium
Amgen 2014 |
Filgrastim (Neupogen®) - Summary of Product Characteristics
|
2014 |
1413 |
Czasopismo
Int J Pharm Compound 1999 ; 3: 67-68. |
Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature.
Lieu CL, Chin A, Gill MA. |
1999 |
3522 |
Laboratorium
Actavis 2013 |
Flucloxacillin - Summary of Product Characteristics.
|
2013 |
3565 |
Laboratorium
Aguettant 2008 |
Flumazenil Aguettant - Résumé des caractéristiques du produit.
|
2008 |
3474 |
Laboratorium
Accord Healthcare Limited 2009 |
Fluorouracil - Summary of Product Characteristics
|
2009 |
1998 |
Czasopismo
Am J Health-Syst Pharm 1998 55: 1315-1316. |
Fluorouracil precipitate.
Allwood MC. |
1998 |
3992 |
Czasopismo
Int J Pharm 2016 ; 509 : 279:284. |
Formulation and charaterization of 0,1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas.
Bougueon G, Lagarce F, Martin L, Pailhoriès H, Bastiat G, Vrignaud S. |
2016 |
3800 |
Czasopismo
Iranian J Pharm Res 2003 : 157-160. |
Formulation and Clinical Evaluation of Povidone-Iodine Ophthalmic Drop.
Rahim Bahri Najafi, Soleyman Mohammadi Samania, Nahid Pishvab, Fateme Moheimania. |
2003 |
2786 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62, 5: 485-491. |
Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus.
Ungphaiboon S, Nittayananta W, Vuddhakul V, Maneenuan D, Kietthubthew S, Wongpoowarak W, Phadoongsombat N. |
2005 |
3321 |
Czasopismo
Int J Pharm Compound 2012 ; 16, 4: 342-346. |
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets.
Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa. |
2012 |
3785 |
Czasopismo
J Pain Palliat Care Pharm 2014 ;,28, 4: 367?370. |
Formulation and Stability of an Extemporaneously Compounded Oral Solution of Chlorpromazine HCl
Prohotsky D.L, . Juba K.M, Zhao F. |
2014 |
4547 |
Czasopismo
EJHP 2021 |
Formulation and stability of an extemporaneously compounded propafenone hydrochloride oral suspension for children with arrhythmia.
Lin Y-S, Lin S-C, Hsieh Y-T,Liu L-Y,Lin C-H, Shen L-J, Huang C-F. |
2021 |
2682 |
Czasopismo
Int J Pharm Pract 1991 ; 1: 19-22. |
Formulation and stability of cefuroxime eye-drops.
Oldham GB. |
1991 |
2476 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1489-1491. |
Formulation and stability of diazepam suspension compounded from tablets
Strom JG, Jr, Kalu AU. |
1986 |
2542 |
Czasopismo
Ann Pharmacotherapy 1997 ;31:1291-1295. |
Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone.
Fawcett JP, Morgan NC, Woods DJ. |
1997 |
3669 |
Czasopismo
Ann Pharm Fr 2015 ; 73, 1: 31-36. |
Formulation and stability study of a pediatric 2% phenylephrine hydrochloride eye drop solution
Dreno C, Gicquel T, Harry .M, Tribut O, Aubin F, Brandhonneur N, Dollo G. |
2015 |
4170 |
Czasopismo
Int J Pharm Compound 2018 22,5:433-439 |
Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding.
Zhao F, Dave V.S, Mar M, Perri J. |
2018 |
4523 |
Czasopismo
Pharm Dev Technol 2021 |
Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
El Mershati S, Thouvenin A , Secretan P-H, De Lonlay P, Tuchmann-Durand C, Cisternino S, Schlatter J. |
2021 |
4360 |
Czasopismo
Hosp Pharm 2019 |
Formulation and Stability Study of Omeprazole Oral Liquid Suspension for Pediatric Patients.
Oriana Boscolo, Francesco Perra, Leandro Salvo, Fabiàn Buontempo, and Silvia Lucangioli. |
2019 |
4008 |
Plakat
Hopipharm Congress 2017-Nancy 2017 |
Formulation et étude de stabilité de crèmes au sirolimus dosées à 0,1, à 0,25 ou à 0,5% m/m.
Vrignaud S, Bougueon G, Briot T, Truffaut C, Martin L, Pailhori?s H, Bastiat G, Clerc M-A, Lagarce F. |
2017 |
4104 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 |
Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method.
Bonnet M, Dermu M, Roessle C, Bellaiche M, Abarou T, Vasseur V, Benakouche S, Storme T. |
2018 |
3017 |
Czasopismo
Eur Hosp Pharm 1996 ; 2: 176-180. |
Formulation of a stable calcium gluconate gel for topical treatment of hydrofluoric acid burns.
Rotheli-Simmen B, Martinelli E, Muhlebach S. |
1996 |
2720 |
Czasopismo
J Ocular Pharm Ther 2007 ; 23, 3: 292-303. |
Formulation of sirolimus eye drops corneal permeation studies.
Buech G, Bertelmann E, Pleyer U, Siebenbrodt I, Borchert HH. |
2007 |
4517 |
Czasopismo
EJHP 2020 |
Formulation, long-term physicochemical and microbiological stability of 15% topical resorcinol for hidradenitis suppurativa.
Cordero-Ramos J, Merino-Bohórquez V, Delgado-Valverde , Barros-Tornay R, Cameán-Fenández M, Calleja-Hernández M.A. |
2020 |
4079 |
Czasopismo
J Pharm Anal 2017 ; 7, 4: 237-243. |
Formulation, stability testing, and analytical characterization of melatonin-based preparation for clinical trial.
Filali S, Bergamelli C, Tall M.L, Salmon D, Laleye D, Dhelens C, Diouf E, Pivot C, Pirot F. |
2017 |
2295 |
Laboratorium
Merck Sharp Dohme 2013 |
Fosaprepitant (Emend®) - Summary of Product Characteristics
|
2013 |
3662 |
Laboratorium
Clinigen 2014 |
Foscavir (Foscarnet®) - Summary of Product Characteristics
|
2014 |
3663 |
Laboratorium
Panpharma 2011 |
Fosfomycine (Fosfomycine Panpharma®) - Résumé des caractéristiques du produit
|
2011 |
1419 |
Czasopismo
Int J Pharm Compound 1999 ; 3: 235-238. |
Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride.
Riggs RM, English BA, Webster AA, McGuire JM, Riordan JM. |
1999 |
2124 |
Czasopismo
EJHP Science 2006 ; 12, 4: 72-75. |
Freeze thaw treatment of ketorolac tromethamine in 5% dextrose infusion polyolein bags: effect of drug concentration and microwave power on the long-term stability at 4°C.
Hecq JD, Boitquin L, Lebrun C, Vanbeckbergen D, Evrard JM, Jamart J, Galanti L. |
2006 |
1329 |
Czasopismo
Br J Parent Ther 1986 ; march/april: 42-44. |
Freeze-thaw stability of antibiotics used in an IV additive service.
Brown AF, Harvey DA, Hoddinott DJ, Britton. |
1986 |
3639 |
Laboratorium
Wockhardt 2013 |
Furosemide - Summary of Product Characteristics
|
2013 |
1855 |
Czasopismo
J Pharm Biomed Anal 2000 ; 23: 803-817. |
Furosemide assay in pharmaceuticals by Micellar liquid chromatography: study of the stability of the drug.
Carla-Broch S, Esteve-Romero J, Garcia-Alvarez-Coque MC. |
2000 |
4060 |
Czasopismo
EJHP 2018 ;25,3:144-149 |
Furosemide ethanol-free oral solutions for paediatric use : formulation, HPLC method and stability study.
Zahalka L, Klovrzova S, Matysova L, Sklubalova Z, Solich P. |
2018 |
3661 |
Laboratorium
Laboratoire L?o 2012 |
Fusidate de sodium (Fucidine®) - Résumé des caractéristiques du produit
|
2012 |
3496 |
Laboratorium
Actavis 2009 |
Gemcitabin Actavis solution - Stability Study
|
2009 |
1913 |
Laboratorium
Pfizer Europe 2020 |
Gemtuzumab ozogamicin (Mylotarg® - Summary of Product Characteristics)
|
2020 |
3643 |
Laboratorium
Sanofi 2015 |
Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
|
2015 |
1395 |
Czasopismo
Thromb Haemost 1980 ; 43: 67. |
Glass adsorption of highly purified urokinase.
Toki N, Sumi H. |
1980 |
4802 |
Laboratorium
Aguettant Laboratory 2021 |
Glucose-1-Phosphate disodique tétrahydraté (Phocytan®) - Résumé des caractéristiques du produit
|
2021 |
3599 |
Laboratorium
Amco Amdipharm Mercry 2013 |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
|
2013 |
1643 |
Czasopismo
Hosp Pharm 1994 ; 29: 76. |
Haldol-benztropine incompatibility.
Raleigh F, Gibler B. |
1994 |
985 |
Czasopismo
Ann Pharmacotherapy 1996 ; 30: 549. |
Haloperidol and diphenhydramine compatibility.
Raleigh FR, Gibler BS. |
1996 |
1022 |
Czasopismo
Drug Intell Clin Pharm 1986 ; 20: 886. |
Heparin and aminoglycosides instability.
Hutchinson SMW. |
1986 |
3540 |
Laboratorium
Wockhardt 2010 |
Heparin sodium - Summary of Product Characteristics.
|
2010 |
3113 |
Książka
Compendium Suisse des m?dicaments 2010 |
Herceptin
|
2010 |
3796 |
Czasopismo
Br Ophtalmol 1995 ; 79: 753-755. |
High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study.
Morlet N, Young S, Naidoo D et al. |
1995 |
1151 |
Czasopismo
J Chromatogr 1981 ; 212: 339-346. |
High-performance liquid chromatographic determination of sodium nitroprusside.
Baaske DM, Smith MD, Karnatz N, Carter JE. |
1981 |
3757 |
Czasopismo
Antimicrob Agents Chemother 2014 ; 58 : 2849-2855. |
How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis?
Bourget P, Amin A, Dupont C, Abely M, Desmazes-Dufeu N, Dubus J.C, Jouani B.-L., Merlette C, Nov?-Josserand R, Pages J, Panzo R |
2014 |
2166 |
Czasopismo
J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929. |
HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine.
Nassr S, Dubuc MC, Lavoie P, Brazier JL. |
2003 |
2011 |
Czasopismo
Krankenhauspharmazie 2005 ; 26, 6: 206-210. |
HPLC-stabilitätuntersuchungen zu rekonstituierten Bortezomib-Lösungen.
Friess D, Nguyen HC, Lipp HP. |
2005 |
1733 |
Czasopismo
Pharmazie 1999 ; 54: 542-544. |
HPTLC-based stability assay for determination of amiodarone in intravenous admixtures.
Kopelent-Frank H, Schimper A. |
1999 |
3617 |
Laboratorium
Wockhardt 2011 |
Hyaluronidase (Hyalase®) - Summary of Product Characteristics
|
2011 |
3184 |
Laboratorium
CP Pharmaceuticals 2005 |
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
|
2005 |
2275 |
Czasopismo
Int J Pharm 1998 ; 173: 221-232. |
Hydrolysis kinetics and stability predictions for a mixture of R and S temocillin isomers.
Craig Dyar S, Notari RE. |
1998 |
2215 |
Czasopismo
Chem Pharm Bull 1984 ; 32, 3: 1113-1119. |
Hydrolysis of succinylcholine chloride in pH range 3.0 to 4.5.
Boehm J.J, Poust R.I. |
1984 |
2364 |
Plakat
PharmSciFair 2009 |
Hydromorphone and dipyrone in PCA devices: Is still a therapy with hydromorphone?
M?ller S, Trittler R, Schubert R, Strehl E. |
2009 |
120 |
Czasopismo
Can J Hosp Pharm 1988 ; 41: 177-182. |
Hydromorphone and morphine stability in portable infusion pump cassettes and minibags.
Walker SE, Coons C, Matte D, DeAngelis C, Iazzetta J, Kolos C, Birkhans B. |
1988 |
3932 |
Laboratorium
Serb Laboratoire 2015 |
Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit
|
2015 |
3600 |
Laboratorium
UCB Pharma SA 2009 |
Hydroxyzine (Atarax®) - Résumé des caractéristiques du produit
|
2009 |
1380 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 74. |
Identification of labetolol precipitate.
Alam AS. |
1984 |
1915 |
Laboratorium
Genzyme 2010 |
Imiglucerase (Cerezyme®) -Summary of product Characteristics
|
2010 |
3530 |
Laboratorium
Hospira 2013 |
Imipenem/Cilastatin – Summary of Product Characteristics
|
2013 |
1871 |
Czasopismo
Int J Pharm 2002 ; 234: 205-212. |
Impact of deep freezing on the stability of 25 mg/ml vancomycin ophtalmic solutions.
Sautou-Miranda V, Libert F, Grand-Boyer A, Gellis C, Chopineau J. |
2002 |
2649 |
Czasopismo
Int J Pharm 2002 ; 234, 1-2: 205-212. |
Impact of deep freezing on the stability of 25 mg/ml vancomycin ophtalmic solutions.
Sautou-Miranda V, Libert F, Grand-Boyer A, Gellis C, Chopineau J. |
2002 |
2733 |
Czasopismo
J Pharm Clin 1999 ; 18: 179-182. |
Impact of deep-freezing on pefloxacin eye drops stability.
Gellis C, Sautou-Miranda V, Arvouet A. |
1999 |
4605 |
Czasopismo
Ann Allergy 2012 ; 2:28. |
Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility.
Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P. |
2012 |
4757 |
Czasopismo
Hosp Pharm 2023 ; 58, 3: 304-308. |
In Vitro Assessment of Compounded Lurasidone Suspensions for Enteral Feeding Tubes.
Wojcinski J, Nathan K, Zhaohttps F. |
2023 |
966 |
Czasopismo
JPEN 1991 ; 15: 536-539. |
In vitro assessment of vancomycin HCl compatibility after coinfusion with a specialized amino acid formulation.
Martins AM, McDougal A, Hamilton D, Igwemezie L, McErlane K. |
1991 |
4352 |
Czasopismo
J Clin Pharm Ther 2019 ; 44: 875-882. |
In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.
Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. |
2019 |
979 |
Czasopismo
Int Pharm J 1995 ; 9: 57. |
In vitro compatibility of granisetron with selected alkaline drugs.
D'Arcy PF. |
1995 |
3294 |
Czasopismo
EJHP 2012 ; 19: 57-64. |
In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs
Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. |
2012 |
3381 |
Czasopismo
EJHP 2013 ; 20:110-116. |
In vitro compatibility of various cardioactive drugs during simulated Y-site administration.
Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A. |
2013 |
4048 |
Czasopismo
Hosp Pharm 2017 ;52,11:752-760 |
In vitro evaluation of eslicarbazepine delivery via enteral feeding tubes.
Reindel K, Zhao F, Hughes S, Dave V. |
2017 |
209 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1574-1579. |
In vitro evaluation of the stability of raniditine hydrochloride in total parenteral nutrient mixtures.
Williams MF, Hak LJ, Dukes G. |
1990 |
643 |
Czasopismo
Cancer Treat Rep 1987 ; 71: 1189-1192. |
In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide.
Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. |
1987 |
3205 |
Czasopismo
AAPS Pharm Sci 2011 ; 15, 2 : 264-272. |
in vitro stability and compatibility of tenecteplase in central venous access devices.
Lentz, Y.K. , Joyce, M., Lam, X. |
2011 |
3953 |
Czasopismo
Hemodial Int 2011 ; 15, 2 : 364-272. |
In vitro stability and compatibility of tenecteplase in central venous access devices.
Lentz Y.K, Joyce M, Lam X. |
2011 |
4484 |
Czasopismo
Drugs R D 2022 ;22, 95–104 |
In Vitro Stability and Recovery Studies of Pimavanserin in Water and in Different Vehicles Orally Administered.
Bokser A D, Holmes Adegbenle Y, Stoisavljevic V, Norton J C. |
2022 |
2793 |
Czasopismo
Hosp Pharm 2015 ; 50, 4 : 296-303. |
In Vitro Stability Evaluation of Different Pharmaceutical Products Containing Meropenem.
Tomasello C, Leggieri A, Cavalli R, Di Perri G, D?Avolio A. |
2015 |
2468 |
Czasopismo
J Pharm Sci 2023 ; 112: 963-973. |
In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps.
Mohnicke M, Blecher A, Beichert K, Bidlingmaier B, Todt E-J, Dette C, Rotthaeuser B, Mukherjee B. |
2023 |
3149 |
Czasopismo
Diabetes Tech and Ther 2006 ; 8, 3: 358-368. |
In Vitro Stability of Insulin Lispro in Continuous Subcutaneous Insulin Infusion.
DeFelippis MR, Bell MA, Heyob JA, Storms SM. |
2006 |
1037 |
Czasopismo
J Pharm Sci 1984 ; 73: 838-839. |
In vitro stability of sodium nitroprusside solutions for intravenous administration.
Mahony C, Brown JE, Stargel WW, Verghese CP, Bjornsson TD. |
1984 |
1322 |
Czasopismo
JPEN 1983 ; 7: 156-158. |
In vitro study of inline filtration of medications commonly administered to pediatric cancer patients.
Ennis CE, Merritt RJ, Neff DN. |
1983 |
4194 |
Czasopismo
Bio Drugs 2018 32;619-625 |
In-Use Physichochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion.
Kim S.J, Lee J.W, Kang H.Y, Kim S.Y, Shin Y.K, Kim K.W, Oh J.S, Lim K.J, Kim J.Y. |
2018 |
3812 |
Czasopismo
Int J Pharm Compound 2015 ; 19, 5 : 432-436. |
In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers.
Bhattacharya S, Parekh S, Dedhiya M. |
2015 |
4518 |
Czasopismo
EJHP 2020 |
In-use stability of diluted thiamazole (methimazole) infusion solutions in prefilled 0.9% sodium chloride infusion bags for continuous infusion.
Mohr A, Krämer I. |
2020 |
2975 |
Plakat
ESCP 2014 2014 |
In-Use stability of herceptin for subcutaneous injection with different administration materials.
Nalenz H, Schoenhammer K, Dietel E, Heynen S.R, Grauschopf U, Mahler H.C. |
2014 |
4784 |
Czasopismo
EJHP 2023 |
In-use stability of ready-to- administer daratumumab subcutaneous injection solution in plastic syringes.
Knoll L, Thiesen J, Klassen .D, Reinders L.M.H, Türk J, Krämer I. |
2023 |
264 |
Czasopismo
Pharm Hosp Fr 1997 ; 121: 124. |
Incompatibilité physico-chimique entre l’oméprazole et la vancomycine.
Leboucher G, Charpiat B. |
1997 |
1625 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 314-321. |
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Trissel LA, Saenz C, Williams YW, Ingram D. |
2001 |
4429 |
Czasopismo
Medicine 2016 ; 95:25(e3824) |
Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration.
Fang B-X, Li P, Shi X-Y, Chen F.C, Wang L.H. |
2016 |
2630 |
Czasopismo
Hosp Pharm 1981 ; 16: 486-487. |
Incompatibilities with orally administered liquid neuroleptic medication combinations.
Raleigh F. |
1981 |
921 |
Czasopismo
Hosp Pharm 1998 ; 33: 284-292. |
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Trissel LA, Gilbert DL, Martinez JF. |
1998 |
241 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2639. |
Incompatibility between ceftriaxone sodium and labetolol hydrochloride.
Leader WG, Jones JM. |
1996 |
1084 |
Czasopismo
Lancet 1988 ; 1(8587): 700. |
Incompatibility between fat emulsion and calcium plus heparin in parenteral nutrition of premature babies.
Raupp P, von Kriek R, Schmidt E, Pfahl HG, G?nther O. |
1988 |
3873 |
Czasopismo
Am J Health-Syst Pharm 2016 ; 73:755. |
Incompatibility between irinotecan and fluorouracil injections
Tan X, Hu J. |
2016 |
205 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 184. |
Incompatibility of amiodarone hydrochloride and evacuated glass bottles.
Strozyk WR, Williamson R, Thompson D. |
1996 |
200 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2340. |
Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections.
Korth-Bradley JM, Ludwig S, Callaghan C. |
1995 |
3868 |
Czasopismo
J Oncol Pharm Practice 2016 ; 22: 571-572 |
Incompatibility of busulfan with 1 ml Luer-Lock syringes.
Loboda C, Lider P, Vigneron J. |
2016 |
106 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 519. |
Incompatibility of cefoperazone and promethazine.
Scott SM. |
1990 |
260 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2054, 2057. |
Incompatibility of cefotaxime sodium and vancomycin sulfate during Y-site administration.
Szof C, Walker PC. |
1993 |
103 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1347. |
Incompatibility of cefotetan disodium and promethazine hydrochloride.
Erickson SH, Ulici D. |
1995 |
1739 |
Czasopismo
Am J Health-Syst Pharm 1990 ; 47: 519. |
Incompatibility of cefperazone and promethazine.
Scott SM. |
1990 |
1399 |
Czasopismo
Pharm J 1987 ; 238: 577. |
Incompatibility of ceftazidime and vancomycin.
Cairns CJ, Robertson J. |
1987 |
1744 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 384. |
Incompatibility of ceftriaxone sodium with lactated Ringer’s injection.
Burkiewicz JS. |
1999 |
95 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 77. |
Incompatibility of ceftriaxone with vancomycin.
Pritts D, Hancock D. |
1991 |
3475 |
Czasopismo
Am J Health-Syst Pharm 2013 ;70:1966-1970. |
Incompatibility of ciprofloxacin and meropenem injections.
Chen L.Y, Chen J, Waters V, Boodhan S. |
2013 |
1085 |
Czasopismo
Radiology 1989 ; 173: 91-92. |
Incompatibility of contrast agents with intravascular medications.
Irving HD, Burbridge BE. |
1989 |
3486 |
Czasopismo
Cardiovasc Intervent Radiol 2013 ; 36: 237-238. |
Incompatibility of contrast medium and trisodium citrate.
Delcour C, Brunnix G. |
2013 |
1607 |
Czasopismo
Hosp Pharm 2000 ; 35: 1192-1196. |
Incompatibility of erythromycin lactobionate and sulfamethoxazole/trimethoprim with linezolid injection.
Trissel LA, Zhang Y, Xu QA. |
2000 |
3664 |
Czasopismo
Am J Health-Syst Pharm 2014 ; 71:901-902. |
Incompatibility of esmolol hydrochloride and furosemide in a central venous access port
Zhao B, Sun W. |
2014 |
155 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 710-715. |
Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium.
Trissel LA, Martinez JF, Xu QA. |
1995 |
1326 |
Czasopismo
Am J Roentgenol 1986 ; 146: 1300-1301. |
Incompatibility of Hexabrix and papaverine.
Pilla TJ, Beshany SE, Shields JB. |
1986 |
2349 |
Czasopismo
Am J Health-Syst Pharm 2009 ; 66: 1253-1254. |
Incompatibility of imipenem–cilastatin and amoxicillin
Pourroy B, Milano Bausset E, Boulamery A, Gauthier Villano L, Braguer B. |
2009 |
1745 |
Czasopismo
Am J Health-Syst Pharm 1992 ; 49: 836-838. |
Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate.
Thompson DF, Heflin NR. |
1992 |
494 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 836,838. |
Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate.
Thompson DF, Heflin NR. |
1992 |
1137 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1745-1746. |
Incompatibility of iron dextran and a total nutrient admixture.
Vaughan LM, Small C, Plunkett V. |
1990 |
228 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2964. |
Incompatibility of ketorolac tromethamine with haloperidol lactate and triethylperazine maleate.
Mendenhall A, Hoyt DB. |
1994 |
476 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2960-2962. |
Incompatibility of ketorolac tromethamine with selected postoperative drugs.
Knapp AJ, Mauro VF, Alexander KS. |
1992 |
89 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2521-2522. |
Incompatibility of labetalol hydrochloride and furosemide.
Zeisler J, Alagna C. |
1993 |
1079 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 2651. |
Incompatibility of morphine sulfate and prochlorperazine edisylate in syringes.
Stevenson JG, Patriarca C. |
1985 |
3380 |
Czasopismo
Ann Pharmacotherapy 2013 ;47:426-427. |
Incompatibility of Piritramide with Cephalosporins.
Eckle V-S, Heim E, Hahn M, Grasshoff C. |
2013 |
1646 |
Czasopismo
Anaesthesia 2001 ; 56: 920. |
Incompatibility of prochlorperazine and ketoprofen.
Kannan S. |
2001 |
1672 |
Czasopismo
Anesthesiology 1998 ; 89: 1609. |
Incompatibility of propofol emulsion with anesthesic drugs.
Lamontagne C, Brouillette D, Hardy JF. |
1998 |
3101 |
Czasopismo
Perit Dial Int 2002 ; 22: 93-94. |
Incompatibility of Vancomycin and Ceftazidime for Intraperitoneal Use.
Wazny LD, Blake PG. |
2002 |
3930 |
Laboratorium
Serb laboratoire 2013 |
Indocyanine (Infracyanine®) - Résumé des caractéristiques du produit
|
2013 |
754 |
Laboratorium
Merck Sharp & Dohme 2019 |
Infliximab (Remicade®) – Summary of Product Characteristics
|
2019 |
3137 |
Czasopismo
Retina 2010 ; 30, 1: 81-84. |
Infliximab stability after reconstitution, dilution, and storage under refrigeration.
Beer PM, Wong SJ, Schartman JP, Kulas KE, Hartman CL, Giganti M, Falk NS. |
2010 |
4452 |
Plakat
Congrès Hopipharm 2019 |
Influence d'un ajout de L-carnitine dans les mélanges de nutrition parentérale destinés aux patients à domicile.
Sémély D, Bello W, Daupin J, Lebland C, Carrez L, Berger M, Sadeghipour F. |
2019 |
3869 |
Czasopismo
J Pharm Pharmacol 2016 ; 68: 433-438. |
Influence of 5% dextrose volume on amphotericin B deoxycholate preparation
Sun P, Chen J, Zhang Z, Gao X, Chen P, Li X. |
2016 |
951 |
Czasopismo
PDA J Pharm Sci Technol 1998 ; 52: 129-133. |
Influence of DL methionine and sodium metasulphite on the photostability of vitamin K1.
Ho PC, Wong VK. |
1998 |
1147 |
Czasopismo
J Pharm Pharmacol 1991 ; 43: 601-604. |
Influence of intravenous administration set composition on the sorption of isosorbide dinitrate.
De Muynck C, Colardyn F, Remon JP. |
1991 |
39 |
Czasopismo
J Pharm Clin 1997 ; 16: 45-48. |
Influence of intravenous admixtures on the stability of the new solution of 5-fluorouracil.
Farhang-Asnafi S, Callaert S, Barre J, Tillement JP, Thebault A. |
1997 |
2134 |
Czasopismo
J Pharm Sci 1998 ; 87, 12: 1572-1576. |
Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions.
Fubara JO, Notari RE. |
1998 |
2005 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 1347-1348. |
Influence of temperature and drug concentration on nafcillin precipitation.
Chan V. |
2005 |
2463 |
Czasopismo
Am J Hosp Pharm 1979 ; 50: 486-488. |
Instability of aqueous captopril solutions
Anaizi NH, Swenson C. |
1979 |
1167 |
Czasopismo
Antimicrob Agents Chemother 1987 ; 31: 610-611. |
Instability of vancomycin in infusaid drug pump model 100.
Grennberg RN, Saeed AM, Kennedy DJ, McMillian R. |
1987 |
1091 |
Czasopismo
Anesthesiology 1974 ; 40: 400-404. |
Insulin adsorption by glass infusion bottles, polyvinylchloride infusion containers, and intravenous tubing.
Petty C, Cunningham NL. |
1974 |
1175 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 995-997. |
Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets.
Hirsch JI, Wood JH, Thomas RB. |
1981 |
1245 |
Czasopismo
JPEN 1989 ; 13: 539-543. |
Insulin adsorption to three-liter ethylen vinyl acetate bags during 24-hour infusion.
Doglietto GB, Bellantone R, Bossola M, Perri V, Ratto C, Pacelli F, Sofo L, Migliore A, Manna R, Crucitti F. |
1989 |
3935 |
Laboratorium
Sanofi Laboratoire 2016 |
Insuline glulisine (Insulines Sanofi Apidra®) - Résumé des caractéristiques du produit
|
2016 |
1359 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 2420-2421. |
Interaction between vancomycin and ticarcillin.
Perest M, Allison J. |
1985 |
433 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 2221-2224. |
Interaction of aztreonam with nafcillin in intravenous admixtures.
Riley CM, Lipford LC. |
1986 |
377 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 1350-1352. |
Interaction of heparin sodium and dopamine hydrochloride in admixtures studied by microcalorimetry.
Pereira-Rosario R, Utamura T, Perrin JH. |
1988 |
1120 |
Czasopismo
Am J Hosp Pharm 1974 ; 31: 72-78. |
Interactions between drugs and plastic intravenous fluid bags. Part I: Sorption studies on 17 drugs.
Moorhatch P, Chiou WL. |
1974 |
1173 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 1308-1314. |
Interactions between drugs and polyvinyl chloride infusion bags.
Kowaluk EA, Roberts MS, Blackburn HD, Polack AE. |
1981 |
499 |
Czasopismo
Hosp Pharm 1991 ; 26: 634-635. |
Intramuscular antibiotic preparation and administration using a 1% lidocaine diluent: policies for the pediatric patient.
Rockwell K, Burch K. |
1991 |
4548 |
Czasopismo
Clin Ther 2020 ; 42, 8: 1580-1586. |
Intravenous Compatibility of Ceftazidime/Avibactam and Aztreonam Using Simulated and Actual Y-site Administration.
O'Donnell J.N, Xu A, Lodise T.P. |
2020 |
1109 |
Czasopismo
Crit Care Med 1990 ; 18: 858-861. |
Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible.
Horrow JC, Digregorio J, Barbieri EJ, Rupp E. |
1990 |
4666 |
Czasopismo
J Anal Sci Tech 2020 ; 11: 32. |
Intravenous patient-controlled analgesia: in vitro stability profiles of mixtures containing fentanyl, hydromorphone, oxycodone, nefopam, ondansetron, and ramosetron.
Lee C.H, Kim A.R, Lee M.K, Oh J.S, Lee D.K, Choi S.S. |
2020 |
4724 |
Czasopismo
Int J Pharm Compound 2022 ;26,6:522-526 |
Intravenous Physical Compatibility of Heparin Sodium and Furosemide.
Maktabi B, Howard MS, Baki G, Churchwell MD |
2022 |
732 |
Czasopismo
Am J Hosp Pharm 1975 ; 32: 575-578. |
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 1: Stability with common intravenous fluids.
Gardella LA, Zaroslinski JF, Possley LH. |
1975 |
738 |
Czasopismo
Am J Hosp Pharm 1978 ; 35: 581-584. |
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives.
Gardella LA, Kesler H, Amann A, Carter JE. |
1978 |
2324 |
Czasopismo
Int J Pharm 2009 ; 369, 1-2 : 30-37 |
Investigation into the sorption of nitroglycerin and diazepam into PVC tubes and alternative tube materials during application
Treleano A, Wolz G, Brandsch R, Welle F. |
2009 |
3666 |
Czasopismo
Int J Pharm Compound 2014 ; 18, 3: 248-252. |
Investigation of Physical and Chemical Stability of an Ointment with Herbals
Zdoryk Oleksandr A,Khokhlova Kateryna O,Georgiyants Victoriya A,Vyshnevska Liliia I. |
2014 |
4644 |
Czasopismo
Adv Ther 2021 ; 38 : 5609–5622 |
Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17.
Kyeong Shin Y, Yong Han W, Jung Kim S, Woo Kim K, Won Ro J, Bin Lee J, Seok Oh J, Astier A. |
2021 |
1961 |
Czasopismo
Int J Pharm 2005 ; 293: 303-310. |
Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles.
Kim SC, Yoon HJ, Lee JW, Yu J, Park ES, Chi SC. |
2005 |
4012 |
Czasopismo
EJHP 2018 ; 25, e2 |
Investigations into the physical and chemical stability of concentrated co-trimoxazole intravenous infusions.
Khaleel I, Tabish R Zaidi S, Shastri M, Suji Eapen M, Chiau Ming L, Wanandy T, P Patel R. |
2018 |
4570 |
Czasopismo
Pharmaceuticals 2019 |
Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients.
Greenhill K, Hornsby E, Gorman G. |
2019 |
2655 |
Czasopismo
Int J Pharm 2008 ; 353, 1-2: 1-7. |
Invitro release and stability of an artesunate rectal gel suitable for pediatric use.
Gaudin K, Barbaud A, Boyer C, Langlois MH, Lagueny AML, Dubost JP, Millet P, Fawaz F. |
2008 |
4782 |
Czasopismo
Drugs R D 2023 ;23,4:363 - 375 |
In‑Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M, Jeong H, Yun J, Kim J, Kim S, Lee Y, Park S-J. |
2023 |
4377 |
Czasopismo
Radiology 1992 ; 184: 385-387. |
Ionic lodinated Contrast Medium and Amobarbital Sodium Mixtures: Potential for Precipitation.
Monsein L.H, Miller T.J, Kuwahara S.K, Sostre S, Debrun G.M. |
1992 |
3352 |
Laboratorium
Bristol Myers Squibb 2011 |
Ipilimumab (Yervoy®) - Summary of Product Characteristics
|
2011 |
3129 |
Laboratorium
Pfizer 2008 |
Irinotécan (Campto®) – Résumé des caractéristiques du produits
|
2008 |
1391 |
Czasopismo
Can J Hosp Pharm 1998 ; 51: 271-272. |
Is heparin always compatible with TPN and fat emulsion admixtures?
Vanstone GL. |
1998 |
4617 |
Laboratorium
Sanofi Genzyme 2021 |
Isatuximab - SARCLISA 20mg/mL concentrate for solution for infusion - Summary of Product Characteristics - updated 16 August 2021
|
2021 |
2864 |
Laboratorium
Astellas Pharma 2015 |
Isavuconazonium (Cresemba®) - Summary of Product Characteristics
|
2015 |
3660 |
Laboratorium
Hospira 2016 |
Isoprenaline (Isuprel®) - Résumé des caractéristiques du produit
|
2016 |
3341 |
Czasopismo
Krankenhauspharmazie 2001 ; 7: 331-333. |
Ist teurer immer auch besser? Analytiklabor der Apotheke unterstütz Einkauf sentcheidungen bei Carboplatin-Präparaten.
Trittler R, Jung B, Strehl E. |
2001 |
1270 |
Czasopismo
J Pharm Belg 1980 ; 35: 389-393. |
IV infusion of glyceryl trinitrate. Study of the sorption on various plastic containers.
Mathot F, Bonnard J, Han P, Bosly J. |
1980 |
3084 |
Laboratorium
Bristol Myers Squibb 2009 |
Ixabepilone (Ixempra®) – Summary of Product Characteristics
|
2009 |
3488 |
Czasopismo
Farm Hosp 1995 ; 19, 1: 41-44. |
Jarabe de midazolam: Estudio de estabilidad de una solucion oral para uso hospitaliaro.
Caldes R, Ciges S.M, Borras E, Calvelo R, Lisart F. |
1995 |
3501 |
Laboratorium
Pfizer 2011 |
Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics
|
2011 |
3593 |
Laboratorium
Beacon Pharmaceuticals 2011 |
Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics
|
2011 |
1703 |
Czasopismo
Krankenhauspharmazie 1995 ; 16: 101-103. |
Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln.
Schuster F, Bernard R. |
1995 |
1481 |
Czasopismo
Krankenhauspharmazie 1994 ; 9: 337-340. |
Kompatibilität von ofloxacin mit ampicillin.
Messerschmidt W. |
1994 |
3686 |
Laboratorium
Eusapharma 2013 |
L asparaginase (Kidrolase®) - Résumé des caractéristiques du produit
|
2013 |
3609 |
Laboratorium
Aspen Pharma 2013 |
Labetalol (Trandate®) - Summary of Product Characteristics
|
2013 |
1014 |
Czasopismo
Clin Pharmacol Ther 1988 ; 43: 183. |
Lack of photodegradation but significant adsorption of nifedipine in administration systems.
Larsen JS, Uden DL, Zaske DE. |
1988 |
1819 |
Czasopismo
J Clin Pharm Ther 2002 ; 27: 139-142. |
Leaching of diethyl hexyl phtalate from polyvinyl chloride bags into intravenous etoposide solution.
Demoré B, Vigneron J, Perrin A, Hoffman MA, Hoffman M. |
2002 |
1984 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 182-188. |
Leaching of diethylhexyl phtalate from multilayer tubing into etoposide infusion solutions.
Bagel-Boithias S, Sautou-Miranda V, Bourdeaux D, Tramier V, Boyer A, Chopineau J. |
2005 |
455 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 2800-2802. |
Leaching of diethylhexyl phtalate from polyvinyl chloride bags into intravenous cyclosporine solution.
Venkataramanan R, Burckart GJ, Ptachcinski RJ, Blaha R, Logue LW, Bahnson A, Giam CS, Brady JE. |
1986 |
140 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 1405-1409. |
Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components.
Pearson SD, Trissel LA. |
1993 |
165 |
Czasopismo
Int J Pharm 1994 ; 105: 89-93. |
Leaching of diethylhexyl phthlate from PVC bags into intravenous teniposide solution.
Faouzi MA, Dine T, Luyckx M, Gressier B, Goudaliez F, Mallevais ML, Brunet C, Cazin M, Cazin JC. |
1994 |
4665 |
Laboratorium
Sanofi Aventis 2021 |
LEMTRADA 12 mg concentrate for solution for infusion - Summary of Product Characteristics. Updated 24-Sep-2021
|
2021 |
3920 |
Laboratorium
Fresenius Kabi 2018 |
Levofloxacine - Résumé Caractéristique du Produit
|
2018 |
3369 |
Laboratorium
MEDAC France 2011 |
Levofolinate de sodium Medac - Résumé des caractéristiques du produits
|
2011 |
4571 |
Laboratorium
Orion Pharma 2010 |
Levosimendan (Simdax 2.5 mg/ml) - Summary of Product Characteristics
|
2010 |
1126 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 97-101. |
Lidocaine stability in cardioplegic solution stored in glass bottles and polyvinyl chloride bags.
Lackner TE, Baldus D, Butler CD, Amyx C, Kessler G. |
1983 |
3286 |
Czasopismo
Yakugaku Zasshi 2010 ; 130, 10: 1369-1374. |
Light-induced Deterioration Test of Carboplatin under Clinical Settings.
Okamoto Y, Tazumi K, Sanada Y, Tsugane M, Uejima E. |
2010 |
3560 |
Laboratorium
Pharmacia 2013 |
Linezolid (Zyvox®) - Summary of Product Characteristics
|
2013 |
2163 |
Czasopismo
Perit Dial Int 2002 ; 22: 419-422. |
Linezolid stability in peritoneal dialysis solutions.
Manley HJ, McClaran ML, Bedenbaugh A, Peloquin CA. |
2002 |
2654 |
Czasopismo
Int J Pharm 2007 ; 344, 1-2: 150-153. |
Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability.
Morand K, Bartoletti AC, Bochot A, Barratt G, Brandely ML, Chast F. |
2007 |
4479 |
Czasopismo
J Oncol Pharm Practice 2020 ;27,6:1328-1332 |
Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5 +/- 3°C.
Closset M, Goderniaux N, Colsoul M-L, Soumoy L, Bihin B, Jamart J, Odou P, Hecq J-D, galanti L. |
2020 |
1291 |
Czasopismo
Int J Pharm Pract 1995 ; 3: 253-255. |
Long term stability of heparin in dextrose-saline intravenous fluids.
Wright A, Hecker J. |
1995 |
35 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2128-2130. |
Long term stability of interferon alfa-2b diluted to 2 million units/mL.
Schepart BS, Burns BA, Evans S, Poleon G. |
1995 |
1962 |
Czasopismo
Pharmakon 2004 ; 36, 1: 8-14. |
Long term stability of sufentanyl citrate with levobupivacaine hydrochloride in 0.9% sodium chloride infusion P.V.C bags at 4°C.
Hecq JD, Boitquin L, Evrard JM, Vanbeckbergen D, Jamart J, Galanti L. |
2004 |
3115 |
Czasopismo
Ann Pharm Fr 2010 ; 68: 157-162. |
Long term stability of the hydrochloride of tramadol and alizapride in dextrose 5% polyolefin bags at 5 +/- 3°C.
Athanasopoulos A, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. |
2010 |
2174 |
Czasopismo
EJHP Science 2006 ; 12, 6: 129-134. |
Long-term physical and chemical stability of a generic paclitaxel infusion under simulated storage and clinical-use conditions.
Kattige A. |
2006 |
4568 |
Czasopismo
Journal of Chemotherapy 2021 |
Long-term physico-chemical stability of 5-fluorouracile at standardised rounded doses (SRD) in MyFuser® portable infusion pump.
Closset M,Onorati S, Colsoul M.L,Goderniaux N,Bihin B, Jamart J, Soumoy L, Hecq J.D, Odou P, Galanti L. |
2021 |
3386 |
Czasopismo
Int J Pharm 2013 ; 448: 101-104. |
Long-term physico-chemical stability of diluted trastuzumab.
Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A. |
2013 |
4735 |
Czasopismo
J Oncol Pharm Practice 2023 ;29,8:1878 - 1883 |
Long-term physicochemical stability of 5-fluorouracil at selected standardised rounded doses in polyolefin bags.
Closset M, Onorati S, Colsoul M-L, Goderniaux N, Bihin B, Jamart J, Soumoy L, Hecq J-D, Odou P, Galanti L. |
2023 |
4573 |
Czasopismo
Am J Health-Syst Pharm 2021 ;78, 9:806–812, |
Long-term physicochemical stability of acyclovir 5 mg/mL solution stored in polypropylene bags as a simulated hospital stock preparation.
Legeron R, Bougueon G, Berroneau A, De-Germay S, Bernadou JM, Djabarouti S, Crauste-Manciet S, Xuereb F. |
2021 |
4374 |
Czasopismo
Int J Pharm Compound 2020 ;24,1:64-68 |
Long-term Physicochemical Stability of Concentrated Solutions of Isosorbide Dinitrate in Polypropylene Syringes for Administration in the Intensive Care Unit.
Lardinois B, Dimitriou A, Delcave C, Soumoy L, Jamart J, Bihin B, Hecq J-H, Galanti L.M. |
2020 |
4342 |
Czasopismo
Int J Pharm Compound 2019 ;23,5:434-437 |
Long-term Physicochemical Stability of Concentrated Solutions of Salbutamol (Albuterol) in Polypropylene Syringes for Use in the Intensive Care Unit and in Obstetrics.
Lardinois B, Baltzis A, Delcave C, Soumoy L, Jamart J, Bihin B, Hecq JD, Galanti L. |
2019 |
4148 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 |
Long-Term Stability Comparison between an Original and a Generic Version of Piperacillin/Tazobactam in Dextrose 5% Infusion Polyolefin Bags at 5+/-3°C after Microwave Freeze-Thaw Treatment.
Huvelle S, Godet M, Galanti L, Closset M, Bihin B, Jamart J, Hecq J.D. |
2018 |
4199 |
Czasopismo
EJHP 2018 |
Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas.
Le Guyader G, Vieillard V, Andrieux K, Rollo M, Thirion O, Wolkenstein P, Paul M. |
2018 |
4584 |
Czasopismo
EJHP 2023 ; 30, 3: 153-159. |
Long-term stability of 10 mg/mL dobutamine injectable solutions in 5% dextrose and normal saline solution stored in polypropylene syringes and cyclic-oleofin- copolymer vials.
Gilliot S, Henry H, Carta N, Genay S, Barthélémy C, Décaudin B, Odou P. |
2023 |
2323 |
Czasopismo
Can J Hosp Pharm 2009 ; 62, 1 |
Long-Term Stability of 5-Fluorouracil in 0.9% Sodium Chloride after Freezing, Microwave Thawing, and Refrigeration
Galanti L, Lebitasy M.P, Hecq J.D, Cadrobbi J, Vanbeckbergen D, Jamart J. |
2009 |
1475 |
Czasopismo
J Pharm Biomed Anal 1996 ; 14: 395-399. |
Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs.
Martel P, Petit I, Pinguet F, Poujol S, Astre C, Fabbro M. |
1996 |
2771 |
Czasopismo
Skin Pharm Appl Skin Physiol 1999 ; 12: 266-270. |
Long-term stability of 8-methoxypsoralen in ointments for topical PUVA therapy (Cream PUVA).
Martens-Lobenhoffer J, Rinke M, Losche D. |
1999 |
2789 |
Czasopismo
Bone Marrow Transplantation 2006 ; 37, 8: 781-784. |
Long-term stability of a patient-convenient 1mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels.
Elefante A, Muindi J, West K, Dunford L, Abel S, Paplham P, Brown K, Hahn T, Padmanabhan S, Battiwalla M, McCarthy PL. |
2006 |
3001 |
Czasopismo
Ann Pharm Fr 2015 ; 73: 108-113. |
Long-term stability of aciclovir in 0.9% NaCl infusion polyolefin bags at 2-8°C after freeze-thaw treatment: A generic product versus the brand name.
Dewulf J, Galanti L, Godet M, Gillet P, Jamart J, Hecq JD. |
2015 |
3312 |
Czasopismo
Ann Pharm Fr 2012 ; 70, 3: 139-154. |
Long-term stability of bevacizumab repackaged in 1 mL polypropylene syringes for intravitreal administration.
Paul M, Vieillard V, Roumi E, Cauvin A, Despiau M.C, Laurent M, Astier A. |
2012 |
656 |
Czasopismo
J Clin Pharm Ther 1996 ; 21: 185-189. |
Long-term stability of cefuroxime and cefazolin sodium in intravenous infusions.
Galanti LM, Hecq JD, Vanbeckbergen D, Jamart J. |
1996 |
2808 |
Czasopismo
Int J Pharm Compound 2015 ; 19, 3: 268-270. |
Long-term Stability of Cocaine Hydrochloride Aqueous Solution 50 mg/mL (5%) at Room Temperature and at 5°C ± 3°C in Glass Bottles.
Dewulf J, Hecq J.D, Huvelle S, Godet M, Gillet P, Jamart J, Galanti L.M. |
2015 |
3925 |
Czasopismo
Ann Pharm Fr 2016 ; 75, 1 : 30-39. |
Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5±3 C.
Simar J, Godet M, Hecq J.-D, Closset M, Gillet P, Langhendries C, Bihin B, Jamart J, Galanti L. |
2016 |
3323 |
Czasopismo
Int J Pharm 2012 ; 436, 1-2: 282-290. |
Long-term stability of diluted solutions of the monoclonal antibody rituximab.
Paul M, Vieillard V, Jaccoulet E, Astier A. |
2012 |
2827 |
Czasopismo
Am J Health-Syst Pharm 2009 ; 66: 1722-1725. |
Long-term stability of extemporaneously prepared captopril oral liquids in glass bottles
Brustugun J, Lao YE, Fagern?s C, Br?nden J, Kristensen S. |
2009 |
394 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2333-2335. |
Long-term stability of famotidine 20 mg/L in a total parenteral nutrient solution.
DiStefano JE, Mitrano FP, Baptista RJ, Der MM, Silvestri Ap, Palombo JD, Bistrian BR. |
1989 |
4021 |
Czasopismo
J Oncol Pharm Practice 2017 ;25,2: 303-308 |
Long-term stability of ganciclovir in polypropylene containers at room temperature.
Guichard N, Bonnabry P, Rudaz S, Fleury S. |
2017 |
3874 |
Czasopismo
Ann Pharm Fr 2016 ; 74: 283-287. |
Long-term stability of ketamine hydrochloride 50 mg/ml injection in 3 ml syringes
Huvelle S, Godet M, Hecq J.D, Gillet P, Bihin B, Jamart J, Galanti L. |
2016 |
4248 |
Czasopismo
Hosp Pharm 2019 ; 55, 3: 199-193. |
Long-Term Stability of Lorazepam in Sodium Chloride 0.9% Stored at Different Temperatures in Different Containers.
Colsoul M.L, Breuer A, Goderniaux N, Hecq J.D, Soumoy L, Bihin B, Jamart J, Galanti L. |
2019 |
1885 |
Czasopismo
Pharm World Sci 1999 ; 21: 144-146. |
Long-term stability of morphine and bupivacaine mixture for spinal use.
Essink-Tjebbes CM, Burger DM, Beelen, Wuis EW, Heckster YA. |
1999 |
3572 |
Czasopismo
Int J Pharm Compound 2014 ; 18, 1 : 78-82. |
Long-term Stability of Morphine Hydrochloride in 0.9% NaCl Infusion Polyolefin Bags After Freeze-thaw Treatment and in Polypropylene Syringes at 5°C ± 3°C.
Hecq J-D, Godet M, Gillet P, Jamart J, Galanti L. |
2014 |
4201 |
Czasopismo
Am J Health-Syst Pharm 2020 ; 77, 9: 681-689. |
Long-term stability of ready-to-use 1-mg/mL midazolam solution.
Gilliot S, Masse M, Feutry F, Barthélémy C, Décaudin B, Genay S, Odou P. |
2020 |
2204 |
Czasopismo
J Oncol Pharm Practice 2007 ; 13: 99-103. |
Long-term stability of sodium folinate in dextrose 5% polyolefin bags at 4°C.
Cadrobbi J, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. |
2007 |
1908 |
Czasopismo
J Pain Symptom Manage 2004 ; 28, 1: 4-6. |
Long-term stability of sufentanil citrate with levobupivacaine hydrochloride in 0.9% sodium chloride infusion PVC bags at 4°C.
Boitquin L, Hecq JD, Evrard JM, Vanbeckbergen D, Jamart J, Galanti L. |
2004 |
3255 |
Czasopismo
Ann Pharm Fr 2011 ; 69, 6 : 296-301. |
Long-term stability of temocillin in dextrose 5% and in sodium chloride 0.9% polyolefin bags at 5±3°C after freeze-thaw treatment
Rolin C, Hecq J.D, Tulkens P, Vanbeckbergen D, Jamart J, LGalanti L. |
2011 |
3154 |
Czasopismo
J Antimicrob Chemother 2010 ; 65, 9: 2045-2046. |
Long-term stability of temocillin in elastomeric pumps for outpatient antibiotic therapy in cystic fibrosis patients.
Carryn S, Couwenbergh N, Tulkens PM |
2010 |
365 |
Czasopismo
Med Sci Monit 2015 ; 21:2528-2534. |
Long-Term Stability of Tramadol and Ketamine Solutions for Patient-Controlled Analgesia Delivery.
Junfeng Gu, Wengang Qin, Fuchao Chen, Zhongyuan Xia. |
2015 |
3082 |
Czasopismo
J Oncol Pharm Practice 2009 ; 15: 195-200. |
Long-term stability of tramadol chlorhydrate and metoclopramide hydrochloride in dextrose 5% polyolefin bag at 4°C.
Athanasopoulos A, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. |
2009 |
2814 |
Czasopismo
Ann Pharm Fr 2009 ; 67: 272-277. |
Long-term stability of tramadol hydrochloride and droperidol mixture in 5% dextrose infusion polyolefin bags at 5 +/- 3°C.
Lebitasy M, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. |
2009 |
1899 |
Czasopismo
Int J Pharm Compound 2004 ; 8, 3: 231-235. |
Long-term stability of Trimix : a three drug injection used to treat rectile dysfunction.
Trissel LA, Zhang Y. |
2004 |
931 |
Czasopismo
J Clin Pharm Ther 1997 ; 22: 353-356. |
Long-term stability of vancomycin hydrochloride in intravenous infusions.
Galanti LM, Hecq JD, Vanbeckbergen D, Jamart J. |
1997 |
2111 |
Czasopismo
EJHP Science 2006 ; 12, 3: 57-59. |
Long-term stability of voriconazole 4 mg/ml in dextrose 5% polyvinyl chloride bags at 4°C.
Cadrobbi J, Hecq JD, Lebrun C, Vanbeckbergen D, Jamart J, Galanti L. |
2006 |
3856 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 2:164-166. |
Long-term Stability of Zonisamide, Amitriptyline, and Glycopyrrolate in Extemporaneously Prepared Liquid-dosage Forms at Two Temperatures
Nahata M.C. |
2016 |
3313 |
Czasopismo
J Oncol Pharm Practice 2012 ; 18, 2: 218-221. |
Long-term stability study of clofarabine injection concentrate and diluted clofarabine infusion solutions.
Kaiser J, Krämer I. |
2012 |
2495 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 380-383. |
Long-term stability study of histamine in sterile bronchoprovocation solutions
Marwaha RK, Johnson BF. |
1986 |
532 |
Czasopismo
Ann Pharmacotherapy 1996 ; 30: 343-346. |
Lorazepam stability in parenteral solutions for continuous intravenous administration.
Hoey LL, Vance-Bryan K, Clarens DM, Wright DH, Konstantinides FN, Guay DRP. |
1996 |
1980 |
Czasopismo
Act Pharm Nord 1991 ; 3, 3: 131-136. |
Loss of nitroglycerin during passage through two different infusion sets.
Hansen HC, Spillum A. |
1991 |
1108 |
Czasopismo
Crit Care Med 1983 ; 11: 50-52. |
Loss of nitroglycerin to cardiopulmonay bypass apparatus.
Dasta JF, Jacobi J, Wu LS, Sokoloski T, Beckley P, Reilley TE, Howie MB. |
1983 |
239 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 655-658. |
Loss of quinidine gluconate injection in a polyvinyl chloride infusion system.
Darbar D, Dell'Orto S, Wilkinson GR, Roden DM. |
1996 |
4739 |
Czasopismo
PlosOne 2023 18(2): e0282164. |
Low-dose erythromycin in pediatrics: Formulation and stability of 20 mg hard gelatin capsules.
Thevin P, Curti C, Benech A, Jean C, Lamy E, Castera Ducros C, Primas N, Bertault-Perez P, Vanelle P. |
2023 |
4740 |
Laboratorium
Roche Products Limited 2021 |
MabThera 500 mg concentrate for solution for infusion. Summary of Product Characteristics Updated 07-Oct-2021
|
2021 |
1522 |
Laboratorium
Maco Pharma 2001 |
Macoflex N®
|
2001 |
3838 |
Laboratorium
Martindale Pharmaceuticals Ltd 2007 |
Magnesium Sulphate - Summary of Product Characteristics
|
2007 |
4457 |
Czasopismo
J Obstet Gynaecol Can 2016 ;38,10:936e944. |
Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes.
Houlihan, S, Decarie, D, Benes, C, Cleve, R, Vidler M, Magee L.A, Ensom M.H.H, vonDadelszen P. |
2016 |
4344 |
Czasopismo
EJHP 2018 |
Management of diabetic foot ulcers: a 25% lidocaine topical cream formulation design, physicochemical and microbiological assessments.
Yay? HS, Faucheron A, Dupont L, El Kouari F, Fekkar A, Bellanger A, Tilleul P. |
2018 |
3307 |
Czasopismo
Hosp Pharm 2012 ; 47, 1: 27-30. |
Managing the intravenous calcium shortage: Evaluation of calcium chloride stability in 0.9% sodium chloride and dextrose 5% water polyvinyl chloride bags.
Kiser T.H, Barber G.R, Robinson A. |
2012 |
1861 |
Czasopismo
Int J Pharm 1996 ; 127: 255-259. |
Medical plastics: compatibility of alfentanil and propofol alone or mixed. Stability of the alfentanil-propofol mixture.
Levadoux E, Sautou V, Bazin JE, Schoeffler P, Chopineau J. |
1996 |
4490 |
Czasopismo
Sci Pharm 2020 ; 88, 25 |
Medication Safety in Intravenous Therapy: A Compatibility Study and Analysis of Reaction Products of Dihydralazine and Metamizole.
Koller A.K, Fischer O, Krebs S. |
2020 |
3584 |
Laboratorium
Aspen Pharma 2013 |
Melphalan (Alkéran®) - Résumé des caractéristiques du produit
|
2013 |
3602 |
Laboratorium
Baxter SAS 2013 |
Mesna (Uromitexan®)- Summary of Product Characteristics
|
2013 |
3637 |
Laboratorium
Hameln Pharmaceuticals 2014 |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
|
2014 |
978 |
Czasopismo
Can J Hosp Pharm 1994 ; 47: 147. |
Methotrexate and cytarabine for intrathecal administration.
Dick DM, Woloschuk DMM. |
1994 |
1021 |
Czasopismo
J Clin Hosp Pharm 1986 ; 11: 343-348. |
Methotrexate in solutions - A stability test for the hospital pharmacy.
Dyvik O, Grislingaas AL, Tonnesen HH, Karlsen J. |
1986 |
3594 |
Laboratorium
Zentiva 2013 |
Metronidazole (Flagyl®) - Summary of Product Characteristics
|
2013 |
3573 |
Laboratorium
Astellas 2013 |
Micafungin (Mycamine®) – Summary of Product Characteristics
|
2013 |
823 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1584-1587. |
Microbial inhibitory properties and stability of topotecan hydrochloride injection.
Patel K, Craig SB, McBride MG, Palepu NR. |
1998 |
3859 |
Czasopismo
RRJHCP 2016 ; 1, 3: 31-37. |
Microbiological and Physico-Chemical Stability of Ketamine Solution for Patient-Controlled Analgesia Systems.
Foy G, Poinsignon V, Mercier L, Laurent S, Paci A. |
2016 |
2118 |
Czasopismo
J Pain Symptom Manage 2006 ; 32, 1: 90-97. |
Microbiological and physicochemical stability of fentanyl and sufentanil solutions for patient-controlled delivery-systems.
Chapalain-Pargade S, Laville I, Paci A, Chachaty E, Mercier L, Bourget Ph. |
2006 |
3126 |
Czasopismo
J Pain Symptom Manage 2010 ; 40, 1: 87-94. |
Microbiological and Physicochemical Stability of Oxycodone Hydrochloride Solutions for Patient-Controlled Delivery Systems.
Amri A, Achour AB, Chachaty E, Mercier L, Bourget P, Paci A. |
2010 |
4366 |
Czasopismo
Braz J Pharm Sci 2019 ;55:e17351 |
Midazolam and haloperidol for palliative sedation: physicochemical stability and compatibility of parenteral admixtures.
Estan-Cerezo G, Rodriguez-Lucena F.J, Matoses Chirivella C, Jiminez-Pulido I, Garcia-Monsalve A, Navarro-Ruiz A. |
2019 |
2007 |
Czasopismo
J Pharm Biomed Anal 2005 ; 38: 709-713. |
Migration of diethylhexyl phtalate from PVC into intravenous cyclosporine solutions.
Gotardo MA, Monteiro M. |
2005 |
1699 |
Czasopismo
Krankenhauspharmazie 2000 ; 21: 107-109. |
Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin.
Plaas S, Heck C, Kubrich M. |
2000 |
3315 |
Plakat
Communication orale Hopipharm 2012 |
Mise en évidence d'une incompatibilité physico-chimique entre la phénytoïne sodique et le paracétamol injectable en flacon.
Louvrier M, Dhennain S, Hocahrt S, Zawadski E, Bouffart S, Moquay E. |
2012 |
3128 |
Laboratorium
Prostrakan 2013 |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
|
2013 |
3575 |
Laboratorium
Prostrakan 2013 |
Mitomycine (Ametycine®) - Résumé des caractéristiques du produit
|
2013 |
3640 |
Laboratorium
Hospira 2013 |
Mitoxantrone - Summary of Product Characteristics
|
2013 |
465 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 297-298. |
More information on the visual compatibility of hetastarch with injectable critical-care drugs.
Wohlford JG, Wright JC, Wilson MR. |
1990 |
322 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2639. |
More on compatibility of mannitol and sodium bicarbonate in injectable fluids.
Matuschka PR, Hill LJ. |
1996 |
2362 |
Plakat
ADKA Congress 2009 2009 |
Morphin-Haloperidol mischungen in PCA Pumpen : Kompatibel?
Trittler R, M?ller S, Esteban M. |
2009 |
2363 |
Plakat
ADKA Congress 2006 |
Morphin-Metamizol mischungen zur kontinuierlichen parenteralen applikation : Sind sie immer inkompatibel?
M?ller S, Trittler R, Schubert R, von Hornstein W.F, Strehl E. |
2006 |
3531 |
Laboratorium
Wockhardt 2014 |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
|
2014 |
2055 |
Czasopismo
Int J Pharm 2006 ; 307: 278-284. |
Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients.
Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. |
2006 |
626 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 1495-1498. |
Moxalactam disodium compatibility with intramuscular and intravenous diluents.
Bornstein M, Lo AY, Thomas PN, Wilham WL. |
1982 |
3162 |
Laboratorium
Bayer HealthCare 2010 |
Moxifloxacine (Izilox®) - Résumé des caractéristiques du produits
|
2010 |
3109 |
Laboratorium
Bayer Schering Pharma 2010 |
Moxifloxacine (Izilox®) -Notice information
|
2010 |
1366 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 462,464. |
Nafcillin sodium incompatibility with acidic solutions.
Jeglum EL, Winter E, Kotos M. |
1981 |
3672 |
Laboratorium
Mylan SAS 2016 |
Nalbuphine Mylan - Résumé des caractéristiques du produit
|
2016 |
3264 |
Plakat
AAPS Congress - Washington, October 2011 2011 |
Nalbuphine stability at 1 mg/mL concentration.
Hammer C, Perello L, Dory A, Lev?que D, Ubeaud-S?quier G. |
2011 |
2678 |
Czasopismo
Int J Pharm Compound 2000 ; 4: 69-71. |
Naratriptan hydrochloride in extemporaneously compounded oral suspensions.
Zhang YP, Trissel LA, Fox JL. |
2000 |
4068 |
Laboratorium
2018 Biogen Idec Ltd |
Natalizumab (Tysabri®) - Summary of Product Characteristics
|
2018 |
3938 |
Laboratorium
Lilly S.A 2016 |
Necitumumab (Portrazza®) – Résumé des caractéristiques du produits
|
2016 |
2311 |
Czasopismo
J Clin Pharm Ther 2009 ; 34: 25-31. |
Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
Kambia N.K, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C. |
2009 |
2265 |
Czasopismo
J Pharm Sci 1990 ; 79, 1: 48-52. |
Nefopam hydrochloride degradation kinetics in solution.
Tu YH, Wang DP, Allen LV. |
1990 |
958 |
Czasopismo
Ann Pharmacotherapy 1990 ; 24: 440-442. |
Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion.
Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M. |
1990 |
4561 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2021 ; 6(1): 20200013. |
New liquid oral formulations of hydroxychloroquine: a physicochemical stability study.
Lebreton V, Bourcier B, Cosson K, Lagarce F, Spiesser-Robelet L, Vrignaud S. |
2021 |
3306 |
Czasopismo
EJOP 2012 ; 6, 1: 1-2. |
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
Trittler R. |
2012 |
3941 |
Laboratorium
Concordia International 2017 |
Nicardipine - Summary of Product Characteristics
|
2017 |
3614 |
Laboratorium
American Regent Inc 2013 |
Nicardipine Injection - Summary of Product Characteristics
|
2013 |
3206 |
Czasopismo
Int J Pharm Compound 2011 ; 15, 2: 166-169. |
Nifedpine in Compounded Oral and Topical Preparations.
McCluskey Susan V, Brunn Gregory J. |
2011 |
708 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 201-205. |
Nitroglycerin compatibility with intravenous fluid filters containers, and administration sets.
Baaske DM, Amann AH, Wagenknecht DM, Mooers M, Carter JE, Hoyt HJ, Stoll RG. |
1980 |
1113 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2031-2035. |
Nitroglycerin delivery through a polyethylene-lined intravenous administration set.
Tracy TS, Bowman L, Black CD. |
1989 |
4652 |
Laboratorium
Bristol Myers Squibb Pharmaceuticals 2022 |
Nivolumab (Opdivo®) - Summary of Product Characteristics
|
2022 |
642 |
Czasopismo
Hosp Pharm 1988 ; 23: 44,49, 59. |
Norepinephrine stability in saline solutions.
Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. |
1988 |
3455 |
Czasopismo
J Drug Deliv Sci Tecnol 2012 ; 22, 4: 347-352. |
Novel formulation and clinical evaluation of nalidixic acid ointment in impetigo.
Tous S.S, El Sayed A.M, Abd El Mohsen M.G, Yoissef E.M.K, Agban M.N, Boushra M.F. |
2012 |
4720 |
Laboratorium
Paratek Pharmaceuticals 2021 |
Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021.
|
2021 |
3768 |
Laboratorium
Roche Products Limited 2014 |
Obinutuzumab (Gazyvaro®) - Summary of Product Characteristics
|
2014 |
4086 |
Laboratorium
Novartis Pharma 2017 |
Octréotide - (Sandostatine®)- Résumé des caractéristiques du produit
|
2017 |
3138 |
Laboratorium
GlaxoSmithKline 2009 |
Ofatumumab (Arzerra®) - Summary of Product Characteristics
|
2009 |
3562 |
Laboratorium
Sanofi 2014 |
Ofloxacin (Tarivid®) - Summary of Product Characteristics
|
2014 |
889 |
Czasopismo
Pharm Weekbl [Sci] 1991 ; 13: 207-209. |
Ofloxacin intravenous. Compatibility with other antibacterial agents.
Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. |
1991 |
3776 |
Laboratorium
Teva Pharmaceuticals 2014 |
Omecetaxine (Synribo®) - Summary of Product Characteristics
|
2014 |
3658 |
Laboratorium
Sandoz 2014 |
Omeprazole - Summary of Product Characteristics.
|
2014 |
3574 |
Laboratorium
Accord Healthcare France SAS 2013 |
Ondansetron - Résumé des caractéristiques du produit
|
2013 |
1396 |
Czasopismo
J Clin Oncol 1993 ; 11: 197. |
Ondansetron compatible with sodium acetate.
Hauser AR, Trissel LA, Martinez JF. |
1993 |
3924 |
Czasopismo
Ann Pharm Fr 2016 ; 75, 1 : 17-29. |
One-month stability study of a biosimilar of infliximab (Remsima®) after dilution and storage at 4 C and 25 C.
Vieillard V, Astier A, Sauzay C, Paul M. |
2016 |
3949 |
Plakat
JFSPH Congress, Bern, Switzerland. 2016 |
Optimisation du processus de préparation des solutions de melphalan destinées à l’administration intra-vitréenne dans le traitement du rétinoblastome et étude de leur stabilité
Brönnimann C, Berger-Gryllaki M, Podilsky G, Sadeghipour F. |
2016 |
3787 |
Laboratorium
The Medicines Company 2016 |
Oritavancin diphosphate (Orbactiv®) - Summary of Product Characteristics
|
2016 |
4211 |
Czasopismo
PlosOne 2019 |
Overcoming stability challenges during continuous intravenous administration of high-dose amoxicillin using portable elastomeric pumps.
Binson G, Grignon C, Le Moal G, Lazaro P, Lelong J, Roblot F, Venisse N, Dupuis A. |
2019 |
3589 |
Laboratorium
PanPharma 2013 |
Oxacilline PanPharma – Résumé des caractéristiques du produits
|
2013 |
3413 |
Czasopismo
Pharm Res 2004 ; 21, 5: 891-894. |
Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex.
Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. |
2004 |
3634 |
Laboratorium
Accord Healthcare 2011 |
Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit
|
2011 |
2366 |
Plakat
ADKA Congress 2009 |
Oxycodon-Metamizol in PCA pumpen : Kompatibel?
M?ller S, Trittler R, Schubert R. |
2009 |
1903 |
Czasopismo
Am J Obstet Gynecol 2002 ; 186: 496-498. |
Oxytocin preparation stability in several common obstetric intravenous solutions.
Gard JW, Alexander JM, Bawdon RE, Albrecht JT. |
2002 |
1956 |
Laboratorium
Hospira UK Limited 2015 |
Paclitaxel - Summary of Product Characteristics
|
2015 |
3157 |
Laboratorium
Celgene Europe Limited 2015 |
Paclitaxel albumin (Abraxane®) - Summary of Product Characteristics
|
2015 |
669 |
Czasopismo
Ann Pharmacotherapy 1994 ; 28: 35-36. |
Paclitaxel stability and compatibility in polyolefin containers.
Chin A, Ramakrishnan RR, Yoshimura NN, Jeong EWS, Nii LJ, DiMeglio LS. |
1994 |
4101 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 |
Paediatric formulation: budesonide 0.1 mg/mL viscous oral solution for eosinophilic esophagitis using cyclodextrins.
Ey C, Hosselet C, Villon B, Mar?on F. |
2018 |
1955 |
Czasopismo
Ann Pharmacotherapy 2005 ; 39: 280-283. |
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Trissel LA, Zhang Y. |
2005 |
2214 |
Czasopismo
Int J Pharm Compound 2007 ; 11, 6: 520-524. |
Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration.
Ben M, Trusley C,Kupiec T.C, Trissel L.A. |
2007 |
3619 |
Laboratorium
Wockhardt 2016 |
Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics
|
2016 |
755 |
Laboratorium
MSD France 2016 |
Pancuronium (Pavulon®) - Résumé des caractéristiques du produit
|
2016 |
3769 |
Laboratorium
B Braun laboratoire 2014 |
Paracatamol (Paracetamol B Braun®) - Résumé des caractéristiques du produit
|
2014 |
3504 |
Laboratorium
Pfizer 2012 |
Parecoxib (Dynastat®) - Summary of Product Characteristics
|
2012 |
4173 |
Laboratorium
Baxalta Innovations GmbH 2018 |
Pegaspargase (Oncaspar®) - Résumé des Caractéristiques du Produit
|
2018 |
3771 |
Laboratorium
Merck Sharp Dohme 2017 |
Pembrolizumab (Keytruda®) - Summary of Product Characteristics
|
2017 |
1914 |
Laboratorium
Eli Lilly 2016 |
Pemetrexed (Alimta®) - Summary of Product Characteristics
|
2016 |
4589 |
Laboratorium
Mylan 2021 |
Pemetrexed Mylan - Résumé des caractéristiques du produit
|
2021 |
4629 |
Laboratorium
2021 Sandoz |
Pemetrexed Sandoz - Summary of Product Characteristics (SmPc)
|
2021 |
3559 |
Laboratorium
Sanofi Aventis France 2013 |
Pentamidine diiséthionate (Pentacarinat®) - Résumé des caractéristiques du produit
|
2013 |
1235 |
Czasopismo
Br J Pharm Pract 1988 ; 10: 22-23. |
Pentamidine infusion stability.
Leigh PH, Buddle GC. |
1988 |
4024 |
Plakat
SFPO Congress 2017 - Nantes 2017 |
Pénurie mondiale d'Etopophos et conséquences pratiques : Intérêt des études de stabilité dans le choix d'un générique.
Sadou Yaye H, Rieber Z, HassaniI L, Hoffmann-Martinot C, Babiard M, Aouti H, Bellanger A, Tilleul P. |
2017 |
4686 |
Laboratorium
Roche Products Ltd. 2022 |
Pertuzumab (Perjeta®) - Summary of Product Characteristics.
|
2022 |
3525 |
Laboratorium
AMCO Amdipharm Mercury 2012 |
Pethidine hydrochloride - Summary of product Characteristics
|
2012 |
3871 |
Plakat
Synprefh Congress Clermont Ferrand, France 2016 |
Peut-on administrer le céfotaxime en Y avec d'autres médicaments injectables ?
Soussi M.A, Soualah-alila R, jenene F, Lazreg O, Razgallah Khrouf M. |
2016 |
2175 |
Czasopismo
J Pharm Clin 2006 ; 25, 3: 147-152. |
Peut-on conditionner les solutions de docétaxel dans des poches en PVC ?
Dalle M, Sautou-Miranda V, Balayssac D, Bourlon S, Bagel S, Chopineau J. |
2006 |
1317 |
Czasopismo
Pharm J 1987 ; 238: 476-478. |
Pharmaceutical aspects of home infusion therapy for cancer patients.
Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. |
1987 |
4747 |
Czasopismo
Pharmaceutics 2023 ,15, 957. |
Pharmaceutical Oral Formulation of Methionine as a Pediatric Treatment in Inherited Metabolic Disease.
Querin B, Schweitzer-Chaput A, Cisternino S, Auvity S, Fauqueur A-S, Negbane A, Hadchouel A, Schlatter J, Cotteret C. |
2023 |
4283 |
Czasopismo
Eur J Pharm Sci 2019 |
Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate.
Lopalco A, Curci A, Lopedota A, Cutrignelli A, Laquintana V, Franco M, Denora N. |
2019 |
1274 |
Czasopismo
TAP Pharmazeutische Zeitung 1997 ; 31: 30-33. |
Pharmazeutische aspekte von topotecan-infusionen.
Krämer I, Thiesen J. |
1997 |
1482 |
Czasopismo
Krankenhauspharmazie 1992 ; 3: 98-100. |
Pharmazeutische kompatibilität der kombination cefotiam und ampicillin.
Messerschmidt W. |
1992 |
1692 |
Czasopismo
Krankenhauspharmazie 1998 ; 19: 226-228. |
Pharmazeutische kompatibilität von piperacillin mit metronidazol.
Messerschmidt W. |
1998 |
1949 |
Czasopismo
Clinical Cancer Research 2001 ; 7: 1569-1576. |
Phase I trial of 96 hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Rashko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz HJ, Gandara D, Doroshow JH. |
2001 |
3620 |
Laboratorium
Beacon Pharmaceuticals 2012 |
Phenylephrine - Summary of Product Characteristics
|
2012 |
3770 |
Laboratorium
Eclat Pharmaceuticals 2014 |
Phenylephrine hydrochloride (Vazculep®) - Summary of Product Characteristics
|
2014 |
1169 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 358-362. |
Phenytoin sodium solubility in three intravenous solutions.
Pfeifle CE, Adler DS, Gannaway WL. |
1981 |
3621 |
Laboratorium
Renaudin 2008 |
Phosphate dipotassique - Résumé des caractéristiques du produit
|
2008 |
1887 |
Czasopismo
Int J Pharm 1995 ; 123: 229-235. |
Photochemical decomposition of midazolam. IV . Study of pH dependant stability by high-performance liquid chromatography.
Andersin R, Tammilehto S. |
1995 |
1265 |
Czasopismo
J Clin Pharm Ther 1990 ; 15: 291-300. |
Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography.
Wood MJ, Irwin WJ, Scott DK. |
1990 |
2816 |
Czasopismo
J Pharm Biomed Anal 1999 ; 25: 269-275. |
Photodegradation of folic acid in aqueous solution
Aktar J, Khan A, Ahmad I. |
1999 |
796 |
Czasopismo
PDA J Pharm Sci Technol 1996 ; 50: 158-162. |
Photodegradation of furosemide solutions.
Asker AF, Ferdous AJ. |
1996 |
1918 |
Czasopismo
J Pharm Sci 1997 ; 86, 12: 1410-1416. |
Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition.
Dodds HM, Craik DJ, Rivory LP. |
1997 |
1383 |
Czasopismo
J Pharm Pharmacol 1978 ; 30: 47P. |
Photodegradation of solutions of the antitumour drug DTIC.
Stevens MFG, Peatey L. |
1978 |
948 |
Czasopismo
J Pharm Sci 1994 ; 83: 463-467. |
Photodegradation of some quinolones used as antimicrobial therapeutics.
Tiefenbacher EM, Haen E, Przybilla B, Kurz H. |
1994 |
1920 |
Czasopismo
Drug Stability 1996 ; 1: 118-122. |
Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution.
Akimoto K, Kaway A, Ohya K et al. |
1996 |
1921 |
Czasopismo
Drug Stability 1996 ; 1; 141-146. |
Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution.
Akimoto K, Kawai A, Ohya K. |
1996 |
1696 |
Czasopismo
J Pharm Biomed Anal 1999 ; 21: 851-857. |
Photodegradation studies on Atenolol by liquid chromatography.
Andrisano V, Gotti R, Leoni A, Cavrini V. |
1999 |
1284 |
Czasopismo
Photochem Photobiol 1981 ; 34: 131-134. |
Photoinactivation of anthracyclines.
Williams BA, Tritton TR. |
1981 |
847 |
Czasopismo
J Pharm Pharmacol 1980 ; 32: 860-862. |
Photolytic degradation of adriamycin.
Tavoloni N, Guarino AM, Berck PD. |
1980 |
145 |
Czasopismo
J Pharm Clin 1992 ; 11: 285-295. |
Photosensibility of 5-fluorouracile and methotrexate in translucent or opaque perfusers.
Lorillon P, Corbel JC, Mordelet MF, Basle B, Guesnier LR. |
1992 |
1851 |
Czasopismo
J Pharm Biomed Anal 2001 ; 25, 3-4: 589-597. |
Photostability and phototoxicity studies on diltiazem.
Andrisano V, Hrelia P, Gotti R, Leoni A, Cavrini V. |
2001 |
2089 |
Czasopismo
Pharmazie 2004 ; 59: 457-463. |
Photostability of epinephrine - the influence of bisulfite and degradation products.
Brustugun J, Kristensen S, Tonnesen HH. |
2004 |
1965 |
Czasopismo
PDA J Pharm Sci Technol 2004 ; 58, 6: 296-308. |
Photostability of sympatomimetic agents in commonly used infusion media in the absence and presence of bisulfite.
Brustugun J, Kristensen S, Tonnesen HH. |
2004 |
3571 |
Czasopismo
Hosp Pharm 2014 ; 49, 1: 42-47. |
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. |
2014 |
289 |
Czasopismo
Ann Pharmacotherapy 1993 ; 27: 704-707. |
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
Jim LK. |
1993 |
4369 |
Czasopismo
J Pharm Biomed Anal 2020 ;178:112896 |
Physical and chemical stability of a generic etoposide formulation as an alternative to etoposide phosphate
Sadou Yayé H, Hassani L, Secrétan PH, Babiard M, Aouati H, Bellanger A, Tilleul P, Yagoubi N, Do B, Rietveld I. |
2020 |
4001 |
Czasopismo
Int J Pharm Compound 2017 ; 21:4 :322-329 |
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox).
Ip K,Carvalho M,Shan A,Banov D. |
2017 |
4059 |
Czasopismo
EJHP 2017 ; 25, e2 |
Physical and chemical stability of ceftaroline in an elastomeric infusion device.
Madfai F, Zaidi S, Ming L, Wanandy T, Patel R. |
2017 |
3183 |
Czasopismo
EJOP 2010 ; 4, 3: 11-13. |
Physical and chemical stability of cisplatin infusions in PVC containers.
Sewell G |
2010 |
4455 |
Czasopismo
J Oncol Pharm Practice 2020 online first |
Physical and chemical stability of cytarabine in polypropylene syringes.
Ben Ayed W, Drira C, Ali Soussi M, Ouesleti H, Hamdene B, Khrouf M, Safta F, Fradi I. |
2020 |
1937 |
Czasopismo
Ann Pharmacotherapy 2004 ; 38: 1612-1616. |
Physical and chemical stability of daptomycin with nine medications.
Lai JJ, Brodeur SK. |
2004 |
4602 |
Czasopismo
Hosp Pharm 2021 ; 56, 4: 215-220. |
Physical and Chemical Stability of Dexamethasone Sodium Phosphate in Intravenous Admixtures Used to Prevent Chemotherapy-Induced Nausea and Vomiting.
Buga I, Uzoma J.I, Reindel K, Rashid K, Diep T, McCartan P, Zhao F. |
2021 |
3195 |
Czasopismo
EJHP 2011 ; 17, 2: 39-43. |
Physical and chemical stability of docetaxel infusions.
MacLeod S, Sewell G. |
2011 |
2270 |
Czasopismo
Ann Pharmacotherapy 2008 ; 42, 9: 1247-1251. |
Physical and chemical stability of esomeprazole sodium solutions.
Kupiec TC, Aloumanis V, Ben M, Trissel LA, Chan P, Patterson J. |
2008 |
4174 |
Czasopismo
Int J Pharm Compound 2018 ;22,6:504-511 |
Physical and Chemical Stability of Estriol 0.025% to 1% Vaginal Creams (VersaBase).
Ip K, Shan A, Yan W, Banov D. |
2018 |
1411 |
Czasopismo
J Am Pharm Assoc 1999 ; 39: 146-150. |
Physical and chemical stability of etoposide phosphate solutions.
Zhang Y, Trissel LA. |
1999 |
1422 |
Czasopismo
J Am Pharm Assoc 1999 ; 39: 509-513. |
Physical and chemical stability of gemcitabine hydrochloride solutions.
Xu QA, Zhang Y, Trissel LA. |
1999 |
3610 |
Czasopismo
J Oncol Pharm Practice 2014 ; 20, 1: 51-57. |
Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion.
Zhang, Y., Kawedia, J.D., Myers, A.L., McIntyre, C.M., Anderson, P.M., Kramer, M.A., Culotta, K. |
2014 |
1706 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 74-76. |
Physical and chemical stability of hydromorphone hydrochloride 1.5 and 80 mg/ml packaged in plastic syringes.
Trissel LA, Xu QA. |
2002 |
1707 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 70-73. |
Physical and chemical stability of low and high concentrations of morphine sulfate with bupivacaine hydrochloride packaged in plastic syringes.
Trissel LA, Xu QA, Pham L. |
2002 |
1708 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 66-69. |
Physical and chemical stability of low and high concentrations of morphine sulfate with clonidine hydrochloride packaged in plastic syringes.
Xu QA, Trissel LA, Pham L. |
2002 |
31 |
Czasopismo
Hosp Pharm 1996 ; 31: 965-970. |
Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott’s B solution.
Zhang Y, Xu QA, Trissel LA, Gilbert DL. |
1996 |
1661 |
Czasopismo
J Oncol Pharm Practice 2002 ; 8: 27-32. |
Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott’s B Solution for intrathecal use.
Trissel LA, King KM, Zhang Y, Wood AM. |
2002 |
1709 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 62-65. |
Physical and chemical stability of morphine sulfate 5 mg/ml and 50 mg/ml packaged in plastic syringes.
Trissel LA, Xu QA. |
2002 |
2172 |
Czasopismo
J Oncol Pharm Practice 2006 ; 12, 4: 211-222. |
Physical and chemical stability of paclitaxel infusions in different container types.
Donyai P, Sewell GJ. |
2006 |
1936 |
Czasopismo
Ann Pharmacotherapy 2004 ; 38: 1608-1611. |
Physical and chemical stability of palonosetron HCl in 4 infusion solusions.
Trissel LA, Xu QA. |
2004 |
1950 |
Czasopismo
J Oncol Pharm Practice 2004 ; 10: 191-195. |
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
Trissel LA, Yanping Z. |
2004 |
2107 |
Czasopismo
Int J Pharm Compound 2006 ; 10: 234-236. |
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.
Trissel LA, Zhang Y, Xu QA. |
2006 |
2279 |
Czasopismo
Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759. |
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
Kupiec T, Trusley C, Ben M, Trissel LA. |
2008 |
2196 |
Czasopismo
Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213. |
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration.
Trissel LA, Trusley C, Ben M, Kupiec TC. |
2007 |
2009 |
Czasopismo
Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322. |
Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration.
Trissel LA, Zhang Y. |
2005 |
2286 |
Czasopismo
Int J Pharm Compound 2008 ; 12, 4: 368-371. |
Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration.
Ben M, Trusley C, Kupiec TC, Trissel LA. |
2008 |
1975 |
Czasopismo
Int J Pharm Compound 2005 ; 9, 3: 235-237. |
Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration.
Trissel LA, Xu QA. |
2005 |
1976 |
Czasopismo
Int J Pharm Compound 2005 ; 9, 3: 238-241. |
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Trissel LA, Xu QA. |
2005 |
2179 |
Czasopismo
Int J Pharm Compound 2007 ; 11, 1: 82-85. |
Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration.
Trusley C, Ben M, Kupiec TC, Trissel LA. |
2007 |
2114 |
Czasopismo
Ann Pharmacotherapy 2006 ; 40, 6: 1082-1085. |
Physical and chemical stability of pemetrexed in infusion solutions.
Zhang Y, Trissel LA. |
2006 |
2036 |
Czasopismo
Ann Pharmacotherapy 2005 ; 39, 12: 2026-2028. |
Physical and chemical stability of pemetrexed solutions in plastic syringes.
Zhang Y, Trissel LA. |
2005 |
4691 |
Czasopismo
Int J Pharm Compound 2022 ;26,3:248-254 |
Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine.
Catry E, Colsoul ML, Closset Me, Hubert J, Soumoy L, Bihin B, Thiry E, Jamart J, Hecq JD, Galanti L. |
2022 |
3691 |
Czasopismo
J Oncol Pharm Practice 2016 ; 22: 21-25 |
Physical and chemical stability of proflavine contrast agent solutions for early detection of oral cancer
Kawedia L.D, Zhang Y-P, Myers A.L, Richards-Kortum R.R, Kramer M.A, Gillenwater A.M, Culotta K.S. |
2016 |
3611 |
Czasopismo
J Oncol Pharm Practice 2014 ; 20, 1: 58-64. |
Physical and chemical stability of reconstituted and diluted dexrazoxane infusion solutions.
Zhang, Y.-P, Myers, A.L., Trinh, V.A, Kawedia, J.D, Kramer, M.A, Benjamin, R.S, Tran, H.T. |
2014 |
3163 |
Czasopismo
EJHP 2010 ; 16, 5: 26-28. |
Physical and chemical stability of Taxotere 1-vial 20mg/mL infusion solution following refrigerated storage.
Acott SR, Hart M. |
2010 |
1898 |
Czasopismo
Int J Pharm Compound 2004 ; 8, 3: 228-230. |
Physical and chemical stability of treprostinil sodium injection packaged in plastic syringe pump reservoirs.
Xu QA, Trissel LA, Pham L. |
2004 |
3881 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 4 : 343-346 |
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump.
Tomasello C, Leggieri A, Rabbia F, Veglio F, Baietto L,Fulcheri C, De Nicol? A, De Perri G, D'Avolio A. |
2016 |
3849 |
Czasopismo
Curr Pharm Biotech 2013 ; 14, 2: 220-225. |
Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions.
Pabari R.M, Ryan B, Ahmad W, Ramtoola Z. |
2013 |
4559 |
Czasopismo
Drug Design Dev Ther 2020 ;14, 4179-4187. |
Physical Compatibility and Chemical Stability of
Fentanyl and Naloxone Hydrochloride in 0.9% Sodium Chloride Injection Solution for Patient-Controlled Analgesia Administration.
Chen P, Chen F, Lei J, Zhou B. |
2020 |
2297 |
Czasopismo
Int J Pharm Compound 2008 ; 11, 6: 550-552 |
Physical compatibility and chemical stability of a concentrated solution of atropine sulfate (2 mg/ml) for use as an antidote in nerve agent casualties.
Donnelly R.F, Corman C. |
2008 |
561 |
Czasopismo
Current Ther Res 1976 ; 20: 359-368. |
Physical compatibility and chemical stability of amikacin sulfate in large-volume parenteral solutions. Part II.
Nunning BC, Granatek AP. |
1976 |
682 |
Czasopismo
Ann Pharmacotherapy 1991 ; 25: 123-126. |
Physical compatibility and chemical stability of amphotericin B in combination with magnesium sulfate in 5% dextrose injection.
Raymond GG, Davis RL. |
1991 |
865 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 79-81. |
Physical compatibility and chemical stability of atracurium besylate and midazolam hydrochloride during intravenous coinfusion.
Bhatt-Mehta V, Hirata S. |
1998 |
1931 |
Czasopismo
Can J Hosp Pharm 2004 ; 4: 230-235. |
Physical compatibility and chemical stability of bupivacaine and hydromorphone in polypropylene syringes.
Donnely RF. |
2004 |
4131 |
Czasopismo
Hosp Pharm 2019 ;54,1:32-36. |
Physical Compatibility and Chemical Stability of Injectable and Oral Ranitidine.
Fleming K, Donnelly R. |
2019 |
2322 |
Czasopismo
Can J Hosp Pharm 2009 ; 62, 1 |
Physical Compatibility and Chemical Stability of Ketamine–Morphine Mixtures in Polypropylene Syringes.
Donnelly R.F. |
2009 |
2192 |
Czasopismo
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414. |
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Cochran BG, Sowinski KM, Fausel C, Overholser BR. |
2007 |
1971 |
Czasopismo
Support Care Cancer 2001 |
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.
Azuara ML, Sanchez Y, Reyes R, Barcia E. |
2001 |
4245 |
Plakat
2019 |
Physical Compatibility and Stability of Ascorbic acid Injection in Polyvinyl Chloride Minibags at 4ºC and Room Temperature (25ºC).
Iazetta J, Law S, Adhikari NKJ, Lamontagne F, Kanji S, Walker SE. |
2019 |
3186 |
Czasopismo
Am J Health-Syst Pharm 2011 ; 68:377-378. |
Physical compatibility of 4% sodium citrate with 23.4% sodium chloride, fluconazole, and micafungin.
Bryan Dotson B, Churchwell MD. |
2011 |
3122 |
Czasopismo
Am J Health-Syst Pharm 2010 ; 67: 1195-1198. |
Physical compatibility of 4% sodium citrate with selected antimicrobial agents.
Dotson B, Lynn S, Savakis K, Churchwell MD. |
2010 |
3201 |
Czasopismo
J Pediatr Pharmacol Ther 2006 ; 11:233?6. |
Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit.
Dice JE. |
2006 |
4491 |
Czasopismo
Eur J Pedia 2020 |
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. |
2020 |
4651 |
Czasopismo
Eur J Pedia 2021 ;180,1169–1176. |
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. |
2021 |
1822 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 1650-1652. |
Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate.
Trissel LA, Seanz C. |
2003 |
3470 |
Czasopismo
Support Care Cancer 2012 ; 20: 2501-2509. |
Physical compatibility of binary and tertiary mixtures of morphine and methadone with other drugs for parenteral administration in palliative care.
Destro M, Ottolini L, Vicentini L, Boschetti S. |
2012 |
3268 |
Czasopismo
Am J Health-Syst Pharm 2012 ;69: 98. |
Physical compatibility of calcium gluconate and magnesium sulfate injections.
Beauregard N, Bertrand N, Dufour A, Blaizel O, Leclair G |
2012 |
4528 |
Czasopismo
Int J Pharm Compound 2021 ;25,1:52-61 |
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. |
2021 |
3429 |
Czasopismo
Am J Health-Syst Pharm 2015 ; 72:483-486 |
Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration
Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. |
2015 |
4055 |
Czasopismo
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. |
2018 |
3131 |
Czasopismo
Can J Hosp Pharm 2010 ; 63, 2: 154-155. |
Physical compatibility of high-concentration bupivacaine with hydromorphone, morphine and fentanyl.
Donnely RF, Wong K, Spencer J. |
2010 |
4419 |
Czasopismo
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161. |
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
Holt R.J, Siegert S.W.K, Krishna A. |
2008 |
4254 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40 |
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
D'Huart E, Vigneron J, Demoré B. |
2019 |
4108 |
Czasopismo
Am J Health-Syst Pharm 2018 ;75;8:510-512 |
Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine.
Cruz K, Chrchwell M, Mauro V, Boddu. |
2018 |
4411 |
Czasopismo
Int J Pharm Compound 2020 ;24,3:238-241. |
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A. |
2020 |
169 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Trissel LA, Martinez JF. |
1993 |
2346 |
Czasopismo
Am J Health-Syst Pharm 2009 ; 66: 986-987. |
Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents
Newland A.M, Mauro V.F, Alexander K.S. |
2009 |
4057 |
Czasopismo
Hosp Pharm 2018 ; 53, 2: 125-127. |
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydratation Fluids Commonly Used With High-Dose Methotrexate Chemotherapy.
Joiner L, Ynes C, Arnold J, Miller R, Gorman G. |
2018 |
4506 |
Czasopismo
Am J Health-Syst Pharm 2020 ;77,23:1938-1940. |
Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration.
Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C. |
2020 |
4144 |
Czasopismo
EJHP 2018 ;75,14:1010-1012 |
Physical compatibility of milrinone with levofloxacin and ceftriaxone injection.
Ross A, Boddu S, Mauro V, Churchwell M. |
2018 |
4545 |
Czasopismo
Journal of Nippon Medical school 2021 |
Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment.
Kondo M, Nagano M, Yoshida M, Yoshida N, Tagui N, Yoshida M, Sugaya K, Takase H. |
2021 |
4655 |
Czasopismo
Am J Health-Syst Pharm 2022 ;79,1:27-33 |
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Holyk A, Lindner A, Lindner S, Shippert B |
2022 |
1902 |
Czasopismo
Can J Hosp Pharm 2004 ; 57, 2: 90-96. |
Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.
Walker SE, Wyllie A, Law S. |
2004 |
1953 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Trissel LA, Saenz CA, Ogundele AB, Ingram DS. |
2004 |
4543 |
Czasopismo
Archives of Disease in Childhood 2018 ;104:292–295. |
Physical compatibility of pentoxifylline and intravenous medications.
Senarathna G, Strunk T, Petrovski M, Batty K. |
2018 |
4145 |
Czasopismo
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. |
2018 |
4080 |
Czasopismo
Anaesthesia 2017 ;124,3:776-781 |
Physical Compatibility of Propofol-Sufentanil Mixtures.
Zbytovska J, Gallusova J, Vidlarova L, Prochazkova K, Simek J, Stepanek F. |
2017 |
3558 |
Czasopismo
Can J Hosp Pharm 2013 ; 66, 5: 332. |
Physical Compatibility of Ranitidine and Metoclopramide in 50-mL Minibags of Normal Saline.
Rowe H, Riley J, Newby B. |
2013 |
58 |
Czasopismo
Can J Hosp Pharm 1985 ; 38: 160-161. |
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Parker WA. |
1985 |
4723 |
Czasopismo
Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a |
Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration.
Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H |
2022 |
3416 |
Czasopismo
Am J Health-Syst Pharm 2013 ; 70: 932-937 |
Physical compatibility of sodium citrate with alcohol and cefepime.
Csaba M, Boddu,S.H.S , Churchwell M.D. |
2013 |
3254 |
Czasopismo
Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. |
2011 |
4524 |
Plakat
ESCP Symposium, Geneva, Switzerland 2009 |
Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology.
Stucki C, Sautter A-M, Bonnabry P. |
2009 |
3967 |
Czasopismo
J Pharm Pharmacol 2017 ;69,7:448-462 |
Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents.
Staven V, Herra I, Wang S, Grönlie I,Tho I. |
2017 |
3942 |
Czasopismo
Am J Health-Syst Pharm 2017 ; 74, 5: 280-281. |
Physical compatibility of valproate sodium injection with dobutamine and dopamine.
Frank M.I, Boddu S.H.S, . Mauro V.F,. Churchwell M.D. |
2017 |
3421 |
Czasopismo
Am J Health-Syst Pharm 2013 ;70:1163-1166. |
Physical compatibility of vancomycin and piperacillin sodium–tazobactam at concentrations typically used during prolonged infusions.
Leung E, Venkatesan N, Ly S.C, Scheetz M.H. |
2013 |
3379 |
Czasopismo
Am J Health-Syst Pharm 2013 ;70:520-524. |
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Fox L.M, Wilder A.G, Foushee J.A. |
2013 |
1801 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 1271-1272. |
Physical compatibility of vasopressin with medications commonly used in cardiac arrest.
Feddema S, Rusho WJ, Tyler LS, Barker B. |
2003 |
1647 |
Czasopismo
Anaesthesia 2001 ; 56: 294. |
Physical incompatibility between atracurium and intravenous diclofenac.
Ackland G. |
2001 |
3557 |
Czasopismo
Can J Hosp Pharm 2013 ; 66, 5: 310-312 |
Physical Incompatibility between Parenteral Cloxacillin and Vancomycin.
Chan A, Tawfik G, Cheng W. |
2013 |
2117 |
Czasopismo
Ann Pharmacotherapy 2006 ; 40, 7: 1289-1292. |
Physical instability of frozen pemetrexed solutions in PVC bags.
Zhang Y, Trissel LA. |
2006 |
4370 |
Czasopismo
EJHP 2018 2018;0:1-7 |
Physical stability of an all-in one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs
Staven V, Wang S, Gronlie I, Tho I. |
2018 |
4368 |
Czasopismo
J Pharm Health Care Sci 2019 ; 5: 25. |
Physical, chemical, and microbiological stability study of diluted atropine eye drops.
Saito J, Imaizumi H, Yamatani A. |
2019 |
1660 |
Czasopismo
Pharm World Sci 1999 ; 21: 137-141. |
Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers.
Thiesen J, Krämer I. |
1999 |
3707 |
Czasopismo
J Oncol Pharm Practice 2014 ; 20: 183-189 |
Physico-chemical stability of eribulin mesylate containing concentrate and ready-to-administer solutions.
Spindeldreier K, Thiesen J, Lipp H.P, Krämer I. |
2014 |
1723 |
Czasopismo
Pharmazie 1998 ; 53: 386-391. |
Physico-chemical stability of infusion solutions for epidural administration containing fentanyl and bupivacaine or lidocaine.
Sattler A, Jage J, Krämer I. |
1998 |
2825 |
Czasopismo
Int J Pharm Compound 2015 ; 19, 3: 261-267. |
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials.
Mueller C, Dietel E, Heynen S, Nalenz H, Goldbach P, Mahler H, Schmidt J, Grauschopf U, Schoenhammer K. |
2015 |
3225 |
Czasopismo
EJHP Science 2011 ; 17, 1: 7-12. |
Physico-chemical stability of nelarabine infusion solutions in EVA infusion bags.
Kaiser J, Krämer I. |
2011 |
4126 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 ;3,3:135-142 |
Physico-Chemical Stability of Sodium Thiosulfate Infusion Solutions in Polyolefin Bags at Room Temperature over a Period of 24 Hours.
D'Huart E, Vigneron J, Ranchon F, Vantard N, Rioufol C, Demor2 B |
2018 |
3041 |
Czasopismo
Acta Pol Pharm 2006 ; 63: 293-299. |
Physicochemical and microbiological properties of eye drops containing cefuroxime.
Kodym A, Zawiswa T, Taberska J , Kukula H. |
2006 |
3755 |
Czasopismo
Int J Pharm Compound 2014 ; 18, 5: 427-431. |
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition.
Bourget P, Amin A, Vidal F, Pieyre M, Dosso E.O, Beauvais R, Loeuillet R. |
2014 |
4052 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2017 |
Physicochemical and microbiological stability of a new paediatric oral solution of clonidine.
Verhlac C, Bourdon F, Titecat M, Frealle E, Dhorne C, Berneron C, Odou P. |
2017 |
4695 |
Czasopismo
Int J Pharm Compound 2022 ;24,6:342-351 |
Physicochemical and Microbiological Stability of Amitriptyline Hydrochloride Oral Liquid Dosage Forms in PCCA Base, SuspendIt.
Pramar Y, Mandal T, Bostanian L, Kader C, Morris T Graves R. |
2022 |
3789 |
Czasopismo
Int J Pharm Compound 2015 ; 19, 1: 73-77. |
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions.
Amin A, Bourget P, Vidal F, Cartier F, Beauvais R, Do Nascimento Afonso V. |
2015 |
4777 |
Czasopismo
Int J Pharm Compound 2023 ; 27, 4: 330-339. |
Physicochemical and microbiological stability of azathioprine suspensions in PCCA base Suspendit.
Pramar Y.V, Mandal T.K, Bostanian L.A, Kader C, Morris T.C, Graves R.A. |
2023 |
4575 |
Czasopismo
Int J Pharm Compound 2021 ;25,2:169-175 |
Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt.
Pramar Y, Mandal T, Bostanian L, Le G, Morris T, Richard A. |
2021 |
4530 |
Czasopismo
Int J Pharm Compound 2021 ;25,5:431-439 |
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt.
Pramar Y, Mandal T, Bostanian L, Kader C, Morris T, Graves R. |
2021 |
4741 |
Czasopismo
Int J Pharm Compound 2023 ;27,2:160-168 |
Physicochemical and Microbiological Stability of Pyrimethamine in Paraben-free PCCA Base,
SuspendIt.
Pramar Y, Mandal T, Bostanian L, Kader C, Morris T, Graves R |
2023 |
4272 |
Czasopismo
Pharm Dev Technol 2019 |
Physicochemical and microbiological stability of two news oral liquid formulations of clonidine hydrochloride for pediatric patients.
Merino-Bohorquez, Delgado-Valverde M, Garcia-Palomo M, Dàvila- Pousa MC, Canete C, Villaronga M, Rodriguez-Marrodan B, Lopez-Ro |
2019 |
2530 |
Czasopismo
Int J Pharm Compound 2022 ;26,4:330-335 |
Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes.
Bartoll A, Bellés Medall M, Peñarrocha J, Escrig L, Clemente R, Azuara J. |
2022 |
761 |
Czasopismo
EJHP 2015 ;22:89-93 |
Physicochemical and microbiological stability studies of a melatonin oral suspension in a commercially available vehicle for paediatric use.
Zerbit J, Bordenave J, Benoit G. |
2015 |
4011 |
Czasopismo
EJHP 2016 2016;0:1-11 |
Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit.
Gersonde F, Eisend S, Haake N, Kunze T. |
2016 |
4461 |
Czasopismo
Molecules 2019 24, 1242. |
Physicochemical Compatibility and Stability of Linezolid with Parenteral Nutrition.
Tomczak S, Stawny M, Dettlaff K, Kieliszek, M, Słominska D, Jelinska A. |
2019 |
1847 |
Czasopismo
J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241. |
Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration.
Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. |
2003 |
1859 |
Czasopismo
Il Farmaco 2002 ; 57: 925-930. |
Physicochemical compatibility between thiocolchicoside injections (Miotens®) and pharmaceutical products frequently used for combined therapy.
Anacardio R, Perilli O, Pagnanelli F, Bartolini S, gentile MM, Mazzeo P, Carlucci G. |
2002 |
4371 |
Czasopismo
Journal of Parenteral and Enteral Nutrition 2018 |
Physicochemical Compatibility of Amiodarone with Parenteral Nutrition.
Mediavilla MM, Molina A, Navarro L, Grau L, Pujol MD, Cardenete J, Cardona D, Riera P. |
2018 |
3705 |
Czasopismo
EJHP 2014 ;21:161-166 |
Physicochemical compatibility of commonly used analgesics and sedatives in the intensive care medicine.
Knudsen L, Eisend S, Haake N, Kunze T. |
2014 |
4357 |
Czasopismo
Nutrition in clinical Practice 2020 ; 35: 967-972. |
Physicochemical Compatibility of Dexmedetomidine With Parenteral Nutrition.
Campos-Baeta, Saavedra-Mitjans M, Garin N, Cardenete J, Cardona D, Riera P. |
2020 |
2790 |
Czasopismo
Int J COPD 2007 ; 1, 4: 599-607. |
Physicochemical compatibility of fluconasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions.
Kamin W, Schwabe A, Krämer I. |
2007 |
1506 |
Czasopismo
EJHP 2015 ;22:107-112. |
Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.
Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. |
2015 |
150 |
Czasopismo
J Pharm Clin 1993 ; 12: 31-35. |
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
Aujoulat P, Coze C, Braguer D, Raybaud C. |
1993 |
3334 |
Czasopismo
EJHP 2013 ;20:36-41 |
Physicochemical compatibility of nebuliser solution admixtures containing colistimethate and hypertonic saline or colistimethate, fluticasone-17-propionate, ipratropium bromide and salbutamol sulfate.
Krämer I, Walz-Jung H, Stanko C, Kamin W. |
2013 |
3440 |
Czasopismo
Pharmazie 2013 ; 68: 744-748. |
Physicochemical compatibility of nebulizable drug admixtures containing colistimethate and tobramycin.
Wollstadt A, Krämer I, Kamin W. |
2013 |
2770 |
Czasopismo
Pharmazie 2007 ; 62, 10: 760-766. |
Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol.
Krämer I, Schwabe A, Lichtinghagen R, Kamin W. |
2007 |
126 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2606-2610. |
Physicochemical compatibility of propofol with thiopental sodium.
Prankerd RJ, Jones RD. |
1996 |
2053 |
Czasopismo
Anesth Analg 2003 ; 97: 1646-1651. |
Physicochemical compatibility of propofol-lidocaine mixture.
Masaki Y, Tanaka M, Nishikawa T. |
2003 |
3919 |
Czasopismo
Eur J Pharm Sci 2017 ; 96: 449-455. |
Physicochemical stability and compatibility testing of levetiracetam in all-in-one parenteral nutrition admixtures in daily practice.
Aeberhard C, Steuer C, Saxer C, Huber A, Stanga Z, Mühlebach S. |
2017 |
4633 |
Czasopismo
Pharmaceutics 2021 ; 13, 1447. |
Physicochemical Stability and Compatibility Testing of Voriconazole in All-in-One Parenteral Nutrition Admixtures.
Reber E, Neyer P, Schönenberger K.A, Saxer C, Bernasconi L, Stanga Z, Huber A, Hammerer-Lercher A, Mühlebach S. |
2021 |
4696 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2022 2022; 7(1): 20220005 |
Physicochemical stability of 20 mg/mL amiodarone hydrochloride oral suspension in SyrSpend® SF PH4 (liquid)
Adoum A, Le P., Faisant S, Legendre P, Lester MA, Boivin PN. |
2022 |
4077 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 |
Physicochemical Stability of 5 mg/mL Pediatric Prednisone Oral Suspensions in Syrspend® SF PH4.
Bonnaure Anne-Claire, Bellay R, Rault P, Lester M.A, Boivin P.N. |
2018 |
3124 |
Czasopismo
EJHP Science 2010 ; 16, 1: 17-22. |
Physicochemical stability of a 1mg/ml dexamethasone acetate oral suspension.
Tiphine T, Armand A, Navas D, Dailly E, Menanteau M, Thomaré P. |
2010 |
4096 |
Czasopismo
Pharm Dev Technol 2014 |
Physicochemical stability of a new topical timolol 0.5% gel formulation for the treatment of infant hemangioma.
Merino-Bohorquez V, Casas M, Caracuel F, Camean M, Fernandez-Anguita M.J, Ramirez*Soto G, Lucero M.J. |
2014 |
4673 |
Czasopismo
Pharmaceutics 2022 ;14,1:118 |
Physicochemical Stability of a Novel Tacrolimus Ophtalmic Formulation for the Treatment of Ophtalmic Inflammatory Diseases.
Barrieu M, Chennell P, Yessaad M, Bouattour Y, Wasiak M, Jouannet M, Le Basle Y, Sautou V. |
2022 |
4350 |
Czasopismo
EJHP 2019 ;0:1-5 |
Physicochemical stability of an admixture of lidocaine and ketamine in polypropylene syringe used in opioid-free anaesthesia.
Beiler B, Barraud D, Vigneron J, Demor? B. |
2019 |
4030 |
Czasopismo
Int J Pharm Compound 2017 ; 21, 5 : 430-435 |
Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt.
Graves R, Phan K, Bostanian L, Mandal T, Pramar Y. |
2017 |
4697 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2022 2022; 7(1): 20220003 |
Physicochemical stability of azacitidine suspensions at 25 mg/mL in polypropylene syringes stored under different conditions of storage.
Trambloy Q, Vigneron J, Clarot I, Blaise F, D’Huart E, Demoré B. |
2022 |
4362 |
Czasopismo
EJHP 2018 Eur J Hosp Pharm 2018;0:1 |
Physicochemical stability of binary admixtures of paracetamol and dexketoprofen-trometamol for patient-controlled analgesia use.
Lopez Navarro AA, Martinez Gomez MA, Gras Colomer E, Campillos P, Climente Marti M. |
2018 |
3804 |
Czasopismo
EJHP 2014 ;22:150-155. |
Physicochemical stability of cabazitaxel and docetaxel solutions.
Lazzarini R, Salvadori S, Trapella C, Guerrini R, Marzola E, Pasini G, Dalpiaz A. |
2014 |
4761 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2023 ; 8(1): 20220009 |
Physicochemical stability of Cabazitaxel Zentiva® solution in vials after opening and diluted- solutions in three infusion bags.
D'Huart E, Sacrez M, Vigneron J, Demoré B. |
2023 |
4097 |
Czasopismo
Pharm Dev Technol 2013 |
Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients.
Casas M, Alvarez J, Lucero M. |
2013 |
4047 |
Czasopismo
J Oncol Pharm Practice 2017 ;25,2: 339-350 |
Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period.
Kim S.H, Krämer I. |
2017 |
4762 |
Czasopismo
EJHP 2023 ; 30, 1: 11-16. |
Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature
Knoll L, Kraemer I, Thiesen J. |
2023 |
4268 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2019 |
Physicochemical Stability of Cefotaxime Sodium in Polypropylene Syringes at High Concentrations for Intensive Care Units.
D'Huart E, Vigneron J, Blaise F, Charmillon A, Demoré B. |
2019 |
4478 |
Czasopismo
Int J Pharm Compound 2020 ;24,5:413-419 |
Physicochemical Stability of Compounded Allopurinol Suspensions in PCCA Base, SuspendIt.
Pramar Y, Mandal T, Bostanian L, Le G, Morris T, Graves R. |
2020 |
4520 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2020 |
Physicochemical stability of compounded midazolam capsules over a one-year storage period.
Boivin P-N, Legendre P, Bonnaure A-C, M-A. |
2020 |
4251 |
Czasopismo
Int J Pharm Compound 2019 ;23,2:157-162 |
Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base, SuspendIt.
Pramar YV, Mandal TK, Bostanian LA, Nguyen ATQ, Morris TC, Graves RA. |
2019 |
4677 |
Plakat
EAHP Congress Vienna 2022 |
Physicochemical stability of diluted "Thiotepa Riemser" infusion solutions in prefilled 5% glucose infusion bags.
Linxweiler H, Thiesen J, Krämer I. |
2022 |
3258 |
Czasopismo
Int J Pharm Compound 2011 ; 15, 6 : 515-520. |
Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags.
Kaiser J, Krämer I. |
2011 |
3343 |
Plakat
ECOP Congress, Budapest, Hungary 2012 |
Physicochemical stability of diluted trastuzumab solutions stored 6 months at 4°C.
Vieillard V, da Silva R, Astier A, Paul M. |
2012 |
4767 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2023 ;8,1 |
Physicochemical stability of durvalumab (Imfinzi® ) concentrate for solution in original vials after first opening.
Almasi K, Thiesen J, Krämer I. |
2023 |
4125 |
Czasopismo
EJHP 2020 ; 27, 1: 43-48. |
Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg/mL in polyolefin bags.
D'Huart E, Vigneron J, Lider P, Demoré B. |
2020 |
4353 |
Czasopismo
J Clin Pharm Ther 2019 |
Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome.
Lu D, Harmanjeet H, Wanandy T, Paine M, . PetersonG.M, Patel R. |
2019 |
4107 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 |
Physicochemical Stability of Extemporaneously Prepared Oral Suspension of Fluconazole 50 mg/mL in SuspendIt.
Ip K, Shan A, Carvalho M, Baker S, Banov D. |
2018 |
4748 |
Czasopismo
Pharmaceutics 2023 ,15, 309. |
Physicochemical Stability of Generic Thiotepa Concentrate and Ready-to-Administer Infusion Solutions for Conditioning Treatment.
Linxweiler H, Thiesen J, Krämer I. |
2023 |
4635 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2021 ; 6(1): 20210005. |
Physicochemical stability of human insulin 1 I.U./mL infusion solution in 50 mL polypropylene syringes.
Mohr A, Erdnüß F, Krämer I. |
2021 |
2241 |
Czasopismo
J Oncol Pharm Practice 2000 ; 6, 3: 115-121. |
Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags.
Thiesen J, Krämer I. |
2000 |
4600 |
Czasopismo
EJOP 2021 ; 4: 3. |
Physicochemical stability of lurbinectedin reconstituted at 500 µg/mL and diluted at 15, 30, and 70 µg/mL in 0.9% sodium chloride and 5% dextrose.
Loeuille G, Vigneron J, D’Huart E, Demoré B. |
2021 |
3896 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2016 ;1,2:73-81 |
Physicochemical Stability of Mozobil® (Plerixafor) Solution for Injection in Glass Vials and Plastic Syringes over a Three-Month Storage Period
Kim S.H, Thiesen J, Krämer I. |
2016 |
4267 |
Czasopismo
EJHP 2019 |
Physicochemical stability of nefopam and nefopam/droperidol solutions in polypropylene syringes for intensive care units.
D'Huart E, Vigneron J, Clarot I, Demoré B. |
2019 |
4250 |
Czasopismo
Ann Pharm Fr 2019 ;77,3:212-221. |
Physicochemical stability of norepinephrine bitartrate in polypropylene syringes at high concentrations for intensive care units.
D'Huart E, Vigneron J, Clarot I, Demoré B. |
2019 |
2883 |
Czasopismo
Am J Health-Syst Pharm 2009 ; 66, 21: 1929-1933. |
Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags.
Eiden C, Philibert L, Bekhtari K, Poujol S, Malosse F, Fr?d?ric Pinguet F. |
2009 |
4143 |
Czasopismo
EJHP 2016 ; 25, 4 |
Physicochemical stability of oxycodone-ketamine solutions in polypropylene syringe and polyvinyl chloride bag for patient-controlled analgesia use.
Daouphars M, Hervou?t C.H, Bohn P, Martin D, Rouvet J, Basuyau F, Varin R. |
2016 |
4334 |
Czasopismo
J Oncol Pharm Practice 2020 ; 26, 3: 641-646. |
Physicochemical stability of pembrolizumab admixture solution in normal saline intravenous infusion bag.
Sundaramurthi P, Sean Chadwick S, Narasimhan C. |
2020 |
4702 |
Czasopismo
EJOP 2022 ; 5: 2. |
Physicochemical stability of pemetrexed diarginine at 25 mg/mL in partially-used vials and at 3 and 12 mg/mL diluted in dextrose 5% or in sodium chloride 0.9% in polyolefin bags.
Nisse Y-E, Sobalak N, Vigneron J, Demoré B. |
2022 |
4754 |
Czasopismo
J Oncol Pharm Practice 2023 ;29,3: |
Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions.
Weiser S, Burns C, Zartler E |
2023 |
4756 |
Czasopismo
J Oncol Pharm Practice 2022 ;29, 5: 1032-1043 |
Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions.
Weiser S, Burns C, Zartler E. |
2022 |
3397 |
Plakat
EAHP Congress Paris 2013 |
Physicochemical stability of ready-to-administer epinephrine injection solutions 20 µg/mL, 50 mL.
Heeb R.M, Krämer I. |
2013 |
4043 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2017 ;2,4: 145-157. |
Physicochemical Stability of Reconstituted Decitabine (Dacogen®) Solutions and Ready-to-Administer Infusion Bags when Stored Refrigerated or Frozen.
Kim S, Heeb R, Krämer I. |
2017 |
4115 |
Czasopismo
Drug Design Dev Ther 2016 ;10:3873-3878 |
Physicochemical stability of ternary admixtures of butorphanol, ketamine, and droperidol in polyolefin bags for patient-controlled analgesia use.
Fang B, Wang L, Gu J, Chen F, Shi X. |
2016 |
4516 |
Czasopismo
GaBI Journal 2020 ; 9, 4:155-162 |
Physicochemical stability of the bevacizumab biosimilar, ABP 215, after preparation and storage in intravenous bags.
Seckute J, Castellanos I, Bane S. |
2020 |
4763 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2023 ;8,1 |
Physicochemical stability of urea-containing Mitomycin C preparations in glass vials (1.0 mg/mL) and plastic syringes (2.0, 0.4, 0.2 mg/mL)
Almasi J, Erdnuss F, Thiesen J, Krämer I. |
2023 |
4348 |
Czasopismo
Can J Hosp Pharm 2019 ;72(5):360-8 |
Physicochemical Stability of Vancomycin at High Concentrations in Polypropylene Syringes.
D'Huart E, Vigneron J, Charmillon A, Clarot I, Demoré B. |
2019 |
4035 |
Czasopismo
EJHP 2017 ;0:1-5 |
Physicochemical stability of voriconazole in elastomeric devices.
Harmanjeet H, Zaidi S.T.R, Ming L.C, Wanandy T, Patel R.P. |
2017 |
4745 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2023 |
Physicochemical stability study of a biosimilar of Bevacizumab in vials and after dilution in 0.9% NaCl in polyolefin intravenous bags.
Vieillard V, Paul M |
2023 |
3448 |
Czasopismo
Ann Pharm Fr 2013 ; 71, 5: 358-363. |
Physicochemical stability study of a new Trimix formulation for treatment of erectile dysfunction.
Vieillard V, Eychenne N, Astier A, Yiou R, Deffaux C, Paul M. |
2013 |
4493 |
Czasopismo
J Oncol Pharm Practice 2020 |
Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
Le Guyader G, Vieillard V, Paul M. |
2020 |
4692 |
Czasopismo
The Scientific World Journal 2022 |
Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease.
Hinterlang M, Sebti M, Cotteret C, Vidal F, Neven B, Cisternino S, Schlatter J. |
2022 |
3895 |
Czasopismo
Ann Pharmacotherapy 2016 ; 50: 790-792. |
Physicochemical Stability Study of Polymyxin B in Various Infusion Solutions for Administration to Critically Ill Patients
Lim Tze-Peng, Kim-Hor Hee D, Lee W, Qi-Min Teo J, Cai Y,Yu-Hng Chia S, Yee-Kiat Leaw J, Jing-Yi Lee S, Soon-U Lee L, Kwa A.L. |
2016 |
4669 |
Czasopismo
Neuromodulation 2021 : 1-16. |
Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration.
Robert J, Sorrieul J, Dupoiron D, Jubier-Hamon S, Bienfait F, Visbecq A, Devys C. |
2021 |
3472 |
Czasopismo
Krankenhauspharmazie 2007 ; 28, 5: 170-178. |
Physikalisch-chemische kompatilibität von Mischinhalationslösungen und suspensionen zur simultanen feuchtinhalationstherapie bei Mukoviszidose Patienten.
Krämer I, Schwabe A, Kamin W. |
2007 |
3538 |
Czasopismo
Krankenhauspharmazie 2013 ; 11: 524-525. |
Physikalisch-chemische Stabilität einer Metoprolol-Injektionslösung 1 mg/ml, 50 ml.
Gilcher Th, Heeb R M, Krämer I. |
2013 |
3986 |
Czasopismo
Krankenhauspharmazie 2017 ;38:377-82. |
Physikalisch-chemische Stabilität von Carfilzomib (Kyprolis®) im Originalbehältnis nach Erstanbruch und in applikationsfertigen Zubereitungen.
Kim S, Krämer I. |
2017 |
3110 |
Plakat
Poster ADKA Congress May 2010 2010 |
Physikalisch-chemische Stabilität von Clofarabin-Zubereitungen.
Kaiser J, Krämer I. |
2010 |
4004 |
Czasopismo
Krankenhauspharmazie 2017 ;38,7:334?340. |
Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln.
Krämer I, Sarakbi I, Thiesen J, Mainz. |
2017 |
4018 |
Czasopismo
Krankenhauspharmazie 2017 ;38:423-429 |
Physikalisch-chemische Stabilität von rekonstituierten Trabectedin-haltigen Lösungen.
Lipp H-P, Gfrörer W |
2017 |
999 |
Czasopismo
JPEN 1985 ; 9: 220-224. |
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
Watson D. |
1985 |
3586 |
Laboratorium
Actavis France 2010 |
Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit
|
2010 |
3590 |
Laboratorium
Dakota Pharm 2011 |
Piperacilline - Résumé des caractéristiques du produit
|
2011 |
3320 |
Laboratorium
CTI Life Sciences Limited 2012 |
Pixantrone (Pixuvri®) - Summary of Product Characteristics
|
2012 |
1223 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 618. |
Plastic IV container for nitroglycerin.
Amann AH, Baaske DM, Wagenknecht DM. |
1980 |
2078 |
Czasopismo
J Ped Surg 2000 ; 35: 1775-1781. |
Polyvinylchloride infusion lines expose infants to large amounts of toxic plasticizers.
Loff S, Kabs F, Witt K, Sartoris J, Mandl B, Niessen KH, Waag KL. |
2000 |
4380 |
Laboratorium
Merck Sharp & Dohme Limited 2019 |
Posaconazole (Noxafil®) - Summary of Product Characteristics
|
2019 |
3839 |
Czasopismo
Current Ther Res 2015 ; 77: 105-110. |
Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions.
Gu Z, Parra C, Wong A, Nguyen A, Cheung R, Catalano T. |
2015 |
1941 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 1586-1589. |
Potency and stability of frozen urokinase solutions in syringes.
Dedrick SC, Ramirez-Rico J. |
2004 |
892 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1156-1164. |
Practical guidelines for preparing and administering amphotericin B.
Kintzel PE, Smith GH. |
1992 |
4716 |
Czasopismo
J Pediatr Pharmacol Ther 2022 ;27,7:625-631 |
Pre-formulation and Stability Study of 20 mcg Clonidine Hydrochloride Pediatric Capsules.
Wasilewski M, Curti C, Panuccio C, Bouguergour C, Primas N, Lamy E, Castera-Ducros C, Jean C, Pirre Bertault-Peres P, Vanelle P |
2022 |
1959 |
Czasopismo
Hosp Pharm 2005 ; 40, 2: 154-155. |
Precipitate formation after subconjonctival administration of ceftazidime and vancomycin.
Mac Lellan C, Papadopoulos A. |
2005 |
2073 |
Czasopismo
Can J Anesth 1998 ; 45: 347-351. |
Precipitate formed by thiopentone and vecuronium causes pulmonary embolism.
Taniguchi T, Yamamoto K, Kobayashi T. |
1998 |
3377 |
Czasopismo
Anaesthesia 1983 ; 38: 601-602. |
Precipitation betwen meptazinol and thiopentone.
Huddy NC, Durcan JJ. |
1983 |
3372 |
Czasopismo
Rev Bras Anestesiol 2013 ; 63, 1: 163-166. |
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. |
2013 |
3374 |
Czasopismo
Anaesthesia 2001 ; 56: 494-495. |
Precipitation in Manchester: ketorolac/cyclizine
Smith R.P.R, Jones M. |
2001 |
270 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1449. |
Precipitation of amphotericin B from IV fat emulsion.
Heide PE. |
1997 |
138 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1845-1848. |
Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint.
Corbrion V, Crauste-Manciet S, Allain P, Brossard D. |
1997 |
233 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1850. |
Precipitation of lorazepam during infusion by volumetric pump.
Grillo JA, Barie PS. |
1996 |
780 |
Czasopismo
Ann Pharmacotherapy 1996 ; 30: 1037-1038. |
Precipitation of lorazepam infusion.
Boullata J, Gelone SP, Mancano MA, Borenstein MR, Zitterman R. |
1996 |
969 |
Czasopismo
N Engl J Med 1991 ; 325: 1315-1316. |
Precipitation of ondansetron in alkaline solutions.
Jarosinski PF, Hirschfeld S. |
1991 |
1741 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2518-2521. |
Precipitation of paclitaxel during infusion by pump.
Pfeifer RW, Hale KN, Cronquist SE, Daniels M. |
1993 |
173 |
Czasopismo
J Infus Chemother 1994 ; 4: 140-142. |
Precipitation of paclitaxel from continuous infusion fluids.
Williams DA, Naik A. |
1994 |
2071 |
Czasopismo
Anesth Analg 2002 ; 95: 785. |
Precipitation of protamine by cefazolin.
Ng HP, Koh KF. |
2002 |
3373 |
Czasopismo
J R Soc Med Sh Rep 2011 ; 2: 58. |
Precipitation of thiopental with muscle relaxants: a potential hazard.
Khan S, Stannard N, Greijn J. |
2011 |
1099 |
Czasopismo
Ann Intern Med 1984 ; 101: 880. |
Precipitation of verapamil in an intravenous line.
Tucker R, Gentile JF. |
1984 |
1351 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 2588. |
Precipitation of verapamil with nafcillin.
Tucker R, Gentle JF. |
1984 |
1100 |
Czasopismo
Ann Intern Med 1982 ; 97: 619. |
Precipitation of verapamil.
Bar-Or D, Kulig K, Marx JA, Rosen P. |
1982 |
4773 |
Czasopismo
Eur J Pharm Sci 2023 ; 187: 106464. |
Predictive stability, novel HPLC-MS analysis and semi-automatic compounding process for the emergency implementation of a production line of pancuronium in injectable solution.
Merienne C, Filali S, Marchand C, Lapras B, Paillet C, Pirot F. |
2023 |
2557 |
Czasopismo
Aust J Hosp Pharm 1991 ; 21: 239-241. |
Prednisolone stability in a hydroalcoholic prednisolone mixture.
Sullivan JA. |
1991 |
1424 |
Czasopismo
Am J Emerg Med 1999 ; 17: 333-337. |
Prehospital stability of diazepam and lorazepam.
Gottwald MD, Akerd LC, Liu PK, Orsulak PJ, Corry M, Bacchetti P, Fields SM, Loxenstein DH, Alldredge BK. |
1999 |
2051 |
Czasopismo
Br J Anaesth 2003 ; 90: 179-182. |
Premixed solutions of diamorphine in ropivacaine for epidural anaesthesia: a study on long-term stability.
Sanchez del Aguila MJ, Jones MF, Vohra A. |
2003 |
4050 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2017 ;2,4:193-201 |
Preparation and physico-chemical stability of dexamethasone oral suspension.
Binson G, Venisse N, Bacle A, Beuzit K, Dupuis A. |
2017 |
4492 |
Czasopismo
Int J Antimicrob Agents 2020 |
Preparation and physicochemical stability of 50 mg/ml hydroxychloroquine oral suspension in Syrspend pH4 dry.
Binson G, Venisse N , Sauvaget A , Bacle A , Lazaro P , Dupuis A. |
2020 |
4256 |
Czasopismo
Pharmaceutics 2019 ;11,190: |
Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients.
Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A. |
2019 |
3624 |
Czasopismo
Int J Pharm Compound 2014 ; 18, 2 : 169-174. |
Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets.
Zaid Abdel Naser, Assali M, Qaddomi A, Ghanem M, Zaaror Yara Abu. |
2014 |
2998 |
Czasopismo
J Pharm Technol 1989 ; 5: 202-205. |
Preparation and stability of an oral suspension of dipyridamole.
Ameer B, Callahan RJ, Dragotakes SC et al. |
1989 |
2692 |
Czasopismo
J Am Pharm Assoc 2007 ; 47, 6; 747-755. |
Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules.
Winiarski AP, Infeld MH, Tscherne R, Bachinsky M, Rucki R, Nagano-Mate K. |
2007 |
2810 |
Czasopismo
Antimicrob Agents Chemother 2009 ; 53, 2: 798-799. |
Preparation and stability of voriconazole eye drop solution.
Dupuis A, Tournier N, Le Moal G, Venisse N. |
2009 |
2567 |
Czasopismo
Pakistan J Biol Sci 2000 ; 3, 10: 1755-1757. |
Preparation and stability study of diclofenac sodium suppositories.
Ahmed M, Jalil R, Islam MA, Shaheen SM. |
2000 |
4719 |
Czasopismo
SAGE Open Medicine 2022 ; 10: 20503121221135568. |
Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump.
Bower J, Wright K, Burdette J. |
2022 |
4751 |
Czasopismo
Pharmaceutics 2023 https://doi.org/10.3390/ |
Product Validation and Stability Testing of Pharmacy Compounded Cholic Acid Capsules for Dutch Patients with Rare Bile Acid Synthesis Defects.
Polak Y, Jacobs B.A.W, Bouwhuis N, Hollak C.E.M, Kroon M.A.G.M, Kemper E.M. |
2023 |
4583 |
Czasopismo
Int J Pharm Compound 2021 ;25,3:246-257 |
Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags
Hui A, Yin J, Liu W, Zheng K. |
2021 |
4163 |
Czasopismo
Int J Pharm Compound 2018 22;5:417-423 |
Prolonged In-Use Stability of Reconstituted Herceptin in Commercial Intravenous Bags.
Nalenz H, K?pf E, Dietel E. |
2018 |
3956 |
Czasopismo
ASAIO Journal 2005 ; 51,6:761-763. |
Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique.
Bastani B; Amin K; Herr A. |
2005 |
3659 |
Laboratorium
AstraZeneca 2016 |
Propofol (Diprivan®) - Résumé des caractéristiques du produit
|
2016 |
3502 |
Laboratorium
Astra Zeneca 2012 |
Propofol (Diprivan®) - Summary of Products Characteristics
|
2012 |
919 |
Czasopismo
Anesth Analg 1998 ; 86: 422-426. |
Propofol and thiopental in a 1:1 volume mixture is chemically stable.
Lazar ER, Jolly DT, Tam YK, Hrazdil J, Tawfik SR, Clanachan AS. |
1998 |
660 |
Czasopismo
Ann Pharmacotherapy 1996 ; 30: 228-232. |
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Michaels MR, Stauffer GL, Haas DP. |
1996 |
3091 |
Czasopismo
Wien Med Wochenschr 2005 ; 155, 13-14: 337-343. |
Prüfung von Stabilität und Kompatibilität von Flucloxacillin (Floxapen®) und Ceftazidim (Fortum®) in zwei Infusionslösungen:Relevanz für die klinische Praxis.
Thalhammer F, Maier-Salamon A, Jäger W. |
2005 |
4044 |
Czasopismo
Pharm Sci Communications 2017 ;9:5:28-35 |
Quality assessment and stability study of compounded furosemide syrup.
Alfred-Ugbendo D, Zdoryk O.A, Georgiyants V.A. |
2017 |
4192 |
Czasopismo
Pediatric Anesthesia 2018 |
Quality control and stability of ketamine, remifentanil and sufentanil syringes in a pediatric operating theater.
Bourdon F, Simon N, Lannoy D, Berneron C, D?caudin B, Reumaux L, Duhamel A, Richart P, Odou P. |
2018 |
2000 |
Czasopismo
J Pharm Biomed Anal 2005 ; 38: 180-185. |
Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products.
Bouligand J, Storme T, Laville I, Mercier L, Oberlin O, Vassal J, Bourget Ph, Paci A. |
2005 |
653 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 125-127. |
Quantification of metoprolol tartrate and propranolol hydrochloride in pharmaceutical dosage forms : stability of metoprolol in aqueous mixture.
Das Gupta V. |
1997 |
1357 |
Czasopismo
Ann Pharmacotherapy 1989 ; 23: 91-92. |
Quinolones and penicillins incompatibility.
Janknegt R, Schrouff GGM, Hooymans PM, Hermens WJHH, Lohman JJHM. |
1989 |
1513 |
Laboratorium
Monarch Pharmaceuticals Ireland 2006 |
Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produit
|
2006 |
1518 |
Laboratorium
Hospira UK Ltd 2013 |
Raltitrexed (Tomudex®) - Summary of Product Characteristics
|
2013 |
3773 |
Laboratorium
Eli Lilly 2014 |
Ramicirumab (Cyramza®) - Summary of Product Characteristics
|
2014 |
1166 |
Czasopismo
Int J Pharm 1980 ; 6: 63-76. |
Rapid adsorptive loss of nitroglycerin from aqueous solution to plastic.
Sokoloski TD, Wu CC, Burkman AM. |
1980 |
514 |
Czasopismo
Ann Pharmacotherapy 1997 ; 31: 297-302. |
Rapid loss of fentanyl citrate admixed with fluorouracil in polyvinyl chloride containers.
Xu QA, Trissel LA, Martinez JF. |
1997 |
4255 |
Czasopismo
J Pharm Anal 2013 ;3,6:408-414 |
Rapid, simple and stability-indicating determination of polyhexamethylene biguanide in liquid and gel-like dosage forms by liquid chromatography with diode-array detection.
Kusters M, Beyer S, Kutschera S, Schlesingera H, Gerhartzb M. |
2013 |
1517 |
Laboratorium
Sanofi-Aventis 2015 |
Rasburicase (Fasturtec®) - Summary of Product Characteristics
|
2015 |
4 |
Czasopismo
Act Pharm Biol Clin 1995 ; 8: 525-528. |
Reconstitution centralisée du ganciclovir : méthode de contrôle et étude de stabilité.
Zazempa V, Morgenszejn J, Paul M, Astier A. |
1995 |
353 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 2519-2524. |
Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid.
Lunn G, Sansone EB. |
1987 |
2341 |
Plakat
Poster ESCP Stockholm May 2005 |
Release of di(2-ethylhexyl)phtalate from polyvinylchloride bags during docetaxel infusions
Bourlon S, Sautou-Miranda V, Dalle M. |
|
1271 |
Czasopismo
J Pharm Belg 1982 ; 37: 153-156. |
Reliable continuous IV perfusion system for diazepam.
Mathot F, Bonnard J, Paris P, Bosly J. |
1982 |
3519 |
Laboratorium
Glaxo Smith Kline 2011 |
Remifentanil hydrochloride(Ultiva®) - Summary of Product Characteristics
|
2011 |
2212 |
Laboratorium
Actavis UK Ltd 2015 |
Reteplase (Rapilysin®) - Summary of Product Characteristics
|
2015 |
3541 |
Laboratorium
Sanofi 2011 |
Rifampicin (Rifadin®) – Summary of Product Characteristics
|
2011 |
3968 |
Laboratorium
Fresenius Kabi 2015 |
Ringer lactate - Résumé des Caractéristiques du Produit
|
2015 |
3564 |
Laboratorium
B Braun 2012 |
Rocuronium B Braun - Résumé des caractéristiques du produit.
|
2012 |
3432 |
Laboratorium
Celgene Corporation 2020 |
Romidepsin (Istodax®) - Summary of Product Characteristics
|
2020 |
2360 |
Czasopismo
Int J Pharm Compound 2008 ; 12, 1: 83-85. |
Room temperature stability of injectable succinylcholine dichloride.
Roy J.J, Boismenu D, Mamer O.A, Nguyen B.T, Forest J.M, Hildgen P. |
2008 |
1516 |
Laboratorium
Mercury Pharmaceuticals Limited 2012 |
Ropivacaine (Naropeine®) - Summary of Product Characteristics
|
2012 |
4438 |
Czasopismo
Pharmaceutics 2020 ; 12: 292 |
Safe Practice of Y-Site Drug Administration: The Case of Colistin and Parenteral Nutrition
Stawny M, Gostyńska A, Nadolna M, Jelińska A. |
2020 |
4103 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 |
Safe use of Dexamethasone in pediatrics: design and evaluation of a novel stable oral suspension.
Santovena--Estevez A, Dorta-Vera D, Gonzelez-Garcia I, Suarez-Gonzalez J, Teigell-Perez N, Farina J. |
2018 |
1496 |
Czasopismo
Hosp Pharm 1996 ; 31: 1425-1428. |
Screening cladribine for Y-site physical compatibility with selected drugs.
Trissel LA, Martinez JF, Gilbert DL. |
1996 |
3781 |
Czasopismo
EJHP 2015 ;22:1 56-58 |
Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide.
Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A |
2015 |
905 |
Czasopismo
Hosp Pharm 1994 ; 29: 1010-1017. |
Screening teniposide for Y-site physical incompatibilities.
Trissel LA, Martinez JF. |
1994 |
2014 |
Czasopismo
J Clin Pharm Ther 2005 ; 30: 455-458. |
Seventy-two-hour stability of Taxol® in 5% dextrose or 0.9% sodium chloride in Viaflo®, Freeflex®, Ecoflac® and Macoflex N® non PVC bags.
Pourroy B, Botta C, Solas C, Lacarelle B, Braguer D. |
2005 |
2683 |
Czasopismo
Int J Pharm Pract 1993 ; 23: 163-167. |
Shelf life of cefuroxime eye-drops when dispensed in artificial tear preparations.
Hebron B, Scott H. |
1993 |
1050 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 300-302. |
Shelf life of unrefrigerated succinylcholine chloride injection.
Boehm JJ, Dutton DM, Poust RI. |
1984 |
2001 |
Czasopismo
J Pharm Biomed Anal 2005 ; 38: 332-336. |
Shelf lives of aseptically prepared medicines - stability of hydrocortisone sodium succinate in PVC and non-PVC bags and in polypropylene syringes.
Rigge DC, Jones MF. |
2005 |
1929 |
Czasopismo
J Pharm Biomed Anal 2004 ; 35: 1251-1256. |
Shelf lives of aseptically prepared medicines - stability of netilmicin injection in polypropylene syringes.
Rigge DC, Jones MF. |
2004 |
2026 |
Czasopismo
J Pharm Biomed Anal 2005 ; 39: 339-343. |
Shelf lives of aseptically prepared medicines - stability of piperacillin/tazobactam in PVC and non-PVC bags.
Rigge D, Jones MF. |
2005 |
119 |
Czasopismo
J Clin Pharm Ther 1994 ; 19: 361-369. |
Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devices.
Strong ML, Schaaf LJ, Pankaskie MC, Robinson DH. |
1994 |
4137 |
Czasopismo
Newsletter Stabilis 2018 41;2-6 |
Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare).
Patel T, Sewell G. |
2018 |
3456 |
Czasopismo
Curr Med Res Opin 2011 ; 27, 12: 2241-2243. |
Short-term stability of a new generic sodium ferric gluconate in complex with sucrose.
Baribeault D. |
2011 |
3772 |
Laboratorium
Janssen Biotech 2017 |
Siltuximab (Sylvant®) - Summary of Product Characteristics
|
2017 |
4675 |
Czasopismo
Pharmaceuticals 2021 ;14, 1242. |
Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and Bioavailability: Experimental and Theoretical Characterizations.
Secretan P-H, Thirion O, Sadou Yayé H, Damy T, Astier A, Paul M, Do B. |
2021 |
2475 |
Czasopismo
Hosp Pharm 2015 ; 50: 376-379. |
Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam
Wade J, Cooper M, Ragan R. |
2015 |
2340 |
Czasopismo
Can J Hosp Pharm 2005 ; 58, 4: 212-222. |
Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers
Walker S.E, Law S, Puodziunas A. |
2005 |
2027 |
Czasopismo
Can J Hosp Pharm 2005 ; 58: 212-222. |
Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers.
Walker SE, Shirley L, Puodziunas A. |
2005 |
4522 |
Czasopismo
J Pharm Biomed Anal 2020 |
Six months stability investigation of sufentanil and ropivacaine/levobupivacaine admixtures in plastic container by LC-UV.
Lin Q, Van Schepdael A, Adams E. |
2020 |
3745 |
Czasopismo
Am J Hosp Pharm 1979 ; 36: 881. |
Sodium chloride residue provides potential for drug incompatibiities.
Kuenhle C, Moore |
1979 |
2028 |
Czasopismo
EJHP Science 2005 ; 11, 4: 88-90. |
Sodium nitroprusside stability at 1 µg/ml in aqueous solutions.
Kaisserlian CE, Razzouq N, Astier A, Paul M. |
2005 |
1316 |
Czasopismo
Pharm J 1987 ; 239: 599-601. |
Sodium nitroprusside stability in light-protective administration sets.
Davidson SW, Lyall D. |
1987 |
3969 |
Czasopismo
Neuromodulation 2017 |
Solubility and stability of Baclofen 3 mg/mL intrathecal formulation and its compatibility with implantable programmable intrathecal infusion systems.
Yue B, Brendel R, Lukitsch A, Prentice T, Doty B. |
2017 |
707 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 95-98. |
Solubility and stability of phenytoin sodium when mixed with intravenous solutions.
Carmichael RR, Mahoney CD, Jeffrey LP. |
1980 |
4282 |
Czasopismo
Drugs R D 2017 |
Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration.
Myers A-L, Zhang Y-P, Kawedia J-D, Zhou X,. Sobocinski S-M, Metcalfe M-J, Kramer M-A, Dinney C.P.N, Kamat A-M. |
2017 |
4701 |
Czasopismo
Pharm Dev Technol 2018 ; 23, 10: 1024-1029. |
Solution stability of Captisol-stabilized melphalan (Evomela) versus Propylene glycol-based melphalan hydrochloride injection.
Singh R, Chen J, Miller T, Bergren M, Mallik R. |
2018 |
2868 |
Czasopismo
Int J Pharm Compound 2000 ; 4, 2: 146-149. |
Some Studies of the Stability of Compounded Cefazolin Ophthalmic Solution.
Kommanaboyina B, Lindauer RF, Rhodes CT, Grady LT. |
2000 |
379 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 2679-2683. |
Sorption of amiodarone to polyvinyl chloride infusion bags and administration sets.
Weir SJ, Szucs Myers VA, Bengtson KD, Ueda CT. |
1985 |
190 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1945-1950. |
Sorption of four drugs to polyvinyl chloride and polybutadiene intravenous administration sets.
Lee MG. |
1986 |
1161 |
Czasopismo
Int J Pharm 1987 ; 39: 183-188. |
Sorption of parenteral nitrates during administration with a syringe pump and extension set.
Allwood MC. |
1987 |
350 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 369-373. |
Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers.
Martens HJ, De Goede PN, Van Loenen AC. |
1990 |
896 |
Czasopismo
J Clin Pharm Ther 1992 ; 17: 223-227. |
Sorption studies of dipotassium clorazepate salt (Tranxene®) and midazolam hydrochloride (Hypnovel®) in polyvinyl chloride and glass infusion containers.
Bianchi C, Airaudo CB, Gayte-Sorbier A. |
1992 |
621 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 1018-1021. |
Sorptive loss of diazepam and nitroglycerin from solutions to three types of containers.
Yliruusi JK, Sothmann AG, Laine RH, Rajasilta RA, Kristoffersson ER. |
1982 |
1472 |
Czasopismo
Int J Pharm 1994 ; 110: 197-201. |
Sorptive loss of diazepam, nitroglycerin and warfarin sodium to polypropylene-lined infusion bags (Softbags).
Salomies HEM, Heinonen RM, Toppila MAI. |
1994 |
2168 |
Czasopismo
Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534. |
Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution.
Ozdemir FA, Anilanmert B, Pekin M. |
2005 |
3563 |
Laboratorium
Sanofi Aventis France 2013 |
Spiramycine adipate (Rovamycine®) - Résumé des caractéristiques du produit
|
2013 |
3235 |
Plakat
ADKA Congress 2011 2011 |
Stabilität von Argatroban-Dauerinjektionslösungen in applikationsfertigen Konzentrationen.
Klemmer A, Krämer I. |
2011 |
2289 |
Czasopismo
Pharmazie 1994 ; 49, 10: 775-777. |
Stabilität von bendamustinhydrochloride in infusion lösungen.
Maas B, Huber C, Krämer I. |
1994 |
1698 |
Czasopismo
Krankenhauspharmazie 1997 ; 18: 474-478. |
Stabilität von dopaminhydrochlorid (Dopamine Solvay°) in mischungen mit infusionlösungen.
Körner A, Bonnacker I. |
1997 |
3346 |
Czasopismo
Krankenhauspharmazie 2012 ; 33: 427-431. |
Stabilität, Qualität und Analytik individueller Noradrenalin-Zubereitungen.
H?llein L, Bennack E, Holzgrabe U. |
2012 |
4323 |
Plakat
ADKA Kongress 2019 |
Stabilitätsprüfung von applikationsfertigen Adrenalin- und Noradrenalinverdünningen.
Wethmar U, Hochbrügge H, Strobel HG. |
2019 |
1688 |
Czasopismo
Krankenhauspharmazie 1999 ; 20: 55-58. |
Stabilitätsstudie zu alizaprid im PVC-infusionbeutel.
Müller H-J, Frank C. |
1999 |
1694 |
Czasopismo
Krankenhauspharmazie 1998 ; 19: 553-557. |
Stabilitätsstudie zu fosfomycin-dinatrium (Fosfocin° p.i. 5.0) in applikationsfertigen perfusorspritzen.
Stahlmann SA, Frey OR, Kovar K-A. |
1998 |
1685 |
Czasopismo
Krankenhauspharmazie 1998 ; 19: 229-234. |
Stabilitätsstudie zu metamizol-natrium im PVC-infusionbeutel.
Müller H-J, Berg J. |
1998 |
1690 |
Czasopismo
Krankenhauspharmazie 1997 ; 18: 75-79. |
Stabilitätsstudie zu tramadolhydrochlorid im PVC-infusionbeutel.
Müller H-J, Berg J. |
1997 |
1697 |
Czasopismo
Krankenhauspharmazie 2000 ; 21: 615-617. |
Stabilitätsuntersuchung von Dipidolor°-zubereitungen.
Witt C, Wolkewitz B, Lorenz C. |
2000 |
3244 |
Plakat
SFPO Congress Mandelieu, France 2011 |
Stabilité chimique et microbiologique d'une suspension de mercaptopurine à 5 mg/mL.
Sutra C, Guillemot C, Monnier S, Puiset F, Canonge JM. |
2011 |
2881 |
Plakat
SFPO Congress 2009 |
Stabilité d'un anticorps monoclonal d'intérêt thérapeutique après reconstitution: le rituximab.
Jaccoulet E, Guirao S, Morand K, Astier A, Paul M. |
2009 |
3317 |
Plakat
APHIF Congress 2009 |
Stabilité de l'infliximab en solutions diluées.
Guirao S, Paul M, Jaccoulet E, Morand K, Astier A. |
2009 |
4128 |
Plakat
GRITA Symposium Perfusion 2017, Lille, France. 2017 |
Stabilité de la vancomycine à des doses méningées dans les seringues au cours d'une perfusion de 24 heures.
Masse M, Genay S, Carta N, Moreau F, Delannoy-Rousselière C, Barthélémy C, Décaudin B, Faure K, Odou P. |
2017 |
3119 |
Plakat
Congrès HOPIPHARM 2010 |
Stabilité de la vincristine sans conservateurs.
Henriet Th, El Kateb N, Jourdan N, Faure P, Bellenger P. |
2010 |
2882 |
Plakat
SFPO Congress 2009 |
Stabilité de solutions diluées de bévacizumab en fonction de la température.
Morand K, Paul M, Lahlou A, Blanchet B, Astier A. |
2009 |
604 |
Laboratorium
Baxter 1998 |
Stabilité des médicaments dans l'Intermate® SV50, 100, 200
|
1998 |
3816 |
Plakat
SFPO Congress, Nantes, France 2015 |
Stabilité des poches d'azacitidine pour injection intraveineuse (1- 4 et 2,4 mg/mL) conservées à 4°C.
Balouzet C, Chanat C, Jobard M, Brandely-Piat ML, Chast F. |
2015 |
3723 |
Czasopismo
Archives de Pédiatrie 1998 ; 5, 10: 1170-1171. |
Stabilité des préparations extemporanées de doxapram (Doprams®) à usage néonatal.
Barb? F, Legagneur H, Boisseau D, Badonnel Y, Boutroy M.J. |
1998 |
2130 |
Czasopismo
Bull Cancer 1999 ; 86, 11: 946-954. |
Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique.
Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J. |
1999 |
3516 |
Plakat
SFPO Congress, Mandelieu, France. 2013 |
Stabilité du melphalan à 2 mg/ml dans le chlorure de sodium 0,9% dans des conditions pratiques d'utilisation.
Vigneron J, Zenier H, May I, Nicolas A. |
2013 |
2261 |
Czasopismo
Can J Hosp Pharm 2008 ; 61, 3: 191-195. |
Stabilité et compatibilité de l'association ondansétron-méthylprednisolone en solution.
Fernandez C, Pelloquin A, Berthoume M, Bellanger A, Farinotti R. |
2008 |
4119 |
Plakat
Hôpitaux Universitaire de Genève 2004 |
Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®)
Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. |
2004 |
1868 |
Czasopismo
Nutr Clin Metab 2003 ; 17: 8-14. |
Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange.
Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D. |
2003 |
2344 |
Laboratorium
Ebewe Pharma 2009 |
Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
|
2009 |
3246 |
Plakat
SFPO Congress Mandelieu, France 2011 |
Stabilité physico-chimique de la suspension d'azacitidine (25 mg/mL) conservée à 4°C.
Vieillard V, Appudurai O, Voytenko S, Astier A, Paul M. |
2011 |
4025 |
Plakat
SFPO Congress 2017 - Nantes 2017 |
Stabilité physico-chimique de solutions de Nivolumab à 1 mois.
Vieillard V, Bardo P, Akrout W, Le Guyader G, Astier A, Paul M. |
2017 |
4358 |
Czasopismo
Ann Fr Anesth Réanim 2014 ; 33, 5: 304-309. |
Stabilité physico-chimique des solutions injectables de bésilate de cisatracurium dans les conditions cliniques d'utilisation
Pignard J, Bourdeaux D, Kauffmann S, Constantin J.M, Sautou V. |
2014 |
3265 |
Plakat
SFPO Congress, France 2011 |
Stabilité physico-chimique du bévacizumab à 25 mg/mL conservée à 4°C en seringue polypropylène.
Vieillard V, Cauvin A, Roumi E, Despiau MC, Laurent M, Voytenko S, Astier A, Paul M. |
2011 |
3446 |
Plakat
SFPO Congress, Mandelieu, France 2013 |
Stabilité physicochimique de solutions diluées d'ipilimumab : résultats préliminaires à 1 mois.
Bardo P, Vieillard V, Astier A, Paul M. |
2013 |
3344 |
Plakat
ECOP Congress, Budapest, Hungary 2012 |
Stabilité physicochimique du bevacizumab 5 mg/mL dilué dans le chlorure de benzalkonium 0.1 mg/mL.
Moine M, Vieillard V, Astier A, Paul M. |
2012 |
196 |
Czasopismo
J Clin Pharm Ther 1991 ; 16: 203-207. |
Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes.
Pramar Y, Das Gupta V, Neal Gardner S, Yau B. |
1991 |
1239 |
Czasopismo
Pharm Weekbl [Sci] 1986 ; 8: 286-288. |
Stability after freezing and thawing of solutions of mitomycin C in plastic minibags for intravesical use.
Stolk LML, Fruijtier A, Umans. |
1986 |
240 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1904-1909. |
Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy.
Lam XM, Ward CA, de C du M?e CPR. |
1995 |
1318 |
Czasopismo
Pharm J 1987 ; 238: 116-118. |
Stability and administration of intravenous Augmentin.
Ashwin J, Lynn B, Taskis CB. |
1987 |
2046 |
Czasopismo
Antimicrob Agents Chemother 2003 ; 47: 1991-1994. |
Stability and antibacterial activity of cefepime during continuous infusion.
Sprauten PF, Beringer PM, Louie ST, Synold TW, Gill MA. |
2003 |
4264 |
Czasopismo
Acta Ophtalmol 2008 |
Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus.
Karampatakis V, Papanikolaou T, Giannousis M, Goulas A, Mandraveli K, Kilmpasani M, Alexiou-Daniel S, Mirtsou-Fidani V. |
2008 |
454 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 94-97. |
Stability and availability of cyclosporine in 5% dextrose injection or 0.9% sodium chloride injection.
Ptachcinski RJ, Logue LW, Burckart GJ, Venkataramanan R. |
1986 |
453 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 692-694. |
Stability and availability of cyclosporine stored in plastic syringes.
Ptachcinski RJ, Walker S, Burckart GJ, Venkataramanan R. |
1986 |
1469 |
Czasopismo
Int J Pharm 1996 ; 128: 283-286. |
Stability and compatibility of 2.5 mg/ml methotrexate solution in plastic syringes over 7 days.
Jacolot A, Arnaud P, Lecompte D, Alamercery S, Caroff E, Naveau C, Guillot T, Bousselet M, Brion F. |
1996 |
1817 |
Czasopismo
J Oncol Pharm Practice 2003 ; 9: 109-112. |
Stability and compatibility of 5-fluorouracil infusions in the Braun Easypump®.
Roberts S, Sewell GJ. |
2003 |
2184 |
Czasopismo
J Pain Symptom Manage 2006 ; 32, 4: 297-299. |
Stability and compatibility of a meperidine-clonidine mixture in portable pump reservoirs for the management of cancer pain syndromes.
Vranken JH, van Kan HJM, ven der Vegt MH. |
2006 |
152 |
Czasopismo
Pharm Acta Helv 1995 ; 70: 141-148. |
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion.
Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. |
1995 |
285 |
Czasopismo
Clin Ther 1996 ; 18: 246-255. |
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. |
1996 |
2086 |
Czasopismo
J Pharm Pract and Res 2003 ; 33: 279-281. |
Stability and compatibility of alfentanil hydrochloride and morphine sulfate in poypropylene syringes.
Sharley NA, Burgess NG. |
2003 |
2648 |
Czasopismo
Int J Pharm 1999 ; 190, 1: 103-107. |
Stability and compatibility of an aerosol mixture including N-acetylcysteine, netilmicin and betamethasone
Rieutord A, Arnaud P, Dauphin JF, Brion F. |
1999 |
1178 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 1914-1918. |
Stability and compatibility of antitumor agents in glass and plastic containers.
Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. |
1981 |
1467 |
Czasopismo
Int J Pharm 1995 ; 118: 181-189. |
Stability and compatibility of baclofen and morphine admixtures for use in an implantable infusion pump.
Sitaram BR, Tsui M, Rawicki HB, Lam S, Courage P, Sitaram M, Chapman CB. |
1995 |
1966 |
Czasopismo
Support Care Cancer 2005 ; 13, 4: 239-245. |
Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.
Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. |
2005 |
4746 |
Plakat
2023 |
Stability and Compatibility of Bupivacaine and Hydromorphone in PVC and non-DEHP bags for 30 days at 4°C and 25°C.
Shead K, Derrick H, Lyons D, Law S, Ma N.H. |
2023 |
1759 |
Czasopismo
Antimicrob Agents Chemother 2001 ; 45: 2643-2647. |
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Servais H, Tulkens PM. |
2001 |
539 |
Czasopismo
Drug Intell Clin Pharm 1988 ; 22: 592-593. |
Stability and compatibility of cimetidine hydrochloride and aminophylline in dextrose 5% in water injection.
Baptista RJ, Mitrano FP. |
1988 |
164 |
Czasopismo
J Clin Pharm Ther 1994 ; 19: 95-100. |
Stability and compatibility of cisplatin and carboplatin with PVC infusion bags.
Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC. |
1994 |
226 |
Czasopismo
Can J Hosp Pharm 1991 ; 44: 289-295. |
Stability and compatibility of combinations of hydromorphone and a second drug.
Walker SE, DeAngelis C, Iazzetta J. |
1991 |
1497 |
Czasopismo
Can J Hosp Pharm 1993 ; 46: 61-65. |
Stability and compatibility of combinations of hydromorphone and dimenhydrinate lorazepam or prochlorperazine.
Walker SE, Iazetta J, DeAngelis C, Lau DWC. |
1993 |
4185 |
Czasopismo
Hosp Pharm 2019 ; 54, 5: 330-334. |
Stability and Compatibility of Diphenhydramine Hydrochloride in Intravenous Admixtures : A New Look at an Old Drug.
Sabins D, Diep T, McCartan P, Patel S, Zhao F |
2019 |
3172 |
Czasopismo
J Clin Pharm Ther 2011 ; 36, 1: 99-102. |
Stability and compatibility of doxofylline with phentolamine mesilate in 0·9% sodium chloride or 5% dextrose injection for intravenous infusion.
Xu F, Xu G, LSu L, Feng E. |
2011 |
2305 |
Czasopismo
Anaesthesia 2008 63, 9: 972-978. |
Stability and compatibility of drug mixtures in an implantable infusion system.
Bianchi F, Ginggen A, Tardy Y. |
2008 |
161 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2706-2709. |
Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers.
Barthes DM, Rochard EB, Pouliquen IJ, Rabouan SM, Courtois PY. |
1994 |
1613 |
Czasopismo
Can J Hosp Pharm 2000 ; 53: 338-345. |
Stability and compatibility of etoposide in normal saline.
Lepage R, Walker SE, Godin J. |
2000 |
262 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 703-706. |
Stability and compatibility of fluconazole and aminophylline in intravenous admixtures.
Johnson CE, Jacobson PA, Pillen HA, Woycik CL. |
1993 |
411 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2158-2160. |
Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration.
Woloschuk DMM, Wermeling JR, Pruemer JM. |
1991 |
513 |
Czasopismo
Ann Pharmacotherapy 1996 ; 30: 756-761. |
Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride.
Xu QA, Trissel LA, Martinez JF. |
1996 |
148 |
Czasopismo
Pharm Weekbl [Sci] 1992 ; 14: 365-369. |
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. |
1992 |
70 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2641-2643. |
Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days.
Silvestri AP, Mitrano FP, Baptista RJ, Williams DA. |
1991 |
1633 |
Czasopismo
Can J Hosp Pharm 2002 ; 55: 27-38. |
Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions.
Walker SE, Law S. |
2002 |
57 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 294-304. |
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Mayron D, Gennaro AR. |
1996 |
1867 |
Czasopismo
J Pain Symptom Manage 2001 ; 22, 6: 1042-1047. |
Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system.
Hildebrand KR, Elsberry DE, Anderson VC. |
2001 |
1678 |
Czasopismo
Int J Pharm 1997 ; 153: 13-24. |
Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine.
Sitaram BR, Tsui M, Rawicki HB, Lam S, Sitaram M. |
1997 |
1988 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 88-92. |
Stability and compatibility of levofloxacin and metronidazole during simulated and actual Y-site administration.
Sprandel KA, Styrszula DE, Deyo K, Sibley C, Rodvold KA. |
2005 |
619 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 1013-1015. |
Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives.
Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. |
1982 |
1620 |
Czasopismo
Am J Health-Syst Pharm 2001 ; 58: 1753-1756. |
Stability and compatibility of methylprednisolone acetate and ropivacaine hydrochloride in polypropylene syringes for epidural administration.
Saverio Robustelli della Cuna F, Mella M, Magistrali G, Ricci M, Losurdo A, Goglio AM. |
2001 |
211 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1237-1241. |
Stability and compatibility of methylprednisolone sodium succinate and cimetidine hydrochloride in 5% dextrose injection.
Strom JG, Miller SW. |
1991 |
263 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 698-702. |
Stability and compatibility of minocycline hydrochloride and rifampicin in intravenous solutions at various temperatures.
Pearson SD, Trissel LA. |
1993 |
1276 |
Czasopismo
Can J Hosp Pharm 1998 ; 51: 110-116. |
Stability and compatibility of morphine with bupivacaine.
Shiffman E, Walker SE, Yoon T, Yeung M. |
1998 |
2083 |
Czasopismo
J Pharm Pract and Res 2002 ; 32: 65-68. |
Stability and compatibility of morphine, midazolam and bupivacaine combinaisons for iontravenous infusion.
La Forgia SP, Sharley NA, Burgess NG, Doecke CJ. |
2002 |
1869 |
Czasopismo
J Pain Symptom Manage 2003 ; 25, 5: 464-471. |
Stability and compatibility of morphine-clonidine admixtures in an implantable infusion system.
Hildebrand KR, Elsberry DD, Hassenbusch SJ. |
2003 |
4036 |
Czasopismo
EJHP 2017 ;25,4: 200-203. |
Stability and compatibility of ondansetron with haloperidol in parenteral admixtures.
Estan-Cerezo G, Matoses-Chirivella C, Soriano-Iriga L, Murcia-Lopez A.C, Rodrguez-Lucena F.J, Navarro-Ruiz A. |
2017 |
2122 |
Czasopismo
EJHP Science 2006 ; 12, 4: 81-84. |
Stability and compatibility of paracetamol injection admixed with ketoprofen.
Kambia NK, Luyckx M, Dine T, Dupin-Sriet T, Gressier B, Brunet C. |
2006 |
1069 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 1835-1838. |
Stability and compatibility of promethazine hydrochloride and dihydroergotamine mesylate in combination.
Peek BT, Webster KD, Da Camara CC. |
1999 |
3140 |
Czasopismo
Int J Pharm Compound 2010 ; 14, 5 : 436-439. |
Stability and Compatibility of Reconstituted Caspofungin in Select Elastomeric Infusion Device.
Tsiouris M, Ulmer M, Yurcho J F, Hooper K L, Gui M. |
2010 |
1906 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 38-45. |
Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions.
McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ. |
2004 |
66 |
Czasopismo
Can J Hosp Pharm 1996 ; 49: 140-145. |
Stability and compatibility of reconstituted hydromorphone with potassium chloride or heparin.
Avelar MA, Walker SE. |
1996 |
345 |
Czasopismo
Can J Hosp Pharm 1996 ; 49: 290-298. |
Stability and compatibility of reconstituted sterile hydromorphone with midazolam.
Walker SE, Meinders A, Tailor H. |
1996 |
1421 |
Czasopismo
J Am Pharm Assoc 1999 ; 39: 505-509. |
Stability and compatibility of tacrolimus and fluconazole in 0.9% sodium chloride.
Johnson CE, Truong NM. |
1999 |
4444 |
Czasopismo
Clinical Nutrition 1999 ; 19, 3: 159-165. |
Stability and compatibility of Teicoplanin in parenteral nutrition solutions used in pediatrics.
Tounian P, Jehl F, Pauliat S, Morgant G, Ghirardi L, Selva M.A, Fontaine J.L, Aymard P, Girardet J.P. |
1999 |
2140 |
Czasopismo
EJHP Science 2006 ; 12, 5: 91-95. |
Stability and compatibility of the ready-to-use solution of paracetamol admixted with phloroglucinol for intravenous infusion.
Kambia NK, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C. |
2006 |
2890 |
Czasopismo
Acta Pharm 2000 ; 50: 219-228. |
Stability and compatibility of thiamine hydrochloride in liquid dosage forms et various temperatures.
El-Khawas M, Boraie NA. |
2000 |
1603 |
Czasopismo
Am J Health-Syst Pharm 2001 ; 58: 1218-1223. |
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Bergquist PA, Manas D, Hunke WA, Reed RA. |
2001 |
1075 |
Czasopismo
J Pharm Biomed Anal 1997 ; 16: 199-205. |
Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers.
Craig SB, Bhatt UH, Patel K. |
1997 |
1026 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 875-881. |
Stability and compatibility of topotecan hydrochloride with selected drugs.
Mayron D, Gennaro AR. |
1999 |
3385 |
Czasopismo
J Antimicrob Chemother 2013 ; 68: 1179-1182. |
Stability and compatibility of vancomycin for administration by continuous infusion.
Raverdi V, Ampe E, Hecq JD, Tulkens PM. |
2013 |
1656 |
Czasopismo
Pharmazie 1994 ; 49: 425-427. |
Stability and compatibility studies of cefaloridine, cefuroxime and ceftazidime with PVC infusion bags.
Faouzi A, Dine T, Luyckx M, Gressier B, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Cazin JC. |
1994 |
40 |
Czasopismo
Pharm Sci Communications 1994 ; 4: 97-101. |
Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags.
Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. |
1994 |
144 |
Czasopismo
Int J Pharm 1991 ; 77: 279-285. |
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML. |
1991 |
1667 |
Czasopismo
Int J Pharm 1996 ; 138: 125-128. |
Stability and compatibility study of a carboplatin solution in syringes for continuous ambulatory infusion.
Valière C, Arnaud P, Caroff E, Dauphin JF, Clément G, Brion F. |
1996 |
166 |
Czasopismo
Int J Pharm 1994 ; 101: 257-262. |
Stability and compatibility study of carboplatin with three portable infusion pump reservoirs.
Rochard E, Barthes D, Courtois P. |
1994 |
2141 |
Czasopismo
J Antimicrob Chemother 2003 ; 51: 651-658. |
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. |
2003 |
423 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 332-335. |
Stability and cost analysis of clindamycin-gentamicin admixtures given every eight hours.
Mansur JM, Abramowitz PW, Lerner SA, Smith RB, Townsend RJ. |
1985 |
2120 |
Czasopismo
J Pharm Biomed Anal 2006 ; 41: 1363-1366. |
Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample.
Mendez A.S.L, Dalomo J, Steppe M; Schapoval E.E.S. |
2006 |
4289 |
Czasopismo
Photochemical & Photobiological Sciences 2018 |
Stability and degradation of indocyanine green in plasma, aqueous solution and whole blood.
Mindt S, Karampinis I, John M, Neumaier M, Nowak K. |
2018 |
4298 |
Czasopismo
Biomed Chromatogr 2019 ; 33, 4:e4471 |
Stability and degradation products of imipenem applying High-Resolution Mass Spectrometry: an analytical study focused on solutions for infusion.
Fabio de Souza Barbosa F, Capra Pezzi L, Tsao M, Franco de Oliveira T, Dias Macedo S.M, Schapoval E.E.S, Mendez A.S.L. |
2019 |
4670 |
Czasopismo
Molecules 2022 ; 27(3): 1070. |
Stability and Formulation of Erlotinib in Skin Creams.
Nguyen D, Secrétan P-H, Cotteret , Jacques-Gustave E, Greco C, Bodemer C, Schlatter J, Cisternino S. |
2022 |
2057 |
Czasopismo
J Antimicrob Chemother 2003 ; 51: 849-855. |
Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis.
Droste JC, Jeraj HA, MacDonald A, Farrington K. |
2003 |
3754 |
Czasopismo
Int J Pharm Compound 2014 ;18, 5: 418-426. |
Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation.
Robert M.C, Spurr-Michaud S, Frenette M, Young D, Gipson Ilene K, Dohlman Claes H. |
2014 |
1379 |
Czasopismo
Aust J Hosp Pharm 1986 ; 16: 55-56. |
Stability and light sensitivity of sodium nitroprusside infusions.
Saunders A. |
1986 |
2076 |
Czasopismo
Ann Emerg Med 2003 ; 42: 9-13. |
Stability and microbiology of inhalant N-acetylcysteine used as an intravenous solution for the treatment of acetaminophen poisoning.
Dribben WH, Porto SM, Jeffords BK. |
2003 |
3844 |
Czasopismo
Ann Pharmacotherapy 2016 ; 50: 243-244. |
Stability and Osmolality of Extemporaneously Prepared Clonidine Oral Liquid for Neonates.
Sauberan J.B, Phuong P, Ilog N.D, Rossi S.S. |
2016 |
1904 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 916-922. |
Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents.
Phares KR, Weiser WE, Miller SP, Myers MA, Wade M. |
2003 |
305 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1463-1466. |
Stability and sorption of calcitriol in plastic tuberculin syringes.
Pecosky DA, Parasrampuria J, Li LC, Stelmach A. |
1992 |
475 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 119-122. |
Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers.
Taormina D, Abdallah HY, Venkataramanan R, Logue L, Burckart GJ, Ptachcinski RJ, Todo S, Fung JJ, Starzl TE. |
1992 |
468 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2631-2634. |
Stability and sterility of biosynthetic human insulin stored in plastic insulin syringes for 28 days.
Tarr BD, Campbell RK, Workman TM. |
1991 |
1346 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 881-883. |
Stability and sterility of cimetidine admixtures frozen in minibags.
Walker SE, Paton TW, Fabian TM, Liu CC, Coates PE. |
1981 |
1986 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 896-899. |
Stability and sterility of dolasetron mesylate in syringes stored at room temperature.
Steiner ME, Lensmeyer G, Vermeulen LC. |
2005 |
4413 |
Czasopismo
J Pediatr Pharmacol Ther 2016 ; 21, 4: 322-326. |
Stability and Sterility of Enoxaparin 8 mg/mL Subcutaneous Injectable Solution.
Moffett B.S, Dinh K, Placencia J, Pelkey G, Rocky Hui S-K, Teruya J. |
2016 |
1679 |
Czasopismo
Int J Pharm 2001 ; 212: 93-99. |
Stability and sterility of meglumine gadoterate injection repackaged in plastic syringes.
Micard S, Rieutord A, Prognon P, Hassan M, Brion F. |
2001 |
2402 |
Czasopismo
Am J Health-Syst Pharm 2006 ; 63: 2240-2247. |
Stability and viscosity of a flavored omeprazole oral suspension for pediatric use
Burnett JE, Balkin ER. |
2006 |
1193 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 1010-1012. |
Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives.
Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ. |
1983 |
3810 |
Czasopismo
Int J Pharm Compound 2015 ; 19, 5 : 420-427. |
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF.
Geiger C M, Sorenson B, Whaley P. |
2015 |
4449 |
Czasopismo
J Pharm Pract and Res 2020 |
Stability assessment of levofloxacin in three different suspension vehicles.
Tardif V.,Lepage O.,Friciu M., St-Jean I., Forest J.M. |
2020 |
4215 |
Czasopismo
Int J Pharm Compound 2019 ;23,1:82-87 |
Stability Assessment of Topical Amitriptyline HCl Extemporaneously Compounded with Lipoderm Base and PLO Gel Mediflo 30.
Shakshuki A, Agu R.U. |
2019 |
4560 |
Czasopismo
J Pediatr Pharmacol Ther 2021 ; 26, 3: 265-270. |
Stability Determination of an Extemporaneously Compounded Ambrisentan Suspension by High Performance Liquid Chromatography Analysis.
Cramer J, Bevry M, Handler S, Tillman K, Abourashed E.A. |
2021 |
4499 |
Czasopismo
J Pharm Pract and Res 2020 |
Stability evaluation of an extemporaneously compounded carbimazole oral suspension.
Song Y, Lwin E, Ellis D, Turner S, Williams D, Garg S. |
2020 |
4648 |
Czasopismo
PlosOne 2021 16(11): e0260279. |
Stability evaluation of compounded clonidine hydrochloride oral liquids based on a solidphase extraction HPLC-UV method.
Coache D, Friciu M, Roullin G, Boule M, Forest J-M, Leclair G. |
2021 |
4694 |
Czasopismo
PlosOne 2022 |
Stability evaluation of compounded hydroxyurea 100 mg/mL oral liquids using a novel analytical method involving chemical derivatization.
Coache D, Friciu M, Bernine Marcellin R, Bonnemain L, Viau A, Gaëlle Roullin V, Forest J.M, Leclair G. |
2022 |
4544 |
Czasopismo
Int J Pharm Compound 2021 ;25,3:236-240 |
Stability Evaluation of Minoxidil in FOAMIL Foam Base with Bracketing Study Design.
Lupatini , Sidhu R, Patel H, Bichar K. |
2021 |
4664 |
Czasopismo
Biomed Chromatogr 2022 ;e5340. |
Stability evaluation of morphine, hydromorphone, metamizole and esketamine containing analgesic mixtures applied for patient-controlled analgesia in hospice and palliative care.
Harder M, Fiegl-Lechner A, Oberacher H, Horvath U.E.I, Schlager A, Jeske M, Kerndler S, Schüllner F, Bonn G.F, Rainer M. |
2022 |
4183 |
Plakat
Professional Practice Conference - the Canadian So 2018 |
Stability if 4 and 10 mcg/mL Remifentanil Solutions Stored in Syringes at Room Temperature (23°C).
Hook R, Riss V, Scharrer E, Law S, Walker S.E. |
2018 |
4403 |
Czasopismo
J Pharm Biomed Anal 2020 ; 179: 112973. |
Stability in clinical use and stress testing of meropenem antibiotic by direct infusion ESI-Q-TOF: Quantitative method and identification of degradation products.
De Souza Barbosa F, Capra Pezzi L, Tsao M, Manoela Dias Macedo S, Franco de Oliveira T, Schapoval EES, Mendez ASL. |
2020 |
3188 |
Czasopismo
J Clin Pharm Ther 2011 ; 36, 2: 161-165. |
Stability indicating HPLC assay for the determination of piritramide and droperidol in PCA solutions.
Selbach S, Diederich WE, Fett, Fründ SD, Koch T, Eberhart LHJ. |
2011 |
3798 |
Czasopismo
Analytical Letter 1994 . 27: 1159-1164. |
Stability indicating HPLC assay of zidovudine in extemporaneously syrup.
Radwan M.A. |
1994 |
2865 |
Czasopismo
Int J Pharm 2001 ; 223: 49-54. |
Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel
Gebauer MG, McClure AF, Vlahakis TL. |
2001 |
4230 |
Plakat
Prof Practice Conference - Canadian Society of PH 2017 |
Stability of 0.2 and 10 mg/mL Hydromorphone Solutions In CADD reservoirs, PVC and Ethylene/Propylene Co-Polymer (PAB) Bags at Room Temperature (23°C°).
Perls W, Law S, Iazetta J, Walker S. |
2017 |
2494 |
Czasopismo
Am J Hosp Pharm 1986 , 43: 2225-2228. |
Stability of 1% rifampin suspensions prepared in five syrups
Krukenberg CC, Mischler PG, Massad EN, Moore LA, Chandler AD. |
1986 |
4216 |
Plakat
Sunnybrook 2019 |
Stability of 1.0, 0.2 and 0.025 mg/mL Milrinone Solutions Stored in Syringes at 4ºC and at Room Temperature (25ºC).
Hook R, Riss V, Scharrer E, Robillard J, Law S, Walker SE. |
2019 |
4228 |
Plakat
Prof Practice Conference - Canadian Society of PH 2017 |
Stability of 10 and 50 microg/mL Fentanyl Solutions in CADD Reservoirs, PVC containers and Ethylene/Propylene Co-Polymer (PAB) Bags at Refrigerated (4°C) and Room Temperature (23°C).
Law S, Perks W, Iazetta J, Walker S. |
2017 |
1972 |
Czasopismo
Drug Dev Ind Pharm 2016 ; 42, 1: 166-174. |
Stability of 10 mg/mL cefuroxime solution for intracameral injection in commonly used polypropylene syringes and new ready-to-use cyclic olefin copolymer sterile vials using the LC–UV stability-indicating method.
Feutry, F., Simon, N., Genay, S., Lannoy, D., Barthelemy, C., Decaudin, B., Labalette, P., Odou, P. |
2016 |
4574 |
Czasopismo
Am J Hosp Pharm 2021 ;78,9:825–831 |
Stability of 10-mg/mL and 50-mg/mL ketamine oral solutions.
Ancedy D, Sebti M, Postaire M, Vidal F, Cisternino S. |
2021 |
4070 |
Czasopismo
Hosp Pharm 2018 ;53, 2: 73-74. |
Stability of 2 mg/mL Adenosine Solution in Polyvinyl Chloride and Polyolefin Infusion Bags.
DeAngelis M, Ferrara A, Gregory K, Zammit K, Zhao F. |
2018 |
4246 |
Plakat
2019 |
Stability of 2.5mg/mL Indocyanine Green (ICG) Solutions Stored in Syringes at 25ºC, 4ºC, -20ºC and -67ºC.
Perks W, Law S, Marchesano R, Walker SE. |
2019 |
4223 |
Plakat
Prof Practice Conference - Canadian Society of PH 2019 |
Stability of 20,40 and 50 microg/mL Fentanyl Solutions Stored in Syringes at Room Temperature (23°C).
Riss V, Hook R, Neault A, Scharrer E, Law s, Walker S.E. |
2019 |
3818 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2017 ;2, 1:11-16. |
Stability of 25 mg/mL 5-azacitidine suspension kept in fridge after freezing.
Balouzet C, Chanat C, Jobard M, Brandely-Piat M-L, Chast F. |
2017 |
4231 |
Plakat
Professional Practice Conference - Canadian Societ 2018 |
Stability of 4 and 10 mcg/mL Remifentanil Solutions Stored in Syringes at Room Temperature (23°C)
Roxanne Hook, Vera Riss, Erica Scharrer, Shirley Law and Scott E. Walker |
2018 |
1675 |
Czasopismo
Int J Pharm Compound 2002 ; 6, 2: 155-157. |
Stability of 4-Aminopyridine and 3,4-Diaminopyridine oral capsules
Trissel LA, Zhang Y, Xu QA. |
2002 |
4087 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 ;3,1:31-37 |
Stability of 5 mg/mL Nitrendipine Oral Suspension in SyrSpend® SF PH4.
Bellay R, Bonnaure A.C, Rault P, Pertuisel S, Lester M.A, Boivin P.N. |
2018 |
4596 |
Czasopismo
Am J Health-Syst Pharm 2021 ;78,15:444–1447 |
Stability of 5% vancomycin ophthalmic solution prepared using balanced salt solution after freezing for 90 days.
Roura-Turet J, Rodriguez-Reyes M, Guerrero-Molina L, Soy-Muner D, López-Cabezas C. |
2021 |
2496 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 118-120. |
Stability of 5-aminosalicylic acid suspension
Montgomery HA, Smith FM, Scott BE, White SJ, Gerald KB. |
1986 |
840 |
Czasopismo
Can J Hosp Pharm 1986 ; 39: 60-66. |
Stability of 5-fluorouracil and flucytosine in parenteral solutions.
Biondi L, Nairn JG. |
1986 |
2331 |
Czasopismo
Hospital Pharmacy Europe 2009 ; 42 : 30-31. |
Stability of 5-fluorouracil and sodium folinate admixture.
Cadrobbi J, Hecq J.D, Vanbeckbergen D, Jamart J, Galanti L. |
2009 |
4759 |
Plakat
Sunnybrook Healt Science Centre 2023 |
Stability of 5-fluorouracil at 4°C, 25°C, and 33°C stored in NiproSureFuser+ Ambulatory Balloon Infusers.
Ma NH, Charbonneau LF, Law S, Walker S. |
2023 |
1812 |
Czasopismo
Int J Pharm Compound 2000 ; 4, 4: 320-323. |
Stability of 5-fluorouracil in an extemporaneously compounded ophtalmic solution.
Fuhrman LC, Godwin DA, Davis RA. |
2000 |
842 |
Czasopismo
J Pharm Clin 1990 ; 9: 155-158. |
Stability of 5-fluorouracil to heat and light.
Pinguet F, Favre G, Canal P, Pujol A, Soula G. |
1990 |
3975 |
Plakat
EAHP congress - Cannes 2017 |
Stability of 50 and 100 µg/0,1mL intraocular solutions of voriconazole at 2-8°C.
Roche M, Simon N, Bourdon F, Dhorne C, Berneron C, Lannoy D, Odou P. |
2017 |
2221 |
Czasopismo
Am J Health-Syst Pharm 2007 ; 64, 23: 2480-2482. |
Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy.
Cober M.P, Johnson C.E. |
2007 |
4284 |
Czasopismo
Journal of Chemotherapy 2018 ; 30, 6-8: 371-374. |
Stability of 90 mg/mL cefuroxime sodium solution for administration by continuous infusion.
Vercheval C, Streel S, Servais A-C, Fillet M, Van Hees T. |
2018 |
4197 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 ;3,4:219-226 |
Stability of a 50 mg/mL Ceftazidime Eye-Drops Formulation.
Gautier E, Saillard J, Deshayes C, Vrignaud S, Lagarce F, Briot T. |
2018 |
1601 |
Czasopismo
Hosp Pharm 2001 ; 36: 950-954. |
Stability of a baclofen and clonidine hydrochloride admixture for intrathecal administration.
Godwin DA, Kim NH, Zuniga R. |
2001 |
442 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 732-737. |
Stability of a concentrated trimethoprim-sulfamethoxazole admixtures.
Jarosinski PF, Kennedy PE, Gallelli JF. |
1989 |
2395 |
Czasopismo
Am J Health-Syst Pharm 2008 ; 65: 558-561. |
Stability of a flavored formulation of acetylcysteine for oral administration
Siden R, Johnson CE. |
2008 |
2191 |
Czasopismo
J Oncol Pharm Practice 2007 ; 13: 33-37 |
Stability of a heparin-free 50% ethanol lock solution for central venous catheters.
Pomplum M, Johnson JJ, Johnston S, Kolesar JM. |
2007 |
4661 |
Czasopismo
J Pharm Biomed Anal 2022 |
Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization
Bourcier B, Lagarce R, Lebreton V. |
2022 |
3473 |
Czasopismo
Int J Pharm 2015 ; 495, 2: 956-962. |
Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization.
Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B. |
2015 |
4053 |
Czasopismo
Am J Health-Syst Pharm 2017 ;74,24:2060-2064 |
Stability of a pyrimethamine suspension compounded from bulk powder.
Lewis P, Cluck D, Huffman J, Ogle A, Brown S. |
2017 |
2591 |
Czasopismo
Can J Hosp Pharm 1988 ; 41: 121-123. |
Stability of a sotalol hydrochloride oral liquid formulation.
Dupuis LL, James G, Bacola G. |
1988 |
2138 |
Czasopismo
Eur J Anaesthesiol 2002 ; 19: 295-297. |
Stability of a sufentanil-ropivacaine mixture in a glass and a PVC reservoir.
Brodner G, Ermert T, Van Aken H et al. |
2002 |
460 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 358-360. |
Stability of acetazolamide sodium in 5% dextrose and 0.9% sodium chloride injection.
Parasrampuria J, Das Gupta V, Stewart KR. |
1987 |
2434 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1944-1949. |
Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids
Allen LV, Jr, Erickson MA, |
1996 |
3999 |
Czasopismo
Int J Pharm Compound 2017 ; 21:4 :339-346 |
Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4.
De Oliveira Ferreira, Polonini H, Loures da Silva S, Buzinari Aglio N.C, Abreu J, Fernandes Brand?o M.A. |
2017 |
2426 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 549-553. |
Stability of acetylcysteine in an extemporaneously compounded ophthalmic solution
Anaizi NH, Swenson CF, Dentinger PJ. |
1997 |
2400 |
Czasopismo
Am J Health-Syst Pharm 2007 ; 64: 762-766. |
Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings
Kiser TH, Oldland AR, Fish DN. |
2007 |
822 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 574-577. |
Stability of acyclovir sodium 1, 7, and 10 mg/ml in 5% dextrose injection and in 0.9% sodium chloride injection.
Zhang Y, Trissel LA, Martinez JF, Gilbert DL. |
1998 |
1717 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 75-77. |
Stability of acyclovir sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Ling J, Das Gupta V. |
2001 |
68 |
Czasopismo
J Clin Pharm Ther 1989 ; 14: 451-456. |
Stability of acyclovir sodium in dextrose and sodium chloride injections.
Das Gupta V, Pramar Y, Bethea C. |
1989 |
2216 |
Czasopismo
J Pharm Biomed Anal 1998 ; 17: 415-418. |
Stability of adenosin infusion.
Proot P, Schepdael A.V, Raymakers A.A, Hoogmartens J. |
1998 |
820 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1161-1164. |
Stability of adenosine 6 microg/ml in 0.9% sodium chloride solution.
Naud C, Marti B, Fernandez C, Astier A, Paul M. |
1998 |
1948 |
Czasopismo
J Pain Symptom Manage 2004 ; 28, 6: 603-611. |
Stability of admixtures containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system.
Classen AM, Wimbish GH, Kupiec TC. |
2004 |
930 |
Czasopismo
J Clin Pharm Ther 1997 ; 22: 339-345. |
Stability of admixtures of pethidine and metoclopramide in aqueous solution, 5% dextrose and 0.9% sodium chloride.
Hor MMS, Chan SY, Yow KL, Lim LY, Chan E. |
1997 |
824 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1602-1605. |
Stability of albumin-free interferon alfa-2b for 42 days.
Appenheimer MM, Schepart BS, Poleon GP, Evans SS. |
1998 |
2960 |
Czasopismo
Respiratory Care 1991 ; 36: 1387-1390. |
Stability of albuterol and tobramycin when mixed for aerosol administration.
Gooch MD. |
1991 |
2670 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 394-396. |
Stability of albuterol in continuous nebulization.
Hunter DA, Yoo SD, Fox JL. |
1998 |
2255 |
Laboratorium
Ebewe Pharma 2007 |
Stability of Alexan "Ebewe" infusion solutions.
|
2007 |
3902 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 5 : 426-434. |
Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions.
Polonini Hudson C, Loures Sharlene,de Araujo Edson Peter, Brand?o Marcos Ant?nio F, Ferreira Anderson O. |
2016 |
3994 |
Czasopismo
Int J Pharm Compound 2017 ; 3: 255-263 |
Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions.
De Oliveira Ferreira A, Polonini H C, Loures da Silva S, Cerqueira de Melo V Augusto, de Andrade L, Fernandes Brand?o Marcos A. |
2017 |
2422 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1915-1920. |
Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids
Allen LV, Jr, Erickson MA, |
1998 |
3961 |
Czasopismo
Int J Pharm Compound 2017 ; 21, 2: 150-153. |
Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers.
McCluskey S.V,Kirkham K,Munson J.M. |
2017 |
1816 |
Czasopismo
Int J Pharm Compound 2003 ; 7, 3: 230-232. |
Stability of amikacin sulfate in autodose infusion system bags.
Zhang Y, Trissel LA. |
2003 |
550 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 132-134. |
Stability of aminocaproic acid injection admixtures in 5% dextrose injection and 0.9% sodium chloride injection.
Zhang YP, Trissel LA. |
1997 |
478 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2962-2963. |
Stability of aminophylline in bacteriostatic water for injection stored in plastic syringes at two temperatures.
Nahata MC, Morosco RS, Hipple TF. |
1992 |
1188 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 428-432. |
Stability of aminophylline injection in three parenteral nutrient solutions.
Niemiec PW, Venderveen TW, Hohenwarter MW, Gadsden RH. |
1983 |
242 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 917-921. |
Stability of amiodarone hydrochloride in admixtures with other injectable drugs.
Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M. |
1986 |
2541 |
Czasopismo
Ann Pharmacotherapy 1997 ;31:851-852. |
Stability of amiodarone in an oral suspension stored under refrigeration and at room temperature.
Nahata MC. |
1997 |
3792 |
Czasopismo
J Ped Pharm Pract 1999 ; 4: 186-189. |
Stability of amiodarone in extemporaneous oral suspension prepared from commercially available vehicles.
Nahata M.C, Morosco R.S, Hipple T.F. |
1999 |
2689 |
Czasopismo
J Am Pharm Assoc 1999 ; 39: 375-377. |
Stability of amlodipine mesylate in two liquid dosage form.
Nahata MC, Morosco RS, Hipple TF. |
1999 |
2951 |
Czasopismo
J Clin Pharm Ther 1994 ; 19: 313-315. |
Stability of amoxicillin and potassium clavulanate in co-amoxiclav oral suspension.
Mehta AC, Hart-Davies S, Payne J, Lacey RW.. |
1994 |
2508 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 1092-1099. |
Stability of amoxicillin trihydrate-potassium clavulanate in original containers and unit dose oral syringes
Tu YH, Stiles ML, Allen LV, Jr, Olsen KM, Barton CI, Greenwood RB. |
1988 |
12 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 683-686. |
Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion.
Owens LC, Fleming RA, Restino MS, Cruz JM, Hurd DD. |
1997 |
2820 |
Czasopismo
J Pharm Biomed Anal 2006 ; 42: 362-366. |
Stability of amphotericin B and nystatin in antifungal mouthrinses containing sodium hydrogen carbonate
Groeschke J, Solassol I, Bressolle F, Pinguet F. |
2006 |
1407 |
Czasopismo
Hosp Pharm 1998 ; 33: 1203-1207. |
Stability of amphotericin B cholesteryl sulfate complex after reconstitution and admixture.
Xu QA, Trissel LA, Gilbert DL. |
1998 |
497 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1681. |
Stability of amphotericin B in 5% dextrose injection at 25°C.
Kintzel PE, Kennedy PE. |
1991 |
439 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 283-285. |
Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line.
Kintzel PE, Kennedy PE. |
1991 |
283 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 394-396. |
Stability of amphotericin B in 5% dextrose injection stored at 4 or 25°C for 120 hours.
Lee MD, Hess MM, Boucher BA, Apple AM. |
1994 |
2867 |
Czasopismo
Int J Pharm Compound 1999 ; 3, 4: 316-320. |
Stability of Amphotericin B in 5% Dextrose Ophthalmic Solution.
Peyron F, Elias R, Ibrahim E, Amirat-Combralier V, Bu?s-Charbit M, Balansard G. |
1999 |
2940 |
Czasopismo
Am J Health-Syst Pharm 2001 ; 58: 1021-1024. |
Stability of amphotericin B in an extemporaneously compounded oral suspension.
Dentinger PJ, Swenson CF, Anaizi NH. |
2001 |
435 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2430-2433. |
Stability of amphotericin B in four concentrations of dextrose injection.
Wiest DB, Maish WA, Garner SS, El-Chaar GM. |
1991 |
3069 |
Czasopismo
Eur Hosp Pharm 1997 ; 3: 59-60. |
Stability of amphotericin B in water solution for inhalation.
Juarez JC, ,Lopez RM, Hucto M et al. |
1997 |
3777 |
Czasopismo
Am J Health-Syst Pharm 2015 ; 72:13-14 |
Stability of ampicillin and amoxicillin in peritoneal dialysis solutions
Patel R.P, Li K, Shastri M, Wanandy T, Jose M.D. |
2015 |
3880 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 4 : 338-342 |
Stability of Ampicillin in Normal Saline and Buffered Normal Saline.
Maher M, Jensen Kara J,Lee David, Nix David E |
2016 |
4640 |
Czasopismo
Hosp Pharm 2021 ; 56, 5: 507–512. |
Stability of Ampicillin in Normal Saline Following Refrigerated Storage and 24-Hour Pump Recirculation.
Huskey M, Lewis P, Brown S.D. |
2021 |
1705 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 226-229. |
Stability of ampicillin sodium, nafcillin sodium, and oxacillin sodium in autodose system bags.
Zhang Y, Trissel LA. |
2002 |
4063 |
Czasopismo
Int J Pharm Compound 2018 ;22,1:66-75 |
Stability of an Alcohol-free, Dye-free Hydrocortisone (2mg/mL) Compounded Oral Suspension.
Manchanda A, Laracy M, Savji T, Bogner R. |
2018 |
342 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 339-342. |
Stability of an analgesic-sedative combination in glass and plastic single-dose syringes.
Conklin CA, Kerege JF, Christensen JM. |
1985 |
3780 |
Czasopismo
EJHP 2015 ;22:7-11 |
Stability of an epidural analgesic admixture containing butorphanol tartrate and ropivacaine hydrochloride
Chen F, Peng L, Zhou B, Fang B, Yang Y. |
2015 |
2306 |
Czasopismo
Anaesthesia 2004 ; 59, 10: 979-983. |
Stability of an epidural analgesic admixture containing epinephrine, fentanyl and bupivacaine.
Priston M.J, Hughes J.M, Santillo M, Christie I.W. |
2004 |
3401 |
Czasopismo
J Clin Pharm Ther 2013 ;38, 2: 104-108 |
Stability of an epidural analgesic admixture of levobupivacaine, fentanyl and epinephrine.
Helin-Tanninen, M., Lehtonen, M., Naaranlahti, T., Ven?l?inen, T., Pentik?inen, J., Laatikainen, A., Kokki, H. |
2013 |
1875 |
Czasopismo
Acta Anaesthesiol Scand 2000 ; 44: 864-867. |
Stability of an epidural analgesic solution containing adrenaline, bupivacaine and fentanyl.
Kjonniksen I, Brustugun J, Breivik H, Anderssen E, Klem W. |
2000 |
3187 |
Czasopismo
Am J Health-Syst Pharm 2011 ; 68:420-423. |
Stability of an extemporaneous alcohol-free melatonin suspension.
Johnson CE, Cober MP, Thome T, Rouse E. |
2011 |
2773 |
Czasopismo
Support Care Cancer 2009 ; 17, 6: 701-706. |
Stability of an extemporaneous oral liquid aprepitant formulation.
Dupuis LL, Lingertat-Walsh K, Walker SE. |
2009 |
2478 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2353-2355. |
Stability of an extemporaneously compounded baclofen oral liquid
Johnson CE, Hart SM. |
1993 |
2502 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 122-125. |
Stability of an extemporaneously compounded clonidine hydrochloride oral liquid
Levinson ML, Johnson CE. |
1992 |
4075 |
Czasopismo
Am J Health-Syst Pharm 2018 ;75,5: 309-315 |
Stability of an extemporaneously compounded minoxidil oral suspension.
Song Y, Whey Chin Z, Ellis D, Mon Phyo Lwin E, Turner S, Williams D, Garg S. |
2018 |
3872 |
Czasopismo
Hosp Pharm 2016 ; 51: 389-395. |
Stability of an Extemporaneously Compounded Oral Suspension of Bosentan.
Malik A, Gorman G, Coward L ,. Arnold J.J. |
2016 |
2851 |
Czasopismo
Int J Pharm Compound 2005 ; 9, 1: 82-86. |
Stability of An Extemporaneously Compounded Propylthiouracil Suspension
Alexander KS, Mitra P. |
2005 |
2503 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 293-295. |
Stability of an extemporaneously compounded terbutaline sulfate oral liquid
Horner RK, Johnson CE. |
1991 |
2657 |
Czasopismo
Int J Pharm Compound 1997 : 60-63. |
Stability of an extemporaneously formulated levothyroxine sodium syrup compounded from commercial tablets.
Alexander KS, Kothapalli MR, Dollimor D. |
1997 |
2401 |
Czasopismo
Am J Health-Syst Pharm 2007 ; 64: 644-646. |
Stability of an extemporaneously prepared alcohol-free phenobarbital suspension
Cober MP, Johnson CE. |
2007 |
3420 |
Czasopismo
J Oncol Pharm Practice 2014 ; 21, 3: 178-187. |
Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology
El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P. |
2014 |
3298 |
Czasopismo
Am J Health-Syst Pharm 2012 ; 69: 592-594 |
Stability of an extemporaneously prepared tadalafil suspension
Pettit R.S, Johnson C.E, Caruthers R.L. |
2012 |
3269 |
Czasopismo
Am J Health-Syst Pharm 2012 ; 69:56-58. |
Stability of an extemporaneously prepared thalidomide suspension.
Kraft S, . Johnson C.E, Tyler R.P. |
2012 |
1341 |
Czasopismo
Pharm J 1983 ; 230: 495-497. |
Stability of an intrathecal morphine injection formulation.
Deeks T, Davis S, Nash S. |
1983 |
444 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2756-2760. |
Stability of an ofloxacin injection in various infusion fluids.
Bornstein M, Kao SH, Mercorelli M, Verma S. |
1992 |
4249 |
Czasopismo
PeerJ 2018 |
Stability of an ophtalmic formulation of polyhexamethylene biguanide in gamma-sterilized and ethylene oxide sterilized low density polyethylene multi dose eyedroppers.
Bouattour Y, Chennell P, Wasiak M, Jouannet M, Sautou V. |
2018 |
2833 |
Czasopismo
Int J Pharm Compound 2001 ; 5, 6: 480-481. |
Stability of an Oral Liquid Dosage Form of Glycopyrrolate Prepared from Tablets
Das Gupta V. |
2001 |
3336 |
Czasopismo
EJHP 2013 ;20:46-49 |
Stability of an oral ranitidine suspension (15 mg/ml).
Petit-Jean E, Perello L, Hernandez C, Gairard Dory A.C, Gourieux B, Ubeaud-Sequier G. |
2013 |
2925 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 2518-2520. |
Stability of anhydrous theophylline in extemporaneously prepared alcohol-free oral suspensions.
Johnson CE, vanDe Koppel S, Myers E. |
2005 |
632 |
Czasopismo
J Parenter Sci Technol 1985 ; 39: 220-222. |
Stability of anthracycline antitumour agents in infusion fluids.
Beijnen JH, Rosing H, De Vries PA, Underberg WJM. |
1985 |
573 |
Czasopismo
Drug Intell Clin Pharm 1977 ; 11: 542-548. |
Stability of antibiotic admixtures frozen in minibags.
Dinel BA, Ayotte DL, Behme RJ, Black BL, Whitby JL. |
1977 |
3888 |
Czasopismo
Perit Dial Int 2016 ; 36:421-426. |
Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study).
Ranganathan D, Naicker S,. Wallis S.C, Lipman J, . Ratanjee S.K, Roberts J.A |
2016 |
574 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 1087-1088. |
Stability of antibiotics frozen and stored in disposable hypodermic syringes.
Kleinberg ML, Stauffer GL, Prior RB, Latiolais CJ. |
1980 |
427 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 3027-3030. |
Stability of aqueous solutions of amoxicillin sodium in the frozen and liquid states.
Concannon J, Lovitt H, Ramage M, Tai LH, McDonald C, Sunderland VB. |
1986 |
960 |
Czasopismo
Can J Hosp Pharm 1990 ; 43: 57-60. |
Stability of aqueous solutions of deferoxamine.
Koren G, Tesoro A, Leeder JS, Bentur Y, Olivieri N. |
1990 |
2469 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 363-364. |
Stability of aqueous suspensions of disulfiram
Das Gupta V. |
1981 |
2345 |
Czasopismo
Can J Hosp Pharm 2009 ; 62, 3: 226-231. |
Stability of aseptically prepared Tazocin solutions in polyvinyl chloride bags.
Donnelly R.F. |
2009 |
3857 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 2: 167-174. |
Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini H.C, Sharlene L, Claudio L,Ferreira A.O,Brand?o M.A.F. |
2016 |
1093 |
Czasopismo
Anesthesiology 1984 ; 61: 347-348. |
Stability of atracurium administered by infusion.
Fisher DM, Canfell, Miller RD. |
1984 |
1039 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 1156-1159. |
Stability of azacitidine in infusion fluids.
Cheung YW, Vishnuvajjala BR, Morris NL, Flora KP. |
1984 |
414 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2500-2505. |
Stability of azacitidine in lactated Ringer’s injection frozen in polypropylene syringes.
Den Hartigh J, Brandenburg HCR, Vermeij P. |
1989 |
3351 |
Czasopismo
Can J Hosp Pharm 2012 ; 65, 5: 352-359 |
Stability of Azacitidine in Sterile Water for Injection.
Walker S.E, Charbonneau L.F, Law S, Earle C. |
2012 |
4227 |
Plakat
Prof Practice Conference - Canadian Society of PH 2019 |
Stability of Azacitidine Solutions In Sterile Water for Injection.
Tyono I, Law S, Charbonneau L.F, Walker S.E. |
2019 |
3204 |
Czasopismo
Ann Pharmacotherapy 2011 ;45, 4:546. |
Stability of Azacitidine Suspensions.
Duriez A, Vigneron J.H, Zenier H.A, May I, Demoré B.M. |
2011 |
4301 |
Czasopismo
Oncotarget 2017 ;8, 63: 106249-106257. |
Stability of azasetron-dexamethasone mixture for chemotherapyinduced nausea and vomiting administration.
Fang B-X, Chen F-C, Zhu D, Guo J, Wang L-H. |
2017 |
4408 |
Czasopismo
Int J Pharm Compound 2020 ;24,3:252-262 |
Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF PH4.
Polonini H, Loures da Silva S, Neves Cunha C, de Oliveira Ferreira A, Anagnostou K, Dijkers E. |
2020 |
258 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 901-904. |
Stability of aztreonam and ampicillin sodium-sulbactam sodium in 0.9% sodium chloride injection.
Belliveau PP, Nightingale CH, Quintiliani R. |
1994 |
1064 |
Czasopismo
Pharm World Sci 1996 ; 18: 74-77. |
Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatement (HIVAT).
Vinks AATMM, Touw DJ, van Rossen RCJM, Heijeiman HGM, Bakker W. |
1996 |
2263 |
Czasopismo
Il Farmaco 2005 ; 60: 599-603. |
Stability of aztreonam in AZACTAM.
Zajac M, Jelinska A, Cielecka-Piontek J, Osqczapowicz I. |
2005 |
2433 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2179-2184. |
Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids
Allen LV, Jr, Erickson MA, |
1996 |
3342 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 ;3,1:13-21 |
Stability of Bendamustine Solutions: Influence of Sodium Chloride Concentration, Temperature and Container.
Vigneron J, D'Huart E, Demoré B. |
2018 |
2056 |
Czasopismo
J Antimicrob Chemother 2004 ; 53: 675-677. |
Stability of benzylpenicillin during continuous home intravenous therapy.
Vella-Brincat JWA, Begg EJ, Gallagher K, kirkpatrick CMJ, Zhang M, Frampton C, Chambers ST. |
2004 |
3449 |
Czasopismo
Ann Pharmacotherapy 2013 ; 47: 1237-1238. |
Stability of Betaxolol Suspensions in Oral Syringes and Glass Bottles.
Auvity S, Chiadmi F.M, Cisternino S, Fontan J.E, Schlatter J. |
2013 |
2421 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1804-1809. |
Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids
Allen LV, Jr, MA Erickson |
1998 |
4383 |
Czasopismo
Crit Care Resusc 2020 ;22(1):83-85. |
Stability of bicarbonate in normal saline: a technical report.
Naorungroj T, Neto AS, Fujii T, Jude B, Udy A, Bellomo R. |
2020 |
252 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 2528-2529. |
Stability of bleomycin sulfate reconstituted in 5% dextrose injection or 0.9% sodium chloride injection stored in glass vials or polyvinyl chloride containers.
Koberda M, Zieske PA, Raghavan NV, Payton RJ. |
1990 |
2010 |
Czasopismo
Ann Pharmacotherapy 2005 ; 39: 1462-1466. |
Stability of bortezomib 1 mg/ml solution in plastic syringe and glass vial.
André P, Cisternino S, Chiadmi F, Toledano A, Schlatter J, Fain O, Fontan JE. |
2005 |
3688 |
Czasopismo
Can J Hosp Pharm 2014 ; 67, 2: 102-107 |
Stability of bortezomib 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C).
Walker S.E, Charbonneau L.F, Law S. |
2014 |
3337 |
Czasopismo
EJHP 2012 ; 19: 428-431. |
Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4 °C and room temperature.
Carati D, Masini C, Minguzzi M, Petocchi B, Romanazzi C, Rondoni C, Sangiorgi E, Sferra S, Simonetta S, Stancari A, Locchi F, Z |
2012 |
2232 |
Czasopismo
Can J Hosp Pharm 2008 ; 61, 1: 14-20. |
Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4°C and Room Temperature (23°C)
Walker SE, Milliken D, Law S. |
2008 |
4590 |
Czasopismo
J Pediatr Pharmacol Ther 2021 ; 51: 231-237. |
Stability of buffered benzylpenicillin and flucloxacillin for a paediatric outpatient parenteral antibiotic therapy service.
Smith E.K, McWhinney MPhil B.C. |
2021 |
3702 |
Czasopismo
J Pharm Pract and Res 2014 ; 44, 1: 26-28. |
Stability of buffered benzylpenicillin solutions for outpatient parenteral antimicrobial therapy.
McDougall D.A.J, McWhinney. |
2014 |
3263 |
Czasopismo
Can J Hosp Pharm 2011 ; 64, 4: 289-290. |
Stability of buffered lidocaine in glass vials.
Donnelly R.F. |
2011 |
42 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 422-423. |
Stability of bumetanide in 5% dextrose injection.
Cornish LA, Montgomery PA, Johnson CE. |
1997 |
306 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 170-173. |
Stability of bupivacaine hydrochloride and hydromorphone hydrochloride during simulated epidural coadministration.
Christen C, Johnson CE, Walters JR. |
1996 |
293 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2364-2365. |
Stability of bupivacaine hydrochloride in polypropylene syringes.
Jones JW, Davis AT. |
1993 |
512 |
Czasopismo
Pharm World Sci 1995 ; 17: 87-92. |
Stability of bupivacaine hydrochloride with diamorphine hydrochloride in an epidural infusion.
Barnes AR, Nash S. |
1995 |
217 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 714-715. |
Stability of bupivacaine hydrochloride, epinephrine hydrochloride, and fentanyl citrate in portable infusion-pump reservoirs.
Allen LV, Stiles ML, Wang DP, Tu YH. |
1993 |
2113 |
Czasopismo
Pharm World Sci 1999 ; 21, 6: 272-274. |
Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution.
Jäppinen A, Kokki H, Naaranlahti TJ, Rasi AS. |
1999 |
658 |
Czasopismo
J Oncol Pharm Practice 1996 ; 2: 101-105. |
Stability of busulfan injection admixtures in 5% dextrose injection and 0.9% sodium chloride injection.
Xu QA, Zhang YP, Trissel LA, Martinez JF. |
1996 |
4033 |
Czasopismo
Am J Health-Syst Pharm 2017 ;74,22:1887-1894 |
Stability of busulfan solutions in polypropylene syringes and infusion bags as determined with an original assay.
Guichard N, Bonnabry P, Rudaz S, Fleury-Souverain S. |
2017 |
668 |
Czasopismo
Medicine 2015 ; 94(6):e432. |
Stability of Butorphanol–Tropisetron Mixtures in 0.9% Sodium Chloride Injection for Patient-Controlled Analgesia Use.
Chen, Fu-Chao; Shi, Xiao-Ya; Li, Peng; Yang, Jin-Guo; Zhou, Ben-Hong. |
2015 |
691 |
Czasopismo
J Clin Pharm Ther 1989 ; 14: 53-55. |
Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions.
Nahata MC, Zingarelli JR, Durell DE. |
1989 |
43 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1106-1108. |
Stability of caffeine citrate injection in polypropylene syringes at room temperature.
Fraser BD, Berod T, Whitney HAK. |
1997 |
698 |
Czasopismo
Ann Pharmacotherapy 1989 ; 23: 466-467. |
Stability of caffeine injection in intravenous admixtures and parenteral nutrition solutions.
Nahata MC, Zingarelli JR, Durell DE. |
1989 |
990 |
Czasopismo
Ann Pharmacotherapy 1989 ; 23: 1035. |
Stability of caffeine injection stored in plastic and glass syringes.
Nahata MC, Zingarelli JR, Hipple TF. |
1989 |
2705 |
Czasopismo
J Clin Pharm Ther 1994 ; 19, 6: 391-396. |
Stability of caffeine oral formulations for neonatal use.
Barnes AR, Hebron BS, Smith J. |
1994 |
2531 |
Czasopismo
J Oncol Pharm Practice 2021 ; 27, 2: 288-296. |
Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin/ polyamide infusion bags.
Sanogo S, Silimbani P, Gaggeri R, Masini C. |
2021 |
4189 |
Czasopismo
Am J Health-Syst Pharm 2022 ;79,12: 1011-1018 |
Stability of Captisol-enabled versus propylene glycol–based melphalan at room temperature and after refrigeration.
Kawedia J, Ramchandran S, Liu X, Gulbis A, Titus M, Bashir Q, Qazilbash M, Champlin R, Ciur S, |
2022 |
3802 |
Czasopismo
J Clin Pharm Ther 1998 ; 23: 451-456. |
Stability of captopril in invert sugar solution
Sam W.J, Ho P.C. |
1998 |
2522 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 1707-1708. |
Stability of captopril in liquid containing ascorbic acid or sodium ascorbate
Nahata MC, Morosco RS, Hipple TF. |
1994 |
2488 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1799-1801. |
Stability of captopril in powder papers under three storage conditions
Taketomo CK, Chu SA, Cheng MH, Corpuz RP. |
1990 |
3436 |
Czasopismo
Int J Pharm Compound 2013 ; 17, 4: 336-338. |
Stability of Captopril in SyrSPend SF.
Geiger C. M, Sorenson B, Whaley P. A. |
2013 |
2245 |
Czasopismo
Int J Pharm 1996 ; 129: 275-277. |
Stability of carboplatin in 5% glucose solution exposed to light.
Torres F, Girona V, Puiol M, Prat J, de Bolos J. |
1996 |
2244 |
Czasopismo
J Pharm Biomed Anal 1994 ; 12, 1: 81-84. |
Stability of carboplatin in 5% glucose solution in glass, polyethylene and polypropylene containers.
Prat J, Pujol M, Girona V, Munoz M, Sol? L-A. |
1994 |
4205 |
Czasopismo
J Kor Soc Hosp Pharm 2006 ;23,3:219-224 |
Stability of Carboplatin in normal saline : dependence on initial dilution concentration and storage time.
Choi S, O La H, Kim K, Kim S, Hwangbo S. |
2006 |
486 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 602, 604. |
Stability of carboplatin in polyvinyl chloride bags.
Diaz Amador F, Sevilla Azzati E, Herreros de Tajeda y Lopez-Coterilla A. |
1998 |
4120 |
Czasopismo
J Oncol Pharm Practice 2018 25,5:1076?1081 |
Stability of carboplatin infusion solutions used in desensitization protocol.
Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T. |
2018 |
3277 |
Czasopismo
Int J Pharm Compound 2012 ; 16, 1 : 82-85. |
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration.
Yang Z, Cameron S, Paul H. |
2012 |
837 |
Czasopismo
Acta Pharm Suec 1986 ; 23: 115-124. |
Stability of carmustine - kinetics and compatibility during administration.
Fredriksson K, Lundgren P, Landersjo L. |
1986 |
1622 |
Czasopismo
Am J Health-Syst Pharm 2001 ; 58: 238-241. |
Stability of carmustine in polyvinyl chloride bags and polyethylene-lined trilayer plastic containers.
Favier M, De Casanove F, Coste A, Cherti N, Bressolle F. |
2001 |
715 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 677-678. |
Stability of carmustine in the presence of sodium bicarbonate.
Colvin M, Hartner J, Summerfield M. |
1980 |
2486 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 992-993. |
Stability of cefadroxil in reconstituted suspension under refrigeration and at room temperature
Nahata MC, Jackson DS. |
1991 |
612 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 622-627. |
Stability of cefamandole nafate injection with parenteral solutions and additives.
Frable RA, Klink PR, Engel GL, Mundell EE. |
1982 |
1979 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 1537-1538. |
Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions.
Wu CC, Wang DP, Wong CY, Lin YF. |
2002 |
4247 |
Czasopismo
Clin Ther 2018 ;40,4:664-667 |
Stability of Cefazolin in Polyisoprene Elastomeric Infusion Devices.
Patel R, Jacob J, Sedeeq M, Ming L.C, Wanandy T, Zaidi S.T.R, Peterson G.M. |
2018 |
582 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 211-215. |
Stability of cefazolin sodium admixtures in plastic bags after thawing by microwave radiation.
Tomecko GW, Kleinberg ML, Latiolais CL, Proior RB, Pesko LJ, Jones BC. |
1980 |
111 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1608,1610. |
Stability of cefazolin sodium and meperidine hydrochloride.
Lee DKT, Wong CY, Wang DP. |
1996 |
671 |
Czasopismo
J Parenter Sci Technol 1993 ; 47: 135-137. |
Stability of cefazolin sodium and metronidazole at 8°C for use as an IV admixture.
Rivers TE, McBride HA, Trang JM. |
1993 |
2707 |
Czasopismo
J Clin Pharm Ther 1998 ; 23, 1: 41-47. |
Stability of cefazolin sodium eye drops
How TH, Loo WY, Yow KL, Lim LY, Chan EW, Ho PC, Chan SY. |
1998 |
1805 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 2362-2364. |
Stability of cefazolin sodium in icodextrin-containing peritoneal dialysis solution.
Lin YF, Wu CC, Lin SH, Wang DP, Wang CN. |
2002 |
2372 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 291 - 292. |
Stability of cefazolin sodium in peritoneal dialysis solutions
Nahata MC, Ahalt PA. |
1991 |
3230 |
Czasopismo
Can J Hosp Pharm 2011 ; 64, 4: 241-245. |
Stability of Cefazolin Sodium in Polypropylene Syringes and Polyvinylchloride Minibags
Donnelly RF. |
2011 |
2505 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 2287-2290 |
Stability of cefazolin sodium in various artificial tear solutions and aqueous vehicles
Ahmed I, Day P. |
1987 |
440 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 1408-1412. |
Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs.
Stiles ML, Tu YH, Allen LV. |
1989 |
1452 |
Czasopismo
Eur Hosp Pharm 2000 ; 6: 17-23. |
Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*.
Muller HJ, Howe K, Frank C, Haker I. |
2000 |
1626 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 151-152. |
Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Ling J, Das Gupta V. |
2001 |
873 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 435-436. |
Stability of cefepime hydrochloride dextrose in 5% dextrose injection and 0.9% sodium chloride injection.
Das Gupta V, Maswoswe J, Bailey RE. |
1997 |
1834 |
Czasopismo
Ann Pharmacotherapy 2003 ; 37, 6: 804-807. |
Stability of cefepime hydrochloride in autodose infusion system bags.
Trissel LA, Xu QA. |
2003 |
1068 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 457-459. |
Stability of cefepime hydrochloride in polypropylene syringes at -20°C, 4°C and 22-24°C.
Stewart JT, Warren FW, Maddox FC. |
1999 |
1046 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 1134. |
Stability of cefepime hydrochloride in polypropylene syringes.
Stewart JT, Maddox FC, Warren FW. |
1999 |
1605 |
Czasopismo
Hosp Pharm 2000 ; 35: 1057-1064. |
Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C.
Stewart JT, Maddox FC, Warren FW. |
2000 |
3182 |
Czasopismo
Pharmazie 2011 ; 66, 1: 17-23. |
Stability of cefepime in eye drops.
Kodym A, PawLowska M, Ruminski JK, Bartosinska A, Kieliba A. |
2011 |
1945 |
Czasopismo
Ann Pharmacotherapy 2004 ; 38: 2041-2044. |
Stability of cefepime in icodextrin peritoneal dialysis solution.
Elwell RJ, Volino LR, Frye RF. |
2004 |
1290 |
Czasopismo
Ann Pharmacotherapy 1999 ; 33: 906-909. |
Stability of cefepime in peritoneal dialysis solution.
Williamson JC, Volles DF, Lynch PLM, Rogers PD, Haverstick DM. |
1999 |
237 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 432. |
Stability of cefmetazole and famotidine.
Lee DKT, Wong CY, Wang DP, Chang LC, Wu KH. |
1996 |
652 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 208-209. |
Stability of cefmetazole sodium in 5% dextrose injection and 0.9% sodium chloride injection.
Das Gupta V, Maswoswe J, Bailey R.E, County H. |
1997 |
1664 |
Czasopismo
J Clin Pharm Ther 1994 ; 19: 317-325. |
Stability of cefmetazole-doxycycline mixtures in sodium chloride and dextrose injections.
King AD, Stewart JT, Warren FW. |
1994 |
420 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 1980-1983. |
Stability of cefonicid sodium in infusion fluids.
Wong WW, Maderich AB, Polli GP, Ravin LJ. |
1985 |
2374 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 147 - 150. |
Stability of cefotaxime in two peritoneal dialysis solutions
CM Paap CM, Nahata MC. |
1990 |
1711 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 234-236. |
Stability of cefotaxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Das Gupta V. |
2002 |
281 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1561-1563. |
Stability of cefotaxime sodium and metronidazole in 0.9% sodium chloride injection or in ready-to-use metronidazole bags.
Belliveau PP, Nightingale CH, Quintiliani R. |
1995 |
593 |
Czasopismo
J Pharm Sci 1984 ; 73: 565-567. |
Stability of cefotaxime sodium as determined by High-Performance Liquid Chromatography.
Das Gupta V. |
1984 |
3840 |
Czasopismo
Acta Pol Pharm 2016 ; 73, 1: 23-27. |
Stability of cefpirome sulfate in aqueous solutions.
Zalewski P, Jelinska A, Paczkowska M, Garbacki P, Talaczynska A, Step-niak P, Cielecka- Piontek J. |
2016 |
280 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2427-2433. |
Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.
Allen LV, Stiles ML, Prince SJ, Sylvestri MF. |
1995 |
443 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2761-2764. |
Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs.
Stiles ML, Allen LV, Fox JL. |
1992 |
287 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1912-1914. |
Stability of ceftazidime (with arginine) in an elastomeric infusion device.
Bednar DA, Klutman NE, Henry DW, Fox JL, Strayer AH. |
1995 |
477 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2954-2956. |
Stability of ceftazidime (with arginine) stored in plastic syringes at three temperatures.
Nahata MC, Morosco RS, Fox JL. |
1992 |
4056 |
Czasopismo
Perit Dial Int 2017 |
Stability of ceftazidime and heparine in four different types of peritoneal dialysis solutions.
Kandel S, Zaidi S, Wanandy T, Ming L, Castelino R, Sud K, Patel R. |
2017 |
2369 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1139 - 1142. |
Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution
Mason NA, Johnson CE, O'Brien MA. |
1992 |
3289 |
Czasopismo
Acta Pol Pharm 2011 ; 68, 1: 99-107. |
Stability of ceftazidime in 1% and 5% buffered eye drops determined by HPLC method.
Kodym A, Hapka-Zmich D, Golab M, Gwizdala M. |
2011 |
2708 |
Czasopismo
J Clin Pharm Ther 1999 ; 24: 299-302 |
Stability of ceftazidime in a viscous eye drop formulation
Barnes AR, Nash R. |
1999 |
445 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2765-2768. |
Stability of ceftazidime in plastic syringes and glass vials under various storage conditions.
Stewart JT, Warren FW, Johnson SM, Fox JL, Mullaney J. |
1992 |
2450 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2731 - 2734. |
Stability of ceftazidime sodium and teicoplanin sodium in a peritoneal dialysis solution
Manduru M, Fariello A, White RL, Fox JL, Bosso JA. |
1996 |
591 |
Czasopismo
Can J Hosp Pharm 1993 ; 46: 13-16. |
Stability of ceftizoxime in 5 percent dextrose and 0.9 percent sodium chloride.
Knoppert DC, Freeman D, Webb D. |
1993 |
282 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2568-2570. |
Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags.
Rivers TE, Webster AA. |
1995 |
4378 |
Czasopismo
Perit Dial Int 2020 ; 40, 5: 470-476. |
Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions.
Harmanjeet H, Jani H, Zaidi S.T.R, Wanandy T, Castelino R.L, Sud K, Peterson G.M, Patel R.P. |
2020 |
276 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 92-94. |
Stability of ceftriaxone sodium and aminophylline or theophylline in intravenous admixtures.
Parrish MA, Bailey LC, Medwick T. |
1994 |
11 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 424-427. |
Stability of ceftriaxone sodium and metronidazole hydrochloride.
Bailey LC, Orosz ST. |
1997 |
259 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2092-2094. |
Stability of ceftriaxone sodium in infusion-pump syringes.
Bailey LC, Tang KT, Medwick T. |
1993 |
279 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2159-2161. |
Stability of ceftriaxone sodium in injectable solutions stored frozen in syringes.
Bailey LC, Cappel KM, Orosz ST. |
1994 |
100 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 43: 2320-2323. |
Stability of ceftriaxone sodium in polypropylene syringes at -20, 4, and 20°C.
Plumridge RJ, Rieck AM, Annus TP, Langton SR. |
1996 |
649 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 280-281. |
Stability of ceftriaxone sodium when mixed with metronidazole injection.
Das Gupta V. |
1997 |
2491 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 256. |
Stability of cefuroxime axetil in beverages
St Claire RL, Caudill WL. |
1989 |
2699 |
Czasopismo
J Clin Pharm Ther 1991 ; 16, 5: 341-345. |
Stability of cefuroxime axetil in suspensions.
Pramar Y, Das Gupta V, Bethea C, Zerai T. |
1991 |
3290 |
Czasopismo
Acta Pol Pharm 2011 ; 68, 4: 555-564. |
Stability of cefuroxime in 1% and 5% buffered eye drops determined with HPLC method.
Kodym A, Wisniewski A, Kniola D, Olejniczak M. |
2011 |
2095 |
Czasopismo
EJHP Science 2006 ; 12, 2: 32-34. |
Stability of cefuroxime infusion: the brand-name drug versus a generic product.
Rodenbach, MP, Hecq JD, Vanbeckbergen D, jamart J, Galanti L. |
2006 |
96 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 809-811. |
Stability of cefuroxime sodium and aminophylline or theophylline.
Stewart JT, Warren FW, Johnson SM. |
1994 |
636 |
Czasopismo
J Clin Hosp Pharm 1986 ; 11: 47-54. |
Stability of cefuroxime sodium in some aqueous buffered solutions and intravenous admixtures.
Das Gupta V, Stewart KR. |
1986 |
3078 |
Czasopismo
Can J Hosp Pharm 2009 ; 62, 6: 464-468. |
Stability of celecoxib oral suspensions.
Donnelly RF, Pascuet E, Ma C, Vaillancourt R. |
2009 |
3135 |
Czasopismo
Am J Health-Syst Pharm 2010 ; 67, 3: 223-226. |
Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags.
Ikesue H, Vermeulen LC, Hoke R, Kolesar JM. |
2010 |
2206 |
Czasopismo
Am J Health-Syst Pharm 2015 ; 72:1292-1297 |
Stability of chlorothiazide sodium in polypropylene syringes
McCluskey S.V, Gardner B, . Graner K.K, Nicole Vu N. |
2015 |
1 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1939-1943. |
Stability of cidofovir in 0.9% sodium chloride and in 5% dextrose injection.
Yuan LC, Samuels GJ, Visor GC. |
1996 |
71 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 2204-2206. |
Stability of cidofovir in 0.9% sodium chloride injection for five days.
Ennis RD, Dahl TC. |
1997 |
1989 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 506-509. |
Stability of cidofovir in extemporaneously prepared syringes.
Hennere G, Havard L, Bonan B, Prognon P. |
2005 |
3722 |
Czasopismo
Acta Pol Pharm 2014 ; 71, 4: 661-666. |
Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms.
Beata J. Stanisz, Sylwia K. Paszun, Anna Zalewska. |
2014 |
80 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2559-2561. |
Stability of cimetidine hydrochloride and of clindamycin phosphate in water for injection stored in glass vials at two temperatures.
Nahata MC, Morosco RS, Hipple TF. |
1993 |
362 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 2208-2210. |
Stability of cimetidine hydrochloride in a total nutrient admixture.
Baptista RJ, Palombo JD, Tahan SR, Valicenti AJ, Bistrian BR, Arkin CF, Blackburn GL. |
1985 |
1503 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 1002-1006. |
Stability of cimetidine hydrochloride in admixtures after microwave thawing
Elliott GT, McKenzie MW, Curry SH, Pieper JA, Quinn SL. |
1983 |
1614 |
Czasopismo
Hosp Pharm 2001 ; 36: 1170-1173. |
Stability of ciprofloxacin and vancomycin hydrochloride in autodose infusion system bags.
Trissel LA, Xu QA, Zhang Y, Saenz CA, Ingram DS. |
2001 |
666 |
Czasopismo
J Clin Pharm Ther 1994 ; 19: 261-262. |
Stability of ciprofloxacin in 5% dextrose and normal saline injections.
Mathew M, Das Gupta V, Zerai T. |
1994 |
1740 |
Czasopismo
Int J Pharm Compound 1998 ; 2, 4: 314-317. |
Stability of ciprofloxacin in an extemporaneous oral liquid dosage form.
Johnson CE, Wong D, Hoppe HL, Bhatt-Mehta V. |
1998 |
2676 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 314-317. |
Stability of ciprofloxacin in an extemporaneous oral liquid dosage form.
Johnson C.E, Wong D.V, Hoppe H.L, Bhatt-Mehta V. |
1998 |
2368 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2956 - 2959. |
Stability of ciprofloxacin in peritoneal dialysis solution
Mawhinney WM, Adair CG, Gorman SP, McClurg B. |
1992 |
3231 |
Czasopismo
Can J Hosp Pharm 2011 ; 64, 4 : 252-256. |
Stability of Ciprofloxacin in Polyvinylchloride Minibags.
Donnelly RF. |
2011 |
4263 |
Czasopismo
Am J Hosp Pharm 1994 ;51:373-377 |
Stability of ciprofloxacin injection in peritoneal dialysis solutions.
Kane MP, Bailie GR, Moon DG, Siu I. |
1994 |
533 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1037-1041. |
Stability of cisatracurium besylate in vials, syringes and infusion admixtures.
Xu QA, Zhang YP, Trissel LA, Gilbert DL, Martinez JF, Fox JL. |
1998 |
1080 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 2652. |
Stability of cisplatin admixtures in polyvinyl chloride bags.
La Folette JM, Arbus MH, Lauper RD. |
1985 |
417 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 1400-1404. |
Stability of cisplatin and etoposide in intravenous admixtures.
Stewart CF, Hampton EM. |
1989 |
53 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2570-2573. |
Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion.
Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD. |
1995 |
1729 |
Czasopismo
Pharmazie 1998 ; 53: 490-492. |
Stability of cisplatin containing infusion.
Mittner A, Vincze Z, Jemnitz K. |
1998 |
742 |
Czasopismo
Am J Hosp Pharm 1979 ; 36: 38-43. |
Stability of cisplatin in aqueous solution.
Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF. |
1979 |
149 |
Czasopismo
J Clin Pharm Ther 1992 ; 17: 315-318. |
Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs.
Rochard E, Barthes D, Courtois P. |
1992 |
147 |
Czasopismo
Pharm World Sci 1993 ; 15: 34-36. |
Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material.
Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque MV. |
1993 |
409 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 124-130. |
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP. |
1987 |
1604 |
Czasopismo
Eur Hosp Pharm 2001 ; 7: 11-14. |
Stability of citalopram hydrochloride in polyvinyl chloride bag for I.V. solutions and compatibility in the presence of dipotassium clorazepate.
Gury C, Dolizy I, Aymard N, Sellali Y, Rochet S. |
2001 |
318 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 512-514. |
Stability of citrated caffeine injectable solution in glass vials.
Donnelly RF, Tirona RG. |
1994 |
1505 |
Czasopismo
Eur Hosp Pharm 1997 3,4: 154-6 |
Stability of cladribine in either polyethylene containers or polyvinylchloride bags.
Daouphars M, Vigneron J, Perrin A, Hoffman MA, Hoffman M. |
1997 |
3901 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 5 : 421-425. |
Stability of Clindamycin Hydrochloride in PCCA Base SuspendIt
Pramar Yashoda V, Graves Richard A, Ledet Grace A, Phan Kelly V, Bostanian Levon A,Mandal Tarun K |
2016 |
567 |
Czasopismo
Can J Hosp Pharm 1989 ; 42: 109-112. |
Stability of clindamycin phophate in dextrose and saline solutions.
Das Gupta V, Parasrampuria J, Bethea C, Wright W. |
1989 |
418 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 2211-2214. |
Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitine sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions.
Bosso JA, Townsend RJ. |
1985 |
1815 |
Czasopismo
Int J Pharm Compound 2003 ; 7, 2: 149-151. |
Stability of clindamycin phosphate in autodose infusion system bags.
Xu QA, Trissel LA. |
2003 |
432 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1732-1736. |
Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions.
Marble DA, Bosso JA, Townsend RJ. |
1986 |
4630 |
Czasopismo
J Pharm Health Care Sci 2021 ; 7:31 |
Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan.
Saito J, Hanawa T, Matsumoto T, Yoshikawa N, Harada T, Iwahashi K, Nakamura H, Yamatani A. |
2021 |
3649 |
Czasopismo
Am J Health-Syst Pharm 2014 ; 71:657-661. |
Stability of clonidine suspension in oral plastic syringes.
Ma C, Decarie D, Ensom M.H.H. |
2014 |
2592 |
Czasopismo
Can J Hosp Pharm 2005 ; 58, 5: 279-284. |
Stability of clozapine stored in oral suspension vehicles at room temperature.
Walker SE, Baker D, Law S. |
2005 |
2397 |
Czasopismo
Am J Health-Syst Pharm 2007 Dentinger PJ, Swenson CF |
Stability of codeine phosphate in an extemporaneously compounded syrup
Dentinger PJ, Swenson CF. |
2007 |
2783 |
Czasopismo
Int J Pharm 2015 ; 486; 1-2: 367-369. |
Stability of colistimethate sodium in a disposable elastomeric infusion device.
Abdulla A,.van Leeuwen R.W.F, de Vries Schultink A.H.M,.Koch B.C.P. |
2015 |
3360 |
Czasopismo
Antimicrob Agents Chemother 2012 ; 56:6432-6433. |
Stability of Colistimethate Sodium in Aqueous Solution.
Healan A. M, Gray W, Fuchs E.J, Griffiss J.M, Salata R.A, Blumer J. |
2012 |
2285 |
Czasopismo
Antimicrob Agents Chemother 2008 ; 52, 9: 3047-3051. |
Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.
Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. |
2008 |
4607 |
Czasopismo
Can J Hosp Pharm 2021 ;74(3):227-34 |
Stability of Compounded Clozapine 25 mg/mL and 50 mg/mL Suspensions in Plastic Bottles.
Walker SE, Sachedina H, Bichar K. |
2021 |
4690 |
Czasopismo
Hosp Pharm 2022 ; 57, 2: 294-299. |
Stability of Compounded Digoxin Solution 0.05mg/mL for Injection.
Friciu M, Marcelin R.B, Bédard P, Forest J.M, Leclair G. |
2022 |
3202 |
Czasopismo
Am J Health-Syst Pharm 2011 ; 68: 900-908. |
Stability of compounded thioguanine oral suspensions
Montazeri Aliabadi H, Romanick M, Somayaji V, Mahdipoor P, Lavasanifar A |
2011 |
4593 |
Czasopismo
Int J Pharm Compound 2021 ;78,4:344-351 |
Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases.
Teimouri A, Yeung P, Agu R. |
2021 |
4214 |
Czasopismo
Int J Pharm Compound 2019 ;23,1:70-76 |
Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt.
Pramar Y.V, Mandal T.K, Bostanian L.A, Nguyen A.TQ, Miller V, Morris T.C, Graves R.A. |
2019 |
4089 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 ;3,1:23-30 |
Stability of Concentrated Solution of Vancomycin Hydrochloride in Syringes for Intensive Care Units.
Godet M, Simar J, Closset M, Hecq J.D, Braibant M, Soumoy L, Gillet P, Jamart J, Bihin B, Galanti L. |
2018 |
2162 |
Czasopismo
Perit Dial Int 1990 ; 10: 157-160. |
Stability of cotrimoxazole in peritoneal dialysis fluid.
Holmes SE, Aldous S. |
1990 |
1833 |
Czasopismo
Ann Pharmacotherapy 2003 ; 37, 12: 1789-1792. |
Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags.
Menard C, Bourguignon C, Schlatter J, Vermerie N. |
2003 |
1728 |
Czasopismo
Pharmazie 1999 ; 54: 224-225. |
Stability of cyclophosphamide containing infusions.
Mittner A, Vincze Z, Jemnitz. |
1999 |
3096 |
Czasopismo
Ann Pharmacotherapy 2010 ;44:295-301. |
Stability of Cyclophosphamide in Extemporaneous Oral Suspensions.
Kennedy R, Groepper D, Tagen M, Christensen R, Navid F, Gajjar A, Stewart CF. |
2010 |
3476 |
Czasopismo
Am J Health-Syst Pharm 2013 ;70:1970-1972. |
Stability of cyclosporine diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in ethylene-vinyl acetate containers.
Li M, Coursol C, Leclair G. |
2013 |
471 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2053-2055. |
Stability of cyclosporine in 5% dextrose injection.
Shea BF, Ptachcinski RJ, O'Neill S, Cersosimo RJ, Sesin GP, Souney PF. |
1989 |
2444 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2204-2207. |
Stability of cyclosporine in an extemporaneously compounded paste
Ghnassia LT, Yau DF, Kaye KI, Duggin GG. |
1995 |
3229 |
Czasopismo
Am J Health-Syst Pharm 2011 ;68:1646-1650. |
Stability of cyclosporine solutions stored in polypropylene–polyolefin bags and polypropylene syringes.
Li M, Forest JM, Coursol C, Leclair G. |
2011 |
291 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 470-472. |
Stability of cyclosporine with magnesium sulfate in 5% dextrose injection.
Nieforth KA, Shea BF, Souney PF, Scavone JM. |
1993 |
1028 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 1802-1806. |
Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures.
Cheung YW, Vishnuvajjala BR, Flora KP. |
1984 |
859 |
Czasopismo
Nor Pharm Acta 1983 ; 45: 61-67. |
Stability of cytotoxic intravenous solutions subjected to freeze-thaw treatment.
Karlsen J, Thonnesen HH, Olsen IR, Sollien AH, Skobba TJ. |
1983 |
1635 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 1351-1356. |
Stability of dacarbazine in amber glass vials and polyvinyl chloride bags.
El Aatmani M, Poujol S, Astre C, Malosse F, Pinguet F. |
2002 |
4031 |
Czasopismo
Int J Pharm Compound 2017 ;21 , 5 : 426-429 |
Stability of Dalteparin 1,000 Unit/mL in 0.9% Sodium Chloride for Injection in Polypropylene Syringes.
Kirkham K, Munson J, McCluskey S, Graner K. |
2017 |
4106 |
Czasopismo
Can J Hosp Pharm 2018 ;71,2/152-154 |
Stability of Dapsone in Extemporaneously Compounded Oral Suspensions.
Alarie H, Friciu M, Leclair G. |
2018 |
2545 |
Czasopismo
Ann Pharmacotherapy 2000 ;34:848-850. |
Stability of dapsone in two oral liquid dosage forms.
Nahata MC, Morosco RC, Trowbridge JM. |
2000 |
3665 |
Czasopismo
Am J Health-Syst Pharm 2014 ; 71:956-959 |
Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer’s injection and stored in polypropylene syringes at 4 and -20°C.
Ortega R, Salmer?n-Garc?a A, Cabeza J, Capit?n-Vallvey L.F, Navas N. |
2014 |
4074 |
Czasopismo
EJHP 2018 ; 25: 107-110. |
Stability of daptomycin reconstituted vials and infusion solutions.
Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T. |
2018 |
5 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1583-1588. |
Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes.
Stiles ML, Allen LV Jr, Prince SJ. |
1996 |
2156 |
Czasopismo
Perit Dial Int 1994 ; 14: 396-398. |
Stability of deferoxamine peritoneal dialysate solutions.
Kane MP, Bailie GR, Moon DG, Siu I. |
1994 |
2961 |
Czasopismo
Can J Hosp Pharm 2001 ; 54: 96-101. |
Stability of dexamethasone in extemporaneously prepared oral suspensions.
Wen-Lin Chow J, Decarie D, Dumont RJ. |
2001 |
24 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 514-517. |
Stability of dexamethasone sodium phosphate, diphenhydramine hydrochloride, lorazepam, and metoclopramide hydrochloride in portable infusion-pump reservoirs.
Stiles ML, Allen LV Jr, Prince SJ, Holland JS. |
1994 |
3299 |
Czasopismo
Am J Health-Syst Pharm 2012 ; 69:595-597. |
Stability of dexmedetomidine 4 µg/mL in polypropylene syringes.
Anderson C.R, Mackay M.W, Holley M, Kay B.A |
2012 |
4029 |
Czasopismo
Int J Pharm Compound 2017 ; 21, 5: 436-439 |
Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags.
Marquis K, Hohlfelder B, Szumita Paul. |
2017 |
3433 |
Czasopismo
Am J Health-Syst Pharm 2013 ; 70:1336-1341 |
Stability of dexmedetomidine in polyvinyl chloride bags containing 0.9% sodium chloride injection.
Preslaski C.R, Mueller S.W, Wempe M.F, Robert MacLaren R. |
2013 |
779 |
Czasopismo
J Pharm Pharmacol 1986 ; 38: 51P. |
Stability of diamorphine hydrochloride with haloperidol in prefilled syringes for continuous subcutaneous administration.
Collins AJ, Abethell JA, Holmes SG, Rain R. |
1986 |
4533 |
Czasopismo
Int J Pharm Compound 2021 ;25,5:427-430 |
Stability of Diazepam Enema Extemporaneous Formulation in Manzoni Base.
Lopalco A, Lopedota A, Aurelio F, La Forgia F, Fontana S, Franco M, Denora N. |
2021 |
1199 |
Czasopismo
Am J Hosp Pharm 1982 ; 1687-1690. |
Stability of diazepam injection repackaged in glass unit-dose syringes.
Smith FM, Nuessle NO. |
1982 |
4313 |
Czasopismo
PlosOne 2017 |
Stability of Diazoxide in Extemporaneously Compounded Oral Suspensions.
Friciu M, Zaraa S, Roullin G, Leclair G. |
2017 |
2840 |
Czasopismo
Can J Hosp Pharm 2010 ; 63, 1 : 25-30. |
Stability of Diclofenac Sodium Oral suspensions Packaged in Amber Polyvinyl Chloride Bottles.
Donnell RF, Pascuet E, Ma C, Vaillancourt R. |
2010 |
618 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 844-846. |
Stability of digoxin in common large-volume injections.
Shank WA, Coupal JJ. |
1982 |
3426 |
Czasopismo
Journal of Addiction Medicine 2013 ; 7,2:113-115. |
Stability of Dilute Oral Morphine Solution for Neonatal Abstinence Syndrome.
Sauberan, Jason; Rossi, Steven; Kim, Jae H. |
2013 |
3422 |
Czasopismo
Hosp Pharm 2013 ; 48, 6: 484-488. |
Stability of Diluted Adenosine Solutions in Polyolefin Infusion Bags.
Almagambetova E, Hutchinson D, Blais D.M, Zhao F. |
2013 |
3223 |
Czasopismo
Am J Health-Syst Pharm 2011 ;68:1533-1536. |
Stability of diluted adenosine solutions in polyvinyl chloride infusion bags
Kaltenbach M, Hutchinson DJ, Bollinger JE, Zhao F. |
2011 |
546 |
Czasopismo
Ann Pharmacotherapy 1994 ; 28: 1018-1019. |
Stability of diluted dexamethasone sodium phosphate injection at two temperatures.
Lugo RA, Nahata MC. |
1994 |
3309 |
Czasopismo
EJHP 2012 ;19:378-380 |
Stability of diluted epinephrine in prefilled syringes for use in neonatology.
Zenoni D, Priori G, Bellan C, Invernizzi R.W. |
2012 |
1183 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 1001-1004. |
Stability of diluted heparin sodium stored in plastic syringes.
Tunbridge LJ, Lloyd JV, Penhall RK, Wise AL, Maloney T. |
1981 |
3443 |
Czasopismo
J Pharm Pract and Res 2013 ; 43: 112-116. |
Stability of Diluted Iron Polymaltose in PVC Infusion Bags.
Patel R.P, Wanandy T, Loring S, Johns C, Hutchinson J, Shastri M. |
2013 |
3435 |
Czasopismo
Can J Hosp Pharm 2013 ; 66, 3 : 198. |
Stability of Diluted Ketamine Packaged in Glass Vials.
Donnelly R.F. |
2013 |
3243 |
Plakat
ECCO Congress Stockholm 2011 |
Stability of diluted L-asparaginase in normal saline solution.
Nicolson O, d'Hayer B, Vieillard V, Dollet S, Astier A, Paul M. |
2011 |
212 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2157-2159. |
Stability of diluted methylprednisolone sodium succinate injection at two temperatures.
Nahata MC, Morosco RS, Hipple TF. |
1994 |
2310 |
Czasopismo
EJHP Science 2008 ; 14, 6: 36-38. |
Stability of diluted nadroparin for the treatment of paediatric thrombosis.
Hunfeld N, Ypma P, Westerman E, Leebeck F, Touw D. |
2008 |
2132 |
Czasopismo
Int J Pharm Compound 2015 ; 19, 4 : 344-347. |
Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes.
Anderson Collin R, Halford Zachery, MacKay Mark. |
2015 |
2471 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 309-310. |
Stability of disopyramide phosphate in cherry syrup
Mathur LK, Lai PK, Shively CD. |
1982 |
2765 |
Czasopismo
Pharm World Sci 1999 ; 21: 275-277. |
Stability of dithranol in creams.
Wuis EW, Burger DM, Beelen M. |
1999 |
3293 |
Czasopismo
EJHP 2012 ; 19: 52-56. |
Stability of dobutamine 500 mg in 50 ml syringes prepared using a Central Intravenous Additive Service
Patel N, Taki M, Tunstell P, Forsey P, Forbes B. |
2012 |
1753 |
Czasopismo
Int J Pharm Compound 1999 ; 3: 412-414. |
Stability of dobutamine hydrochloride 4 mg/ml in 5% dextrose injection at 5 and 23°C.
Webster AA, English BA, McGuire JM, Riggs RM, Lander V, Buckle T. |
1999 |
1045 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 686-689. |
Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5 % dextrose injections.
Das Gupta V, Stewart KR. |
1984 |
2371 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1234 - 1237. |
Stability of dobutamine hydrochloride in peritoneal dialysis solutions
Gora ML, Seth S, Visconti JA, Shields B, Bay W. |
1991 |
628 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 1923-1925. |
Stability of dobutamine hydrochloride in selected large-volume parenterals.
Kirschenbaum HL, Aronoff W, Perentesis GP, Piltz GW, Goldberg RJ, Cutie AJ. |
1982 |
4141 |
Czasopismo
J Clin Pharm Ther 2018 : 530-535. |
Stability of dobutamine in continuous ambulatory delivery devices.
Al Madfai F, Valah B, Zaidi S.T.R, Wanandy T, Ming M.C, Peterson G.M, Patel R.P. |
2018 |
2210 |
Czasopismo
Can J Hosp Pharm 2007 ; 60, 4: 231-237. |
Stability of Docetaxel Solution after Dilution in Ethanol and Storage in Vials and after Dilution in Normal Saline and Storage in Bags.
Walker S.E, Charbonneau F, Law S. |
2007 |
1807 |
Czasopismo
Can J Hosp Pharm 2003 ; 56, 2: 87-92. |
Stability of dolasetron mesylate in 0.9% sodium chloride and 5% dextrose in water.
Chan J, Walker SE, Law S. |
2003 |
3712 |
Czasopismo
Pediatr Crit Care Med 2001 ; 2, 4: 315-317. |
Stability of dopamine and epinephrine solutions up to 84 hours.
Ghanayem N.S, Lee L, Nelson T, Wong S, Gordon G.B, Markdante K et al. |
2001 |
1820 |
Czasopismo
J Clin Pharm Ther 2003 ; 28: 471-474. |
Stability of dopamine hydrochloride 0.5 mg/ml in polypropylene syringes.
Braenden JU, Stendal TL, Fagernaes CB. |
2003 |
206 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 186. |
Stability of dopamine hydrochloride and of dobutamine hydrochloride in plastic syringes and administration sets.
Sautou-Miranda V, Gremeau I, Chamard I, Cassagnes J, Chopineau J. |
1996 |
1249 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 595-597. |
Stability of dopamine hydrochloride exposed to blue-light phototherapy.
Dandurand KR, Stennett DJ. |
1985 |
3145 |
Czasopismo
Am J Health-Syst Pharm 2010 ; 67: 1539-1544. |
Stability of doripenem in polyvinyl chloride bags and elastomeric pumps.
Crandon JL, Sutherland C, Nicolau DP. |
2010 |
2316 |
Czasopismo
Clin Ther 2008 ; 30, 11: 2075-2087. |
Stability of doripenem in vitro in representative infusion solutions and infusion bags.
Psathas P.A, Kuzmission A, Ikeda K, Yasuo S. |
2008 |
2256 |
Laboratorium
Ebewe Pharma 2007 |
Stability of doxorubicin "Ebewe" infusion solutions.
|
2007 |
32 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1171-1173. |
Stability of doxorubicin and vincristine sulfate in two portable infusion-pump reservoirs.
Nyhammar EK, Johansson SG, Seiving BE. |
1996 |
686 |
Czasopismo
J Clin Pharm Ther 1990 ; 15: 279-289. |
Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags.
Wood MJ, Irwin WJ, Scott DK. |
1990 |
3207 |
Czasopismo
Int J Pharm Compound 2011 ; 15, 2: 170-173. |
Stability of Droperidol 0.625 mg/mL Diluted with 0.9% Sodium Chloride Injection and Stored in Polypropylene Syringes.
McCluskey Susan V, Lovely Jenna K . |
2011 |
2425 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1155-1157. |
Stability of enalapril maleate in three extemporaneously prepared oral liquids
Nahata MC, Morosco RS, Hipple TF. |
1998 |
1720 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 394-396. |
Stability of ephedrine sulfate at ambient temperature and 4°C in polypropylene syringes.
Storms ML, Stewart JT, Warren FW. |
2001 |
1292 |
Czasopismo
Int J Pharm Pract 1995 ; 3: 174-177. |
Stability of epidural opiate solutions in 0.9 per cent sodium chloride infusion bags.
Grassby PF, Roberts DE. |
1995 |
3704 |
Czasopismo
Can J Hosp Pharm 2014 ; 67, 3:179-202. |
Stability of Epinephrine at Standard Concentrations
Carr R.R, Decarie D, Ensom M.H.H |
2014 |
2437 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 659-662. |
Stability of epinephrine hydrochloride in an extemporaneously compounded topical anesthetic solution of lidocaine, racepinephrine, and tetracaine
Larson TA, Uden DL, Schilling CG. |
1996 |
2077 |
Czasopismo
Ann Emerg Med 1990 ; 19: 1242-1244. |
Stability of epinephrine in alkalinized solutions.
Bonhomme L, Benhamou D, Comoy E, Preaux N. |
1990 |
2257 |
Laboratorium
Ebewe Pharma 2007 |
Stability of epirubicin "Ebewe" infusion solutions.
|
2007 |
3891 |
Czasopismo
Can J Hosp Pharm 2015 ; 68, 2: 121-126. |
Stability of Ertapenem 100 mg/mL in Manufacturer’s Glass Vials or Syringes at 4°C and 23°C
Walker S.E, Law S, Perks W, Iazzetta J. |
2015 |
3717 |
Czasopismo
Am J Health-Syst Pharm 2014 ; 71:1480-1484 |
Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C.
Jain J.G, Sutherland C, Nicolau D.P, Kuti J.L. |
2014 |
3208 |
Czasopismo
Int J Pharm Compound 2011 ; 15, 3: 252-254. |
Stability of Ertapenem in an Elastomeric Infusion Device.
Phipps Stephen D, Peacock Gina F, Smith Douglas L . |
2011 |
2178 |
Czasopismo
J Pharm Biomed Anal 2007 ; 43: 445-449. |
Stability of ertapenem in aqueous solutions.
Zajac M, Cielecka-Piontek J, Jelinska A. |
2007 |
20 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 2732,2738. |
Stability of erythromycin in intravenous admixtures.
Pluta PL, Morgan PK. |
1986 |
363 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 101-104. |
Stability of esmolol hydrochloride and sodium nitroprussiate in intravenous admixtures.
Karnatz NN, Wong J, Baaske DM, Johnson JH, Speicher ER, Herbranson DE. |
1989 |
204 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2693-2696. |
Stability of esmolol hydrochloride in intravenous solutions.
Baaske DM, Dyskstra SD, Wagenknecht DM, Karnatz NN. |
1994 |
174 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1567-1571. |
Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride.
Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. |
1990 |
1716 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 73-75. |
Stability of ethacrynate sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Ling J, Das Gupta V. |
2001 |
2482 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2784-2785. |
Stability of etoposide solution for oral use
McLeod HL, Relling MV. |
1992 |
4304 |
Czasopismo
Drugs R D 2014 ; 14:13?23. |
Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices.
Klasen K, Kessari R, Mercier L, Valade C, Grill J, Desmaris R, Paci A. |
2014 |
2852 |
Czasopismo
Int J Pharm Compound 2004 ; 8, 6: 486-488. |
Stability of Extemporaneous Oral Ribavirin Liquid Preparation
Chan JP, Tong HHY, Chow AHL. |
2004 |
3893 |
Czasopismo
Can J Hosp Pharm 2016 ; 69, 4: 327-329. |
Stability of Extemporaneously Compounded Amlodipine Besylate Oral Suspensions
Friciu M, Zaraa S, Leclair G. |
2016 |
3714 |
Czasopismo
Can J Hosp Pharm 2014 ; 67, 4: 274-280. |
Stability of Extemporaneously Compounded Clonidine in Glass and Plastic Bottles and Plastic Syringes.
Ensom M.H.H, Décarie D. |
2014 |
3713 |
Czasopismo
Can J Hosp Pharm 2014 ; 67, 4 : 274-278 |
Stability of Extemporaneously Compounded Dexamethasone in Glass and Plastic Bottles and Plastic Syringes.
Ensom M.H.H, Décarie D. |
2014 |
3409 |
Czasopismo
Am J Health-Syst Pharm 2013 ; 70:894-899. |
Stability of extemporaneously compounded diltiazem hydrochloride infusions stored in polyolefin bags
Kaushal G, Sayre B.E, Prettyman T. |
2013 |
4142 |
Czasopismo
Can J Hosp Pharm 2018 ;71,3:165-172 |
Stability of Extemporaneously Compounded Domperidone 5 mg/mL Suspension in Oral Mix in Plastinc and Glass Bottles and Plastic Syringes.
Lingertat-Walsh K, Law S, Walker S.E. |
2018 |
677 |
Czasopismo
Can J Hosp Pharm 2015 ; 68, 4 : 346-348. |
Stability of Extemporaneously Compounded Levetiracetam in Glass and Plastic Bottles and Plastic Syringes.
Ensom M.H.H, D?carie D. |
2015 |
3826 |
Czasopismo
Can J Hosp Pharm 2015 ; 68, 6: 489-491. |
Stability of Extemporaneously Compounded Naproxen 25 mg/mL Suspension in Glass and Plastic Bottles and Plastic Syringes.
Ensom M.H.H, D?carie D, Lingertat-Walsh K. |
2015 |
3763 |
Czasopismo
Can J Hosp Pharm 2014 ; 67, 5: |
Stability of Extemporaneously Compounded Pyridoxine in Glass and Plastic Bottles and Plastic Syringes.
Ensom M.H.H, Décarie D. |
2014 |
2489 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2040-2042. |
Stability of extemporaneously compounded spironolactone suspensions
Mathur LK, Wickman A |
1989 |
4638 |
Czasopismo
Can J Hosp Pharm 2021 2021;74(4):327-33 |
Stability of Extemporaneously Compounded Suspensions of Trimethoprim and Sulfamethoxazole in Amber Plastic Bottles and Amber Plastic Syringes.
St-Jean I, Friciu M, Monfort A, MacMahon J, Forest J-M, Walker S, Leclair G. |
2021 |
3946 |
Czasopismo
Can J Hosp Pharm 2017 ; 70,1 :51-53. |
Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes
Friciu M, Zaraa S, Leclair G. |
2017 |
4397 |
Czasopismo
J Oncol Pharm Practice 2021 ;27,1:78–87 |
Stability of extemporaneously compounded temozolomide 10 mg/mL suspensions in Oral Mix SF in glass and plastic syringes.
Lingertat-Walsh K, Weilnau J, Cober M P, Ostrenga A, Poon B, Pacita S, Law S, Dupuis LL, Walker SE. |
2021 |
3854 |
Czasopismo
Can J Hosp Pharm 2016 ; 69, 2: 171-173. |
Stability of extemporaneously compounded trimethioprim in glass and plastic bottles and plastic syringes.
Ensom M.H.H, Decarie D. |
2016 |
3308 |
Czasopismo
Antimicrob Agents Chemother 2012 ; 56: 3435-3437; |
Stability of Extemporaneously Prepared 0.5-Percent Caspofungin Eye Drops: a Potential Cost-Savings Exercise.
Neoh C.F, Jacob J, Leung L, Li J, Stathopoulos A, Stewart K, Kong D.C.M. |
2012 |
4500 |
Czasopismo
J Pediatr Pharmacol Ther 2020 ;25, 8:723-729. |
Stability of Extemporaneously Prepared Acetazolamide Oral Suspensions at Two Temperatures.
Gillium C, Friciu M, Abatzoglou N, Leclair G. |
2020 |
3165 |
Czasopismo
Am J Health-Syst Pharm 2011 ; 68: 69-72. |
Stability of extemporaneously prepared acetylcysteine 1% and 10% solutions for treatment of meconium ileus
Fohl AL, Johnson CE, Cober P. |
2011 |
3275 |
Czasopismo
Am J Health-Syst Pharm 2012 ; 69: 232-240. |
Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate
D'Hondt M, Vangheluwe E, Van Dorpe S, Boonen J, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De Spiegeleer B |
2012 |
3921 |
Czasopismo
Can J Hosp Pharm 2016 ; 69, 6: 505-507. |
Stability of extemporaneously prepared enalapril maleate suspensions in glass bottles and plastic syringes.
Friciu M, Zaraa S, Leclair G. |
2016 |
2547 |
Czasopismo
Ann Pharmacotherapy 2001 ;35:1293-1294. |
Stability of extemporaneously prepared gentamicin ophthalmic solutions.
Ho PC, Soh H, Lim SM, Yow KL. |
2001 |
3203 |
Czasopismo
Am J Health-Syst Pharm 2011 ; 68:843-845. |
Stability of extemporaneously prepared glycopyrrolate oral suspensions.
Cober MP, Johnson CE, Sudekum D, Penprase K |
2011 |
3963 |
Czasopismo
Int J Pharm Compound 2017 ; 21, 2: 160-163. |
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions.
Kabiche D,Balde I.B,Majoul E,Kabiche S,Bourguignon E,Fontan J-E,Cisternino S,Schlatter J. |
2017 |
3993 |
Czasopismo
Int J Pharm Compound 2017 ; 3: 251-254 |
Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes.
McHenry A.R,Wempe M.F., Rice P.J. |
2017 |
4307 |
Czasopismo
J Pediatr Pharmacol Ther 2013 ;18(2):122-127. |
Stability of Extemporaneously Prepared Lansoprazole Suspension at Two Temperatures.
Morrison J.T, Lugo R.A, Thigpen J.C, Brown S.D. |
2013 |
2556 |
Czasopismo
Aust J Hosp Pharm 1989 ; 19,: 344-346. |
Stability of extemporaneously prepared mixtures of metoprolol and spironolactone.
Peterson GM, Meaney MF, Reid CA. |
1989 |
2394 |
Czasopismo
Am J Health-Syst Pharm 2009 ; 66: 665-667. |
Stability of extemporaneously prepared moxifloxacin oral suspensions
Hutchinson DJ, Johnson CE, Klein KC. |
2009 |
4111 |
Czasopismo
Am J Health-Syst Pharm 2018 ;75,9:231-235 |
Stability of extemporaneously prepared ophtalmic solutions for mydriasis.
Camp N, Nadra J, Hughes S, Gilbert J, Zhao F. |
2018 |
3185 |
Czasopismo
Am J Health-Syst Pharm 2011 ; 68:519-521. |
Stability of extemporaneously prepared oxandrolone oral suspensions.
Johnson CE, Cober MP, hawkins KA, Julian JD. |
2011 |
4054 |
Czasopismo
Am J Health-Syst Pharm 2018 , 75, 1: 28-35 |
Stability of extemporaneously prepared preservative-free prochlorperazine nasal spray.
Yellepeddi V. |
2018 |
3095 |
Czasopismo
Am J Health-Syst Pharm 2010 ; 67: 287-289. |
Stability of extemporaneously prepared rifaximin oral suspensions.
Cober MP, Johnson CE, Lee J, Currie K. |
2010 |
4022 |
Czasopismo
Am J Health-Syst Pharm 2017 ; 74,19: 1579-1583 |
Stability of extemporaneously prepared rosuvastatin oral suspension.
Zaid A.N, Shtayah R, Qadumi A, Ghanem M, Qedan R, Daibes M, Abu Awwad S, Jaradat N, Kittana N. |
2017 |
2381 |
Czasopismo
Ann Pharmacotherapy 2010 ;44:462-465. |
Stability of Extemporaneously Prepared Rufinamide Oral Suspensions .
Hutchinson DJ, Liou Y, Best R, Zhao F. |
2010 |
2824 |
Czasopismo
J Clin Pharm Ther 2003 ; 28: 457-463. |
Stability of extemporaneously prepared saquinavir formulations
Tan LK, Thenmozhiyal JC, Ho PC. |
2003 |
4679 |
Czasopismo
PlosOne 2022 17(3): e0262068. |
Stability of extemporaneously prepared sitagliptin phosphate solution.
Zaid A.N, Abu Zaaror Y, Kaddumi A , Ghanem M , Jaradat N , Abu Salah T, Siaj S, Omari L. |
2022 |
4139 |
Czasopismo
Int J Pharm Compound 2018 ;22,4:326-328 |
Stability of Extemporaneously Prepared Sodium Benzoate Oral Suspensions.
Atkins J.R, Lull M.E, Decker A.S, Hutchinson D.J. |
2018 |
2399 |
Czasopismo
Am J Health-Syst Pharm 2007 ; 64: 1513-1515. |
Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions
Caruthers RL, Johnson CE. |
2007 |
3083 |
Czasopismo
Am J Health-Syst Pharm 2009 ; 66: 1478-1483. |
Stability of extemporaneously prepared voriconazole ophthalmic solution
Al-Badriyeh D, Li J, Stewart K, Kong DCM, Leung L, Davies GE, Robert Fullinfaw R. |
2009 |
4576 |
Czasopismo
Int J Pharm Compound 2021 ;25,2:163-168 |
Stability of Extemporaneously-compounded Nadolol 10-mg/mL Suspension in Oral Mix in Glass and Plastic Bottles and Plastic Syringes.
Walsh A, Ziegler B, Lingertat-Walsh K, Law S, Walker S. |
2021 |
4577 |
Czasopismo
Int J Pharm Compound 2021 ;25,2:156-162 |
Stability of Fagron's Phytobase Cream Compounded with Various Hormones.
Wynn T, Taylor S, Zander C. |
2021 |
356 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2321-2325. |
Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions.
Bullock LS, Fitzgerald JF, Glick MR, Parks RB, Schnabel JG, Hancock BG. |
1989 |
354 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2329-2332. |
Stability of famotidine 20 and 40 mg/L in total nutrient admixtures.
Montoro JB, Pou L, Salvador P, Pastor C, Cano SM. |
1989 |
355 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2326-2329. |
Stability of famotidine 20 and 50 mg/L in total nutrient admixtures.
Bullock L, Fitzgerald JF, Glick MR. |
1989 |
77 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 2073-2074. |
Stability of famotidine frozen in polypropylene syringes.
Shea BF, Souney PF. |
1990 |
687 |
Czasopismo
Ann Pharmacotherapy 1990 ; 24: 232-235. |
Stability of famotidine in a 3-in-1 total nutrient admixture.
Shea BF, Souney PF. |
1990 |
2392 |
Czasopismo
Am J Health-Syst Pharm 2000 ; 57: 1340-1342. |
Stability of famotidine in an extemporaneously compounded oral liquid
Dentinger PJ, Swenson CF, Anaizi NH. |
2000 |
2516 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 691-693. |
Stability of famotidine in an extemporaneously prepared oral liquid.
Quercia RA, Jay GT, Fan C. |
1993 |
553 |
Czasopismo
Ann Pharmacotherapy 1989 ; 23: 132-135. |
Stability of famotidine in minibags refrigerated and/or frozen.
Bullock LS, Fitzgerald JF, Glick MR. |
1989 |
215 |
Czasopismo
Ann Pharmacotherapy 1993 ; 27: 422-426. |
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. |
1993 |
1618 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 846-848. |
Stability of fenoldopam in two infusion solutions.
Trissel LA, Zhang Y, Baker MB. |
2002 |
2334 |
Czasopismo
Am J Health-Syst Pharm 2009 ; 66, 9: 860-863. |
Stability of fentanyl 5 µg/mL diluted with 0.9% sodium chloride injection and stored in polypropylene syringes
McCluskey S.V, Graner K.K, Kemp J, Aloumanis V, Ben M, Kupiec T, Nicole Vu N. |
2009 |
60 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 2037-2040. |
Stability of fentanyl citrate and bupivacaine hydrochloride in portable pump reservoirs.
Tu YH, Stiles ML, Allen LV Jr. |
1990 |
225 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 511-513. |
Stability of fentanyl citrate and midazolam hydrochloride during simulated intravenous coadministration.
Bhatt-Mehta V, Johnson CE, Leininger N, Agarwal M. |
1995 |
222 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1572-1574. |
Stability of fentanyl citrate in 0.9% sodium chloride solution in portable infusion pumps.
Allen LV, Stiles ML, Tu YH. |
1990 |
223 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1584-1587. |
Stability of fentanyl citrate in glass and plastic containers and in a patient-controlled delivery system.
Kowalski SR, Gourlay GK. |
1990 |
3916 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 6 : 514-516. |
Stability of Fentanyl Citrate in Polyolefin Bags.
Donnelly R F. |
2016 |
4303 |
Czasopismo
Pharmacy 2015 3, 379-385. |
Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes.
Anderson C, MacKay M. |
2015 |
507 |
Czasopismo
Br J Anaesth 1992 ; 68: 414-417. |
Stability of fentanyl, bupivacaine and adrenaline solutions for extradural infusion.
Dawson PJ, Bjorksten AR, Duncan IP, Barnes RK, Beemer GH. |
1992 |
1832 |
Czasopismo
Pharmazie 2003 ; 6 |
Stability of fentanyl/ropivacain preparations for epidural application.
Hartmann M, Knoth H, K?ler W, Meissner W. |
2003 |
3694 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 985-989. |
Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration.
Smith J.A, Morris A, Duafala M.E, Bertino J.R, Markman M, Kleinberg M. |
1989 |
286 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1459-1462. |
Stability of fluconazole and amino acids in parenteral nutrient solutions.
Couch P, Jacobson P, Johnson CE. |
1992 |
2527 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2366-2367. |
Stability of fluconazole in an extemporaneously prepared oral liquid
Yamreudeewong W, Lopez-Anaya A, Rappaport H. |
1993 |
256 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 1206-1208. |
Stability of fluconazole in commonly used intravenous antibiotic solutions.
Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. |
1993 |
257 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 1186-1187. |
Stability of fluconazole in injectable solutions.
Hunt-Fugate AK, Hennessey CK, Kazarian CM. |
1993 |
2405 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 1853-1855. |
Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations
VandenBussche HL, Johnson CE, Yun J, Patel SA. |
2002 |
2455 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 1853-1855. |
Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations
VandenBussche HL, Johnson CE, Yun J, Patel SA. |
2002 |
2440 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 407-409. |
Stability of flucytosine in an extemporaneously compounded oral liquid
Wintermeyer SM, Nahata MC. |
1996 |
2621 |
Czasopismo
Eur J Pharm Biopharm 2003 ; 55: 209-213. |
Stability of fludrocortisone acetate solutions prepared from tablets and powder.
Cisternino S, Schlatter J, Saulnier JL. |
2003 |
187 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 1907-1912. |
Stability of flumazenil with selected drugs in 5% dextrose injection.
Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. |
1993 |
415 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2036-2040. |
Stability of fluorouracil administered through four portable infusion pumps.
Stiles ML, Allen LV, Tu YH. |
1989 |
844 |
Czasopismo
J Pharm Clin 1989 ; 9: 31-35. |
Stability of fluorouracil and cytarabine in ethylvinylacetate containers.
Rochard E, Chapelle G, Bouquet S, Barthes D, Courtois PH. |
1989 |
1040 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 1153-1156. |
Stability of fluorouracil in plastic containers used for continuous infusion at home.
Quebbeman EJ, Hamid AAR, Hoffman NE, Ausman RK. |
1984 |
33 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1457-1458. |
Stability of fluorouracil in polypropylene syringes and ethylene vinyl acetate infusion-pump reservoirs.
Baud-Camus F, Crauste-Manciet S, Klein E, Richard L, Brossard D. |
1996 |
142 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 619-623. |
Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs.
Rochard EB, Barthes DMC, Courtois PY. |
1992 |
153 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 98-99. |
Stability of fluorouracil-metoclopramide hydrochloride admixture.
Wang DP, Chang LC, Lee DK. |
1995 |
3155 |
Czasopismo
J Ocular Pharm Ther 2010 ; 26, 5: 485-490. |
Stability of Fortified Cefazolin Ophthalmic Solutions Prepared in Artificial Tears Containing Surfactant-Based Versus Oxidant-Based Preservatives.
Rojanarata T, Tankul J, Woranaipinich C, Potawanich P, Plianwong S, Sakulma S, Saehuan C. |
2010 |
2 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 88-90. |
Stability of foscarnet in 0.9% sodium chloride injection.
Woods K, Steinmann W, Bruns L, Neels JT. |
1994 |
75 |
Czasopismo
J Clin Pharm Ther 1994 ; 19: 35-36. |
Stability of foscarnet sodium in 5% dextrose and 0.9% sodium chloride injections.
Mathew M, Das Gupta V, Bethea C. |
1994 |
800 |
Czasopismo
Ann Pharmacotherapy 1997 ; 31: 553-559. |
Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes.
Fischer JH, Cwik MJ, Luer MS, Sibley CB, Deyo KL. |
1997 |
3974 |
Czasopismo
Eur J Pharm Sci 2020 |
Stability of frozen 1% voriconazole eye drops in glass and in innovative containers.
Roche M, Lannoy D, Bourdon F, Dhorne C, Berneron C, Danel C, G.Fernandez, M.J,Simon N, Odou P. |
2020 |
3561 |
Czasopismo
Am J Health-Syst Pharm 2015 ; 72:479-482 |
Stability of frozen 1% voriconazole ophthalmic solution.
Amoros-Reboredo P, Bastida-Fernandez C, Guerrero-Molina L, Soy-Muner D, Lopez-Cabezas C. |
2015 |
4032 |
Plakat
EAHP Congress - Paris 2013 |
Stability of frozen ceftazidime in polypropylene syringes for intravitreal injection.
Daul A, Vigneron J, Zenier H, May I, Demor? B. |
2013 |
581 |
Czasopismo
Am J Hosp Pharm 1976 ; 33: 639-641. |
Stability of frozen solutions of cefazolin sodium.
Carone SM, Bornstein M, Coleman DL, Thomas PN, Boylan JC. |
1976 |
563 |
Czasopismo
Am J Hosp Pharm 1978 ; 35: 1386-1387. |
Stability of frozen solutions of doxycycline hyclate for injection.
Petrick RJ, Wolleben JE, Vargas TA. |
1978 |
580 |
Czasopismo
Am J Hosp Pharm 1972 ; 29: 687-689. |
Stability of frozen solutions of sodium cephalothin and cephaloridine.
Boylan JC, Simmons JL, Winely CL. |
1972 |
2382 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 547-550. |
Stability of fumagillin in an extemporaneously prepared ophthalmic solution
Abdel-Rahman SM, Nahata MC. |
1999 |
4341 |
Czasopismo
Int J Pharm Compound 2019 ;23,5:414-417 |
Stability of Furosemide 5 mg/mL in Polypropylene Syringes.
Van der Schaar JAJ, Grouls R, Franssen EJF, Crul M. |
2019 |
3821 |
Czasopismo
Am J Health-Syst Pharm 2015 ; 72:2182-2188 |
Stability of furosemide and chlorothiazide stored in syringes.
Cies J.J, Moore W.S, Chopra A, Lu G, Mason R.W. |
2015 |
3490 |
Czasopismo
Ann Pharmacotherapy 2002 ; 36: 423-426. |
Stability of furosemide in human albumin solution.
Elwell R.J, Spencer A.P, Barnes J.F, Wynn J.E, Jones C.E. |
2002 |
4308 |
Czasopismo
PlosOne 2017 |
Stability of gabapentin in extemporaneously compounded oral suspensions.
Friciu M, Roullin G, Leclair G. |
2017 |
3322 |
Czasopismo
Int J Pharm Compound 2012 ; 16, 4 : 347-349. |
Stability of Gabapentin in SyrSpend SF.
Sorenson B, Voudrie M, Gehrig D. |
2012 |
141 |
Czasopismo
Hosp Pharm 1989 ; 24: 929-934. |
Stability of gallium nitrate and mitoguazone dihydrochloride in commonly used intravenous fluids.
Kleinberg ML, Oberdier J, Muller RJ, Duafala M, Boylan JC. |
1989 |
245 |
Czasopismo
J Pharm Belg 1992 ; 47: 494-498. |
Stability of ganciclovir sodium (Cymevan*) after dilution in PVC infusions and polypropylene syringes.
Phaypradith S, Vigneron J, Perrin A, Durney-Archeray MJ, Hoffman MA, Hoffman M. |
1992 |
69 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 2810-2812. |
Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections.
Visor GC, Lin LH, Jackson SE, Winterle JS, Lee G, Kenley RA. |
1986 |
72 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 503-508. |
Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions.
Johnson CE, Jacobson PA, Chan E. |
1994 |
76 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 116-118. |
Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days.
Parasrampuria J, Li LC, Stelmach AH, Sykes TR, Gordon GA. |
1992 |
74 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 1348-1349. |
Stability of ganciclovir sodium in an infusion-pump syringe.
Mulye NV, Turco SJ, Speaker TJ. |
1994 |
4147 |
Czasopismo
Minerva Anestesiologica 2014 ;81,3:283-287 |
Stability of generic brands of meropenem reconstituted in isotonic saline.
Carlier M, Stove V, Verstraete A.G, De Waele J.J. |
2014 |
4485 |
Czasopismo
Can J Hosp Pharm 2021 ;74;1:57-69 |
Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored 4°C and Room Temperature (23°C)
Law S, Charbonneau L, Iazetta J, Perks W, Ma N, Walker S.E. |
2021 |
1486 |
Czasopismo
Hosp Pharm 1987 ; 22: 1131-1132. |
Stability of gentamicin diluted in 0.9% sodium chloride injection in glass syringes.
Nahata MC, Hipple TF, Strausbaugh SD. |
1987 |
1704 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 152-154. |
Stability of gentamicin sulfate and tobramycin sulfate in autodose infusion system bags.
Xu QA, Trissel LA, Saenz A. |
2002 |
2487 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 507-509. |
Stability of gentamicin sulfate and tobramycin sulfate in extemporaneously prepared ophthalmic solutions at 8 degrees C
McBride HA, Martinez DR, Trang JM, Lander RD, Helms HA. |
1991 |
1756 |
Czasopismo
Int J Pharm Compound 2003 ; 7: 65-67. |
Stability of glycopyrrolate injection at ambient temperature and 4°C in polypropylene syringes.
Storms ML, Stewart JT, Flynn WW. |
2003 |
51 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1541-1543. |
Stability of granisetron hydrochloride in a disposable elastomeric infusion device.
Chung KC, Chin A, Gill MA. |
1995 |
2427 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1404-1406. |
Stability of granisetron hydrochloride in an extemporaneously prepared oral liquid
Quercia RA, Zhang J, Fan C, Chow MS. |
1997 |
2429 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1404-1406. |
Stability of granisetron hydrochloride in an extemporaneously prepared oral liquid
Quercia RA, Zhang J, Fan C, Chow MS. |
1997 |
48 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2744-2746. |
Stability of granisetron hydrochloride in polypropylene syringes.
Quercia RA, Zhang J, Fau C, Chow MSS. |
1996 |
2423 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 2511-2513. |
Stability of granisetron hydrochloride in two oral suspensions
Nahata MC, Morosco RS, Hipple TF. |
1998 |
27 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1174-1176. |
Stability of granisetron hydrochloride with dexamethasone sodium phosphate for 14 days.
Chin A, Moon YSK, Chung KC, Gill MA. |
1996 |
605 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 292-294. |
Stability of haloperidol in 5% dextrose injection.
Das Gupta V, Stewart KR. |
1982 |
2037 |
Czasopismo
J Antimicrob Chemother 2005 ; 56: 951-953. |
Stability of heparin and physical compatibility of heparin/antibiotic solutions ...
Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B. |
2005 |
791 |
Czasopismo
JPEN 1996 ; 20: 219-220. |
Stability of heparin anticoagulant activity over time in parenteral nutrition solutions.
Hensrud DD, Buritt MF, Hall LG. |
1996 |
4166 |
Czasopismo
J Clin Pharm Ther 1978 3:211-214 |
Stability of heparin in sodium chloride solution.
Bowie H.M, Haylor V. |
1978 |
339 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 377-381. |
Stability of heroin hydrochloride in infusion devices and containers for intravenous administration.
Kleinberg ML, Duafala ME, Nacov C, Flora KP, Hines J, Davis K, McDaniel A, Scott D. |
1990 |
4641 |
Czasopismo
Eur J Pharm Sci 2021 ;167: 106039. |
Stability of high concentrated triple intrathecal therapy for pediatrics and mitigation strategies.
Zanon D, Selmin F, Centin G, Maximova N, Casiraghi A, Minghetti P. |
2021 |
192 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1417-1419. |
Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection.
Peddicord TE, Olsen KM, ZumBrunnen TL, Warner DJ, Webb L. |
1997 |
1416 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 246-248. |
Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions.
Stamatakis MK, Leader G, Tracy TS. |
1999 |
3256 |
Czasopismo
EJHP 2011 ; 17, 5: 49-56. |
Stability of Hospira filgrastim following changes to thermal and photic storage conditions.
Burnett B, Radic I. |
2011 |
2836 |
Czasopismo
Int J Pharm Compound 2003 ; 7, 4: 313-319. |
Stability of Hydralazine Hydrochloride in Both Flavored and Nonflavored Extemporaneous Preparations
Okoka CC, Modwick T, Naira G, Khuspo S, Grady LT. |
2003 |
3168 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 683-686. |
Stability of hydralazine hydrochloride syrup compounded from tablets.
Alexander KS, Pudipeddi M, Parker GA. |
1993 |
909 |
Czasopismo
J Informed Pharmacother 2003 ; 13: 100-110. |
Stability of hydrocortisone in extemporaneously compounded suspensions.
Chong G, Decarie D, Ensom M.H.H. |
2003 |
4616 |
Czasopismo
Pharmaceutics 2021 ; 13, 1267. |
Stability of Hydrocortisone in Oral Powder Form Compounded for Pediatric Patients in Japan.
Saito J, Yoshikawa N, Hanawa T, Ozawa A, Matsumoto T, Harada T, Iwahashi K, Nakamura H, Yamatani A. |
2021 |
2538 |
Czasopismo
Ann Pharmacotherapy 1995 ;29:987-990. |
Stability of hydrocortisone oral suspensions prepared from tablets and powder.
Fawcett JP, Boulton DW, Jiang R, Woods DJ. |
1995 |
4416 |
Czasopismo
J Pediatr Pharmacol Ther 2015 ; 20, 3: 197-202. |
Stability of Hydrocortisone Preservative-Free Oral Solutions.
Chappe J, Osman N, Cisternino S, Fontan J-E, Schlatter J. |
2015 |
2354 |
Czasopismo
Int J Pharm Compound 2000 ; 4, 5: 396-397. |
Stability of hydrocortisone sodium succinate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Das Gupta V, Ling J. |
2000 |
3892 |
Czasopismo
Can J Hosp Pharm 2016 ; 69, 4 : 329-333. |
Stability of Hydrocortisone, Nifedipine, and Nitroglycerine Compounded Preparations for the Treatment of Anorectal Conditions
Friciu M, Chefson A, Leclair G. |
2016 |
4667 |
Czasopismo
Int J Pharm Pharm Sci 2019 ;81(6):1140-114 |
Stability of Hydromorphone Hydrochloride and Morphine under Different Clinical Infusion Conditions.
Ping L, juan H, Li R-L, Feng Z-Y, Zhou X-J, Liu M-F, Jing B, Jian L. |
2019 |
2336 |
Czasopismo
Can J Hosp Pharm 2009 ; 62, 2: 112-118. |
Stability of Hydromorphone–Ketamine Solutions in Glass Bottles, Plastic Syringes, and IV Bags for Pediatric Use
Ensom M.H.H, Decarie D, Leung K, MontgomeryC |
2009 |
3779 |
Czasopismo
Am J Health-Syst Pharm 2014 ; 71:2061-2065 |
Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection
Kintzel P.E, Zhao T, Wen B, Sun D. |
2014 |
1981 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 2434-2439. |
Stability of i.v. mycophenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags.
Certain E, Beteta F, Goudou-Sinha C, Darbord JC, Prognon P, Jacquot C. |
2002 |
1985 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 630-633. |
Stability of ibuprofen in injection solutions.
Volonté MG, Valora PD, Congolani A, Ferrara M. |
2005 |
489 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1137-1139. |
Stability of ifosfamide in 0.9% sodium chloride solution or water for injection in a portable IV pump cassette.
Munoz M, Girona V, Pujol M, Duran S, Vicente P, Solé LA. |
1992 |
898 |
Czasopismo
JPEN 1990 ; 14: 306-309. |
Stability of imipenem and cilastatin sodium in total parenteral nutrient solution.
Zaccardelli DS, Sanders Kromarik C, Wolk R, Khalidi N. |
1990 |
1811 |
Czasopismo
Hosp Pharm 2003 ; 38: 130-134. |
Stability of imipenem-cilastatin sodium in autodose infusion system bags.
Trissel LA, Xu QA. |
2003 |
923 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 170-171. |
Stability of indomethacin in 0.9% sodium chloride injection.
Das Gupta V, Maswoswe J. |
1998 |
3333 |
Czasopismo
Am J Health-Syst Pharm 2012 ; 69:1509-1512. |
Stability of infliximab in polyvinyl chloride bags.
Ikeda R, Vermeulen L.C, Lau E, Jiang Z, Saha S, Reichelderfer M, Kolesar J.M. |
2012 |
4049 |
Czasopismo
J Pharm Biomed Anal 2018 ; 150 : 386-395 |
Stability of infliximab solutions in different temperature and dilution conditions.
Tokhadze N, Chennell P, Le Basle Y, Sautou V. |
2018 |
1288 |
Czasopismo
Int J Pharm Pract 1994 ; 3: 57-59. |
Stability of injections containing diamorphine and midazolam in plastic syringes.
Allwood MC, Brown PW, Lee M. |
1994 |
2091 |
Czasopismo
J Pharm Pract and Res 2004 ; 34: 11-13. |
Stability of insulin aspart in normal saline infusion.
Lim SC, Roberts MJ, Paech MJ, Peng L, Jones A. |
2004 |
803 |
Czasopismo
Diabetes Care 1997 ; 20: 1061-1065. |
Stability of insulin lispro in insulin infusion systems.
Lougheed WD, Weymouth AB, Zinman B, Bernstein EA, Strack TR, Korbas AM, Janis LJ, Frank BH. |
1997 |
426 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 925-927. |
Stability of intravenous admixtures containing aztreonam and cefazolin.
Riley CM, James MJ. |
1986 |
422 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 1095-1100. |
Stability of intravenous admixtures of aztreonam and ampicillin.
James MJ, Riley CM. |
1985 |
19 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1444-1453. |
Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin.
Bell RG, Lipford LC, Massanari MJ, Riley CM. |
1986 |
419 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 1984-1986. |
Stability of intravenous admixtures of aztreonam and clindamycin phosphate.
James MJ, Riley CM. |
1985 |
2094 |
Czasopismo
EJHP Science 2006 ; 12, 1: 10-12. |
Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS.
Trittler R. |
2006 |
408 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 3022-3027. |
Stability of intravenous admixtures of doxorubicin and vincristine.
Beijnen JH, Neef C, Meuwissen OJAT, Rutten JJMH, Rosing H, Underberg WJM. |
1986 |
1655 |
Czasopismo
Pharmacotherapy 1999 ; 19: 484. |
Stability of intravenous citalopram hydrochloride in either polyvinyl chloride bags or glass containers for infusion therapy, and compatibility with dipotassium clorazepate admixed.
Gury C, Dolizy I, Aymard N, Sellali Y. |
1999 |
690 |
Czasopismo
Ann Pharmacotherapy 1989 ; 23: 588-590. |
Stability of intravenous famotidine stored in polyvinyl chloride syringes.
Bullock LS, Fitzgerald JF, Mazur HI. |
1989 |
3189 |
Czasopismo
J Pharm Pract and Res 2010 ; 40, 2: 101-105. |
Stability of intravenous flucloxacillin solutions used for hospital-in-the-home.
Tho T-P, Ching MS, Elis AG, Williams L, Garrett MK. |
2010 |
694 |
Czasopismo
Can J Hosp Pharm 1988 ; 41: 233-238, 242. |
Stability of intravenous vancomycin.
Walker SE, Birkhans B. |
1988 |
1823 |
Czasopismo
J Clin Pharm Ther 2003 ; 28: 349-353. |
Stability of intravesical epirubicin infusion: a sequential temperature study.
Sewell GJ, Rigby-Jones AE, Priston MJ. |
2003 |
3850 |
Czasopismo
Eur J Cancer 2016 ; 58: 8-16. |
Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues.
Bardo-Brouard P, Vieillard V, Shekarian T, Marabelle A, Astier A, Paul M. |
2016 |
2685 |
Czasopismo
Int J Pharm Pract 1995 ; 3: 169-173. |
Stability of ipratropium bromide and salbutamol nebuliser admixtures.
Jacobson GA, Peterson GM. |
1995 |
1617 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 539-544. |
Stability of irinotecan hydrochloride in aqueous solutions.
Li WY, Koda RT. |
2002 |
2671 |
Czasopismo
J Oncol Pharm Practice 2010 ; 16: 53-61. |
Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization.
Kaiser J, Thiesen J, Krämer I. |
2010 |
2818 |
Czasopismo
J Pharm Biomed Anal 1998 ; 17: 885-890. |
Stability of isoniazid in isoniazid syrup: formation of hydrazine
Carlin A, Gregory N, Simmons J. |
1998 |
4113 |
Czasopismo
Am J Health-Syst Pharm 2018 ; 75, 10: 622-626. |
Stability of isoniazid injection in i.v. solutions.
Lee J, Moriyama B, Henning S, Danner R, Walsh T, Penzak S, Grimes G, Gopal K. |
2018 |
2523 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2409-2411. |
Stability of isradipine in an extemporaneously compounded oral liquid
MacDonald JL, Johnson CE, Jacobson P. |
1994 |
2442 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 189-191. |
Stability of itraconazole in an extemporaneously compounded oral liquid
Jacobson PA, Johnson CE, Walters, JR. |
1995 |
2982 |
Czasopismo
J Ped Pharm Pract 1998 ; 3: 115-118. |
Stability of itraconazole in an extemporaneously suspension.
Abdel-Rahman SM, Nahata MC. |
1998 |
1714 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 316-317. |
Stability of ketamine hydrochloride injection after reconstitution in water for injection and storage in 1-ml tuberculin polypropylene syringes for pediatric use.
Gupta VD. |
2002 |
2329 |
Czasopismo
Can J Hosp Pharm 2008 ; 61, 6: 426-430. |
Stability of Ketamine-Propofol mixtures for procedural sedation and analgesia in the emergency department.
Donnely R.F, Willman E, Andolfatto G. |
2008 |
2441 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2073-2078. |
Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids
Allen LV, Jr, Erickson MA, |
1996 |
451 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 206-207. |
Stability of ketorolac tromethamine in 5% dextrose injection and 0.9% sodium chloride injections.
Das Gupta V, Maswoswe J, Bailey RE. |
1997 |
1634 |
Czasopismo
Can J Hosp Pharm 2000 ; 53: 263-269. |
Stability of ketorolac tromethamine in IV solutions and waste reduction.
Shi A, Walker SE, Law S. |
2000 |
1858 |
Czasopismo
Pharm Acta Helv 1999 ; 74: 1-9. |
Stability of L-asparaginase: an enzyme used in leukemia treatment.
Stecher AL, Morgantetti de Deus P, Polikarpov I, Abrahao-Neto J. |
1999 |
3793 |
Czasopismo
Drug Intell Clin Pharm 1991 ; 25: 465-469. |
Stability of labetalol hydrochloride in distilled water, simple syrup, and three fruit juices.
Nahata M.C. |
1991 |
199 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2143-2145. |
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection.
Hassan E, Leslie J, Martir-Herrero ML. |
1994 |
2435 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2304-2309. |
Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids
Allen LV, Jr, Erickson MA, |
1996 |
2416 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 240-242. |
Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4 and 25 degrees C
Nahata MC, Morosco RS, Hipple TF. |
1999 |
2594 |
Czasopismo
Can J Hosp Pharm 2007 ; 60, 3: 184-191. |
Stability of lansoprazole in extemporaneously compounded suspensions for nasogastric or oral administration.
Ensom MHH, Decarie D, Sheppard I. |
2007 |
2635 |
Czasopismo
Hosp Pharm 2008 ; 43, 4: 303-306. |
Stability of levalbuterol in a mixture of levalbuterol and ipratropium nebulizer solution.
Yamreudeewoh W, Teixeira G, Mayer GE. |
2008 |
2970 |
Czasopismo
J Pharm Pharm Sci 2005 ; 8: 322-325. |
Stability of levamisole oral solutions prepared from tablets and powder.
Chiadmi F, Lyer A, Cisternino S et al. |
2005 |
3221 |
Czasopismo
Can J Hosp Pharm 2011 ; 64, 3: 207-211. |
Stability of Levetiracetam in Extemporaneously Compounded Suspensions.
Ensom MHH, Decarie D, Rudolph S. |
2011 |
3568 |
Czasopismo
Am J Health-Syst Pharm 2014 ;71:219-222 |
Stability of levetiracetam oral solution repackaged in oral plastic syringes.
Prohotsky D.L, Hughes S.E, Zhao F. |
2014 |
3926 |
Czasopismo
Hosp Pharm 2016 ; 51 ; 11 : 915-921. |
Stability of Levodopa/Carbidopa Rectal Suspensions.
Donnelly R.F. |
2016 |
2409 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 2316-2318. |
Stability of levofloxacin in an extemporaneously compounded oral liquid
VandenBussche HL, Johnson CE, Fontana EM, Meram JM. |
1999 |
108 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 2309-2313. |
Stability of levofloxacin in intravenous solutions in polyvinyl chloride bags.
Williams NA, Bornstein M, Johnson K. |
1996 |
3166 |
Czasopismo
Can J Hosp Pharm 2011 ; 63, 6: 437-443. |
Stability of Levothyroxine in Sodium Chloride for IV Administration.
Strong DK, Decarie D, Ensom MHH. |
2011 |
3228 |
Czasopismo
Am J Health-Syst Pharm 2011 ;68:1723-1728. |
Stability of levothyroxine injection in glass, polyvinyl chloride, and polyolefin containers
Frenette AJ, MacLean RD, Williamson D, Marsolais P, . Donnelly RF |
2011 |
2358 |
Czasopismo
Int J Pharm Compound 2000 ; 4, 6: 482-483. |
Stability of levothyroxine sodium injection in polypropylene syringes.
Das Gupta V. |
2000 |
3811 |
Czasopismo
Int J Pharm Compound 2015 ; 19, 5 : 428-431. |
Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures.
Nahata Milap C. |
2015 |
1202 |
Czasopismo
Am J Hosp Pharm 1981 ; 38: 1745-1747. |
Stability of lidocaine hydrochloride in 5% dextrose injection in plastic bags.
Smith FM, Nuessle NO. |
1981 |
1715 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 388-390. |
Stability of lidocaine hydrochloride injection at ambient temperature and 4°C in polypropylene syringes.
Storms ML, Stewart JT, Warren FW. |
2002 |
2549 |
Czasopismo
Ann Pharmacotherapy 2004 ;38:396-399. |
Stability of Lisinopril in Two Liquid Dosage Forms
Nahata MC, Morosco RS. |
2004 |
2680 |
Czasopismo
Int J Pharm Compound 2000 : 398-399. |
Stability of lisinopril syrup (2 mg/ml) extemporaneously compounded from tablets.
Rose DJ, Webster AA, English BA. |
2000 |
2647 |
Czasopismo
Int J Pharm 1998 ; 51, 2: 157-160. |
Stability of loperamide hydrochloride in aqueous solutions as determined by high performance liquid chromatography
Tu YH, Allen LV, Wang DP. |
1998 |
765 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 2013-2015. |
Stability of lorazepam 1 and 2 mg/ml in glass bottles and polypropylene syringes.
Share MJ, Harrison RD, Folstad J, Fleming RA. |
1998 |
1935 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 1039-1041. |
Stability of lorazepam in 0.9% sodium chloride stored in polyolefin bags.
Norenberg JP, Achusim LE, Steel TH, Anderson TL. |
2004 |
935 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 322-324. |
Stability of lorazepam in 5% dextrose injection.
Das Gupta V, Pramar Y. |
1998 |
1234 |
Czasopismo
Br J Pharm Pract 1989 ; 11: 34-36. |
Stability of low-dosage heparin in pre-filled syringes.
Parkinson R, Wilson JV, Ross M, Denyer SP. |
1989 |
1414 |
Czasopismo
J Pharm Technol 1999 ; 15: 13-17. |
Stability of low-dose vancomycin hydrochloride in heparin sodium 100 UI / ml.
Mayer JLR, Pascale VJ, Clyne LP, Malkus H, Santos FS, van Hoff J. |
1999 |
2294 |
Czasopismo
Can J Hosp Pharm 2008 ; 61, 5: 356-357. |
Stability of magnesium sulfate 20% in Viaflex bags.
Newby B.D, Benes C, Palmer L, Cleve R. |
2008 |
2356 |
Czasopismo
Int J Pharm Compound 1998 ; 2, 5: 385-388. |
Stability of magnesium sulfate in 0.9% sodium chloride and lactated Ringers solutions.
Sarver J.G, Pryka R, Alexander K.S, Weinstein L, Erhardt P.W. |
1998 |
2668 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 89-91. |
Stability of mechlorethamine hydrochloride 0.01% ointment in Aquafor Base.
Zhang Y, Trissel LA, Johansen JF, Kimball CL. |
1998 |
2872 |
Czasopismo
Int J Pharm Compound 2009 ; 13, 2: 170-174. |
Stability of Melatonin in an Extemporaneously Compounded Sublingual Solution and Hard Gelatin Capsule.
Haywood A, Burrell A, van Breda K, Testa C, Norris R. |
2009 |
3977 |
Czasopismo
Drugs R D 2015 ;15:253-259. |
Stability of Melphalan in 0,9% Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection.
Desmaris R.P, Mercier L, Paci A. |
2015 |
3786 |
Czasopismo
JAMA Ophtalmology 2014 ; 132, 11: 1372-1373. |
Stability of Melphalan Solution for Intravitreal Injection for Retinoblastoma
Buitrago E, Lagomarsino E; Mato G; Schaiquevich P. |
2014 |
2842 |
Czasopismo
Int J Pharm Compound 2006 ; 10, 4: 316-317. |
Stability of Memantine in an Extemporaneously Prepared Oral Liquid
Yamreudeewong W, Teixeira MJ, Mayer GE. |
2006 |
1735 |
Czasopismo
J Pharm Biomed Anal 1999 ; 21: 577-583. |
Stability of mepiridine in an implantable infusion pump using capillary gas chromatography-mass spectrometry and a deuterated internal standard.
Harvey SC, Toussaint CP, Coe SE, Watson EE, O?Neil MG, Patrick KS. |
1999 |
4122 |
Czasopismo
Hosp Pharm 2018 ;54,3:190?196 |
Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion.
Fawaz S, Barton S, Whitney L, Swinden J, Nabhani-Gebara S. |
2018 |
3112 |
Czasopismo
J Antimicrob Chemother 2010 ; 65: 1073-1075 |
Stability of meropenem and doripenem solutions for administration by continuous infusion
Berthoin K, Le Duff, CS , Marchand-Brynaert J, Carryn S, Tulkens PM |
2010 |
4180 |
Czasopismo
Perit Dial Int 2018 ;38,6:430-440 |
Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions.
Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wanandy T, Zaidi S, Ming L, Castelino R, Sud K, Peterson G, Patel R. |
2018 |
1454 |
Czasopismo
Am J Health-Syst Pharm 2000 ; 57: 992-995. |
Stability of meropenem in a portable infusion device in a cold pouch.
Grant EM, Zhong MK, Ambrose PG, Nicolau DP, Nightingale CH, Quiniliani R. |
2000 |
1639 |
Czasopismo
Eur Hosp Pharm 1997 ; 3: 168-171. |
Stability of meropenem in elastomeric portable infusion devices.
Krämer I. |
1997 |
10 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 412-421. |
Stability of meropenem in intravenous solutions.
Patel PR, Cook SE. |
1997 |
3837 |
Czasopismo
South Asian J Trop Med Pub Health 2003 ; 34: 627-629. |
Stability of meropenem in normal saline solution after storage at room temperature.
Jaruratanasirikul S, Sriwiriyajan S. |
2003 |
1942 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 1682-1685. |
Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device.
Smith DL, Bauer SM, Nicolau DP. |
2004 |
1275 |
Czasopismo
Can J Hosp Pharm 1998 ; 51: 156-168. |
Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride.
Walker SE, Varrin S, Yannicelli D, Law S. |
1998 |
2524 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2955-2957. |
Stability of mesalamine in rectal suspension diluted with distilled water
Henderson LM, Johnson CE, Berardi RR. |
1994 |
3033 |
Czasopismo
Eur Respir J 1998 ; 11: 946-948. |
Stability of metacholine chloride solutions under different storage conditions over a 9 months period.
Haynes RD, Beach JR, Rutherford DM et al. |
1998 |
646 |
Czasopismo
J Clin Pharm Ther 1999 ; 24: 365-368. |
Stability of methacholine chloride in isotonic sodium chloride using a capillary electrophoresis assay.
Henn S, Monfort P, Vigneron JH, Hoffman MA, Hoffman M. |
1999 |
4406 |
Czasopismo
Can J Hosp Pharm 2020 2020;73(2):141-4 |
Stability of Methadone Hydrochloride for Injection in Saline Solution
Friciu M, Alarie H, Beauchemin M, Forest JM, Leclair G. |
2020 |
224 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 515-517. |
Stability of methadone hydrochloride in 0.9% sodium chloride injection in single-dose plastic containers.
Denson DD, Crews JC, Grummich KW, Stirm EJ, Sue CA. |
1991 |
1158 |
Czasopismo
Int J Pharm 1988 ; 47: 239-247. |
Stability of methotrexate and vinblastine in burette administration sets.
McElnay JC, Elliott DS, Cartwright-Shamoon J, D?Arcy PF. |
1988 |
1155 |
Czasopismo
Int J Pharm 1988 ; 45: 237-244. |
Stability of methotrexate injection in prefilled plastic disposable syringes.
Wright MP, Newton JM. |
1988 |
1922 |
Czasopismo
J Am Pharm Assoc 2002 ; 42: 868-870. |
Stability of methylprednisolone sodium succinate in autodose infusion system bags.
Trissel LA, Zhang Y. |
2002 |
180 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1300-1302. |
Stability of metoclopramide hydrochloride in plastic syringes.
Zhang Y, Trissel LA, Martinez JF, Gilbert DL. |
1996 |
2634 |
Czasopismo
Hosp Pharm 1997 ; 32: 691-693. |
Stability of metolazone in a liquid dosage form.
Nahata MC, Morosco RS, Hipple TF. |
1997 |
238 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 950-952. |
Stability of metoprolol tartrate in 5% dextrose injection or 0.9% sodium chloride injection.
Belliveau PP, Shea BF, Scavone JM. |
1993 |
2267 |
Czasopismo
Am J Health-Syst Pharm 2008 ; 65, 7: 636-638. |
Stability of metoprolol tartrate injection 1 mg/ml undiluted and 0.5 mg/ml in 0.9% sodium chloride injection and 5% dextrose injection.
Kraft MD, Johnson CE, Chung C, Julian F. |
2008 |
267 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1046-1048. |
Stability of metronidazole and ceftizoxime sodium in ready-to-use metronidazole bags stored at 4 and 25°C.
Nahata MC, Edmonds JJ, Morosco RS. |
1996 |
630 |
Czasopismo
J Clin Hosp Pharm 1985 ; 10: 67-72. |
Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions.
Das Gupta V, Stewart KR. |
1985 |
2702 |
Czasopismo
J Clin Pharm Ther 1994 ; 19, 1: 31-34. |
Stability of metronidazole benzoate in suspensions
Mathew M, Gupta VD, Bethea C. |
1994 |
2250 |
Czasopismo
Int J Pharm Compound 2008 ; 12, 6: 558-564. |
Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System.
Vu N.T, Aloumanis V, Ben MJ, Kupiec T.C, Patterson E K, Radke J, Erickson M A III, Schneider G. |
2008 |
4375 |
Czasopismo
Int J Pharm Compound 2020 ;24,1:77-82 |
Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets.
Jarouche M, Ibrahim M, Pearson J, Venkataya B, Low M, Rowe J. |
2020 |
2695 |
Czasopismo
Int J Pharm Compound 2015 ; 19, 3: 248-251. |
Stability of Metronidazole Suspensions.
Donnelly Ronald F, Ying James. |
2015 |
2690 |
Czasopismo
J Am Pharm Assoc 2000 ; 40: 257-259. |
Stability of mexiletine in two extemporaneously liquid formulations stored under refrigeration and et room temperature
Nahata MC, Morosco RS, Hipple TF. |
2000 |
1889 |
Czasopismo
Int J Pharm 2015 ; 492 : 137?140. |
Stability of micafungin sodium solutions at different concentrations in glass bottles and syringes.
Briota Th, Vrignaud S, Lagarce F. |
2015 |
929 |
Czasopismo
J Pain Symptom Manage 1998 ; 16: 52-58. |
Stability of midazolam and fentanyl in infusion solutions.
Wilson KM, Schneider JJ, Ravenscroft PJ. |
1998 |
3989 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2017 ; 2,1: 35 |
Stability of midazolam and noradrenaline stored in cyclic olefin copolymer AT-Closed Vials® and polypropylene syringes during 365 days.
Feutry F, Genay S, Velghe C, Barthélémy C, Décaudin B, Odou, P. |
2017 |
86 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2812-2815. |
Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration.
Johnson CE, Bhatt-Mehta V, Mancari SC, McKown JA. |
1994 |
231 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2379-2381. |
Stability of midazolam hydrochloride in 5% dextrose injection or 0.9% sodium chloride injection over 30 days.
Hagan RL, Jacobs III LF, Pimsler M, Merritt GJ. |
1993 |
2499 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 615-618. |
Stability of midazolam hydrochloride in a flavored, dye-free oral solution
Steedman SL, Koonce, JR, Wynn JE, Brahen NH. |
1992 |
232 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 285-288. |
Stability of midazolam hydrochloride in parenteral nutrient solutions.
Bhatt-Mehta V, Rosen DA, King RS, Marsym CJ. |
1993 |
185 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2018-2020. |
Stability of midazolam hydrochloride in polyvinyl chloride bags under fluorescent light.
McMullin ST, Burns Schaiff RA, Dietzen DJ. |
1995 |
41 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 913-915. |
Stability of midazolam hydrochloride in syringes and IV fluids.
Pramar YV, Loucas VA, El-Rachidi A. |
1997 |
3222 |
Czasopismo
Am J Health-Syst Pharm 2011 ;68:1537-1540. |
Stability of midazolam hydrochloride injection 1-mg/mL solutions in polyvinyl chloride and polyolefin bags
Karlage K, Earhart Z, Green-Boesen K, . Myrdal PB |
2011 |
399 |
Czasopismo
Aust J Hosp Pharm 1993 ; 23: 260-262. |
Stability of midazolam in sodium chloride infusion packs.
Bleasel MD, Peterson GM, Jestrimski KW. |
1993 |
3437 |
Czasopismo
Int J Pharm Compound 2013 ; 17, 4: 344-346. |
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry.
Geiger C.M, Sorenson B, Whaley P.A. |
2013 |
2772 |
Czasopismo
South Med J 1993 ; 86: 771-772. |
Stability of midazolam prepared for oral administration
Gragory DF, Koestner JA, Tobias JD. |
1993 |
191 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 2079-2091. |
Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection.
Riley CM. |
1988 |
366 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 2218-2220. |
Stability of milrinone in 0.45% sodium chloride, 0.9% sodium chloride, or 5% dextrose injections.
Wilson TD, Forde MD, Crain AVR, Dombrowski LJ, Joyce MA. |
1986 |
4109 |
Czasopismo
Am J Health-Syst Pharm 2018 ;75,9:241-245 |
Stability of milrinone in continuous ambulatory delivery devices.
Madfai F, Zaidi S, Ming L, Wanandy T, Patel R. |
2018 |
922 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 168-169. |
Stability of milrinone lactate 200 microg /mL in 5% dextrose injection and 0.9% sodium chloride injection.
Wong F, Gill MA. |
1998 |
928 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 246-248. |
Stability of milrinone lactate in 5% dextrose injection and 0.9% sodium chloride injection at concentrations of 400, 600 and 800 microg/mL.
Nguyen D, Gill MA, Wong F. |
1998 |
813 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 63-68. |
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Akkermann SR, Zhang H, Mullins RE, Yaughn K. |
1999 |
3403 |
Czasopismo
Int J Pharm Compound 2013 ; 17 ; 2 : 165-167. |
Stability of Minoxidil in Espumil Foam Base
Geiger C.M, Sorenson B, Whaley P.A. |
2013 |
2785 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62, 11: 1192-1194. |
Stability of misoprostol in suppositories.
Hafirassou H, Chaidmi F, Schlatter J, Ratiney R, Fontan JE. |
2005 |
407 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 1750-1754. |
Stability of mitomycin admixtures.
Quebberman EJ, Hoffman NE, Ausman RK, Hamid AAR. |
1985 |
648 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 282-283. |
Stability of mitomycin aqueous solution when stored in tuberculin syringes.
Das Gupta V. |
1997 |
485 |
Czasopismo
J Oncol Pharm Practice 1995 ; 1: 19-24. |
Stability of mitomycin C in different infusion fluids: compatibility with heparin and glucocorticosteroids.
Dorr RT, Liddil JD. |
1995 |
4526 |
Czasopismo
EJOP 2021 4: 1. |
Stability of mitomycin in polypropylene syringes for use in glaucoma surgery.
Nisse, Y.E, Vigneron J, Zenier H, D'Huart E, Demoré B. |
2021 |
828 |
Czasopismo
J Pharm Clin 1990 ; 9: 159-165. |
Stability of mitoxantrone (Novantrone*) after dilution in PVC infusions.
Lecompte D, Bousselet M, Magnam J. |
1990 |
3052 |
Czasopismo
J Pharm Pract and Res 2007 ; 37: 95-97. |
Stability of mixtures formulated from warfarin tablets or powder.
Sharley NA, Yu AMC, Williams DB. |
2007 |
4082 |
Czasopismo
EJHP 2018 ; 25, e2 |
Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures.
Espinosa-Bosch M, Sanchez-Rojas F, Bosche-Ojeda C. |
2018 |
1968 |
Czasopismo
Hosp Pharm Pract 1992 ; 2, 9: 597-600. |
Stability of morphine and droperidol separately and combined, for use as an infusion.
Williams OA, Middleton M, Henderson P, Reilly CS. |
1992 |
679 |
Czasopismo
Pharm Weekbl [Sci] 1992 ; 14: 23-26. |
Stability of morphine hydrochloride in a portable pump reservoir.
Roos PJ, Glerum JH, Meilink JW. |
1992 |
515 |
Czasopismo
J Pharm Clin 1998 ; 17: 35-39. |
Stability of morphine hydrochloride solutions in portable single-use PCA systems. Additives leaching into the morphine solutions.
Le Hoang MD, Sarbach C, Prognon P, Delvordre P, Mignot A, Pradeau D. |
1998 |
4395 |
Plakat
Sunnybrook Health Sciences Centre 2020 |
Stability of Morphine Solutions of 20, 40, 100 , 200 and 1,000 µg/mL in Syringes Following Dilution with 0.9% Sodium Chloride or D5W at Room Temperature (25°C).
Hook R, Riss V, Neault A, Ma N, Law S, Walker S.E. |
2020 |
340 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 1087-1094. |
Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation.
Macias JM, Martin WJ, Lloyd CW. |
1985 |
115 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2785-2786. |
Stability of morphine sulfate in bacteriostatic 0.9% sodium chloride injection stored in glass vials at two temperatures.
Nahata MC, Morosco RS, Hipple TF. |
1992 |
65 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 143-146. |
Stability of morphine sulfate in infusion devices and containers for intravenous administration.
Duafala ME, Kleinberg ML, Nacov C, Flora KP, Hines J, Davis K, McDaniel A, Scott D. |
1990 |
2064 |
Czasopismo
Int J Pharm Compound 2006 ; 10: 69-73. |
Stability of morphine sulfate in polypropylene infusion bags for use in patient-controlled analgesia pumps for postoperative pain management.
Nguyen-Xuan Tho, Griffiths W, Kern C, Van Gessel E, Bonnabry P. |
2006 |
116 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 1404-1407. |
Stability of morphine sulfate in portable pump reservoirs during storage and simulated administration.
Stiles ML, Tu YH, Allen LV Jr. |
1989 |
4730 |
Czasopismo
Neuromodulation 2022 |
Stability of Morphine Sulfate-Clonidine and Sufentanil-Clonidine Mixtures.
Sorrieul J, Robert J, Vincent L, Andre M, Bourcier B, Bienfait F, Jubier Hamon S, Dupoiron D, Devys C. |
2022 |
2914 |
Czasopismo
Palliative Med 2005 ; 19: 131-136. |
Stability of morphine sulphate and diamorphine hydrochloride in Intrasite gel.
Zepetella G, Joel SP, Ribiero MDC. |
2005 |
2123 |
Czasopismo
EJHP Science 2006 ; 12, 4: 76-80. |
Stability of morphine sulphate in ANAPA Plus ambulatory infusion device and PEGA infusion sets.
Lee G, Sabra K. |
2006 |
1810 |
Czasopismo
EJHP 2003 ; 1:1-3. |
Stability of morphine sulphate in P.C.A.s.
Lee G, Sabra K, Doyle N, Malley GO. |
2003 |
932 |
Czasopismo
J Clin Pharm Ther 1997 ; 22: 405-410. |
Stability of morphine sulphate in saline under simulated patient administration conditions.
Hor MMS, Chan SY, Yow KL, Lim LY, Chan E, Ho PC. |
1997 |
2350 |
Czasopismo
Int J Pharm Compound 2000 ; 4, 3: 225-228. |
Stability of morphine-ketamine in 0.9% sodium chloride injection packaged in syringes, plastic bags and MEDICATION CASSETTE Reservoirs.
Roy J.J, Hildgen P. |
2000 |
2145 |
Czasopismo
J Clin Pharm Ther 2006 ; 31: 641-643. |
Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36%® and Dianeal PD1 3.86%®).
Fernandez-Varon E, Marin P, Espuny A, Villamayor L, Escudero E, Carceles C. |
2006 |
1804 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 464-468. |
Stability of multidose, preserved formulation epoetin alfa in syringes for three and six weeks.
Naughton CA, Duppong LM, Forbes KD, Sehgal I. |
2003 |
2543 |
Czasopismo
Ann Pharmacotherapy 1998 ;32:755-757. |
Stability of mycophenolate mofetil as an extemporaneous suspension.
Venkataramanan R, McCombs, JR, Zuckerman S, McGhee B, Pisupati J, Dice JE. |
1998 |
2857 |
Czasopismo
Can J Hosp Pharm 2002 ; 55, 1: 63-65. |
Stability of Mycophenolate Mofetil in a 1:1 Mixture of Ora-Sweet and Ora-Plus.
Ensom MHH, Decarle D. |
2002 |
2448 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 926-929. |
Stability of mycophenolate mofetil in an extemporaneously compounded oral liquid
Anaizi NH, Swenson CF, Dentinger PJ. |
1998 |
2414 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 2224-2226. |
Stability of mycophenolate mofetil in an extemporaneously compounded sugar-free oral liquid
Swenson CF, Dentinger PJ, Anaizi NH. |
1999 |
4299 |
Czasopismo
Biomed Chromatogr 2019 ; 33, 7: e4529. |
Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device.
Ezquer-Garin C, Ferriols-Lisart R, Alos-Alminana M. |
2019 |
4639 |
Czasopismo
Can J Hosp Pharm 2021 2021;74(4):344-9 |
Stability of N-Acetylcysteine 60 mg/mL in Extemporaneously Compounded Injectable Solutions.
Friciu M, Monfort A, Dubé P-A, Leclair G. |
2021 |
2352 |
Czasopismo
Int J Pharm Compound 2000 ; 4, 6: 480-481. |
Stability of nafcillin sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Ling J, Das Gupta V. |
2000 |
278 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 521-523. |
Stability of nafcillin sodium in the presence of lidocaine hydrochloride.
Hagan RL, Carr-Lopez S, Strickland JS. |
1995 |
13 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1068-1070. |
Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs.
Stiles ML, Allen LV. |
1997 |
665 |
Czasopismo
Int J Pharm Compound 2005 ; 9, 4: 323-326. |
Stability of Nebulizer Admixtures.
Blondino, FE, Baker M. |
2005 |
1682 |
Czasopismo
Int J Pharm Compound 2002 ; 6: 475-477. |
Stability of neostigmine methylsulfate injection at ambient temperature and 4°C in polypropylene syringes.
Storms M, Stewart JT, Warren FW. |
2002 |
1236 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1241-1242. |
Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline.
Kuhn RJ, Nahata MC. |
1986 |
44 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1701-1705. |
Stability of nicardipine hydrochloride in intravenous solutions.
Baaske DM, DeMay JF, Latona CA, Mirmira S, Sigvardson KW. |
1996 |
2408 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 1019-1022. |
Stability of nifedipine in an extemporaneously compounded oral solution
Dentinger PJ, Swenson CF, Anaizi NH. |
2003 |
2691 |
Czasopismo
J Am Pharm Assoc 2002 ; 42: 865-867. |
Stability of nifedipine in two oral suspensions stored at two temperatures.
Nahata MC, Morosco RS, Willhite EA. |
2002 |
2403 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 1493-1496. |
Stability of nimodipine solution in oral syringes
Green AE, Banks S, Jay M, Hatton J. |
2004 |
3536 |
Czasopismo
Int J Pharm Compound 2013 ; 17, 6: 515-519 |
Stability of Nitroglycerin 100 mcg/mL Stored in Polypropylene Syringes
McCluskey S V, Vu N, Rueter J. |
2013 |
90 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2561-2563. |
Stability of nitroglycerin concentrate for injection stored in plastic syringes.
Driver PS, Jarvi EJ, Gratzer PL. |
1993 |
1049 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 303-305. |
Stability of nitroglycerin in intravenous admixtures.
Klamerus KJ, Ueda CT, Newton DW. |
1984 |
1027 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 1807-1811. |
Stability of nitroglycerin solutions in polyolefin and glass containers.
Wagenknecht DM, Baaske DM, Alam AS, Carter JE, Shah J. |
1984 |
4505 |
Czasopismo
Eur J Cancer 2020 ; 135: 192-202. |
Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion.
Le Guyader G, Vieillard V, Mouraud S, Do B, Marabelle A, Paul M. |
2020 |
388 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 1523-1529. |
Stability of nizatidine in commonly used intravenous fluids and containers.
Raineri DL, Cwik MJ, Rodvold KA, Deyo KL, Scaros LP, Fischer JH. |
1988 |
2500 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 2716-2719. |
Stability of nizatidine in extemporaneous oral liquid preparations
Lantz MD, Wozniak TJ. |
1990 |
361 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1507-1510. |
Stability of nizatidine in total nutrient admixtures.
Hatton J, Holstad SG, Rosenbloom AD, Westrich T, Hirsch J. |
1991 |
3535 |
Czasopismo
Int J Pharm Compound 2013 ; 17, 6 : 508-511. |
Stability of Non-aqueous Topical Tetracaine and Clotrimazole Solutions in Polypropylene Droptainer Bottles
McPherson T. B, Neumann W L, Kolling W M. |
2013 |
3111 |
Czasopismo
Can J Hosp Pharm 2010 ; 63, 2: 113-118. |
Stability of Norepinephrine Solutions in Normal Saline and 5% Dextrose in Water.
Walker SE, Law S, Garland J, Fung E, Iazzetta J. |
2010 |
2412 |
Czasopismo
Am J Health-Syst Pharm 2001 ; 58: 577-579. |
Stability of norfloxacin in an extemporaneously prepared oral liquid
Johnson CE, Price J, Hession JM. |
2001 |
127 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1910-1911. |
Stability of octreotide acetate in polypropylene syringes at 5 and -20°C.
Ripley RG, Ritchie DJ, Holstad SG. |
1995 |
294 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 2356-2358. |
Stability of octreotide acetate in polypropylene syringes.
Stiles ML, Allen LV, Resztak KE, Prince SJ. |
1993 |
2155 |
Czasopismo
Perit Dial Int 1995 ; 15: 72-74. |
Stability of ofloxacin in peritoneal dialysis solutions.
Battista C, Kane MP, Moon DG, Bailie GR. |
1995 |
4766 |
Czasopismo
Int J Pharm Compound 2023 ;27,3:250-255 |
Stability of omeprazole extemporaneous oral solution in Chopin Base.
Spennacchio A, Assunta Lopedota A, Maria la Forgia F, Fontana S, Denora N, Lopalco A. |
2023 |
4683 |
Czasopismo
J Pharm Pract and Res 2022 2022; 52, 34-41 |
Stability of omeprazole in a commercial calcium carbonate based oral suspension at 2, 5 and 10 mg/mL stored under refrigeration (4°C) for 70 days
Low M, Singh S, Venkataya B, Pearson J, Ibrahim M, Jarouche M, Khoo C, Rowe J, Li CG. |
2022 |
2430 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1833-1836. |
Stability of omeprazole in an extemporaneously prepared oral liquid
Quercia RA, Fan C, Liu X, Chow MS. |
1997 |
3302 |
Czasopismo
Int J Pharm Compound 2012 ; 16, 2 : 164-166. |
Stability of Omeprazole in SyrSpend SF Alka (Reconstituted).
Whaley P A, Voudrie M A, Sorenson B. |
2012 |
4316 |
Czasopismo
J Pharm Technol 2006 ;22:95-98. |
Stability of Omeprazole Sodium and Pantoprazole Sodium Diluted for Intravenous Infusion.
Carpenter J.F, McNulty M-A, Dusci L.J, Ilett K.F. |
2006 |
3174 |
Czasopismo
Ann Pharmacotherapy 2011 ; 45: 130-131. |
Stability of Ondansetron and Dexamethasone Infusion upon Refrigeration.
Rolin C, Hecq JD, Vanbeckbergen DF, Jamart J, Galanti LM. |
2011 |
815 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 2630-2634. |
Stability of ondansetron hydrochloride and 12 medications in plastic syringes.
Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. |
1998 |
50 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 514-516. |
Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions.
Fleming RA, Olsen DJ, Savage PD, Fox JL. |
1995 |
23 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1065-1068. |
Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection.
Evrard B, Ceccato A, Gaspard O, Delattre L, Delporte JP. |
1997 |
30 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1431-1435. |
Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days.
Hagan RL, Mallett MS, Fox JL. |
1996 |
184 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1297-1300. |
Stability of ondansetron hydrochloride and five antineoplasic medications.
Stewart JT, Warren FW, King DT, Fox JL. |
1996 |
52 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1557-1558. |
Stability of ondansetron hydrochloride in a total parenteral nutrient admixture.
Kirkham JC, Rutherford ET, Cumingham GN, Daneshmand KA, Falls AL. |
1995 |
183 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2223-2225. |
Stability of ondansetron hydrochloride in injectable solutions at -20, 5, and 25°C.
Bosso JA, Prince RA, Fox JL. |
1992 |
179 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1471-1473. |
Stability of ondansetron hydrochloride in portable infusion-pump reservoirs.
Stiles ML, Allen LV Jr, Fox JL. |
1992 |
2517 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 806-809. |
Stability of ondansetron hydrochloride in syrups compounded from tablets
Williams CL, Sanders PL, Laizure SC, Stevens RC, Fox JL, Hak LJ. |
1994 |
2481 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 106-108. |
Stability of ondansetron hydrochloride injection in extemporaneously prepared oral solutions
Graham CL, Dukes GE, Fox JL, Kao CF, Hak LJ. |
1993 |
2445 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2011-2014. |
Stability of ondansetron hydrochloride injection in various beverages
Yamreudeewong W, Danthi SN, Hill RA, Fox JL. |
1995 |
113 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 1918-1920. |
Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4°C.
Jhee SS, Jeong EW, Chin A, Inagaki K, Fox JL, Gill MA. |
1993 |
26 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 915-920. |
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. |
1997 |
333 |
Czasopismo
Ann Pharmacotherapy 1992 ; 26: 768-771. |
Stability of ondansetron in large-volume parenteral solutions.
Graham CL, Dukes GE, Kao CF, Bertch JM, Hak LJ. |
1992 |
915 |
Czasopismo
Ann Pharmacotherapy 1994 ; 28: 712-714. |
Stability of ondansetron stored in polypropylene syringes.
Casto DT. |
1994 |
4772 |
Czasopismo
J Pharm Sci 2023 ; 112, 9: 2412-2418. |
Stability of Opened Durvalumab (IMFINZI) Vials. The Beginning of the End of Costly Product Wastage?
Porlier A, Gagnon P-Y, Chénard V, Michael N-J, Simard C, Drolet B. |
2023 |
4472 |
Czasopismo
Pharmaceutics 2020 ;12, 781 |
Stability of Ophthalmic Atropine Solutions for Child Myopia Control.
Berton B, Chennell P, Yessaad M, Bouattour Y, Jouannet M, Wasiak M, Sautou V. |
2020 |
3363 |
Czasopismo
J Pharm Pract and Res 2012 ; 42, 3: 213-217. |
Stability of Oral Cholecalciferol (Vitamin D3) Liquid Formulations in Olive Oil.
Joseph P.M, Hemmens V.J, Munns C.F. |
2012 |
2834 |
Czasopismo
Int J Pharm Compound 2003 ; 7, 5: 386-388. |
Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared With the Use of Powder
Das Gupta V. |
2003 |
2387 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 1268-1270. |
Stability of oral liquid preparations of tramadol in strawberry syrup and a sugar-free vehicle
Wagner DS, Johnson CE, Cichon-Hensley BK, DeLoach SL. |
2003 |
2406 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 1268-1270 |
Stability of oral liquid preparations of tramadol in strawberry syrup and a sugar-free vehicle
Wagner DS, Johnson CE, Cichon-Hensley BK, DeLoach SL. |
2003 |
2410 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 361-363. |
Stability of oral suspensions of ursodiol made from tablets
Johnson CE, Streetman DD. |
2002 |
918 |
Czasopismo
EJHP 1994 ; 4: 17-19. |
Stability of ornidazole in PVC bags under various storage conditions.
Rodriguez-Sasiain JM, Prieto M, Errecalde F, Jaio N, Martinez-Bengoechea MJ. |
1994 |
3090 |
Czasopismo
Int J Pharm Compound 2010 ; 14, 1: 82-85. |
Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution).
Voudrie MA, Brett Allen D. |
2010 |
2258 |
Laboratorium
Ebewe Pharma 2007 |
Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution.
|
2007 |
2259 |
Laboratorium
Ebewe Pharma 2007 |
Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions.
|
2007 |
2791 |
Czasopismo
Int J Pharm 2015 ; 479 : 23-27. |
Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.
Mehta A.M,.Van den Hoven J.M, Rosing H,.Hillebrand M.J.X, Nuijen B,. Huitema A.D.R, Beijnen J.H,.Verwaal V.J. |
2015 |
2207 |
Czasopismo
Am J Health-Syst Pharm 2007 ; 64, 18: 1950-1954. |
Stability of oxaliplatin in infusion bags containing 5% dextrose injection.
André A, Cisternino S, Roy A.L, Chiadmi F, Schlatter J, Agranat P, Fain O, Fontan J.E. |
2007 |
2321 |
Czasopismo
Ann Pharmacotherapy 2009 ; 43,2: 390-391. |
Stability of Oxaliplatin Solution.
Junker A, Roy S, Desroches M.C, Moussay C, Berhoune M, Bellanger A, Fernandez C,Farinotti R. |
2009 |
2511 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1265-1266. |
Stability of oxybutynin chloride syrup after repackaging in unit doses
Van Gansbeke B. |
1991 |
1726 |
Czasopismo
Can J Hosp Pharm 2002 ; 55: 272-277. |
Stability of oxycodone hydrochloride for injection in dextrose and saline solutions.
Turnbull K, Bielech M, Walker SE, Law S. |
2002 |
151 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2704-2706. |
Stability of paclitaxel and fluconazole during simulated Y-site administration.
Burm JP, Choi JS, Jhee SS, Chin A, Ulrich RW, Gill MA. |
1994 |
157 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 3058-3060. |
Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32°C.
Xu QA, Trissel LA, Martinez JF. |
1994 |
47 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 1201-1204. |
Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration.
Burm JP, Jhee SS, Chin A, Moon YSK. |
1994 |
1940 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 1596-1598. |
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
Xu QA, Trissel LA. |
2004 |
2030 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 2410-2412. |
Stability of pantoprazole in 0.9% sodium chloride injection in polypropylene syringes.
Johnson CE. |
2005 |
2385 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 953-956. |
Stability of pantoprazole in an extemporaneously compounded oral liquid
Dentinger PJ, Swenson CF, Anaizi NH. |
2002 |
3220 |
Czasopismo
Can J Hosp Pharm 2011 , 64, 32: 192-198. |
Stability of Pantoprazole Sodium in Glass Vials, Polyvinyl Chloride Minibags, and Polypropylene Syringes.
Donnelly RF. |
2011 |
456 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 2524-2527. |
Stability of papaverine hydrochloride and phentolamine mesylate in injectable mixtures.
Tu YH, Allen LV, Wang DP. |
1987 |
589 |
Czasopismo
J Pharm Sci 1989 ; 78: 73-77. |
Stability of parenteral ceftriaxone disodium solutions in frozen and liquid states: effect of freezing and microwave thawing.
Kedzierewicz F, Finance C, Nicolas A, Dixneuf P, Hoffman M. |
1989 |
2575 |
Czasopismo
Anest Prog 1997 ; 44, 1: 17-22. |
Stability of parenteral midazolam in an oral formulation.
Walker SE, Grad HA, Haas DA, Mayer A. |
1997 |
2980 |
Czasopismo
Ann Pharmacotherapy 2007 ; 41: 1954-1961. |
Stability of partial doses of omeprazole-sodium bicarbonate oral suspension.
Johnson CE, Cober MP, Ludwig JL. |
2007 |
2183 |
Czasopismo
EJHP Science 2007 ; 13, 1: 14-16. |
Stability of pemetrexed 25 mg/ml in a glass vial and 5 mg/ml stored in a PVC container after storage for one month at 2-8°C.
Rondelot G, Serrurier C, Vigneron J, Zenier H, May I, Demoré B. |
2007 |
4546 |
Czasopismo
EJHP 2021 |
Stability of pemetrexed diarginine concentrates for solution in vials and diluted in 0.9% sodium chloride and dextrose 5% polyolefin infusion bags.
Vidal F, Cotteret C, Negbane A, Sebti M, Hinterlang M, Cisternino S, Schlatter J. |
2021 |
4624 |
Czasopismo
EJHP 2023 ; 30: e2-e9. |
Stability of pemetrexed disodium in sodium chloride 0.9% w/v intravenous Viaflo infusion bags.
Nelson L, Dwier P, Corris M, Santillo M, Davies L, Milligan K, Rahman R, Clarke I. |
2023 |
3648 |
Czasopismo
Am J Health-Syst Pharm 2014 ; 71:669-673. |
Stability of penicillin G sodium diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in polyvinyl chloride bag containers and elastomeric pump containers.
Hossain M.A, Friciu M, Aubin S, Leclair G. |
2014 |
424 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1486-1488. |
Stability of pentamidine isethionate in 5% dextrose and 0.9% sodium chloride injections.
De NC, Alam AS, Kapoor JN. |
1986 |
3845 |
Czasopismo
Ann Pharmacotherapy 2016 ; 50: 245-246 |
Stability of Pentobarbital in Water and Oral Pediatric Suspensions.
Schlatter J, Kabiche S, Balde I-S, Majoul E, Cisternino S, Fontan J.E. |
2016 |
1628 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 482-484. |
Stability of pentobarbital sodium after reconstitution in 0.9% sodium chloride injection and repackaging in glass and polypropylene syringes.
Das Gupta V. |
2001 |
2453 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1301-1303. |
Stability of pentoxifylline in an extemporaneously prepared oral suspension
Abdel-Rahman S, Nahata MC. |
1997 |
349 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 384-385. |
Stability of phenobarbital sodium diluted in 0.9% sodium chloride injection.
Nahata MC, Hipple TF, Strausbaugh SD. |
1986 |
2431 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 2073-2078. |
Stability of phenoxybenzamine hydrochloride in various vehicles
Lim LY, Tan LL, Chan EW, Yow KL, Chan SY, Ho PC. |
1997 |
2194 |
Czasopismo
Am J Health-Syst Pharm 2007 ; 64, 10: 1092-1095. |
Stability of phenylephrine hydrochloride injection in polypropylene syringes.
Kiser TH, Oldland AR, Fish DN. |
2007 |
1826 |
Czasopismo
Ann Pharmacotherapy 2001 ; 35: 1360-1363. |
Stability of piperacillin and ticarcillin in autodose infusion system bags.
Zhang Y, Trissel LA. |
2001 |
1718 |
Czasopismo
Int J Pharm Compound 2001 ; 5: 230-231. |
Stability of piperacillin sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Das Gupta V, Ling J. |
2001 |
600 |
Czasopismo
Am J IV Ther Clin Nut 1984 ; 11: 14-15, 18-19. |
Stability of piperacillin sodium in dextrose 5% and sodium chloride 0.9% injections.
Das Gupta V, Davis DD, Stewart KR. |
1984 |
235 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2273-2276. |
Stability of piperacillin sodium-tazobactam sodium and ranitidine hydrochloride in 0.9% sodium chloride injection during simulated Y-site administration.
Choi JS, Burm JP, Jhee SS, Chin A, Ulrich RW, Gill MA. |
1994 |
2451 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2022 - 2024. |
Stability of piperacillin sodium-tazobactam sodium in peritoneal dialysis solutions
Park TW, Le-Bui LP, Chung KC, Rho JP, Gill MA. |
1995 |
274 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 999-1001. |
Stability of piperacillin sodium-tazobactam sodium in polypropylene syringes and polyvinyl chloride minibags.
Moon YSK, Chung KC, Chin A, Gill MA. |
1995 |
3121 |
Czasopismo
Am J Health-Syst Pharm 2010 ; 67: 1191-1194. |
Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 °C
He J, Figueroa DA, Lim TP, Chow DS, Tam VH. |
2010 |
2054 |
Czasopismo
Int J Pharm Compound 2015 ; 19, 4 : 337-339. |
Stability of Prednisone in Oral Mix Suspending Vehicle.
Friciu M, Plourde K, Leclair G, Danapoulos P, Savji T. |
2015 |
2308 |
Czasopismo
Int J Obstet Anesth 2005 ; 14, 4: 284-287. |
Stability of premixed syringes of diamorphine and hyperbaric bupivacaine.
Hudson S.J, Jones M.F, Nolan S, Ellis H, Duncombe R, Alexander-Williams J.M. |
2005 |
3431 |
Czasopismo
Can J Hosp Pharm 2001 ; 54, 3: 214-215. |
Stability of preservative-free tobramycin in half-normal saline.
Law S. |
2001 |
2501 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1720-1724. |
Stability of procainamide hydrochloride in an extemporaneously compounded oral liquid
Metras JI, Swenson CF, McDermott MP. |
1992 |
1115 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 1050-1052. |
Stability of procainamide hydrochloride in dextrose solutions.
Baaske DM, Malick AW, Carter JE. |
1980 |
370 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 2513-2517. |
Stability of procainamide hydrochloride in neutralized 5% dextrose injection.
Raymond GG, Reed MT, Teagarden JR, Story K, Geberbauer CW. |
1988 |
4028 |
Czasopismo
Hosp Pharm 2017 ;52,10 :704-708 |
Stability of Procainamide Injection in Clear Glass Vials and Polyvinyl Chloride Bags.
Donnelly R. |
2017 |
193 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1293-1295. |
Stability of propafenone hydrochloride in IV solutions.
Dupuis LL, Wong B, Trope A. |
1997 |
309 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 192-196. |
Stability of propofol with parenteral nutrient solutions during simulated Y-site injection.
Bhatt-Mehta V, Paglia RE, Rosen DA. |
1995 |
3356 |
Czasopismo
Int J Pharm Compound 2012 ; 16, 6 : 513-515. |
Stability of Propranolol Hydrochloride in SyrSpend SF.
Geiger C M, Voudrie M A, Sorenson B. |
2012 |
2504 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 530-531. |
Stability of propranolol hydrochloride suspension and solution
Rooney M, Creurer I. |
1988 |
2513 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 360-361. |
Stability of propranolol hydrochloride suspension and solution compounded from injection or tablets
Das Gupta V, Stewart KR. |
1987 |
2477 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1492-1495. |
Stability of propranolol hydrochloride suspension compounded from tablets
Henry DW, Repta AJ, Smith FM, White SJ. |
1986 |
3410 |
Czasopismo
Can J Hosp Pharm 2013 ; 66, 2: 118-124. |
Stability of Propranolol in Extemporaneously Compounded Suspensions
Ensom M.H, Kendrick J, Rudolph S, Decarie D. |
2013 |
2415 |
Czasopismo
Am J Health-Syst Pharm 2000 ; 57: 1141-1143. |
Stability of propylthiouracil in extemporaneously prepared oral suspensions at 4 and 25 degrees C
Nahata MC, Morosco RS, Trowbridge JM. |
2000 |
2003 |
Czasopismo
EJHP Science 2005 ; 2: 31-36. |
Stability of prostaglandin E1 (PGE1) in aqueous solutions.
Paul M, Razzouq N, Tixier G, Astier A. |
2005 |
4069 |
Czasopismo
EJHP 2018 ; 25, e2 |
Stability of prostaglandin E1 solutions stored in polypropylene syringes for continuous intravenous administration to newborns.
Palmero D, Chavan E, Berger-Gryllaki M, Tolsa J-F, Di Paolo E, Pannatier A, Henry H, Sadeghipour F. |
2018 |
1121 |
Czasopismo
Am J Hosp Pharm 1973 ; 30: 236-239. |
Stability of prostaglandins.
Roseman TJ, Sims B, Stehle RG. |
1973 |
2454 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1558-1560. |
Stability of pyrazinamide in two suspensions
Nahata MC, Morosco RS, Peritore SP. |
1995 |
2447 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 2714-2716. |
Stability of pyrimethamine in a liquid dosage formulation stored for three months
Nahata MC, Morosco RS, Hipple TF. |
1997 |
916 |
Czasopismo
J Clin Pharm Ther 1993 ; 18: 343-345. |
Stability of quinine dihydrochloride in commonly used intravenous solutions.
Lerkiatbundit S. |
1993 |
2443 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2433-2436. |
Stability of ramipril in water, apple juice, and applesauce
Allen LV, Jr, Stiles ML, Prince SJ, McLaury HJ, Sylvestri MF. |
1995 |
358 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 921-925. |
Stability of ranitidine admixtures frozen and refrigerated in minibags.
Lampasona V, Mullins RE, Parks RB. |
1986 |
689 |
Czasopismo
Can J Hosp Pharm 1988 ; 41: 105-108. |
Stability of ranitidine hydrochloride admixtures refrigerated in polyvinyl chloride minibags.
Walker SE, Kirby K. |
1988 |
359 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 2683-2687. |
Stability of ranitidine hydrochloride and amino acids in parenteral nutrient solutions.
Bullock LS, Parks RB, Lampasona V, Mullins RE. |
1985 |
208 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1304-1306. |
Stability of ranitidine hydrochloride and human insulin in 0.9% sodium chloride injection.
Nolan PE, Hoyer GL, Ledoux JH, Fox JL. |
1997 |
210 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 1802-1807. |
Stability of ranitidine hydrochloride and seven medications.
Stewart JT, Warren FW, King AD. |
1994 |
213 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1580-1584. |
Stability of ranitidine hydrochloride at dilute concentration in intravenous infusion fluids at room temperature.
Galante LJ, Stewart JT, Warren FW, Johnson SM, Duncan R. |
1990 |
1927 |
Czasopismo
EJHP 2004 ; 4: 60-63. |
Stability of ranitidine hydrochloride in different aqueous solutions.
Ferreira MO, Bahia MF, Costa P. |
2004 |
357 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 1100-1102. |
Stability of ranitidine hydrochloride in total nutrient admixtures.
Cano SM, Montoro JB, Pastor C, Pou L, Sabin P. |
1988 |
1248 |
Czasopismo
Am J Hosp Pharm 1985 ; 42: 590-592. |
Stability of ranitidine hydrochloride in total parenteral nutrient solution.
Walker SE, Bayliff CD. |
1985 |
46 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1588-1590. |
Stability of ranitidine hydrochloride in water for injection in glass vials and plastic syringes.
Nahata MC, Morosco RS, Fox JL. |
1996 |
360 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2769-2772. |
Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration.
Inagaki K, Gill MA, Okamoto MP, Takagi J. |
1992 |
2355 |
Czasopismo
Int J Pharm Compound 2000 ; 4, 2: 150-153. |
Stability of ranitidine hydrochloride with cefazolin sodium, cefbuperazone sodium, cefoxitin sodium nd cephalotin sodium during simulated Y-site administration.
Inagaki K, Miyamoto Y, Kurata N, Nakane S, Gill M.A, Nishida M. |
2000 |
214 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 1606-1610. |
Stability of ranitidine hydrochloride with eight medications in intravenous admixtures.
Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. |
1990 |
18 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 391-394. |
Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration.
Pompilio FM, Fox JL, Inagaki K, Burm JP, Jhee S, Gill MA. |
1994 |
78 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 2043-2046. |
Stability of ranitidine in intravenous admixtures stored frozen, refrigerated, and at room temperature.
Stewart JT, Warren FW, Johnson SM, Galante LJ. |
1990 |
3318 |
Czasopismo
Ann Pharm Fr 2012 ; 70, 3: 155-162. |
Stability of ready-to-use temsirolimus infusion solution (100 mg/L) in polypropylene containers under different storage conditions.
Poujol S, Bressolle F, Solassol I, Pinguet F. |
2012 |
3897 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2016 ;1,2:83-89 |
Stability of Reconstituted and Diluted Mitomycin C Solutions in Polypropylene Syringes and Glass Vials.
Briot T, Truffaut C, Le Quay L, Lebreton A, Lagarce F. |
2016 |
640 |
Czasopismo
Can J Hosp Pharm 1987 ; 40: 161-166. |
Stability of reconstituted ceftriaxone in dextrose and saline solutions.
Walker SE, Dranitsaris G. |
1987 |
1638 |
Czasopismo
Eur Hosp Pharm 1996 ; 2: 47-48. |
Stability of reconstituted ceftriaxone solution in polypropylene syringes.
O'Connell C, Sabra K, Scott K. |
1996 |
303 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 154-158. |
Stability of reconstituted indomethacin sodium trihydrate in original vials and polypropylene syringes.
Walker SE, Gray S, Schmidt B. |
1998 |
531 |
Czasopismo
J Oral Maxillofac Surg 1994 ; 52: 393-396. |
Stability of reconstituted methohexital sodium.
Beeman CS, Dembo J, Bogardus A. |
1994 |
558 |
Czasopismo
Br J Parent Ther 1986 ; july/august : 86-92. |
Stability of reconstituted mustine injection BP during storage.
Kirk B. |
1986 |
1824 |
Czasopismo
J Clin Pharm Ther 2003 ; 28: 363-369. |
Stability of reconstituted parecoxib for injection with commonly used diluents.
Crane IM, Mulhern MG, Nema S. |
2003 |
1857 |
Czasopismo
J Pharm Biomed Anal 1999 ; 20-521-530. |
Stability of reconstituted solutions of ceftazidime for injections: an HPLC and CE approach.
Farina A, Porra R, Cotichini V, Doldo A. |
1999 |
2006 |
Czasopismo
Hosp Pharm 2015 ; 50, 7: 609-614. |
Stability of Reconstituted Telavancin Drug Product in Frozen Intravenous Bags.
Gu Z, Wong A, Raquinio E, Nguyen A. |
2015 |
2050 |
Czasopismo
Current Ther Res 2000 ; 61: 1-6 |
Stability of reconstituted urokinase solutions.
Kohles JD, Weld M, Asa?d H, Gunning P, Reid Sterrett J, Debari VA. |
2000 |
740 |
Czasopismo
Am J Hosp Pharm 1979 ; 36: 1536-1538. |
Stability of refrigerated and frozen solutions of doxorubicin hydrochloride.
Hoffman DM, Grossano DD, Damin LA, Woodcock TM. |
1979 |
917 |
Czasopismo
EJHP 1994 ; 4: 12-13. |
Stability of refrigerated and frozen solutions of ondansetron hydrochloride.
Blaise N, Vigneron J, Perrin A, Noirez V, Hoffman MA, Hoffman M. |
1994 |
234 |
Czasopismo
J Clin Pharm Ther 1997 ; 22: 257-260. |
Stability of refrigerated and frozen solutions of tropisetron in either polyvinylchloride or polyolefin infusion bags.
Georget S, Vigneron J, Blaise N, Perrin A, Hoffman MA, Hoffman M. |
1997 |
3310 |
Czasopismo
Hosp Pharm 2012 ; 47, 5: 367-370. |
Stability of Regular Human Insulin Extemporaneously Prepared in 0.9% Sodium Chloride in a Polyvinyl Chloride Bag.
Greenwood B.C, Chesnick M.A, Szumita P.M, Caryn Belisle C, Cotugno M. |
2012 |
4198 |
Czasopismo
Pharmazie 2018 73;196-201 |
Stability of regularly prescribed oral liquids formulated with SyrSpend® SF.
Uriel M, Gomez-Rincon C, Marro D. |
2018 |
3008 |
Czasopismo
Pharm J 1987 ; 238: 214-215. |
Stability of retinoic acid eye-drops.
Mehta AC, Calvert RT. |
1987 |
1477 |
Czasopismo
J Pharm Biomed Anal 1996 ; 15: 221-226. |
Stability of revex, nalmefene hydrochloride injection, in injectable solutions.
Murthy SS, Brittain HG. |
1996 |
3917 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 6 : 521-525. |
Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature.
Larson B L, Bushman L R, Casciano M L, Oldland A R, Kiser J J, Kiser T H. |
2016 |
2419 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 333-336. |
Stability of rifabutin in two extemporaneously compounded oral liquids
Haslam JL, Egodage KL, Chen Y, Rajewski RA, Stella V. |
1999 |
3404 |
Czasopismo
Int J Pharm Compound 2013 ; 17, 2 : 162-164. |
Stability of Rifampin in SyrSpend SF
Sorenson B, Whaley P |
2013 |
2704 |
Czasopismo
J Clin Pharm Ther 1994 ; 19, 4: 263-265. |
Stability of rifampin in two suspensions at room temperature
Nahata MC, Morosco RS, Hippie TF. |
1994 |
1987 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 289-291. |
Stability of roxatidine acetate in parenteral nutrient solutions containing different amino acid formulations.
Oh J, Gwak H, Moon H, Choi I. |
2005 |
3274 |
Czasopismo
Intensice Care Medecine 2011 ; 37, 11: 1899. |
Stability of sildenafil (Revatio®) dolutions in dextrose 5%.
Al HadithyF.F.Y, De Goede A.L; Eckhardt M, Hanff L, Koch B.C.P. |
2011 |
3923 |
Czasopismo
Am J Health-Syst Pharm 2017 ; 74, 1: e64-e71 |
Stability of sildenafil in combination with heparin and dopamine.
Luu Y, Thigpen J, Brown S.D. |
2017 |
3116 |
Czasopismo
Am J Health-Syst Pharm 2010 ;67: 1026-1029. |
Stability of sodium bicarbonate solutions in polyolefin bags.
Wear J, McPherson TB, Kolling WM. |
2010 |
1951 |
Czasopismo
Chin Pharm J 2001 ; 53: 185-189. |
Stability of sodium cefazolin and tenoxicam in 5% dextrose.
Wang DP, Lee D, Wang CN. |
2001 |
4020 |
Czasopismo
Hosp Pharm 2010 ;45,10:779?784 |
Stability of Sodium Nitroprusside and Sodium Thiosulfate 1:10 Intravenous Admixture.
T. Schulz L, J. Elder E, Jones K, Vijayan A, D. Johnson B, E. Medow J, Vermeulen L. |
2010 |
3903 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 5 : 435-437. |
Stability of Sodium Nitroprusside in 5% Dextrose Stored at 4°C in Polypropylene Syringes Protected from Light.
Anderson Collin R, Collins D, Laursen T, Arave T, Helm M. |
2016 |
1237 |
Czasopismo
Pharm Weekbl [Sci] 1986 ; 8: 194-197. |
Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation.
Keusters L, Stolk LML, Umans R, Van Asten P. |
1986 |
2548 |
Czasopismo
Ann Pharmacotherapy 2003 ;37:506-509. |
Stability of Sotalol in Two Liquid Formulations at Two Temperatures
Nahata MC, Morosco RS. |
2003 |
2928 |
Czasopismo
EJHP Science 2005 ; 11: 68-73. |
Stability of spironolactone in an extemporaneously prepared aqueous suspension: the importance of microbiological quality of compounded paediatric formulations.
Salgado AC, Rosa ML, Duarte MA et al. |
2005 |
2534 |
Czasopismo
Ann Pharmacotherapy 1993 ;27:1198-1199. |
Stability of spironolactone in an extemporaneously prepared suspension at two temperatures
Nahata MC, Morosco RS, Hipple TF. |
1993 |
4000 |
Czasopismo
Int J Pharm Compound 2017 ; 21:4 :334-338 |
Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt.
Graves R, Phan K.V,Bostanian L.A,Mandal T.K, Pramar Y.V. |
2017 |
107 |
Czasopismo
J Pharm Biomed Anal 2001 ; 25: 861-869. |
Stability of stored methacholine solutions: study of hydrolysis kinetic by IP-LC.
Acar V, Houri JJ, Le Hoang MD, Pradeau D, Guyon F. |
2001 |
1755 |
Czasopismo
Int J Pharm Compound 2003 ; 7: 68-70. |
Stability of succinylcholine chloride injection at ambient temperature and 4°C in polypropylene syringes.
Storms ML, Stewart JT, Warren FW. |
2003 |
45 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 501-506. |
Stability of succinylcholine chloride injection.
Schmutz CW, Mühlbach SF. |
1991 |
4162 |
Czasopismo
Ann Pharm Fr 2018 ;76,6:444-452 |
Stability of sufentanil and baclofen mixtures for intrathecal analgesia at different concentrations in polypropylene syringes.
Sorrieul J, Robert J, Gibory V, Kieffer H, Folliard C, Dupoiron D, Devys C. |
2018 |
1835 |
Czasopismo
Eur J Pharm Sci 2003 ; 19, 1: 31-36. |
Stability of sufentanil and levobupivacain solutions and a mixture in a 0.9% sodium chloride infusion stored in polypropylene syringes.
Jäppinen A, Turpeinen M, Kokki H, ,Rasi A, Ojanen T, Pelkonen O, Naaranlahti T. |
2003 |
1491 |
Czasopismo
Eur Hosp Pharm 1995 ; 1: 12-14. |
Stability of sufentanil citrate and sufentanil citrate/bupivacaine mixture in portable infusion pump reservoirs.
Brouwers JRBJ, van Doorne H, Meevis RF, Boersma FP. |
1995 |
675 |
Czasopismo
Pharm Weekbl [Sci] 1992 ; 14: 196-200. |
Stability of sufentanil citrate in a portable pump reservoir, a glass container and a polyethylene container.
Roos PJ, Glerum JH, Meilink JW. |
1992 |
1938 |
Czasopismo
Ann Pharmacotherapy 2004 ; 38: 1836-1839. |
Stability of sufentanil citrate with levobupivacaine hydrochloride in NaCl 0.9% after microwave freeze-thaw treatment.
Boitquin LP, Hecq JD, Vanbeckbergen DF, Jamart J, Galanti LM. |
2004 |
1752 |
Czasopismo
Int J Pharm Compound 1998 ; 2: 466-468. |
Stability of sufentanil in a syringe pump under simulated epidural infusion.
Jäppinen AL, Hokki H, Rasi AS, Naaranlathi TJ. |
1998 |
2795 |
Czasopismo
J Pharm Pharm Sci 2004 ; 7, 1: 84-87. |
Stability of sulfadiazine oral liquids prepared from tablets and powder.
Pathmanathan U, Halgrain D, Chiadmi F, Schlmatter J, Vermerie N. |
2004 |
2593 |
Czasopismo
Can J Hosp Pharm 2006 ; 59, 4: 194-200. |
Stability of sulfasalazine oral suspension.
Linger-Walsh K, Walker SE, Law S, Abesamis M, Sales P. |
2006 |
121 |
Czasopismo
Can J Hosp Pharm 1989 ; 42: 195-200. |
Stability of sulfite free high potency morphine sulfate solutions in portable infusion pump cassettes.
Walker SE, Iazzetta J, Lau DWC. |
1989 |
2428 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 1619-1622 |
Stability of sumatriptan succinate in extemporaneously prepared oral liquids
Fish DN, Beall HD, Goodwin SD, Fox JL. |
1997 |
1029 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 983-985. |
Stability of sumatriptan succinate in polypropylene syringes.
Nii LJ, Chin A, Cao TM, Gill MA. |
1999 |
4105 |
Czasopismo
Ann Pharmacotherapy 2008 ;42:962-966 |
Stability of Sunitinib in Oral Suspensions.
Navid F, Christensen R, Minkin P, Stewart C, Furman W, Baker S. |
2008 |
2546 |
Czasopismo
Ann Pharmacotherapy 2000 ;34:600-605. |
Stability of suspension formulations of lansoprazole and omeprazole stored in amber-colored plastic oral syringes.
DiGiacinto JL, Olsen KM, BergmanKL, Hoie EB. |
2000 |
4274 |
Czasopismo
J Clin Anesth 2016 ; 35: 551-559. |
Stability of suxamethonium in pharmaceutical solution for injection by validated stability-indicating chromatographic method.
Beck W, Kabiche S, Balde I-B, Carret S, Fontan J-E, Cisternino S, Schlatter J. |
2016 |
2436 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 178-180. |
Stability of tacrolimus in an extemporaneously compounded oral liquid
Jacobson PA, Johnson CE, West NJ, Foster JA. |
1997 |
3915 |
Czasopismo
Am J Health-Syst Pharm 2016 ; 73,24: 2083-2088. |
Stability of tacrolimus injection diluted in 0.9% sodium chloride injection and stored in Excel bags
Myers A.L, Zhang Y, . Kawedia J.D, Shank B.R, Deaver M.A, Kramer M.A. |
2016 |
907 |
Czasopismo
J Pharm Technol 1996 ; 12: 58-61. |
Stability of tacrolimus injection in total parenteral nutrition solution.
Ku YM, Min DI, Kumar V, Noormohamed SA. |
1996 |
3988 |
Czasopismo
Am J Health-Syst Pharm 2017 ; 74:13 : 1002-1006 |
Stability of tacrolimus ophthalmic solution.
Ezquer-Garin C, Ferriols-Lisart R, Al?s-Almi?ana M. |
2017 |
3842 |
Czasopismo
Am J Health-Syst Pharm 2016 ; 73:137-142. |
Stability of tacrolimus solutions in polyolefin containers.
Lee J.H, Goldspiel B.R, Ryu S, Potti G.K. |
2016 |
814 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 164-169. |
Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration.
Johnson CE, VandenBussche HL, Chio CC, Jacobson PA. |
1999 |
4405 |
Czasopismo
Pharmazie 2020 ; 75: 172-176. |
Stability of tedizolid phosphate-sodium rifampicin and tedizolid phosphate-meropenem admixtures in intravenous infusion bags stored at different temperatures
Ezquer-Garin C, Ferriols-Lisart R, Martinez-López LM, Sangrador-Pelluz C, Nicolás-Picó J, Alós-Almiñana M. |
2020 |
2417 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 243-245. |
Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4 degrees C
Abdel-Rahman SM, Nahata MC. |
1999 |
448 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1760-1762. |
Stability of terbutaline sulfate admixtures stored in polyvinyl chloride bags.
Mehta J, Searcy CJ, Jung DT. |
1986 |
449 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 2291-2293. |
Stability of terbutaline sulfate repackaged in disposable plastic syringes.
Glascock JC, DiPiro JT, Cadwallader DE, Perri M. |
1987 |
3173 |
Plakat
SNPHPU Congress France 2010 |
Stability of tetracaine eye-drops
Chaussard M, Bouche V, labat L, Brandely ML, Batista R, Chast F. |
2010 |
3651 |
Czasopismo
Perit Dial Int 2014 ; 34:212-218 |
Stability of the Combination of Ceftazidime and Cephazolin in Icodextrin or pH Neutral Peritoneal Dialysis Solution.
Patel R.P, Shastri M.D, Bakkari M, Wanandy T, Jose M.D. |
2014 |
2167 |
Czasopismo
Cancer Chemother Pharmacol 1995 ; 37, 1: 117-124. |
Stability of the iv and oral formulations of etoposide in solution.
Joel SP, Clark PI, Slevin ML. |
1995 |
3074 |
Czasopismo
Int J Pharm 2008 ; 362: 67-73. |
Stability of the nitrogen mustard mechlorethamine in novel formulations for dermatological use.
Ritschel WA, Ye W, Buhse L, Reepmeyer JC. |
2008 |
3331 |
Czasopismo
Ann Pharm Fr 2012 ; 70, 5: 249-255. |
Stability of the ready-to-use solutions of eribulin for intravenous infusion.
Poujol S, Dell'ova M, Bekhtari K, Bressolle F, Pinguet F. |
2012 |
4477 |
Czasopismo
GaBI Journal 2020 ; 9, 1: 5-13. |
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions.
Crampton S, Polozoxa A, Asbury D, Lueras A, Breslin P, Hippenmeyer J, Litkowski J,,Goss M. |
2020 |
4396 |
Czasopismo
GaBI Journal 2020 ; 9, 1: |
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions.
Lueras A, Polozova A, Asbury D, Hippenmeyer J, Litowski J, Goss M, Breslin P, Crampton S. |
2020 |
1116 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 471-474. |
Stability of thiamine hydrochloride repackaged in disposable syringes.
Nolly RJ, Stach PE, Latiolais CJ, Sokoloski TD, Nahata MC. |
1982 |
4085 |
Czasopismo
Can J Hosp Pharm 2005 ; 58: 26-30. |
Stability of Thiamine in Extemporaneously Compounded Suspensions.
Ensom M, Decarie D |
2005 |
125 |
Czasopismo
Am J Health-Syst Pharm 1996 ; 53: 1576-1579. |
Stability of thiopental sodium and propofol in polypropylene syringes at 23 and 4°C.
Chernin EL, Stewart JT, Smiler B. |
1996 |
302 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 2588-2591. |
Stability of thiotepa (lyophilized) in 0.9% sodium chloride injection.
Murray KM, Erkkila D, Gombotz WR, Pankey S. |
1997 |
1840 |
Czasopismo
J Am Pharm Assoc 2002 ; 42: 428-431. |
Stability of three cephalosporin antibiotics in autodose infusion system bags.
Xu QA, Trissel LA, Saenz CA et al. |
2002 |
1408 |
Czasopismo
J Oncol Pharm Practice 1998 ; 4: 143-149. |
Stability of three cytotoxic drugs infusions in the Graseby 9000 ambulatory infusion pump.
Priston MJ, Sewell GJ. |
1998 |
2388 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 75-77. |
Stability of tiagabine in two oral liquid vehicles
Nahata MC, Morosco RS. |
2003 |
3887 |
Czasopismo
Perit Dial Int 2016 ; 36:410-414. |
Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions.
Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. |
2016 |
1600 |
Czasopismo
Am J Health-Syst Pharm 2001 ; 58: 1850-1851. |
Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days.
Garabito MJ, Jimenez L, Bautista J, Santos-Rubio MD, Perez Rodrigo I. |
2001 |
1071 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 1627-1629. |
Stability of tirofiban hydrochloride in three commonly used IV solutions and polyvinyl chloride administration sets.
Bergquist PA, Zimmermann J, Kenney RR, Han RYH, Hunke WA. |
1999 |
503 |
Czasopismo
Am J Hosp Pharm 1985 ; 45: 1987-1988. |
Stability of tobramycin sulfate in admixtures with calcium gluconate.
Nahata MC, Durrell DE. |
1985 |
709 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 1614-1615. |
Stability of tobramycin sulfate in plastic syringes.
Seitz DJ, Archambault JR, Brinck-Johnsen T. |
1980 |
1425 |
Czasopismo
J Oncol Pharm Practice 1999 ; 5: 75-82. |
Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices.
Krämer I, Thiesen J. |
1999 |
818 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1042-1043. |
Stability of torsemide in 5% dextrose injection.
Montgomery PA, Cornish LA, Johnson CE, Fitzpatrick KA. |
1998 |
2024 |
Czasopismo
J Pain Symptom Manage 2005 ; 30: 192-199. |
Stability of tramadol and haloperidol for continuous infusion at home.
Negro S, Martin A, Azuara ML, Sanchez Y, Barcia E. |
2005 |
2407 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 54-57. |
Stability of tramadol hydrochloride--acetaminophen (Ultracet) in strawberry syrup and in a sugar-free vehicle
Johnson CE, Wagner DS, DeLoach SL, Cichon-Hensley BK. |
2004 |
4116 |
Czasopismo
Drug Design Dev Ther 2016 ;10:1869-1875 |
Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems.
Chen F, Zhu J, Li B, Yuan F, Wang K. |
2016 |
3756 |
Czasopismo
Int J Pharm Compound 2014 ; 18, 5: 423-437. |
Stability of Tranexamic Acid in 0.9% Sodium Chloride, Stored in Type 1 Glass Vials and Ethylene/Propylene Copolymer Plastic Containers.
McCluskey S.V, Sztajnkrycer M.D, Jenkins D.A, Zietlow S P, Berns K.S, Park Myung S. |
2014 |
4164 |
Czasopismo
Int J Pharm Compound 2018 ;22,5:412-416 |
Stability of Tranexamic Acid Mouth Rinse.
Donnelly R. |
2018 |
2339 |
Czasopismo
Can J Hosp Pharm 2002 ; 55, 3: 207-211. |
Stability of Trimethoprim in Admixtures of Trimethoprim–Sulfamethoxazole Prepared in Polyvinylchloride Bags and Glass Bottles
Curtis J.M, Edwards D.J. |
2002 |
3002 |
Czasopismo
J Ped Pharm Pract 1997 ; 2: 82-84. |
Stability of trimethoprim in an extemporaneous liquid dosage form.
Nahata MC. |
1997 |
3860 |
Czasopismo
J Pharm Pract and Res 2016 ; 46: 10-14. |
Stability of trimethoprim in newly formulated liquid dosage form.
Patel R.P, Wanandy T, Zani R, Jose M.D, Shastri M, Zaidi S.T.R. |
2016 |
1197 |
Czasopismo
Am J Hosp Pharm 1982 ; 39: 1681-1684. |
Stability of trimethoprim-sulfamethoxazole injection in five infusion fluids.
Deans KW, Lang JR, Smith DE. |
1982 |
3141 |
Czasopismo
Can J Hosp Pharm 2010 ; 63, 4: 304-311. |
Stability of Trisodium Citrate and Gentamicin Solution for Catheter Locks after Storage in Plastic Syringes at Room Temperature.
Cote D, Lok CE, Battistella M, Vercaigne L. |
2010 |
4502 |
Czasopismo
TH Open 2020 ;4:e354–e361. |
Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro.
Takeyama M, Nøhr A.M, Pollard D. |
2020 |
874 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 433-434. |
Stability of two concentrations of heparin sodium prefilled in CADD-Micro pump syringes.
Stiles ML, Allen LV, Mc Laury HJ. |
1997 |
920 |
Czasopismo
Aust J Hosp Pharm 1997 ; 27: 452-454. |
Stability of two concentrations of morphine tartrate in 10 mL polypropylene syringes.
Targett PL, Keefe PA, Merridew CG. |
1997 |
2858 |
Czasopismo
Int J Pharm Compound 2003 ; 7, 6: 485-489. |
Stability of Two Concentrations of Tiagabine in an Extemporaneously Compounded Suspension.
Haase MR, Khan MA, Bonilla J. |
2003 |
2931 |
Czasopismo
Hosp Pharm 2006 ; 41: 254-259. |
Stability of two extemporaneously prepared oral metoprolol and carvedilol liquids.
Yamreudeewong W, Dolence EK, Pahl D. |
2006 |
4309 |
Czasopismo
J Am Pharm Assoc 2013 ; 53, 3: 304-306. |
Stability of U-500 regular
insulin in prefilled syringes
Lull M.E, Piacentino J.J, Traina A.N. |
2013 |
816 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 466-470. |
Stability of undiluted and diluted adenosine at three temperatures in syringes and bags.
Kektar VA, Kolling WM, Nardviriyakul N, VanDer Kamp K, Wurster DE. |
1998 |
446 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2782-2783. |
Stability of undiluted trimethoprim-sulfamethoxazole for injection in plastic syringes.
Kaufman MB, Scavone JM, Foley JJ. |
1992 |
2449 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 1798-1800. |
Stability of ursodiol in an extemporaneously compounded oral liquid
Johnson CE, Nesbitt J. |
1995 |
2413 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 1957-1960 |
Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids
Fish DN, Vidaurri VA, Deeter RG. |
1999 |
2384 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 1267-1270. |
Stability of valganciclovir in an extemporaneously compounded oral liquid
Anaizi NH, Dentinger PJ, Swenson CF. |
2002 |
2386 |
Czasopismo
Am J Health-Syst Pharm 203 ; 60: 687-690. |
Stability of valganciclovir in extemporaneously compounded liquid formulations
Henkin CC, Griener JC, Ten Eick AP. |
203 |
3153 |
Czasopismo
Can J Hosp Pharm 2010 ; 63, 5: 366-372. |
Stability of Vancomycin 25 mg/mL in Ora-Sweet and Water in Unit-Dose Cups and Plastic Bottles at 4°C and 25°C.
Ensom M.H.H, Decarie D, Lakhani A. |
2010 |
2732 |
Czasopismo
J Pharm Clin 1999 ; 18: 183-189. |
Stability of vancomycin eye drops.
Barbault S, Aymard G, Feldman D, Pointereau-Bellanger A, Thuillier A. |
1999 |
430 |
Czasopismo
Am J Hosp Pharm 1986 ; 43: 1729-1731. |
Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections.
Das Gupta V, Stewart KR, Nohria S. |
1986 |
654 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 123-124. |
Stability of vancomycin hydrochloride in Medication Cassette* reservoirs.
Allen LV. |
1997 |
2370 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 137 - 139. |
Stability of vancomycin hydrochloride in peritoneal dialysis solution
Mawhinney WM, Adair CG, Gorman SP, McClurg B. |
1992 |
428 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 802-804. |
Stability of vancomycin hydrochloride in various concentrations of dextrose injection.
Nahata MC, Miller MA, Durrell DE. |
1987 |
2420 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1386-1388 |
Stability of vancomycin in an extemporaneously compounded ophthalmic solution
Fuhrman LC, Jr, RT Stroman |
1998 |
2147 |
Czasopismo
Ann Pharmacotherapy 2006 ; 40, 11: 1950-1954. |
Stability of vancomycin in icodextrin peritoneal dialysis solution.
Nornoo AO, Elwell RJ. |
2006 |
913 |
Czasopismo
J Clin Pharm Ther 1995 ; 20: 319-325. |
Stability of vancomycin in plastic syringes measured by high-performance liquid chromatography.
Wood MJ, Lund R, Beavan M. |
1995 |
702 |
Czasopismo
J Pharm Clin 1998 ; 17: 145-148. |
Stability of vancomycin in polyolefine or PVC bags and glass vials.
Biellmann-Berlaud V, Willemin JC. |
1998 |
3303 |
Czasopismo
Int J Pharm Compound 2012 ; 16, 2: 167-169. |
Stability of Vancomycin in SyrSpend SF.
Whaley P A, Voudrie M. |
2012 |
2209 |
Czasopismo
Am J Health-Syst Pharm 2007 ; 64, 22: 2356-2358. |
Stability of vecuronium in sterile water for injection stored in polypropylene syringes for 21 days.
Johnson CE, Petrea Cober M. |
2007 |
3181 |
Czasopismo
Int J Pharm Compound 2011 ; 15, 1: 81-84. |
Stability of venlafaxine immediate-release suspension.
Donnelly RF, Wong K, Goddard R |
2011 |
3209 |
Czasopismo
Int J Pharm Compound 2011 ; 15, 3: 255-258. |
Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles.
Voudrie Mark A, Alexander Bridget, Allen D Brett. |
2011 |
827 |
Czasopismo
Drug Intell Clin Pharm 1988 ; 22: 634-636. |
Stability of vinblastine sulfate when exposed to light.
Black J, Buechter DD, Thurston DE. |
1988 |
1727 |
Czasopismo
Pharmazie 1999 ; 54: 625-626. |
Stability of vinblastine sulphate containing infusions.
Mittner A, Vincze Z, Jemnitz K. |
1999 |
481 |
Czasopismo
J Parenter Sci Technol 1989 ; 43: 84-87. |
Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids.
Beijnen JH, Vendrig DEMM, Underberg WJM. |
1989 |
3214 |
Czasopismo
EJOP 2011 ; 5,1: 10-14. |
Stability of vincristine (TEVA) in original vials after re-use in dilute infusions in polyolefin bags and in polypropylene syringes.
Trittler R, Sewell G. |
2011 |
4102 |
Czasopismo
J Oncol Pharm Practice 2018 ;25,4:831-840. |
Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care.
Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y. |
2018 |
2260 |
Laboratorium
Ebewe Pharma 2007 |
Stability of vinorelbin "Ebewe" infusion solutions.
|
2007 |
4705 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2022 2022; 7(1): 20210010 |
Stability of voriconazole 10 mg/mL ophthalmic solution during 90 days
Khan A, Venet A, Bernadou J-M, Cresto S, Servant V, Boulestreau H, Xuereb F, Crauste-Manciet S. |
2022 |
2131 |
Czasopismo
Am J Health-Syst Pharm 2006 ; 63: 1423-1426. |
Stability of voriconazole injection in 0.9% sodium chloride and 5% dextrose injections.
Sahraoui L, Chiadmi F, Schlatter J, Toledano A, Cisternino S, Fontan JE. |
2006 |
4013 |
Czasopismo
EJHP 2018 ; 25, e2 |
Stability of warfarin sodium flavoured preservative-free oral liquid formulations.
Schlatter J, Cisternino S. |
2018 |
1878 |
Czasopismo
Int J Pharm Compound 2004 ; 8, 1: 73-76. |
Stability of zidovudine and dobutamine hydrochloride injections in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23±2°C) and 4°C in 50 ml polyvinyl chloride bags up to 24 hours.
Musami P, Stewart JT, Will Taylor E. |
2004 |
1900 |
Czasopismo
Int J Pharm Compound 2004 ; 8, 3: 236-239. |
Stability of zidovudine and ranitidine in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23°C±2°C) and 4°C in 50 ml polyvinylchloride bags up to 24 hours.
Musami P, Stewart JT, Taylor EW. |
2004 |
338 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 280-282. |
Stability of zidovudine in 5% dextrose injection and 0.9% sodium chloride injection.
Lam NP, Kennedy PE, Jarosinski PF, Galleli JF. |
1991 |
1926 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 394-396. |
Stability of zidovudine with oxytocin in a simulated Y-site injection.
Anderson PL, Miller S, Bushman LR. |
2004 |
2383 |
Czasopismo
Am J Health-Syst Pharm 2009 ; 66: 1105-1109. |
Stability of zonisamide in extemporaneously compounded oral suspensions
Abobo CV, Wei B, Liang D. |
2009 |
4744 |
Laboratorium
Samsung laboratory 2023 |
Stability Report of Extended SB8 Opened Vial (400 mg) Stability (personal communication).
|
2023 |
4634 |
Czasopismo
Antibiotics 2022 ;11,4: 458 |
Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. |
2022 |
1746 |
Czasopismo
EJHP 2010 ; 16, 30-37. |
Stability studies of amoxicillin/clavulanic acid combinaison in polyolefin infusion bags.
Kambia N, Merite N, Dine T, Dupin-Spriet T, Gressier B, Luyckx M, Watinne C, Brunet C. |
2010 |
4326 |
Czasopismo
Pharmazie 2019 ; 74: 357-362. |
Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion.
Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P. |
2019 |
3832 |
Czasopismo
Ann Pharmacotherapy 2016 ; 50: 155-156. |
Stability Studies of Extemporaneously Compounded Clobazam Oral Suspension.
Ei Mon Phyo Lwin, Ellis D, SonY, Turner S, Garg S. |
2016 |
4646 |
Czasopismo
Int J Pharm Compound 2022 ;26,2:150-154 |
Stability Studies of Fludrocortisone Acetate Capsules and Fludrocortisone Acetate Titrated Powders (Powder Triturates).
Brandin T, Wasilewski M, Panuccio C, Bouguergour C, Primas N, Lamy E, Jean C, Bertault-Peres P, Rathelot P, Curti C, Vanelle P. |
2022 |
957 |
Czasopismo
J Parenter Sci Technol 1990 ; 44: 30-34. |
Stability studies of hydralazine in aqueous solutions.
Halasi S, Nairn JG. |
1990 |
4118 |
Czasopismo
Drug Design Dev Ther 2016 ;10:1029-1034 |
Stability studies of lincomycin hydrochloride in aqueous solution and intravenous infusion fluids.
Czarniak P, Boddy M, Sunderland B, Hughes J. |
2016 |
4510 |
Czasopismo
J Oncol Pharm Practice 2020 ;26,8:1894–1902 |
Stability studies of parenteral nutrition with a high dose of vitamin C.
Stawny M, Gostyńska A, Olijarczyk R, Dettlaff K, Jelińska A, Ogrodowczyk M. |
2020 |
163 |
Czasopismo
J Clin Pharm Ther 1994 ; 19: 127-133. |
Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens.
Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA. |
1994 |
4758 |
Czasopismo
Curr Pharm Anal 2023 ; 19, 4: 307-316. |
Stability Study and Simultaneous Determination of Norepinephrine, Moxifloxacin, and Piperacillin + Tazobactam Mixtures Applied in Intensive Care Medicine .
Schmidt J.P, Steppe M. |
2023 |
4622 |
Laboratorium kontroli jakości
Quality Control North West, Stockport NHS Foundati 2021 |
Stability Study for Clindamycin 9.52mg/mL in 0.9% w/v Sodium Chloride 50mL Infusion Bags.
Simms D, Roberts J, Rigge D. |
2021 |
4619 |
Laboratorium kontroli jakości
Quality Control North West, Stockport NHS Foundati 2021 |
Stability Study for Clindamycin 9.52mg/mL in 5.0% w/v Glucose 50mL Infusion Bags.
Simms D, Roberts J, Rigge D. |
2021 |
4621 |
Laboratorium kontroli jakości
Quality Control North West, Stockport NHS Foundati 2021 |
Stability Study for Piperacillin/Tazobactam 56.9 mg/mL in Glucose 5.0% w/v in 50mL Infusion Bags.
Simms D, Roberts J, Rigge D. |
2021 |
4620 |
Laboratorium kontroli jakości
Quality Control North West, Stockport NHS Foundati 2021 |
Stability Study for Piperacillin/Tazobactam 56.9 mg/mL in Sodium Chloride 0.9% w/v in 50mL Infusion Bags.
SimmsD, Roberts J, Rigge D. |
2021 |
4090 |
Czasopismo
Pharm Dev Technol 2017 |
Stability study of a clonidine oral solution in a novel vehicle designed for pediatric patients.
Potier A, Voyat J, Nicolas A. |
2017 |
4563 |
Czasopismo
Eur J Pharm Sci 2021 ; 160: 105738. |
Stability study of a compounded oral solution of nicardipine for the treatment of hypertension in children.
Fuss D, Gondé H, Lamoureux F, Pereira T, Colnot M, Buchbinder N, Coquard A, Varin R, Hervouët C. |
2021 |
3324 |
Czasopismo
J Pharm Pract and Res 2012 ; 42, 2: 115-117. |
Stability study of a thalidomide suspension.
Hopkins AM, Sharley NA, Tang CD. |
2012 |
4496 |
Czasopismo
Neuromodulation 2020 ; 24, 7: 1145-1156. |
Stability Study of Admixtures Combining Ziconotide With Morphine or Sufentanil in Polypropylene Syringes.
Sorrieul J, Robert J, Dupoiron D, Devys, C. |
2020 |
3300 |
Czasopismo
Ann Pharm Fr 2012 ; 70, 2: 88-93. |
Stability study of amiodarone hydrochloride in capsules for paediatric patients using a high-performance liquid chromatography method.
Rughoo L, Vigneron J, Zenier H, May I, Demoré B. |
2012 |
2906 |
Czasopismo
Farm Hosp 2005 ; 29: 30-36. |
Stability study of an aqueous formulation of captopril at 1 mg/ml.
Escribano Garcia MJ, Torrado Duran S, Torrado Duran JJ. |
2005 |
3830 |
Czasopismo
J Oncol Pharm Practice 2016 ; 22: 31-36. |
Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags.
Myers A.Ls, Zhang Y-P, Kawedia L, Trinh V.A, Tran H, Smith J.A, Kramer M.A. |
2016 |
1673 |
Czasopismo
Int J Pharm 1997 ; 154: 185-190. |
Stability study of cefepime in different infusion solutions.
Rabouan-Guyon M, Guet AF, Courtois PY, Barthes DMC. |
1997 |
4430 |
Czasopismo
Medicine 2017 96:35(e7979) |
Stability study of dezocine in 0.9% sodium chloride solutions for patient-controlled analgesia administration.
Fang B-X, Wang L-H, Liu H-M, Chen F-C, Liu J. |
2017 |
3937 |
Czasopismo
Biomat Res 2015 ; 19, 2 |
Stability study of docetaxel solution (0.9% saline) using Non-PVC and PVC tubes for intravenous administration.
Park K.H, Chung D.J. |
2015 |
887 |
Czasopismo
Ann Pharmacotherapy 1997 ; 31: 992-995. |
Stability study of epirubicin in NaCl 0.9% injection.
Pujol M, Munoz M, Prat J, Giona V, De Bolos J. |
1997 |
1762 |
Czasopismo
J Pharm Biomed Anal 1998 ; 18: 373-381. |
Stability study of fotemustine in PVC infusion bags and sets under various conditions using a stability-indicating high-performance liquid chromatographic assay.
Dine T, Khalfi F, Gressier B, Luyckx M, Brunet C, Ballester L, Goudaliez F, Kablan J, Cazin M, Cazin JC. |
1998 |
4200 |
Czasopismo
EJHP 2018 |
Stability study of hydromorphone and bupivacaine mixture by HPLC-UV.
Macorigh C, Guibbert V, Casanova M, Haenni C. |
2018 |
3980 |
Czasopismo
Am J Health-Syst Pharm 2017 ; 74,9: e211-e223 |
Stability study of methotrexate in 0.9% sodium chloride injection and 5% dextrose injection with limit tests for impurities.
Nissen K.B, Jorgensen L.B, Berg D.L, Andersen G. |
2017 |
4051 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2017 ;2,4:173-180 |
Stability study of morphine and baclofen solution in polypropylene syringes.
Robert J, Sorrieul J, Kieffer H, Folliard C, Gibory V, Dupoiron D, Devys C. |
2017 |
4092 |
Czasopismo
Pharm Dev Technol 2016 |
Stability study of oral paediatric idebenone suspensions.
Schlatter J, Bourguignon E, Majoul E, Kabiche S, Balde I.B, Cisternino S, Fontan J.E. |
2016 |
4727 |
Czasopismo
Pharmaceuticals 2023 ;16,72 |
Stability Study of Parenteral N-Acetylcysteine, and Chemical Inhibition of Its Dimerization
Primas N, Lano G, Brun D, Curti C, Sallée M, Sampol-Manos E, Lamy E, Bornet C, Burtey S, Vanelle P. |
2023 |
2151 |
Czasopismo
Int J Pharm 1995 ; 115: 113-117. |
Stability study of prostaglandin E1 (PGE1) in physiological solutions by liquid chromatography (HPLC).
Gatti R, Gotti R, Cavrini V, Soli M, Bertaccini A, Carparelli F. |
1995 |
1287 |
Czasopismo
Pharm Ind 1991 ; 53: 90-94. |
Stability study of reconstituted and diluted solutions of calcium folinate.
Lecompte D, Bousselet M, Gayrard D, Poitou P. |
1991 |
4728 |
Czasopismo
J Pharm Biomed Anal 2021 ; 203:114209. |
Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies.
Hermosilla J, Pérez-Robles R, Salmerón-García A, Casares S, Cabeza J, Navas N. |
2021 |
412 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1520-1524. |
Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers.
Waugh WN, Trissel LA, Stella VJ. |
1991 |
1879 |
Czasopismo
Clin J Pain 2001 : 17: 239-244. |
Stability, compatibility, and safety of intrathecal bupivacaine administered via an implantable delivery system.
Hildebrand KR, Elsberry DE, Deer TR. |
2001 |
304 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1455-1458. |
Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacterostatic diluent.
Corbo DC, Suddith RL, Sharma B, Naso RB. |
1992 |
3415 |
Czasopismo
Pharmaceut Anal Acta 2013 ; 4: 205 |
Stability-Indicating HPLC Assay and Stability Study Over Two Years of Morphine Hydrochloride Diluted Solutions in Polypropylene Syringes
d?Hayer B, Vieillard V, Astier A, Paul M |
2013 |
3347 |
Czasopismo
Drug Discov Ther 2012 ; 6, 1 : 49-54. |
Stability-indicating HPLC method for the determination of the stability of oxytocin parenteral solutions prepared in polyolefin bags.
Kaushal, G., Sayre, B.E., Prettyman, T. |
2012 |
4587 |
Czasopismo
J Pediatr Pharmacol Ther 2021 ; 26, 4: 395–404. |
Stability-indicating LC-MS Method for Determination of Stability of Extemporaneously Compounded Buprenorphine Oral Syringes for Neonatal Abstinence Syndrome.
Rochani A, Nguyen V, Becker R, Kraft W, Kaushal G. |
2021 |
4280 |
Czasopismo
J Pediatr Pharmacol Ther 2019 ; 24, 1: 53-57. |
Sterility and Stability Testing of Preservative-free Albuterol.
Gulley, S.L, Baltzley, S.M, Junkins, A.D, Murray, T.D, Simms, S.F, Sullivan, J.E, Al-Ghananeem A.M, O?Hagan A.R. |
2019 |
4123 |
Czasopismo
J Oncol Pharm Practice 2018 ;24,3:201-208 |
Storage and transport of reconstituted omacetaxine mepesuccinate: Considerations for home administration.
Parikh A, Van de Rijn J, Melville C, Sarkari M, Peltier S, McKean R. |
2018 |
175 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 368-372. |
Storage of lorazepam in three injectable solutions in polyvinyl chloride and polyolefin bags.
Trissel LA, Pearson SD. |
1994 |
2661 |
Czasopismo
Eye 2015 ; 29, 6: 820-827. |
Storage stability of bevacizumab in polycarbonate and polypropylene syringes
Khalili H, Sharma G, Froome A, Khaw P.T, Brocchini S. |
2015 |
3625 |
Laboratorium
CSL Behring 2013 |
Streptokinase (Streptase®) - Summary of Product Characteristics
|
2013 |
3654 |
Laboratorium
Keocyt 2012 |
Streptozocine (Zanosar®) - Résumé des caractéristiques du produit
|
2012 |
3670 |
Czasopismo
EJOP 2014 ; 8, 3: 26-30. |
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
Sewell G, Massimini M. |
2014 |
1009 |
Czasopismo
J Pharm Sci 1988 ; 77: 630-634. |
Studies on the stability of vinblastine sulfate in aqueous solution.
Black J, Buechter DD, Chinn JW, Gard J, Thurston DE. |
1988 |
2225 |
Czasopismo
Bolletino SIFO 2006 ; 77:81 |
Studio di stabilità chimico-fisica di una formulazione per la terapia antalgica a base di levobupivacaina e fentanyl.
Sacco R, Sacchetto G, Francalanci M, Boselli C. |
2006 |
1264 |
Czasopismo
Ann Pharm Fr 1997 ; 55: 216-223. |
Study of Lavoisier morphine chlorhydrate in different active perfusion systems after reconstitution in different solvents.
Truelle-Hugon B, Tourette G, Couineaux B, Gache-Charrette C. |
1997 |
4473 |
Czasopismo
Neuromodulation 2020 |
Study of Physicochemical Stability of Ziconotide in Medication Cassette Reservoir.
Robert J, Sorrieul J, Andrieu A, Mounsef F, Dupoiron D, Devys C. |
2020 |
4708 |
Czasopismo
Drugs R D 2022 ; 22,3: 225–234 |
Study of the Stability of Sandoz Rituximab Biosimilar Rixathon®/Riximyo® When Subjected for up to 21 Days to Ambient Storage.
Borišek R, Mischo A, Šmid I. |
2022 |
2185 |
Czasopismo
J Pharm Biomed Anal 2007 ; 43: 1849-1853. |
Study on the compatibility of cefotaxime with tinidazole in glucose injection.
Guo P, Li X, Wan J, You A. |
2007 |
4606 |
Czasopismo
Int J Pharm Compound 2021 ;25,3:258-262 |
Study on the Optimal Conditions for Long-term Storage of Melatonin Powder as an In-hospital Preparation.
Odanak K, Kojima H, Nakagawa N. |
2021 |
219 |
Czasopismo
J Clin Pharm Ther 1997 ; 22: 283-290. |
Study protocol : stability of morphine injected without preservative, delivered with a disposable infusion device.
Oustric-Mendes AC, Huart B, Le Hoang MD, Perrin-Rosset M, Pailler FM, Darbord JC, Prognon, Gard C, Pradeau D. |
1997 |
788 |
Czasopismo
Lancet 1989 ; 2 (8670): 1044-1045. |
Subcutaneous drug compatibility in palliative care.
Regnard CFB, Mannix K. |
1989 |
2328 |
Laboratorium
Organon 2009 |
Sugammadex (Bridion®) – Résumé des caractéristiques du produits
|
2009 |
855 |
Czasopismo
Cancer Chemother Pharmacol 1992 ; 29: 252-255. |
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump.
Hrubisko M, Mc Gown AT, Prendiville JA, Radford JA, Thatcher N, Fox BW. |
1992 |
3583 |
Laboratorium
Roche 2013 |
Sulfaméthoxazole triméthoprime (Bactrim®) - Résumé des caractéristiques du produit
|
2013 |
3407 |
Czasopismo
Farm Hosp 2013 ; 37, 21: 103-110. |
Suspensiones extratemporáneas de clobazam para uso pediátrico preparadas a partir de tabletas disponibles comercialmente y fármaco puro.
Buontempo F, Moretton M.A, E. Quiroga y D. A. Chiappetta. |
2013 |
1907 |
Czasopismo
Hosp Pharm 2004 ; 39: 554-557. |
Sustaining treatment of coccidioidal meningitidis by extending the stability of amphotericin B.
Burger DE, Caldwell JW. |
2004 |
3631 |
Laboratorium
Aguettant 2016 |
Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit
|
2016 |
3626 |
Laboratorium
Astellas Pharma 2014 |
Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit
|
2014 |
3215 |
Czasopismo
EJOP 2011 ; 5,1: 24-27. |
Taxotere 1-vial (docetaxel 20 mg/ml) physical and chemical stability over 28 days in infusion bags containing 0.9% saline solution and 5% glucose solution.
Hart MC, Ahmed W. |
2011 |
3753 |
Laboratorium
Cubist Pharmaceuticals 2014 |
Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics
|
2014 |
3656 |
Laboratorium
Sanofi Aventis France 2014 |
Teicoplanine (Targocid®) - Résumé des caractéristiques du produit
|
2014 |
3260 |
Laboratorium
Astellas Pharma Europe 2011 |
Telavancin (Vibativ®) - Summary of Products characteristics
|
2011 |
2296 |
Laboratorium
Eumedica 2017 |
Témocilline (Negaban®) - Résumé des caractéristiques du produit
|
2017 |
3117 |
Laboratorium
Merck Sharp Dohme 2009 |
Temozolomide (Temodal ®) - Summary of Product Characteristics
|
2009 |
2855 |
Czasopismo
Int J Pharm Compound 2006 ; 10, 5: 396-399. |
Temozolomide Stability in Extemporaneously Compounded Oral Suspensions
Trissel LA, Zhang Y, Koontz SE. |
2006 |
2226 |
Laboratorium
Pfizer Ltd 2016 |
Temsirolimus (Torisel®) - Summary of Product Characteristics
|
2016 |
3627 |
Laboratorium
Boeringer Ingelheim 2013 |
Tenecteplase (Metalyse®) - Summary of Product Characteristics
|
2013 |
3597 |
Laboratorium
AstraZeneca 2013 |
Terbutaline sulfate (Bricanil®) - Summary of Product Characteristics
|
2013 |
1462 |
Czasopismo
J Pharm Pharmacol 1989 ; 41: 273-275. |
The availability of diltiazem: a study on the sorption by intravenous delivery systems and on the stability of the drug.
De Vroe C, de Muynck C, Remon JP, Scheldewaert R, Colardyn F. |
1989 |
22 |
Czasopismo
Int J Pharm 1991 ; 72: 57-63. |
The chemical and physical stability of three intravenous infusions subjected to frozen storage and microwave thawing.
Sewell GJ, Palmer AJ. |
1991 |
871 |
Czasopismo
Anesth Analg 1998 ; 86: 208-213. |
The chemical stability and sterility of sodium thiopental after preparation.
Haws JL, Herman N, Clark Y, Bjoraker R, Jones D. |
1998 |
1901 |
Czasopismo
J Pain Symptom Manage 2004 ; 27, 5: 471-475. |
The compatibility and stability of midazolam and dexamethasone in infusion solutions.
Good PD, Schneider JJ, Ravenscroft PJ. |
2004 |
2404 |
Czasopismo
Palliative Med 2000 ; 14: 205-208. |
The compatibility and stability of octreotide acetate in the presence of diamorphine hydrochloride in polypropylene syringes
Fielding H, Kyaterekera , Skellern GG, Tettey JN, McDade JR, ZMsuya Z, Watson DG, Urie J. |
2000 |
4550 |
Czasopismo
Crit Care Resusc 2013 ;15, 1: 63–66. |
The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration.
Semark, A.J, Venkatesh, K, McWhinney B.C, Pretorius, C, Roberts, J.A, Cohen J, Venkatesh B. |
2013 |
55 |
Czasopismo
J Clin Hosp Pharm 1982 ; 7: 181-186. |
The compatibility of diazepam with infusion fluids and their containers.
Smith A, Bird G. |
1982 |
1490 |
Czasopismo
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254. |
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Halpern NA, Colucci RD, Alicea M, Greenstein R. |
1989 |
3743 |
Czasopismo
Int J Pharm 1991 ; 69: 197-210. |
The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles.
Allsopp M.A, Sewell G.J, Rowland C.G, Riley C.M, Schowen R.L. |
1991 |
4367 |
Czasopismo
J Glaucoma 2016 ; 25, 6: 477-481. |
The Degradation of Mitomycin C Under Various Storage Methods.
Kinast R.M, Akula K.K, DeBarber A.E, Barker G.T, Gardiner S.K, Whitson E, Mansberger S.L. |
2016 |
2143 |
Czasopismo
J Pharm Biomed Anal 1998 ; 17: 785-792. |
The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry.
Dodds HM, Robert J, Rivory LP. |
1998 |
2304 |
Czasopismo
Int J Pharm 2005 304; 1-2: 135-144. |
The development and stability assessment of extemporaneous pediatric formulations of Accupril.
Freed A.L, Silbering S.B, Kolodsick K.J, Rossi D, Mahjour M, Kingsmill C.A. |
2005 |
2984 |
Czasopismo
EJHP Science 2007 ; 13-67-72. |
The development of a stable oral solution of captopril for paediatric patients.
Berger-Gryllaki M, Podilsky G, Widmer N, Gloor S, Testa B, Pannatier A. |
2007 |
1263 |
Czasopismo
Int J Pharm Pract 1992 ; 1: 242-244. |
The effect of buffering on the stability of reconstituted benzylpenicillin injection.
Allwood MC, Brown PW. |
1992 |
4501 |
Czasopismo
BMC Anesthesiology 2020 ;20:283. |
The effect of concentration, reconstitution solution and pH on the stability of a remifentanil hydrochloride and propofol admixture for simultaneous co-infusion.
Henkel E, Vella R, Behan K, Austin D, Kruger P, Fenning A. |
2020 |
4388 |
Czasopismo
Int J Pharm Compound 2020 ;24,2:140-147 |
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment.
Meissner S, Bansal M, Donamae P, Hanning S, Svirskis D. |
2020 |
2325 |
Czasopismo
Pharmazie 2009 ; 64, 2: 94-97. |
The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions.
Nemec K, Germ E, Schulz-Siegmund M, Ortner A. |
2009 |
2079 |
Czasopismo
Can J Anesth 1987 ; 34: 87-89. |
The effect of pancuronium on the solubility of aqueous thiopentone.
Morton WD, Lerman J. |
1987 |
794 |
Czasopismo
Anaesthesia 1996 ; 51: 815-818. |
The effect of the addition of lignocaine on propofol emulsion stability.
Lilley EMM, Isert PR, Carasso ML, Kennedy RA. |
1996 |
38 |
Czasopismo
Int J Pharm 1996 ; 127: 65-71. |
The extraction of diethylhexylphtalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection.
Allwood MC, Martin HJ. |
1996 |
2697 |
Czasopismo
J Clin Pharm Ther 1988 ; 13, 1: 73-76. |
The formulation and stability of a unit-dose oral vitamin K1 preparation.
Sewell GJ, Palmer AJ. |
1988 |
2663 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 200-205. |
The formulation development and stability of metronidazole suspension.
Alexander KS, Vangala SSKS, Dollimore D. |
1997 |
2854 |
Czasopismo
Int J Pharm Compound 1997 ; 1, 3: 195-199. |
The Formulation Development and Stability of Spironolactone Suspension
Alexander KS, Sundar S, White DB, Dollimore D. |
1997 |
2559 |
Czasopismo
Aust J Hosp Pharm 1993 ; 23: 83. |
The formulation of spironolactone solution for paediatric use.
Mc Knight DL. |
1993 |
4040 |
Czasopismo
J Oncol Pharm Practice 2017 ;25,2: 269-278 |
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
Lamanna W.C, Heller K, Schneider D, Guerrasio R, Hampl V, Fritsch C, Schiestl M. |
2017 |
1153 |
Czasopismo
Int J Pharm 1992 ; 80: R7-R9. |
The influence of buffering on the stability of erythromycin injection in small-volume infusions.
Allwood MC. |
1992 |
4112 |
Czasopismo
Int J Pharm Compound 2018 ;22,2:164-171 |
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions.
Svirskis D, Lin S.W, Brown H, Sangaroothong A, Wang Z, Xu H, Dean R, Vareed P, Jensen M, Wu Z. |
2018 |
4441 |
Czasopismo
Pharmaceutics 2020 ; 12, 27 |
The Interactions between Ciprofloxacin and Parenteral Nutrition Admixtures.
Gostynska, A, Stawny M, Dettlaff K, Jelinska A. |
2020 |
168 |
Czasopismo
J Pharm Pharmacol 1993 ; 45: 6-9. |
The long term stability of mechlorethamine hydrochloride (Nitrogen Mustard) ointment measured by HPLC.
Cummings J, Maclellan A, Langdon SJ, Smyth JF. |
1993 |
1669 |
Czasopismo
Can J Hosp Pharm 1994 ; 47: 9-14. |
The pharmaceutical stability of deferoxamine mesylate.
Hayes DM, Reilly RM, Lee MMC. |
1994 |
4556 |
Czasopismo
J Pharm Technol 2020 ; 36, 4: 126-129. |
The Physical Compatibility of Clinically Used Concentrations of Diltiazem Hydrochloride With Heparin Sodium.
Dobson, S.R, Mauro, V.F, Boddu, S.H.S, Churchwell, M.D. |
2020 |
4592 |
Czasopismo
Antibiotics 2021 ; 10: 715. |
The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body.
Liebchen U, Rakete S, Vogeser M, Arend F.M, Kinast C, Scharf C, Zoller M, Schönermarck U, Paal M. |
2021 |
1148 |
Czasopismo
J Pharm Pharmacol 1988 ; 40: 601-604. |
The sorption of isosorbide dinitrate to intravenous delivery systems.
De Muynck C, Remon JP, Colardyn F. |
1988 |
1663 |
Czasopismo
EJHP 2002 ; 1: 23-25. |
The stability of (lyophilized) gemcitabine in 0.9% sodium chloride injection.
Ponton JL, Munoz C, Rey M, Val M. |
2002 |
2558 |
Czasopismo
Aust J Hosp Pharm 1993 ; 23: 18-21. |
The stability of acetylcysteine eyedrops.
Fawcett JP, Woods DJ, Hayes P. |
1993 |
673 |
Czasopismo
JPEN 1989 ; 13: 505-509. |
The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures.
Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD. |
1989 |
1845 |
Czasopismo
EJHP 2003 ; 6: 106-111. |
The stability of amoxicillin, ampicillin, benzylpenicillin, flucloxacillin, mezlocillin and piperacillin in isotonic saline solutions when stored in an innovative infusion container (Freeflex container).
Müller HJ, Haker I. |
2003 |
1333 |
Czasopismo
J Clin Hosp Pharm 1982 ; 7: 245-250. |
The stability of amoxycillin sodium in intravenous infusion fluids.
Cook B, Hill SA, Lynn B. |
1982 |
598 |
Czasopismo
J Clin Pharm Ther 1989 ; 14: 45-52. |
The stability of amoxycillin sodium in normal saline and glucose (5%) solutions in the liquid and frozen states.
Mc Donald C, Sunderland VB, Lau H, Shija R. |
1989 |
2561 |
Czasopismo
Aust J Hosp Pharm 1994 ; 24: 151-156. |
The stability of an enalapril maleate oral solution prepared from tablets.
Boulton DW, Woods DJ, Fawcett JP. |
1994 |
645 |
Czasopismo
J Clin Pharm Ther 1987 ; 12: 427-432. |
The stability of carboplatin in ambulatory continuous infusion regimes.
Sewell GJ, Riley CM, Rowland CG. |
1987 |
484 |
Czasopismo
J Clin Pharm Ther 1991 ; 16: 123-129. |
The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions.
Northcott M, Allsopp MA, Powell H, Sewell GJ. |
1991 |
1886 |
Czasopismo
Palliative Med 1991 ; 5: 330-333. |
The stability of diamorphine alone and in combinaison with antiemetics in plastic syringes.
Allwood MC. |
1991 |
1300 |
Czasopismo
Hosp Pharm Pract 1992 ; 2: 285-289. |
The stability of drugs in pre-filled syringes: flucloxacillin, ampicillin, cefuroxime, cefotaxime and ceftazidime.
Ahmed ST, Parkinson R. |
1992 |
1154 |
Czasopismo
Int J Pharm 1990 ; 62: R1-R3. |
The stability of erythromycin injection in small-volume infusions.
Allwood MC. |
1990 |
246 |
Czasopismo
Aust J Hosp Pharm 1996 ; 26: 560-561. |
The stability of foscarnet in the presence of potassium.
McDonald C, Boddy M, Garas G. |
1996 |
197 |
Czasopismo
J Clin Pharm Ther 1991 ; 16: 337-340. |
The stability of four catecholamines in 5% glucose infusions.
Allwood MC. |
1991 |
2665 |
Czasopismo
Int J Pharm Compound 1997 ; 1: 352-353. |
The stability of lisinopril as an extemporaneous syrup.
Webster AA, English BA, Rose DJ. |
1997 |
854 |
Czasopismo
J Pharm Pharmacol 1979 ; 31: 853-854. |
The stability of melphalan in the presence of chloride ion.
Chang SY, Evans TL, Alberts DS. |
1979 |
346 |
Czasopismo
J Pain Symptom Manage 1994 ; 9: 308-311. |
The stability of mixtures of morphine hydrochloride, bupivacaine hydrochloride, and clonidine hydrochloride in portable pump reservoirs for the management of chronic pain syndromes.
Wulf H, Gleim M, Mignat C. |
1994 |
1062 |
Czasopismo
Int J Pharm 1997 ; 146: 213-223. |
The stability of morphine and the stability of concentrated morphine solutions in glass, polypropylene syringes and PVC containers.
Vermeire A, Remon JP. |
1997 |
117 |
Czasopismo
Can J Hosp Pharm 1988 ; 41: 5-9. |
The stability of morphine intravenous infusion solutions.
Vecchio M, Walker SE, Iazzetta J, Hardy BG. |
1988 |
1495 |
Czasopismo
Pharm J 1995 ; 254: 153-155. |
The stability of morphine sulphate and metoclopramide hydrochloride in various delivery presentations.
Nixon AR, O'Hare MCB, Chisakuta AM. |
1995 |
4160 |
Czasopismo
J Pharm Pharmacol 1952 560-565 |
The Stability of Noradrenaline Solutions.
West G.B. |
1952 |
1241 |
Czasopismo
Can J Hosp Pharm 1985 ; 38: 162-163. |
The stability of penicillin G sodium in 5% dextrose in water minibags after freezing.
Rayani S, Jamali F. |
1985 |
4609 |
Czasopismo
PlosOne 2021 ; 16(8): e0255963. |
The stability of quetiapine oral suspension compounded from commercially available tablets.
Tran J, Gervase M.A, Evans J, Deville R, Dong X. |
2021 |
2035 |
Czasopismo
EJHP Science 2005 ; 11: 107-110. |
The stability of ready-to-use (RTU) ephedrine hydrochloride in polypropylene syringes for use in maternal hypotension.
Griffiths W, Ing H, Fleury-SouverainS, Kern C, Sadeghipour F, Bonnabry P. |
2005 |
1233 |
Czasopismo
Br J Pharm Pract 1990 ; 12: 328, 330, 334. |
The stability of reconstituted aztreonam.
McLaughlin JP, Simpson C. |
1990 |
1301 |
Czasopismo
Hosp Pharm Pract 1992 ; 2: 59-62. |
The stability of reconstituted diethanolamine fusidate in a 5% dextrose infusion.
McLaughlin JP, Simpson C. |
1992 |
633 |
Czasopismo
J Clin Hosp Pharm 1985 ; 10: 351-360. |
The stability of sodium nitroprusside infusion during administration by motorized syringe-pump.
Sewell GJ, Forbes DR, Munton TJ. |
1985 |
3224 |
Czasopismo
EJHP Science 2011 ; 1: 3-6. |
The stability of soluble insulin in plastic syringes
Fleury-Souverain S, Sigrist T, Griffiths W, Ing H, Matthey B; Sadeghipour F, Bonnabry P. |
2011 |
1602 |
Czasopismo
Hosp Pharm 2001 ; 36: 740-745. |
The stablity of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection.
Trissel LA, Zhang Y, Cohen MR. |
2001 |
1734 |
Czasopismo
J Pharm Biomed Anal 1993 ; 11: 723-727. |
The suitability of carboplatin solutions for 14-day continuous infusion by ambulatory pump : an HPLC-dynamic FAB study.
Hadfield JA, McGown AT, Dawson MJ, Thatcher N, Fox BW. |
1993 |
4121 |
Czasopismo
Int J Pharm Compound 2018 ;22,3:252-256 |
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia.
Cote B, Ross B, Fortner J, Rao D. |
2018 |
1243 |
Czasopismo
Can J Hosp Pharm 1989 ; 42: 143-146. |
The use of stability-indicating assays to determine the in vitro compatibility and stability of metronidazole / gentamicin admixtures.
Rovers JP, Meneilly G, Souny PF, Rekhi GS, Drum D. |
1989 |
3731 |
Czasopismo
J Pharm Sci 1978 ; 67, 4: 526-530. |
Thermal and photolytic decomposition of methotrexate in aqueous solutions.
Chatterji D.C, Gallelli J.F. |
1978 |
3675 |
Laboratorium
Archimedes Pharma UK Ltd 2015 |
Thiopental sodium - Summary of Product Characteristics
|
2015 |
3603 |
Laboratorium
Adienne Pharma Biotech 2011 |
Thiotepa (Tepadina®) - Summary of Product Characteristics
|
2011 |
1649 |
Czasopismo
Aust J Hosp Pharm 1997 ; 27: 470. |
Ticarcillin-potassium clavulanate and vancomycin incompatibility.
Gilbar P, McAllan Z. |
1997 |
3587 |
Laboratorium
GlaxoSmithKline 2014 |
Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics
|
2014 |
3332 |
Laboratorium
Pfizer 2012 |
Tigecycline (Tigacyl®) - Summary of Product characteristics
|
2012 |
1512 |
Laboratorium
Beacon Pharmaceuticals Ltd 2015 |
Tirofiban (Aggrastat®) - Summary of Product Characteristics
|
2015 |
1168 |
Czasopismo
Antimicrob Agents Chemother 1983 ; 23: 653-657. |
Tobramycin inactivation by carbenicillin, ticarcillin and piperacillin.
Konishi H, Goto M, Nakamoto Y, Yamamoto I, Yamashina H. |
1983 |
2686 |
Czasopismo
J Am Acad Dermatol 1989 ; 21: 979-984. |
Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate.
Krochm?al L, Wang JCT, Patel B. |
1989 |
753 |
Laboratorium
Hospira 2016 |
Topotecan (Topotecan Hospira®) - Summary of Product Characteristics
|
2016 |
4572 |
Czasopismo
Antibiotics 2021 ; 10, 217. |
Toward Safe Pharmacotherapy: The Interplay between Meropenem and Parenteral Nutrition Admixtures.
Gostynska A, Piwowarczyk L, Nadolna M, Jelinska A, Dettlaff K, Ogrodowczyk M, Popielarz-Brzezinska M, Stawny M. |
2021 |
2276 |
Laboratorium
Pharma Mar SA 2015 |
Trabectedine (Yondelis®) - Summary of Product Characteristics
|
2015 |
4725 |
Czasopismo
J Pharm Biomed Anal 2022 |
Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers.
Perez-Robles R, Hermosilla J, Navas N, Clemente-Batuista S, Jimenez-Lozano I, Cabanas-Poy MJ, Ruiz-Trave J et al. |
2022 |
4290 |
Czasopismo
Microbiology Insights 2018 ; 11, 1-6 |
Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion.
Venugopalan V, Manigaba K, Borgert S.J, Cope J, Peloquin C.A, Klinker K.P. |
2018 |
1992 |
Czasopismo
J Pharm Clin 1999 ; 18, 3: 251-257. |
Traitement par étoposide oral : présentation adaptée à une meilleure observance pédiatrique hospitalière.
Drouard, VigneronJ, May I. |
1999 |
2176 |
Czasopismo
Support Care Cancer 2007 ; 15: 57-62. |
Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.
Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. |
2007 |
3521 |
Laboratorium
Beacon Pharmaceuticals 2012 |
Tramadol® - Summary of Product Characteristics.
|
2012 |
3647 |
Laboratorium
Roche 2019 |
Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics
|
2019 |
3077 |
Laboratorium
Roche 2019 |
Trastuzumab (Herceptin®) – Summary of Product Characteristics
|
2019 |
2990 |
Laboratorium
Roche 2014 |
Trastuzumab Emtansine (Kadcyla®) - Summary of Product Characteristics.
|
2014 |
3087 |
Czasopismo
BJID 2008 ; 12, 5: 400-404. |
Treatment of invasive fungal infections: Stability of voriconazole infusion solutions in PVC bags.
Adams, A.I.H., Morimoto, L.N., Meneghini, L.Z., Bergold, A.M. |
2008 |
1990 |
Czasopismo
Krankenhauspharmazie 2000 ; 11: 576-580. |
Treosulfan : chemisch-physikalische stabilität, Hinweise für die pharmazeutisch-onkologische praxis.
Hilger RA, Kredtke S, Barth J. |
2000 |
2197 |
Laboratorium
Medac 2003 |
Treosulfan injection : details about handling and stability.
|
2003 |
3931 |
Laboratorium
Pfizer Laboratoire 2016 |
Trimébutine (Débridat®) - Résumé des caractéristiques du produit
|
2016 |
248 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 300-304. |
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Trissel LA, Martinez JF. |
1993 |
85 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1716-1719. |
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Trissel LA, Bready BB. |
1992 |
4130 |
Czasopismo
Pharmaceutics 2021 , 13, 21. |
Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen.
Koller AK, Krebs S, Dörje F. |
2021 |
2128 |
Czasopismo
Pharmazie 2006 ; 10: 845-850. |
Untersuchungen zur Stabilität der Busulfan-Stammlösung (Busilvex®, Busulfex TM) in B/Braun Injekt® Einmalspritzen.
Karstens A, Krämer I. |
2006 |
3996 |
Czasopismo
Int J Pharm Compound 2017 ; 21,3 : 240-241. |
Updated Stability Data of Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSprend SF and Minoxidil in Espumil.
Dijkers E,Nanhekhan V,Thorissen A. |
2017 |
1189 |
Czasopismo
Am J Hosp Pharm 1983 ; 40: 1692-1693. |
Uptake of clonazepam by plastic intravenous infusion bags and administration sets.
Nation RL, Hackett LP, Dusci LJ. |
1983 |
4065 |
Laboratorium
Mylan 2018 |
Urapidil (Eupressyl® - résumé des caractéristiques du produit)
|
2018 |
1061 |
Czasopismo
Am J Health-Syst Pharm 1999 ; 56: 2047-2051. |
Urokinase after freezing : Implications for thrombolysis in intraventricular hemorrhage.
Rhoney DH, Coplin WM, Zaran FK, Brish LK, Weingarten CM. |
1999 |
1394 |
Czasopismo
Thromb Haemost 1981 ; 45: 296. |
Urokinase therapy: dose reduction by administration in plastic material.
Zimmermann R, Sch?ffel G, Harenberg J. |
1981 |
4770 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2023 ; 8(1): 20220010 |
Use of a liquid chromatography-tandem mass spectrometry method to assess the concentration of epinephrine, norepinephrine, and phenylephrine stored in plastic syringes.
Cohen A.C, Wiseman L, Al Faraj A, Andreou P, Hall R, Neira V.M. |
2023 |
4611 |
Czasopismo
J Pharm Anal 2021 ;10 532e545. |
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes.
Navas N, Hermosilla J, Torrente-Lopez A, Hernandez-Jimenez J, Cabeza J, Perez-Robles R, Salmeron-García A. |
2021 |
4179 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2018 ;3,4:207-218 |
Validation of an HPLC Assay Method for Routine QC Testing and Stability Study of Compounded Low-Dose Capsules of Acetylsalicylic Acid.
Lonca N, Maillard F, Leguelinel G, Sharkawi T, Soulairol I. |
2018 |
4293 |
Czasopismo
J Pharm Pract and Res 2019 ;49, 219?223 |
Validation of the stability of paracetamol in extemporaneously compounded suppositories.
Tianzhi Y, Hae Jung S, Kayla N, Shuhua B. |
2019 |
3794 |
Czasopismo
Can J Hosp Pharm 2017 ; 70,3 :247-249 |
Vancomycin 50 mg/mL Suspension in Oral Syrup: Stability in Plastic Bottles and Syringes at 2 Temperatures.
Smith A.D, Rempel G, Szeitz A, Klassen T.L, Ensom M.H.H. |
2017 |
1877 |
Czasopismo
Br Ophtalmol 2000 ; 84: 117. |
Vancomycin and ceftazidime incompatibility upon vitreal injection.
Lifshitz T, Lapid-Gortzak R, Finkelman Y, Klemperer I. |
2000 |
3485 |
Czasopismo
Anaesthesia 2000 ; 55, 10: 1039-1040. |
Vancomycin causes dangerous precipitation when infused with gelatin fluid.
Huey-Ping Ng, Kwong-Fah Koh, Lai-San Tham. |
2000 |
895 |
Czasopismo
JPEN 1992 ; 16: 268-274. |
Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections.
Yao JDC, Arkin CF, Karchmer AW. |
1992 |
3588 |
Laboratorium
Sandoz 2011 |
Vancomycine (Vancocin®) - Résumé des caractéristiques du produit
|
2011 |
2150 |
Czasopismo
J Urology 1998 ; 160; 2: 551-555. |
Vasoactive cocktails for erectile dysfunction: chemical stability of PGE1, papaverine and phentolamine.
Soli M, Bertaccini A, carparelli F, Gotti R, Cavrini V, Andrisano V, Martorana G. |
1998 |
3630 |
Laboratorium
Merck Sharp Dohme 2012 |
Vecuronium (Norcuron®) - Summary of Product Characteristics
|
2012 |
3711 |
Laboratorium
Takeda 2015 |
Vedolizumab (Entyvio®) - Summary of Product Characteristics
|
2015 |
1098 |
Czasopismo
Ann Intern Med 1983 ; 98: 672. |
Verapamil precipitation.
Cutie MR. |
1983 |
1514 |
Laboratorium
Novartis Pharmaceuticals UK Ltd 2015 |
Verteporfin (Visudyne®) – Summary of Product Characteristics
|
2015 |
3775 |
Laboratorium
Talon Therapeutics 2014 |
Vincristine sulfate liposome (Marqibo®) - Summary of Product Characteristics
|
2014 |
2838 |
Laboratorium
Pierre Fabre 2010 |
Vinflunine (Javlor®) – Résumé des caractéristiques du produits
|
2010 |
3641 |
Laboratorium
Pierre Fabre 2011 |
Vinorelbine (Navelbine®) - Summary of Product Characteristics
|
2011 |
3841 |
Czasopismo
Am J Health-Syst Pharm 2016 ; 73:241-246 |
Visual and absorbance analyses of admixtures containing vancomycin and piperacillin–tazobactam at commonly used concentrations.
Nicholas O?Donnell J, Venkatesan N, Manek M, Rhodes N.J, Scheetz M.H. |
2016 |
92 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 606-608. |
Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs.
Lee CY, Mauro VF, Alexander KS. |
1990 |
336 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 1408-1409. |
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Forman JK, Lachs JR, Souney PF. |
1987 |
1036 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 1379-1380. |
Visual compatibility of amiodarone hydrochloride injection with other injectable drugs.
Hasegawa GR, Eder JF. |
1984 |
1611 |
Czasopismo
Am J Health-Syst Pharm 2001 ; 58: 504-506. |
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Chalmers JR, Bobek MB, Militello MA. |
2001 |
385 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 1117-1118. |
Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection.
Benedict MK, Roche VF, Banakar UV, Hilleman DE. |
1988 |
253 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 2525-2528. |
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Trissel LA, Chandler SW, Folstad JT. |
1990 |
1964 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 1784-1785. |
Visual compatibility of argatroban with selected drugs.
Hartman CA, Baroletti SA, Churchill WW et al. |
2002 |
1800 |
Czasopismo
Am J Health-Syst Pharm 2002 ; 59: 853-855. |
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Voytilla KL, Tyler LS, Rusho WJ. |
2002 |
1944 |
Czasopismo
Am J Health-Syst Pharm 2004 ; 61: 1774. |
Visual compatibility of bivalirudin with selected drugs.
Hartman CA, Faria CE, Mago K. |
2004 |
3976 |
Czasopismo
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218 |
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. |
2017 |
2233 |
Czasopismo
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457. |
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Condie C.K, Tyler L.S, Barker B, Canann D.M. |
2008 |
1438 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 1840-1841. |
Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications.
Souney PF, Solomon MA, Stancher D. |
1984 |
500 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 1910-1911. |
Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection.
Tucker DR, Sieradzan R. |
1988 |
261 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 715-716. |
Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection.
Percy LA, Rho JP. |
1993 |
2018 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 1968-1969. |
Visual compatibility of clonidine with selected drugs.
Veggeland T. |
2005 |
3997 |
Czasopismo
Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102 |
Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration.
Katip W. |
2017 |
3728 |
Czasopismo
Am J Health-Syst Pharm 2014 ; 71: 1288-1291. |
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. |
2014 |
198 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 516-520. |
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Gayed AA, Kheshary PR, Hinkle RL. |
1995 |
524 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 1911. |
Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration.
Farquhar Zanetti LA. |
1992 |
1041 |
Czasopismo
Am J Hosp Pharm 1984 ; 41: 949-951. |
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Hasegawa GR, Eder JF. |
1984 |
1221 |
Czasopismo
Am J Hosp Pharm 1980 ; 37: 460,464. |
Visual compatibility of dobutamine with seven parenteral drug products.
Dahlin PA, Paredes SM. |
1980 |
1802 |
Czasopismo
Am J Health-Syst Pharm 2003 ; 60: 193-194. |
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Bell MS, Nolt DH. |
2003 |
1315 |
Czasopismo
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297. |
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Halpern NA, Colucci RD, Alicea M, Greenstein R. |
1989 |
201 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 2530-2531. |
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection.
Thompson DF, Allen LV, Stiles ML. |
1990 |
523 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 2740. |
Visual compatibility of esmolol hydrochloride and furosemide in 5% dextrose or 0.9% sodium chloride injections.
Thompson DF, Thompson GD. |
1987 |
384 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 630-632. |
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Colucci RD, Cobuzzi LE, Halpern NA. |
1988 |
398 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 1556-1557. |
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Jay GT, Fanikos J, Souney PF. |
1988 |
821 |
Czasopismo
Am J Health-Syst Pharm 1998 ; 55: 1194,1197. |
Visual compatibility of fentanyl citrate with parenteral nutrient solutions.
Moshfeghi M, Ciuffo JD. |
1998 |
63 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 811-812. |
Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection.
Marquardt Ed, Lam SSY. |
1994 |
496 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 744-746. |
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Lor E, Sheybani T, Takagi J. |
1991 |
255 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2290,2292. |
Visual compatibility of fluconazole with drugs given by continuous infusion.
Ishisaka DY. |
1994 |
492 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Trissel LA, Parks NPT, Santiago NM. |
1991 |
1135 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 2075-2077. |
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Baltz JK, Kennedy P, Minor JR, Gallelli J. |
1990 |
73 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 157-159. |
Visual compatibility of foscarnet with other injectable drugs.
Lor E, Takagi J. |
1990 |
2116 |
Czasopismo
Am J Health-Syst Pharm 2006 ; 63: 906-908. |
Visual compatibility of furosemide with phenylephrine and vasopressine.
Faria CE, Fiumara K, Patel N, Tran DC. |
2006 |
91 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 1208-1210. |
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Lober CA, Dollard PA. |
1993 |
67 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1538-1539. |
Visual compatibility of ganciclovir sodium and parenteral nutrient solution during simulated Y-site injection.
Outman WR, Mitrano FP, Baptista RJ. |
1991 |
2019 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 1548-1550. |
Visual compatibility of gentamicin sulfate and 4% sodium citrate solutions.
Wazny L, Walker S, Moist L. |
2005 |
403 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 1539-1541. |
Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection.
Outman WR, Monolakis J. |
1991 |
230 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 905-906. |
Visual compatibility of haloperidol lactate with injectable solutions.
Fraser GL, Riker RR. |
1994 |
472 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 995-996. |
Visual compatibility of hetastarch with injectable critical-care drugs.
Wohlford JG, Fowler MD. |
1989 |
331 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 2127. |
Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents.
Marquardt ED. |
1988 |
2335 |
Czasopismo
Am J Health-Syst Pharm 2009 ; 66, 8: 727-729 |
Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients
Canann D, Tyler L.S, Barker B, Condie C. |
2009 |
491 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2181-2184. |
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Turowski RC, Durthaler JM. |
1991 |
467 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 2442-2443. |
Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion.
Ishisaka DY, van Vleet J, Marquardt E. |
1991 |
288 |
Czasopismo
Hosp Pharm 1992 ; 27: 957-958,961-962. |
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Cervenka P, Dejong DJ, Butler BL, Monzingo MD. |
1992 |
314 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 64-65. |
Visual compatibility of injectable drugs used in the intensive care unit.
Chiu MF, Schwartz ML. |
1997 |
1508 |
Czasopismo
EJHP 2015 ;22:123-124. |
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. |
2015 |
129 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 125-126. |
Visual compatibility of insulin with secondary intravenous drugs in admixtures.
Smythe M, Malouf E. |
1991 |
397 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 125-126. |
Visual compatibility of intravenous famotidine with selected drugs.
Fong PA, Ward J. |
1989 |
386 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 1357-1358. |
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Colucci RD, Cobuzzi LE, Halpern NA. |
1988 |
517 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 838-839. |
Visual compatibility of magnesium sulfate with narcotic analgesics.
Letourneau M. |
1992 |
3364 |
Czasopismo
Am J Health-Syst Pharm 2012 ; 69:2130. |
Visual compatibility of micafungin sodium and levofloxacin injections.
Fleischbein E, Montgomery P.A, Zhou C.Z. |
2012 |
404 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 2298-2299. |
Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
Forman JK, Souney PF. |
1987 |
176 |
Czasopismo
Am J Health-Syst Pharm 1995 ; 52: 2567-2568. |
Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection.
Mantong ML, Marquardt ED. |
1995 |
62 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 123-125. |
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Pugh CB, Pabis DJ, Rodriguez C. |
1991 |
518 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 1278. |
Visual compatibility of nalbuphine hydrochloride and promethazine hydrochloride.
Jimenez MD. |
1988 |
406 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 819-820. |
Visual compatibility of narcotic analgesics with selected intravenous admixtures.
Smythe MA, Patel MA, Gasloli RA. |
1990 |
188 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 2709-2710. |
Visual compatibility of neuroleptics with anticholinergics or antihistamines in polyethylene syringes.
Gibler B, Kim MS, Raleigh F. |
1994 |
402 |
Czasopismo
Am J Hosp Pharm 1990 ; 47: 820-821. |
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Savitsky ME. |
1990 |
992 |
Czasopismo
Ann Pharmacotherapy 1991 ; 25: 869. |
Visual compatibility of ondansetron and dexamethasone.
Beijnen JH, Koks CHW. |
1991 |
334 |
Czasopismo
Am J Hosp Pharm 1991 ; 48: 988-992. |
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Trissel LA, Tramonte SM, Grilley BJ. |
1991 |
3152 |
Czasopismo
Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Kumar A, Mann HJ. |
2010 |
317 |
Czasopismo
Am J Hosp Pharm 1993 ; 50: 1360-1362. |
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Kershaw BP, Monnier HL, Mason JH. |
1993 |
396 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 2057-2058. |
Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications.
Chilvers MR, Lysne JM. |
1989 |
891 |
Czasopismo
Hosp Pharm 1992 ; 27: 200, 202, 209. |
Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents.
Matsuura G. |
1992 |
335 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 402-406. |
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Trissel LA, Bready BB, Kwan JW, Santiago NM. |
1992 |
479 |
Czasopismo
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Min DI, Brown T, HWang GC. |
1992 |
939 |
Czasopismo
Aust J Hosp Pharm 1994 ; 24: 167-170. |
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Gilbar PJ, Groves CF. |
1994 |
2375 |
Czasopismo
Am J Hosp Pharm 1989 ; 46: 1832 - 1833. |
Visual compatibility of vancomycin and heparin in peritoneal dialysis solutions
Strong DK, Ho W, Nairn JG. |
1989 |
1724 |
Czasopismo
Can J Hosp Pharm 2001 ; 54: 102-105. |
Visual compatibility of various injectable neuroleptic agents with benztropine and lorazepam in polypropylene syringes.
Elbe D, Condé C. |
2001 |
2017 |
Czasopismo
Am J Health-Syst Pharm 2005 ; 62: 1969-1976. |
Visual compatibility of vasopressin with other injectable drugs.
Barker B, Feddema S, Rusho WJ, Dengg R. |
2005 |
315 |
Czasopismo
Am J Health-Syst Pharm 1997 ; 54: 2599-2600. |
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Bahal SM, Lee TJ, McGinnes M, Dobler GL. |
1997 |
337 |
Czasopismo
Am J Hosp Pharm 1988 ; 45: 2532-2533. |
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Bashaw ED, Amantea MA, Minor JR, Galleli JF. |
1988 |
860 |
Czasopismo
Am J Hosp Pharm 1987 ; 44: 2028. |
Visual incompatibility of dacarbazine and heparin.
Nelson RW, Young R, Lamnin M. |
1987 |
84 |
Czasopismo
Am J Hosp Pharm 1994 ; 51: 495-499. |
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Trissel LA, Martinez JF. |
1994 |
3566 |
Laboratorium
Pfizer 2013 |
Voriconazole (Vfend®) - Summary of Product characteristics.
|
2013 |
4671 |
Czasopismo
Int J Antimicrob Agents 2020 ; 56: 106083. |
Voriconazole topical cream formulation: evidence for stability and antifungal activity.
Bouchand C, Nguyen D, Secretan P-H, Vidal F, Guery R, Auvity S, Cohen J.F, Lanternier |
2020 |
1494 |
Czasopismo
Hosp Pharm Pract 1993 ; 3: 553-556. |
When is flucloxacillin stable ?
McLaughlin JP, Simpson C. |
1993 |
4709 |
Laboratorium
Tetraphase Pharmaceuticals. 2021 |
XERAVA® (eravacycline) for injection, for intravenous use. HIGHLIGHTS OF PRESCRIBING INFORMATION.
|
2021 |
4433 |
Czasopismo
Clin Ther 2020 ; 42, 3: 475-485. |
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. |
2020 |
4569 |
Czasopismo
Hosp Pharm 2021 ; 56, 4: 282-286. |
Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
Lee T.M , Villareal C.L, Meyer L.M. |
2021 |
4698 |
Czasopismo
Pharmaceutical Technology in Hospital Pharmacy 2022 |
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Ayari G, D'Huart E, Vigneron J, Demoré B. |
2022 |
3365 |
Czasopismo
Hosp Pharm 2013 ; 1: 44-47 |
Y-Site Compatibility of Vancomycin and Piperacillin/Tazobactam at Commonly Utilized Pediatric Concentrations.
Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A. |
2013 |
3428 |
Czasopismo
Hosp Pharm 2013 ; 48, 1: 44-47. |
Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations.
Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A. |
2013 |
3960 |
Czasopismo
Hosp Pharm 2017 ;52,2:132-137. |
Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story?
Kufel W.D, Miller C.D, Johnson P.R, Reid K., Zahra J.J, Seabury R.W. |
2017 |
4768 |
Czasopismo
Journal of Nippon Medical school 2023 |
Y-site injection physical compatibility of remdesivr with select intravenous drugs used in palliative care and for treating coronavirus disease 2019.
Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H. |
2023 |
3879 |
Czasopismo
Int J Pharm Compound 2016 ; 20, 4 : 328-332. |
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. |
2016 |
4465 |
Czasopismo
Am J Health-Syst Pharm 2020 ;77,14:1144-1148 |
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
Foushee A, Meredith P, Fox Laura, Wilder A. |
2020 |
4488 |
Czasopismo
Pharmaceutics 2020 ; 12, 677. |
Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care.
Nezvalova-Henriksen K, Niklas Nilsson N, Tomine Østerberg C, Staven Berge V, Tho I. |
2020 |
1412 |
Czasopismo
Int J Pharm Compound 1999 ; 3: 64-66. |
Y-site stability of fosphenytoin and sodium phenobarbital.
Brett A, Riggs RM, Webster AA, Benner KW. |
1999 |
4482 |
Laboratorium
Cipla USA 2020 |
ZEMDRI (plazomicin) injection, Highlights of Prescribing Information, Cipla USA, Revised: 1/2020
|
2020 |
4503 |
Laboratorium
RIEMSER Pharma GmbH 2018 |
Ziconotide (Prialt®) - Summary of Product Characteristics
|
2018 |
3782 |
Czasopismo
Int J Pharm 2014 , 477, 1-2 : 32-38. |
Study of quality and stability of ursodeoxycholic acid formulations for oral pediatric administration
A. Santove?a, E. S?nchez-Negr?n, L. Charola, M. Llabr?s, J.B. Fari?a |
2014 |